0000950170-25-01880910-Q MEI Pharma, Inc. 20250212202502121600201600211600210 0000950170-25-018809 10-Q 68 20241231 20250212 20250212 MEI Pharma, Inc. 0001262104 2834 510407811 DE 0630 10-Q 34 001-41827 25614662 11455 EL CAMINO REAL SUITE 250 SAN DIEGO CA 92130 858-369-7100 11455 EL CAMINO REAL SUITE 250 SAN DIEGO CA 92130 MARSHALL EDWARDS INC 20030902 10-Q 1 meip-20241231.htm 10-Q 10-Q Q2false000126210406-302025DE2028-03-312028-03-310001262104us-gaap:RevenueFromContractWithCustomerMember2023-10-012023-12-3100012621042024-12-310001262104us-gaap:PropertyPlantAndEquipmentMember2024-10-012024-12-310001262104us-gaap:TransferredAtPointInTimeMemberus-gaap:RevenueFromContractWithCustomerMember2023-07-012023-12-310001262104meip:BeigeneLtdMember2023-07-012023-12-310001262104us-gaap:RetainedEarningsMember2024-12-310001262104meip:InducementPlanMember2024-12-3100012621042024-07-012024-12-310001262104us-gaap:RetainedEarningsMember2023-06-300001262104us-gaap:CommonStockMember2024-12-310001262104meip:PresageLicenseAgreementMembermeip:PresageBiosciencesIncMember2024-12-310001262104meip:PresageLicenseAgreementMember2024-12-3100012621042024-10-222024-10-220001262104us-gaap:EmployeeStockOptionMember2023-07-012023-12-310001262104us-gaap:EmployeeStockOptionMembermeip:InducementPlanMember2024-12-310001262104us-gaap:WarrantMember2023-10-012023-12-3100012621042024-09-300001262104us-gaap:GeneralAndAdministrativeExpenseMember2023-07-012023-12-310001262104us-gaap:AccountingStandardsUpdate201602Member2022-07-310001262104us-gaap:AdditionalPaidInCapitalMember2024-06-3000012621042023-12-062023-12-0600012621042024-12-3100012621042023-07-012023-09-300001262104meip:TwoThousandAndEightOmnibusPlanMember2024-12-310001262104srt:DirectorMemberus-gaap:EmployeeStockOptionMember2024-07-012024-12-310001262104us-gaap:AdditionalPaidInCapitalMember2023-12-310001262104meip:InducementPlanMember2023-06-090001262104meip:AtTheMarketSaleAgreementMember2024-02-200001262104meip:RevenueFromCollaborationAgreementsMember2024-07-012024-12-310001262104us-gaap:AdditionalPaidInCapitalMember2023-10-012023-12-310001262104us-gaap:CommonStockMember2023-09-300001262104us-gaap:RetainedEarningsMember2024-09-300001262104us-gaap:LeaseholdImprovementsMember2024-06-300001262104us-gaap:AdditionalPaidInCapitalMember2024-09-300001262104meip:AtTheMarketSaleAgreementMember2024-07-012024-12-310001262104meip:SanDiegoCaliforniaMember2022-07-310001262104meip:AtTheMarketSaleAgreementMember2024-01-020001262104us-gaap:WarrantMember2024-10-012024-12-310001262104meip:TwoThousandAndEightOmnibusPlanMemberus-gaap:EmployeeStockOptionMember2024-12-310001262104us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001262104us-gaap:FurnitureAndFixturesMember2024-06-300001262104meip:AssetPurchaseAgreementMember2024-10-220001262104meip:UsLicenseMembermeip:KyowaKirinCoMembermeip:KkcAgreementsMember2023-06-3000012621042024-08-012024-08-310001262104us-gaap:FairValueMeasurementsRecurringMember2024-06-300001262104us-gaap:AdditionalPaidInCapitalMember2023-12-310001262104us-gaap:CommonStockMember2024-09-300001262104us-gaap:EquipmentMember2024-06-300001262104srt:MaximumMember2024-07-012024-12-310001262104us-gaap:EmployeeStockOptionMember2024-07-012024-12-310001262104us-gaap:RetainedEarningsMember2024-10-012024-12-310001262104us-gaap:CommonStockMember2024-06-300001262104us-gaap:CommonStockMember2023-06-300001262104meip:RevenueFromCollaborationAgreementsMember2024-10-012024-12-310001262104us-gaap:WarrantMember2023-07-012023-12-310001262104us-gaap:ResearchAndDevelopmentExpenseMember2023-10-012023-12-310001262104meip:KyowaKirinCoMember2020-04-300001262104us-gaap:AdditionalPaidInCapitalMember2023-06-300001262104us-gaap:GeneralAndAdministrativeExpenseMember2023-10-012023-12-310001262104us-gaap:RetainedEarningsMember2023-07-012023-09-3000012621042024-06-182024-06-180001262104us-gaap:AdditionalPaidInCapitalMember2024-12-310001262104us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-12-310001262104meip:AssetPurchaseAgreementMember2024-10-222024-10-220001262104us-gaap:GeneralAndAdministrativeExpenseMember2024-07-012024-12-3100012621042024-10-012024-12-3100012621042023-10-012023-10-010001262104meip:PresageLicenseAgreementMembermeip:PresageBiosciencesIncMembermeip:IncrementalPaymentMember2024-12-310001262104us-gaap:TransferredOverTimeMemberus-gaap:RevenueFromContractWithCustomerMember2023-07-012023-12-3100012621042020-07-310001262104us-gaap:WarrantMembermeip:TorreyaPartnersLlcMember2024-12-310001262104us-gaap:EmployeeStockOptionMember2023-10-012023-12-310001262104us-gaap:OneTimeTerminationBenefitsMember2024-12-310001262104us-gaap:OneTimeTerminationBenefitsMember2023-06-300001262104meip:PresageLicenseAgreementMembermeip:PresageBiosciencesIncMembermeip:PotentialPaymentsOnAchievementOfDevelopmentRegulatoryAndCommercialMilestonesMember2024-12-310001262104meip:AtTheMarketSaleAgreementMember2024-02-202024-02-200001262104us-gaap:OneTimeTerminationBenefitsMember2023-07-012024-06-300001262104us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001262104meip:KyowaKirinCoMembermeip:KkcAgreementsMembermeip:DevelopmentServicesMember2022-07-012023-06-300001262104meip:RevenueFromCollaborationAgreementsMember2024-07-012024-12-310001262104us-gaap:OneTimeTerminationBenefitsMember2024-06-180001262104us-gaap:EmployeeStockOptionMembermeip:EmployeesMember2024-07-012024-12-310001262104us-gaap:OneTimeTerminationBenefitsMember2024-06-300001262104meip:O2024Q2DividendsMember2024-07-012024-12-310001262104us-gaap:EmployeeStockOptionMember2024-07-012024-12-3100012621042023-10-312023-10-310001262104us-gaap:RetainedEarningsMember2024-07-012024-09-300001262104meip:AssetPurchaseAgreementMembersrt:MaximumMember2024-10-2200012621042024-06-300001262104meip:RevenueFromCollaborationAgreementsMember2023-07-012023-12-3100012621042023-09-3000012621042023-07-012024-06-300001262104us-gaap:EmployeeStockOptionMember2024-12-310001262104meip:PassThroughServicesMember2024-07-012024-12-3100012621042024-06-300001262104us-gaap:RevenueFromContractWithCustomerMember2024-10-012024-12-3100012621042022-07-012022-07-310001262104us-gaap:WarrantMember2024-07-012024-12-310001262104us-gaap:RetainedEarningsMember2023-09-300001262104meip:InducementPlanMember2021-05-310001262104us-gaap:FairValueMeasurementsRecurringMember2024-12-310001262104us-gaap:OneTimeTerminationBenefitsMember2024-07-012024-12-310001262104meip:PresageLicenseAgreementMembermeip:PresageBiosciencesIncMember2017-09-012017-09-300001262104us-gaap:AdditionalPaidInCapitalMember2024-10-012024-12-3100012621042025-02-070001262104us-gaap:FurnitureAndFixturesMember2023-07-012024-06-300001262104us-gaap:RetainedEarningsMember2023-10-012023-12-310001262104us-gaap:CommonStockMember2023-12-310001262104us-gaap:PropertyPlantAndEquipmentMember2023-10-012023-12-310001262104us-gaap:ResearchAndDevelopmentArrangementMember2024-12-3100012621042024-07-012024-09-300001262104us-gaap:RetainedEarningsMember2024-06-300001262104meip:KyowaKirinCoMember2023-07-142023-07-1400012621042023-10-012023-12-310001262104us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-12-310001262104meip:RevenueFromCollaborationAgreementsMember2023-10-012023-12-310001262104us-gaap:RevenueFromContractWithCustomerMember2023-07-012023-12-3100012621042023-07-012023-12-3100012621042023-10-010001262104us-gaap:GeneralAndAdministrativeExpenseMember2024-10-012024-12-310001262104us-gaap:AdditionalPaidInCapitalMember2023-09-300001262104us-gaap:RevenueFromContractWithCustomerMember2024-07-012024-12-310001262104us-gaap:RetainedEarningsMember2023-12-310001262104us-gaap:EmployeeStockOptionMember2024-10-012024-12-31xbrli:pureiso4217:USDxbrli:sharesutr:sqftxbrli:sharesiso4217:USD Table of Contents ROC Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Â FORM 10-Q Â (Mark One) â˜’ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Â Â For the quarterly period ended December 31, 2024 OR â˜ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Â Â For the transition period from Â to Â Â Â Commission File Number: 001-41827 Â MEI Pharma, Inc. (Exact name of registrant as specified in its charter) Â Â Â Â Â DELAWARE 51-0407811 (State or other jurisdiction ofincorporation or organization) (I.R.S. EmployerIdentification No.) 9920 Pacific Heights Blvd., Suite 150, San Diego, CA 92121 (Address of principal executive offices) (Zip Code) (858) 369-7100 (Registrantâ€™s telephone number, including area code) Â Securities registered pursuant to Section 12(b) of the Act: Â Title of each class Â TradingSymbol(s) Â Name of each exchange on which registered Common Stock, $0.00000002 par value Â MEIP Â The NasdaqÂ Stock Market LLC Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes â˜’ No â˜ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes â˜’ No â˜ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act. Â Large accelerated filer â˜ Accelerated filer â˜ Non-accelerated filer â˜’ Smaller reporting company â˜’ Emerging growth company Â â˜ Â Â Â Â Â If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. â˜ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes â˜ No â˜’ As of February 7, 2025, the number of shares outstanding of the issuerâ€™s common stock, $0.00000002 par value, was 6,662,857. Â Table of Contents MEI PHARMA, INC. Table of Contents Â Â Â Â Â Â Page Â Â Â PART I FINANCIAL INFORMATION 3 Â Â Â Item 1. Condensed Consolidated Financial Statements (Unaudited) 3 Â Â Â Â Â Â Â Â Condensed Consolidated Balance Sheets as of December 31, 2024 and June 30, 2024 (Unaudited) 3 Â Â Â Â Â Â Â Â Condensed Consolidated Statements of Operations for the three and six months ended December 31, 2024 and 2023 (Unaudited) 4 Â Â Â Â Â Â Â Â Condensed Consolidated Statements of Stockholdersâ€™ Equity for the three and six months ended December 31, 2024 and 2023 (Unaudited) 5 Â Â Â Â Â Â Â Â Condensed Consolidated Statements of Cash Flows for the six months ended December 31, 2024 and 2023 (Unaudited) 6 Â Â Â Â Â Â Â Â Notes to Condensed Consolidated Financial Statements (Unaudited) 7 Â Â Â Â Â Â Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations 19 Â Â Â Â Â Â Item 3. Quantitative and Qualitative Disclosures about Market Risk 28 Â Â Â Â Â Â Item 4. Controls and Procedures 28 Â Â Â PART II OTHER INFORMATION 30 Â Â Â Â Â Â Item 1. Â Legal Proceedings Â Â 30 Â Â Â Â Â Â Item 1A. Risk Factors 30 Â Â Â Â Â Â Item 2. Â Unregistered Sales of Equity Securities and Use of Proceeds Â Â 30 Â Â Â Â Â Â Item 3. Â Defaults upon Senior Securities Â Â 30 Â Â Â Â Â Â Item 4. Â Mine Safety Disclosures Â Â 30 Â Â Â Â Â Â Item 5. Â Other Information Â Â 30 Â Â Â Â Â Â Item 6. Exhibits 31 Â Â SIGNATURES 32 Â 2 Table of Contents PART I FINANCIAL INFORMATION Item 1. Condensed Consolidated Financial Statements MEI PHARMA, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except par value data) Â Â Â December 31, Â Â June 30, Â Â Â 2024 Â Â 2024 Â Â Â (Unaudited) Â Â Â Â ASSETS Â Â Â Â Â Â Current assets: Â Â Â Â Â Â Cash and cash equivalents Â $ 23,739 Â Â $ 3,705 Â Short-term investments Â Â Â â€” Â Â Â 34,640 Â Prepaid expenses and other current assets Â Â 646 Â Â Â 2,424 Â Total current assets Â Â 24,385 Â Â Â 40,769 Â Operating lease right-of-use asset Â Â â€” Â Â Â 214 Â Property and equipment, net Â Â â€” Â Â Â 392 Â Total assets Â $ 24,385 Â Â $ 41,375 Â Â Â Â Â Â Â Â LIABILITIES AND STOCKHOLDERSâ€™ EQUITY Â Â Â Â Â Current liabilities: Â Â Â Â Â Â Accounts payable Â $ 596 Â Â $ 3,168 Â Accrued liabilities Â Â 1,691 Â Â Â 5,187 Â Total current liabilities Â Â 2,287 Â Â Â 8,355 Â Total liabilities Â Â 2,287 Â Â Â 8,355 Â Â Â Â Â Â Â Â Commitments and contingencies (Note 6) Â Â Â Â Â Â Stockholdersâ€™ equity: Â Â Â Â Â Â Preferred stock, $0.01Â par value; 100Â shares authorized; none outstanding Â Â â€” Â Â Â Â â€” Â Common stock, $0.00000002Â par value; 226,000Â shares authorized; 6,663Â Â Â Â shares issued and outstanding at December 31, 2024 and June 30, 2024. Â Â â€” Â Â Â â€” Â Additional paid-in capital Â Â 421,001 Â Â Â 421,239 Â Accumulated deficit Â Â (398,903) Â Â (388,219) Total stockholdersâ€™ equity Â Â 22,098 Â Â Â 33,020 Â Total liabilities and stockholdersâ€™ equity Â $ 24,385 Â Â $ 41,375 Â Â See accompanying notes to condensed consolidated financial statements. 3 Table of Contents MEI PHARMA, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share amounts) (Unaudited) Â Â For the Three Months Ended December 31, Â Â For the Six Months Ended December 31, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Revenues: Â Â Â Â Â Â Â Â Â Â Revenue from customers Â $ â€” Â Â $ â€” Â Â $ â€” Â Â $ 752 Â Revenue from collaboration agreements Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 64,545 Â Total revenues Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 65,297 Â Â Â Â Â Â Â Â Â Â Operating expenses: Â Â Â Â Â Â Â Â Â Â Research and development Â Â 308 Â Â Â 3,912 Â Â Â 3,471 Â Â Â 7,397 Â General and administrative Â Â 3,143 Â Â Â 8,018 Â Â Â 8,332 Â Â Â 14,549 Â Total operating expenses Â Â 3,451 Â Â Â 11,930 Â Â Â 11,803 Â Â Â 21,946 Â (Loss) income from operations Â Â (3,451) Â Â Â (11,930) Â Â Â (11,803) Â Â Â 43,351 Â Other income (expense): Â Â Â Â Â Â Â Â Â Â Interest and dividend income Â Â 279 Â Â Â 869 Â Â Â 634 Â Â Â 1,963 Â Gain on disposition of a non-financial asset Â Â 500 Â Â Â â€” Â Â Â 500 Â Â Â â€” Â Other expense, net Â Â (5) Â Â (2) Â Â (15) Â Â (3) Total other income, net Â Â 774 Â Â Â 867 Â Â Â 1,119 Â Â Â 1,960 Â Net (loss) income Â $ (2,677) Â $ (11,063) Â $ (10,684) Â $ 45,311 Â Â Â Â Â Â Â Â Â Â Net (loss) income per share - basic and diluted Â $ (0.40) Â $ (1.66) Â $ (1.60) Â $ 6.80 Â Â Â Â Â Â Â Â Â Â Â Â Weighted-average shares used in computing net (loss) Â Â Â Â income per share - basic and diluted Â Â 6,663 Â Â Â 6,663 Â Â Â 6,663 Â Â Â 6,663 Â Â See accompanying notes to condensed consolidated financial statements. 4 Table of Contents MEI PHARMA, INC. CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERSâ€™ EQUITY (In thousands) (Unaudited) Â Â CommonShares Â Â AdditionalPaid-InCapital Â Â AccumulatedDeficit Â Â TotalStockholdersâ€™Equity Â Balance at June 30, 2024 Â Â 6,663 Â Â $ 421,239 Â Â $ (388,219) Â $ 33,020 Â Net loss Â Â â€” Â Â Â â€” Â Â Â (8,007) Â Â (8,007) Share-based compensation Â Â â€” Â Â Â (135) Â Â â€” Â Â Â (135) Balance at September 30, 2024 Â Â 6,663 Â Â Â 421,104 Â Â Â (396,226) Â Â 24,878 Â Net loss Â Â â€” Â Â Â â€” Â Â Â (2,677) Â Â (2,677) Share-based compensation Â Â â€” Â Â Â (103) Â Â â€” Â Â Â (103) Balance at December 31, 2024 Â Â 6,663 Â Â Â $ 421,001 Â Â $ (398,903) Â $ 22,098 Â Â Â Â Â Â CommonShares Â Â AdditionalPaid-InCapital Â Â AccumulatedDeficit Â Â TotalStockholdersâ€™Equity Â Balance at June 30, 2023 Â Â 6,663 Â Â $ 430,621 Â Â $ (405,997) Â $ 24,624 Â Net income Â Â â€” Â Â Â â€” Â Â Â 56,374 Â Â Â 56,374 Â Share-based compensation Â Â â€” Â Â Â 363 Â Â Â â€” Â Â Â 363 Â Balance at September 30, 2023 Â Â 6,663 Â Â Â 430,984 Â Â Â (349,623) Â Â 81,361 Â Net loss Â Â â€” Â Â Â â€” Â Â Â (11,063) Â Â (11,063) Cash dividends declared ($1.75Â per share) Â Â â€” Â Â Â (11,660) Â Â â€” Â Â Â (11,660) Share-based compensation Â Â â€” Â Â Â 850 Â Â Â â€” Â Â Â 850 Â Balance at December 31, 2023 Â Â 6,663 Â Â Â $ 420,174 Â Â $ (360,686) Â $ 59,488 Â See accompanying notes to condensed consolidated financial statements. 5 Table of Contents MEI PHARMA, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) (Unaudited) Â Â Â For the Six Months Ended December 31, Â Â Â 2024 Â Â 2023 Â Cash flows from operating activities: Â Â Â Â Â Â Net (loss) income Â $ (10,684) Â $ 45,311 Â Adjustments to reconcile net (loss) income to net cash used in operating activities: Â Â Â Â Â Â Share-based compensation Â Â (238) Â Â 1,213 Â Noncash lease expense Â Â 214 Â Â Â 750 Â Depreciation expense Â Â 368 Â Â Â 172 Â Loss on disposal of property and equipment Â Â 14 Â Â Â â€” Â Gain on disposition of a non-financial asset Â Â (500) Â Â Â â€” Â Changes in operating assets and liabilities: Â Â Â Â Â Â Unbilled receivables Â Â â€” Â Â Â 85 Â Prepaid expenses and other current assets Â Â 1,778 Â Â Â 58 Â Accounts payable Â Â (2,572) Â Â (4,756) Accrued liabilities Â Â (3,496) Â Â (6,816) Deferred revenue Â Â â€” Â Â Â (64,862) Operating lease liability Â Â â€” Â Â Â (701) Net cash used in operating activities Â Â (15,116) Â Â (29,546) Â Â Â Â Â Â Cash flows from investing activities: Â Â Â Â Â Â Purchases of short-term investments Â Â â€” Â Â Â (33,938) Proceeds from maturity of short-term investments Â Â 34,640 Â Â Â 63,419 Â Proceeds from sale of property and equipment Â Â 10 Â Â Â â€” Â Proceeds from the disposition of a non-financial asset Â Â 500 Â Â Â â€” Â Purchases of property and equipment Â Â â€” Â Â Â (7) Net cash provided by investing activities Â Â 35,150 Â Â Â 29,474 Â Â Â Â Â Â Cash flows from financing activities: Â Â Â Â Â Â Payment of cash dividend Â Â â€” Â Â Â (11,660) Net cash used in financing activities Â Â â€” Â Â Â (11,660) Net increase (decrease) in cash and cash equivalents Â Â 20,034 Â Â Â (11,732) Cash and cash equivalents at beginning of the period Â Â 3,705 Â Â Â 16,906 Â Cash and cash equivalents at end of the period Â $ 23,739 Â Â $ 5,174 Â Â See accompanying notes to condensed consolidated financial statements. 6 Table of Contents MEI PHARMA, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) 1. Description of Business and Basis of PresentationDescription of BusinessMEI Pharma, Inc. (Nasdaq: MEIP) is a pharmaceutical company that has been developing novel and differentiated cancer therapies. We built our pipeline by acquiring promising cancer agents and creating value in programs through development, strategic partnerships, and out-licensing or commercialization, as appropriate. Our approach to oncology drug development has been to evaluate our drug candidates in combinations with standard-of-care therapies to overcome known resistance mechanisms and address clear medical needs to provide improved patient benefit. Our pipeline includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and prior to its sale, ME-344 as more fully discussed in Note 12. Disposition of a Non-financial Asset, an intravenous small molecule mitochondrial inhibitor targeting the oxidative phosphorylation pathway.Strategic AlternativesOn July 22, 2024, we

announced that our Board of Directors (Board) had determined unanimously to begin the evaluation of our strategic alternatives, including potential transactions as well as an orderly wind down of operations, if appropriate, to maximize the value of our assets for our stockholders. We commenced a reduction-in-force (the Strategic Alternatives RIF) beginning August 1, 2024, which will continue in stages as our operational and strategic direction evolves. We have discontinued the clinical development of voruciclib, while certain nonclinical activities related to MEIâ€™s drug candidate assets will continue to be conducted by us. As part of the review of strategic alternatives, we may consider options such as out-licensing opportunities for existing programs and merger and acquisition opportunities.Consistent with our intention to preserve cash, David M. Urso, our former President and Chief Executive Officer, and Richard Ghalie, M.D., our former Chief Medical Officer, stepped down effective August 1, 2024. Mr. Urso also left the Board at that date. We have entered into consulting agreements with both Mr. Urso and Dr. Ghalie under which they will remain available to assist us in our strategic efforts. Charles V. Baltic III, the former Chairperson of the Board, also stepped down from the Board contemporaneously with the announcement on July 22, 2024. Our Board appointed Justin J. File, our Chief Financial Officer, to assume the position of Acting Chief Executive Officer and appointed Frederick W. Driscoll as our Chairperson of the Board. Â Basis of Presentation and ConsolidationUnaudited Interim Financial InformationThe interim condensed consolidated financial statements are unaudited. These interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. (U.S. GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the accompanying interim condensed financial statements do not include all of the information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying condensed interim consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) that are necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. These statements do not include all disclosures required by U.S. GAAP and should be read in conjunction with the Companyâ€™s audited consolidated financial statements and notes for the fiscal year ended June 30, 2024. Consolidation PrinciplesThe accompanying unaudited condensed consolidated financial statements include the accounts of MEI Pharma, Inc. and our wholly owned subsidiary, Meadow Merger Sub, Inc. We have eliminated all intercompany accounts and transactions in consolidation. The accompanying unaudited interim condensed consolidated financial statements for the quarterly and six month periods ended December 31, 2024 should be read in conjunction with the audited financial statements and notes thereto as of and for the fiscal year ended June 30, 2024, included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on September 19, 2024 (2024 Annual Report). Interim results are not necessarily indicative of results for a full year.Subsequent EventsThe Company has evaluated subsequent events through the date the condensed consolidated financial statements were issued. 7 Table of Contents LiquidityTo date, we have obtained cash and funded our operations primarily through equity financings and license agreements. We have accumulated losses of $398.9 million since inception and expect to incur operating losses and generate negative cash flows from operations for the foreseeable future. As of December 31, 2024, we had $23.7 million in cash and cash equivalents. In connection with our July 2024 announcement regarding the evaluation of our strategic alternatives, we discontinued the clinical development of voruciclib, while certain nonclinical research and development activities continued. As a result, we continue to incur research and development expenses in connection with clinical trial closing costs and the completion of our nonclinical projects. We believe that our cash balance, will be sufficient to meet our obligations and fund operations for at least the next 12 months from the issuance of these condensed consolidated financial statements. 2. Summary of Significant Accounting PoliciesThere have been no material changes to our significant accounting policies from those described in the notes to our audited consolidated financial statements contained in the 2024 Annual Report. Risks and UncertaintiesUse of EstimatesThe preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to the valuation of share-based awards, the discount rate used in estimating the present value of the right-of-use assets and lease liabilities, the useful lives of property and equipment, the recoverability of long-lived assets, clinical trial accruals, periods over which revenue should be recognized, relative stand-alone selling price, deferred income taxes and related valuation allowances, and the assessment of our ability to fund our operations for at least the next 12 months from the date of issuance of these condensed consolidated financial statements. We base our estimates on historical experience and other market-specific or other relevant assumptions that we believe to be reasonable under the circumstances. Estimates are assessed each reporting period and updated to reflect current information. As future events and their effects cannot be determined with precision, actual results may materially differ from those estimates or assumptions. Short-term InvestmentsShort-term investments are marketable securities with maturities greater than three months but less than one year from date of purchase. As of December 31, 2024 we had no short-term investments. As of June 30, 2024, our short-term investments consisted of $34.6 million, in United States government securities. The short-term investments held as of June 30, 2024 were considered to be held to maturity and are carried at amortized cost. As of December 31, 2024, we had no unrealized gains and losses. As of June 30, 2024, gross unrealized gains and losses were immaterial.Revenue RecognitionRevenues from CustomersIn accordance with ASC Topic 606, Revenue from Contracts with Customers (Topic 606), we recognized revenue when control of the promised goods or services was transferred to our customers, in an amount that reflects the consideration we expected to be entitled to in exchange for those goods or services. For enforceable contracts with our customers, we first identified the distinct performance obligations â€“ or accounting units â€“ within the contract. Performance obligations are commitments in a contract to transfer a distinct good or service to the customer. Payments received under commercial arrangements, such as licensing technology rights, may include non-refundable fees at the inception of the arrangements, milestone payments for specific achievements designated in the agreements, and royalties on the sale of products. At the inception of arrangements that include milestone payments, we used judgment to evaluate whether the milestones were probable of being achieved, and we estimated the amount, if any, to include in the transaction price using the most likely method. If it were probable that a significant revenue reversal would not occur, the estimated amount was included in the transaction price. Milestone payments that were not within our or the licenseeâ€™s control, such as regulatory approvals, were not included in the transaction price until those approvals were received. At the end of each reporting period, we re-evaluated the probability of achievement of development milestones and any related constraint and, as necessary, we adjusted our estimate of the overall transaction price.To the extent a contract included multiple promised deliverables, we applied judgment to determine whether promised deliverables were capable of being distinct and were distinct within the context of the contract. If these criteria were not met, the promised deliverables were accounted for as a combined performance obligation. For arrangements with multiple distinct performance 8 Table of Contents obligations, we allocated variable consideration related to our 50-50 cost share for development services directly to the associated performance obligation and then allocated the remaining consideration among the performance obligations based on their relative stand-alone selling price. When not directly observable, we typically estimated the stand-alone selling price for each distinct performance obligation. Variable consideration that related specifically to our efforts to satisfy specific performance obligations was allocated entirely to those performance obligations. Other components of the transaction price were allocated based on the relative stand-alone selling price, over which management has applied significant judgment. We developed assumptions that required judgment to determine the stand-alone selling price for license-related performance obligations, which may have included forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical, regulatory and commercial success. We estimated stand-alone selling price for research and development performance obligations by forecasting the expected costs of satisfying a performance obligation plus an appropriate margin.In the case of a license that is a distinct performance obligation, we recognized revenue allocated to the license from non-refundable, up-front fees at the point in time when the license was transferred to the licensee and the licensee can use and benefit from the license. For licenses that are bundled with other distinct or combined obligations, we used judgment to assess the nature of the performance obligation to determine whether the performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. If the performance obligation is satisfied over time, we evaluated the measure of progress in each reporting period and, if necessary, adjusted the measure of performance and related revenue recognition.The selection of the method to measure progress towards completion requires judgment and is based on the nature of the products or services to be provided. Revenue is recorded proportionally as costs are incurred. We generally used the cost-to-cost measure of progress because it best depicted the transfer of control to the customer which occurred as we incurred costs. Under the cost-to-cost measure of progress, the extent of progress towards completion was measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation (an input method under Topic 606). We used judgment to estimate the total cost expected to complete the research and development performance obligations, which included subcontractorsâ€™ costs, labor, materials, other direct costs and an allocation of indirect costs. We evaluated these cost estimates and the progress each reporting period and, as necessary, we adjusted the measure of progress and related revenue recognition. In connection with our, now terminated, April 2020 License, Development and Commercialization Agreement with Kyowa Kirin Co., Ltd. (KKC) (the KKC Commercialization Agreement) described in Note 7. License Agreements, we performed development services related to our 50-50 cost sharing arrangement for which revenue was recognized over time. Additionally, we performed services for KKC at their request, the costs of which were fully reimbursed to us. We recorded the reimbursement for such pass through services as revenue at 100% of reimbursed costs, as control of the additional services for KKC was transferred at the time we incurred such costs. The costs of these services were recognized in the condensed consolidated statements of operations as research and development expense. During the three and six months ended December 31, 2024 and the three months ended December 31, 2023, we did not recognize any revenue associated with the KKC Commercialization Agreement. During the six months ended December 31, 2023, we recognized revenue associated with the KKC Commercialization Agreement as follows (in thousands): Timing of Revenue Recognition: Â Â Services performed over time $ 743 Â Pass through services at a point in time Â 9 Â $ 752 Â Contract BalancesContract liabilities were included in deferred revenue and deferred revenue, long-term in our condensed consolidated balance sheets. Our contract liabilities accounted for under Topic 606 related to the amount of initial upfront consideration allocated to the development services performance obligations.As of June 30, 2024 and December 31, 2024, we had no accounts receivable, unbilled receivable balances or contract liabilities. A reconciliation of the beginning and ending amount of contract liabilities as of June 30, 2024, which was primarily related to the 9 Table of Contents combined performance obligation for the transfer of development services under the KKC Commercialization Agreement and was a separate performance obligation in our contracts pursuant to research plans under the agreements, was as follows: Beginning balance $ 317 Â Recognized as revenue: Â Â Revenue recognized upon satisfaction of performance obligations Â (317) Ending balance $ â€“ Â The timing of revenue recognition, invoicing and cash collections results in billed accounts receivable and unbilled receivables (contract assets) and deferred revenue (contract liabilities). We invoiced our customers in accordance with agreed-upon contractual terms, typically at periodic intervals or upon achievement of contractual milestones. Invoicing may have occurred subsequent to revenue recognition, resulting in unbilled receivables. Advanced payments from our customers before revenue was recognized resulted in contract liabilities. Revenues from CollaboratorsAt contract inception, we assessed whether the collaboration arrangements were within the scope of ASC Topic 808 Collaborative Agreements (Topic 808), to determine whether such arrangements involved joint operating activities performed by parties that were both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment was performed based on the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of Topic 808 that contain multiple units of account, we first determined which units of account within the arrangement were within the scope of Topic 808 and which elements were within the scope of Topic 606. For units of account within collaboration arrangements that were accounted for pursuant to Topic 808, an appropriate recognition method was determined and applied consistently, by analogy to authoritative accounting literature. For elements of collaboration arrangements that were accounted for pursuant to Topic 606, we recognized revenue as discussed above. Consideration received that did not meet the requirements to satisfy Topic 606 revenue recognition criteria was recorded as deferred revenue and classified as either current or long-term deferred revenue based on our best estimate of when such amounts would be recognized.Disposition of Non-Financial AssetsThe Company accounts for infrequent dispositions of assets in its product pipeline in accordance with ASC 610-20, Other Income - Gains and Losses from the Derecognition of Nonfinancial Assets, which requires dispositions of long-lived assets that are not a discontinued operation be accounted for on a net basis and included in income from continuing operations before income taxes in accordance with ASC 350, Intangible Assets - Goodwill and Other. Proceeds from sales designated as dispositions of non-financial assets are classified as cash flows from investing activities in the condensed consolidated statements of cash flows.Net (Loss) Income Per ShareBasic and diluted net (loss) income per share is computed using the weighted-average number of shares of common stock outstanding during the period, less any shares subject to repurchase or forfeiture. There were no shares of common stock subject to repurchase or forfeiture for the three and six months ended December 31, 2024 and 2023. Diluted net (loss) income per share is computed based on the sum of the weighted-average number of common shares and potentially dilutive common shares outstanding during the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net (loss) income per share calculation for the three and six months ended December 31, 2024 and 2023, potentially dilutive securities are excluded from the calculation of diluted net (loss) income per share because their weighted-average exercise prices were above our weighted-average share price as of December 31, 2024 and 2023, respectively, therefore, basic and diluted net (loss) income per share were the same for the three and six months ended December 31, 2024 and 2023. The following table presents potentially dilutive shares that have been excluded from the calculation of net (loss) income per share because of their anti-dilutive effect (in thousands): Â Â For the Three Months Ended December 31, Â Â For the Six Months Ended December 31, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Stock options Â Â 955 Â Â Â 1,398 Â Â Â 955 Â Â Â 1,398 Â Warrants Â Â 103 Â Â Â 103 Â Â Â 103 Â Â Â 103 Â Total anti-dilutive shares Â Â 1,058 Â Â Â 1,501 Â Â Â 1,058 Â Â Â 1,501 Â Â 10 Table of Contents Recent Accounting PronouncementRecently IssuedFrom time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standards setting bodies that are adopted as of the specified effective date. The Company believes the impact of recently issued standards and any issued but not yet effective standards will not have a material impact on its condensed consolidated financial statements upon adoption. In November 2023, the FASB issued Accounting Standard Update (ASU) No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires a public entity to disclose significant segment expenses and other segment items on an annual and interim basis and provide in interim periods all disclosures about a reportable segmentâ€™s profit or loss and assets that are currently required annually. Additionally, it requires a public entity to disclose the title and position of the Chief Operating Decision Maker. This ASU does not change how a public entity identifies its operating segments, aggregates them, or applies the quantitative thresholds to determine its reportable segments. The new standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. We expect this ASU to only impact our disclosures with no impact to our results of operations, cash flows, and financial condition.In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which focuses on the rate reconciliation and income taxes paid. ASU No. 2023-09 requires a public business entity (PBE) to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local, and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. For PBEs, the new standard is effective for annual periods beginning after December 15, 2024, with early adoption permitted. An entity may apply the amendments in this ASU prospectively by providing the revised disclosures for the period ending December 31, 2025 and continuing to provide the pre-ASU disclosures for the prior periods, or may apply the amendments retrospectively by providing the revised disclosures for all periods presented. We expect this ASU to only impact our disclosures with no impact to our results of operations, cash flows, and financial condition.In November 2024, the FASB issued ASU No. 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40) (ASU 2024-03). The amendments in this update require disclosure, in the notes to the financial statements, of specific expense categories present within expense captions presented on the face of the statement of operations within continuing operations of PBEs. The amendments in this update are effective for annual periods beginning after December 15, 2026 and interim periods beginning after December 15, 2027. Early adoption is permitted. The amendments should be applied either prospectively to financial statements issued for reporting periods after the effective date of this ASU or retrospectively to any and all prior periods presented in the financial statements. The impact of adoption of this ASU on the Companyâ€™s disclosures is currently being evaluated.In January 2025, the FASB issued ASU No. 2025-01, Income Statementâ€”Reporting Comprehensive Incomeâ€”Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date. The amendment in this

update clarifies the effective date of ASU 2024-03, which is that PBEs are required to adopt the guidance in annual reporting periods beginning after December 15, 2026 and in interim periods within annual reporting periods beginning after December 15, 2027. The impact of adoption of this ASU on the Companyâ€™s disclosures is currently being evaluated.Â 3. Balance Sheet DetailsPrepaid and Other Current AssetsPrepaid and other current assets consisted of the following, in thousands: Â Â December 31, 2024 Â Â June 30, 2024 Â Insurance Â $ 350 Â Â $ 460 Â Software licenses Â Â 225 Â Â Â 442 Â Security deposit Â Â â€” Â Â Â 263 Â Prepaid clinical costs Â Â â€” Â Â Â 1,050 Â Other Â Â 71 Â Â Â 209 Â Total prepaid and other current assets Â $ 646 Â Â $ 2,424 Â Â Â Â Â Â Â Â Â 11 Table of Contents Property and EquipmentAs of December 31, 2024, we had no property and equipment. Property and equipment consisted of the following as of June 30, 2024, in thousands: Furniture and equipment Â $ 1,000 Â Equipment Â Â 187 Â Leasehold improvements Â Â 969 Â Â Â Â 2,156 Â Less: accumulated depreciationÂ (1) Â Â (1,764) Property and equipment, net Â $ 392 Â _____(1) Includes impairment charge of $0.5 million, see below discussion on Impact of the Agreement (as discussed in Note 9. Leases).Depreciation expense of property and equipment for the six months ended December 31, 2024 and 2023 are presented in the condensed consolidated statements of cash flows. During the three months ended December 31, 2024, we did not record depreciation expense. During the three months ended December 31, 2023, depreciation expense was approximately $0.1 million.Impact of the Agreement (as discussed in Note 9. Leases)As noted in Note 9. Leases, we agreed to sell our furniture and fixtures to the landlord for $1.00 on our lease termination date of September 30, 2024. We completed an evaluation of the impact of the Agreement, as defined in Note 9. Leases, on the carrying value of our property and equipment (Other Long-Lived Assets). This process included evaluating the remaining estimated useful lives, significant changes in the use and potential impairment charges related to the Other Long-Lived Assets. Based upon our evaluation, we recorded an impairment charge during our fiscal year ended June 30, 2024 of approximately $0.5 million for the furniture and fixtures sold to the landlord on September 30, 2024, which was included in the impairment of long-lived assets in the condensed consolidated statements of operations for the fiscal year ended June 30, 2024. We also changed our estimate of the remaining useful lives of our leasehold improvements resulting in an acceleration of depreciation of approximately $0.1 million during our fiscal year ended June 30, 2024. Accrued LiabilitiesAccrued liabilities consisted of the following, in thousands: Â Â Â Â Â Â Â Â Â December 31, 2024 Â Â June 30, 2024 Â Accrued compensation and benefits (1) Â $ 1,476 Â Â $ 2,821 Â Accrued pre-clinical and clinical trial expenses Â Â 151 Â Â Â 1,407 Â Accrued legal and professional services Â Â 6 Â Â Â 33 Â Accrued reimbursement to KKC Â Â â€” Â Â Â 892 Â Other Â Â 58 Â Â Â 34 Â Total accrued liabilities Â $ 1,691 Â Â $ 5,187 Â _____ (1) Includes employee termination benefits of approximately $1.3 million and $21,000 as of December 31, 2024 and June 30, 2024, respectively, as more fully described in Note 5. Employee Termination Benefits. 4. Fair Value MeasurementsThe carrying amounts of financial instruments such as cash equivalents, short-term investments and accounts payable approximate the related fair values due to the short-term maturities of these instruments. We invest our excess cash in financial instruments which are readily convertible into cash, such as money market funds and U.S. government securities. Cash equivalents and short-term investments are classified as Level 1 as defined by the fair value hierarchy. As of December 31, 2024 and June 30, 2024, we had no assets or liabilities measured on a recurring or non-recurring basis. 12 Table of Contents 5. Employee Termination BenefitsIn connection with our joint decision to discontinue development of zandelisib outside of Japan in December 2022, we announced a realignment of our clinical development efforts that streamlined our organization towards the continued clinical development of our two earlier clinical-stage assets, voruciclib and ME-344. As a result, our Board approved a staggered workforce reduction (the 2023 RIF), which was completed during fiscal year 2024. In August 2024, we commenced the Strategic Alternatives RIF, as discussed in our strategic alternatives announcement described in Note 1. Description of Business and Basis of Presentation. Including contractual pro-rata fiscal year 2025 bonuses, we expect to incur charges not to exceed a total of $6.5 million in retention, severance and COBRA costs related to the termination of our employees due to our related wind down activities. The charges that we expect to incur in connection with the Strategic Alternatives RIF are subject to a number of assumptions, and actual results may differ materially. We may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the Strategic Alternatives RIF.For the three months ended December 31, 2024, we recorded employee termination benefits of $0.3 million and $0.9 million within research and development and general and administrative expense, respectively. For the three months ended December 31, 2023, we recorded employee termination benefits of $0.1 million and $0.2 million within research and development expense and general and administrative expense, respectively.For the six months ended December 31, 2024, we recorded employee termination benefits of $1.6 million and $2.7 million within research and development and general and administrative expense, respectively. For the six months ended December 31, 2023, we recorded employee termination benefits of $0.2 million in both research and development expense and general and administrative expense.The following table summarizes our activity related to employee benefits included in accrued liabilities (in thousands): Â Â December 31, 2024 Â Â June 30, 2024 Â Beginning balance Â $ 21 Â Â $ 993 Â Increase in accrued restructuring Â Â 4,333 Â Â Â 556 Â Cash payments Â Â (3,069) Â Â (1,528) Ending Balance Â $ 1,285 Â Â $ 21 Â Â 6. Commitments and ContingenciesWe have contracted with various consultants and third parties to assist us in pre-clinical research and development and clinical trials work for our leading drug compounds and general and administrative activities. The contracts are terminable at any time but obligate us to reimburse the providers for any time or costs incurred through the date of termination. See the discussion of the sale of ME-344 within Note 12. Disposition of a Non-financial Asset for additional information regarding contracts associated with ME-344 assumed by the Purchaser (as defined in Note 12. Disposition of a Non-financial Asset). We also have an employment agreement with our acting chief executive officer and chief financial officer that provides for severance payments and accelerated vesting for share-based awards if their employment is terminated under specified circumstances.LitigationFrom time to time, we may be involved in various lawsuits, legal proceedings, or claims that arise in the ordinary course of business. Management believes there are no claims or actions pending against us as of December 31, 2024, which will have, individually or in the aggregate, a material adverse effect on its business, liquidity, financial position, or results of operations. Litigation, however, is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. IndemnificationIn accordance with our amended and restated certificate of incorporation and sixth amended and restated bylaws, we have indemnification obligations to our officers and directors for certain events or occurrences, subject to certain limits, while they are serving in such capacity. There have been no claims to date, and we have a directors and officers liability insurance policy that may enable it to recover a portion of any amounts paid for future claims. Presage License AgreementAs discussed in Note 8. Other License Agreements, we are party to a license agreement with Presage Biosciences, Inc. (Presage) under which we may be required to make future payments upon the achievement of certain development, regulatory and commercial milestones, as well as potential future royalties based upon net sales. As of December 31, 2024, we had no accruals for potential future payments as achievement of the milestones had not been met. 13 Table of Contents 7. License AgreementsKyowa Kirin Co., Ltd. License, Development and Commercialization AgreementIn April 2020, we entered into the KKC Commercialization Agreement under which we granted to KKC a co-exclusive, sublicensable, payment-bearing license under certain patents and know-how controlled by us to develop and commercialize zandelisib and any pharmaceutical product containing zandelisib for all human indications in the U.S. (the U.S. License), and an exclusive (subject to certain retained rights to perform obligations under the KKC Commercialization Agreement), sublicensable, payment-bearing, license under certain patents and know-how controlled by us to develop and commercialize zandelisib and any pharmaceutical product containing zandelisib for all human indications in countries outside of the U.S. KKC granted to us a co-exclusive, sublicensable, license under certain patents and know-how controlled by KKC to develop and commercialize zandelisib for all human indications in the U.S., and a co-exclusive, sublicensable, royalty-free, fully paid license under certain patents and know-how controlled by KKC to perform our obligations in the Ex-U.S. under the KKC Commercialization Agreement. KKC paid us an initial nonrefundable payment of $100.0 million.In July 2023, we entered into a termination agreement with KKC to mutually terminate the KKC Commercialization Agreement and all other related agreements between the parties (Termination Agreement) and jointly decided to discontinue zandelisib development in the U.S. Prior to the execution of the Termination Agreement, KKC was responsible for the development and commercialization of zandelisib in Ex-U.S. and, subject to certain exceptions, was solely responsible for all costs related thereto. We also provided to KKC certain drug supplies necessary for the development and commercialization of zandelisib in the Ex-U.S., with the understanding that KKC would have assumed responsibility for manufacturing for the Ex-U.S. as soon as practicable.During fiscal year 2023, we updated our assessment of the total transaction price from the KKC Commercialization Agreement to reflect the upfront payment, milestone payments, estimated development cost-sharing, and deferred revenue. After announcing our plan to discontinue the global development of zandelisib outside of Japan, in December 2022, we decreased our estimate for variable consideration related to development cost sharing.With the execution of the Termination Agreement, we regained full, global rights (subject to KKC's limited rights for compassionate use) and KKC has no further rights to develop, use or commercialize zandelisib in the U.S., nor do we have any remaining performance obligations with all consideration received from KKC being nonrefundable. Therefore, the remaining long-term deferred revenue as of June 30, 2023, of $64.5 million that was allocated to the U.S. License obligation accounted for under Topic 808 at inception of the KKC Commercialization Agreement was recognized as revenue from collaboration agreements in the three months ended September 30, 2023, utilizing contract termination analogous to guidance provided in Topic 606.The $64.5 million transaction price allocated to the U.S. License obligation accounted for under Topic 808 was included as noncurrent deferred revenue as of June 30, 2023. As of June 30, 2023, we also had deferred revenue of approximately $0.3 million related to the transaction price allocated to the Development Services performance obligations and recognized the remaining revenue based on the proportional performance of these development activities. The KKC Agreement was terminated on July 14, 2023 and all remaining amounts of deferred revenue were recognized during the fiscal year ended June 30, 2024. 8. Other License AgreementsPresage License AgreementIn September 2017, we, as licensee, entered into a license agreement with Presage. Under the terms of the license agreement, Presage granted us exclusive worldwide rights to develop, manufacture and commercialize voruciclib, a clinical-stage, oral and selective CDK inhibitor, and related compounds. In exchange, we paid $2.9 million to Presage. With respect to the first indication, an incremental $2.0 million payment, due upon dosing of the first subject in the first registration trial, will be owed to Presage, for total payments of $4.9 million prior to receipt of marketing approval of the first indication in the U.S., EU or Japan. Additional potential payments of up to $179.0 million will be due upon the achievement of certain development, regulatory and commercial milestones. We will also pay mid-single digit tiered royalties on the net sales of any product successfully developed. As an alternative to milestone and royalty payments related to countries in which we sublicense product rights, we will pay to Presage a tiered percentage (which decreases as product development progresses) of amounts received from such sublicensees. During the three and six months ended December 31, 2024 and 2023, we made no payments under the Presage license agreement. BeiGene CollaborationIn October 2018, we entered into a clinical collaboration with BeiGene, Ltd. (BeiGene) to evaluate the safety and efficacy of zandelisib in combination with BeiGeneâ€™s zanubrutinib (marketed as BrukinsaÂ®), an inhibitor of Brutonâ€™s tyrosine kinase, for the treatment of patients with B-cell malignancies. Under the terms of the clinical collaboration agreement, we amended our ongoing Phase 1b trial to include evaluation of zandelisib in combination with zanubrutinib in patients with B-cell malignancies. Study costs are being shared equally by the parties, and we agreed to supply zandelisib and BeiGene agreed to supply zanubrutinib. We record the costs reimbursed by BeiGene as a reduction of our research and development expenses. We retained full commercial rights for 14 Table of Contents zandelisib and BeiGene retained full commercial rights for zanubrutinib. With the discontinuation of the zandelisib program outside of Japan, this clinical collaboration was terminated on September 28, 2023. The Company did not recognize any cost reimbursement reductions within research and development during the three and six months ended December 31, 2024 and three months ended December 31, 2023. Cost reimbursements recorded as a reduction of research and development costs, in the condensed consolidated statements of operations, during the six months ended December 31, 2023 were approximately $0.1 million. 9. LeasesIn July 2020, we entered into a lease agreement for approximately 32,800 square feet of office space in San Diego, California. The lease agreement was scheduled to expire in March 2028. We accounted for the lease agreement as an operating lease. The lease agreement contained an option to renew and extend the lease term, which was not included in the determination of the right-of-use (ROU) asset and operating lease liability, as it was not reasonably certain to be exercised. In July 2022, we amended the lease to extend the lease termination date from March 2028 to November 30, 2029 and to add an additional 12,300 square feet of office space adjacent to our current office in San Diego (the Amended Lease). Upon commencement of the Amended Lease, we recognized an additional ROU asset and a corresponding operating lease liability of $4.3 million. The Amended Lease includes variable non-lease components (e.g., common area maintenance, maintenance, etc.) that are not included in the ROU asset and operating lease liability and are reflected as an expense in the period incurred as a component of the lease cost.Lease TerminationOn June 18, 2024 (the Agreement Date), we entered into a lease termination agreement (Agreement) with our landlord pursuant to which the parties agreed to terminate the lease for our existing office space as of September 30, 2024. The original (as amended) scheduled expiration date was November 30, 2029. As consideration for the Agreement, we agreed to pay the landlord a termination fee of approximately $11.1 million (the Termination Fee) and to prepay the remaining rent due under the Agreement in the amount of approximately $0.2 million (the Remaining Rent) and sell all the furniture and fixtures to the landlord for $1.00 (see Property and Equipment within Note 3. Balance Sheet Details for further discussion on the impact of the Agreement on our property and equipment). We received our security deposit, which is classified as a component of prepaid and other current assets, from the landlord in October 2024. The Agreement was accounted for as a lease modification of the original contract. As a result of the Agreement, we reduced both the remaining ROU asset and lease liability by approximately $22,000, resulting in no impact to our consolidated statements of operations for the fiscal year ended June 30, 2024. We reassessed the lease classification, as of the Agreement Date, noting the current classification as an operating lease remained appropriate. Both the Termination Fee and the Remaining Rent were paid prior to June 30, 2024. Subsequent to the payment of both the Termination Fee and the Remaining Rent, our lease liability was relieved and the balance was reduced to zero.We incurred direct costs of approximately $0.2 million in connection with the Agreement which accordingly was recorded to the ROU assets as a direct cost of modifying the Agreement. As of the Agreement Date, we determined a triggering event, in accordance with ASC 360, had occurred and therefore completed an impairment analysis on its ROU asset resulting in an impairment charge of approximately $10.4 million being recorded in our consolidated statements of operations for the fiscal year ended June 30, 2024.During the three months ended December 31, 2024 we did not recognize lease costs. The total operating lease costs for the Amended Lease were as follows for the periods presented (in thousands): Â Â For the Three Months Ended December 31, Â Â For the Six Months Ended December 31, Â Â Â 2023 Â Â 2024 Â Â 2023 Â Operating lease cost Â $ 609 Â Â $ 214 Â Â $ 1,217 Â Variable lease costs Â Â 12 Â Â Â Â â€” Â Â Â 24 Â Total lease costs included in operating expenses Â $ 621 Â Â $ 214 Â Â $ 1,241 Â Â 15 Table of Contents During the three and six months ended December 31, 2024, we had no supplemental cash flow activity. Supplemental cash flow information related to our operating leases was as follows for the periods presented (in thousands): Â Â For the Three Months Ended December 31, Â Â For the Six Months Ended December 31, Â Â Â 2023 Â Â 2023 Â Cash paid for amount included in the measurement Â Â Â Â of lease liabilities: Â Â Â Â Â Â Operating cash flows from operating leases Â $ 583 Â Â $ 1,167 Â As of June 30, 2024, we had no remaining future minimum rental payments for our operating leases and the remaining ROU asset balance was $0.2 million. As of September 30, 2024, we had vacated the facility and the leased property reverted to the landlord. In addition, the ROU asset has been fully amortized. During fiscal year 2024, the ROU asset balance was increased by approximately $0.2 million related to direct costs associated with the Agreement. Additionally, the ROU asset balance was decreased by: (1) approximately $22,000 associated with our reassessment of the lease liability as of the Agreement Date and (2) $10.4 million associated with the impairment of the ROU asset, as discussed above. 10. Stockholdersâ€™ EquityEquity TransactionsShelf Registration StatementWe have a shelf registration statement (February 2024 Shelf Registration Statement) that permits us to sell, from time to time, up to $100.0 million of common stock, preferred stock, warrants, rights and units, subject to the "Baby Shelf Limitation" described below. The February 2024 Shelf Registration Statement was filed February 20, 2024 and declared effective February 28, 2024.At-The-Market Equity OfferingOn February 20, 2024, we entered into a capital on demand sales agreement with JonesTrading Institution Services LLC, pursuant to which we can offer and sell shares having an aggregate offering price of up to $25.0 million (the ATM Program). In no event will we sell securities registered on this registration statement in a public primary offering with a value exceeding more than one-third of our public float in any 12-month period so long as our public float remains below $75.0 million (Baby Shelf Limitation) As of January 2, 2024, the date used under applicable rules of the SEC to determine our public float at the commencement of the offering, one-third of our public float was equal to approximately $9.9 million. As of December 31, 2024, no shares have been issued and sold under our ATM Program.Cooperation Agreement and Cash DividendOn October 31, 2023, we announced our entry into a cooperation agreement with Anson Funds Management LP and Cable Car Capital LLC, which, among other non-financial related items provided for a capital return to stockholders in the form of a dividend in the amount of $1.75 per share of common stock that was declared on November 6, 2023 to stockholders of record at the close of business on November 17, 2023 (Cooperation Agreement). The total dividend of $11.7 million was paid on December 6, 2023 and was recorded as a reduction of additional paid-in capital in the condensed consolidated

statements of stockholders' equity, as we have an accumulated deficit, rather than retained earnings.Rights Agreement On October 1, 2023, our Board approved and adopted a rights agreement (Rights Agreement) by and between us and Computershare, Inc., as Rights Agent (as defined in the Rights Agreement). Pursuant to the Rights Agreement, the Board declared a dividend of one preferred share purchase right (each, a Right) for each outstanding share of our common stock, par value $0.00000002 (each a Common Share and collectively, the Common Shares). The Rights are distributable to stockholders of record as of the close of business on October 12, 2023. One Right also will be issued together with each Common Share issued by us after October 12, 2023, but before the Distribution Date, as defined in the Rights Agreement (or the earlier of the redemption or expiration of the Rights) and, in certain circumstances, after the Distribution Date. The Rights and the Rights Agreement expired at the close of business on September 30, 2024. No rights were redeemed or exchanged under the Rights Agreement.WarrantsAs of December 31, 2024, we have outstanding warrants to purchase 102,513 shares of our common stock issued to Torreya Partners LLC. The warrants are fully vested, exercisable at a price of $6.80 per share and expire in October 2027. No warrants were exercised as of December 31, 2024. 16 Table of Contents Description of Capital StockOur total authorized share capital is 226,100,000 shares consisting of 226,000,000 shares of common stock, $0.00000002 par value per share, and 100,000 shares of preferred stock, $0.01 par value per share.Common StockThe holders of common stock are entitled to one vote per share. In the event of a liquidation, dissolution or winding up of our affairs, holders of the common stock will be entitled to share ratably in all our assets that are remaining after payment of our liabilities and the liquidation preference of any outstanding shares of preferred stock. All outstanding shares of common stock are fully paid and non-assessable. The rights, preferences and privileges of holders of common stock are subject to any series of preferred stock that we have issued or that we may issue in the future. The holders of common stock have no preemptive rights and are not subject to future calls or assessments by us.Preferred StockOur Board has the authority to issue up to 100,000 shares of preferred stock with a par value of $0.01 per share in one or more series and to fix the rights, preferences, privileges and restrictions in respect of that preferred stock, including dividend rights, dividend rates, conversion rights, voting rights, terms of redemption (including sinking fund provisions), redemption prices and liquidation preferences, and the number of shares constituting such series and the designation of any such series, without future vote or action by the stockholders. Therefore, the Board, without the approval of the stockholders, could authorize the issuance of preferred stock with voting, conversion and other rights that could affect the voting power, dividend and other rights of the holders of shares or that could have the effect of delaying, deferring or preventing a change of control. There were no shares of preferred stock outstanding as of December 31, 2024 and June 30, 2024. 11. Share-based CompensationWe use equity-based compensation programs to provide long-term performance incentives for our employees. These incentives consist primarily of stock options and RSUs. In December 2008, we adopted the MEI Pharma, Inc. 2008 Stock Omnibus Equity Compensation Plan (Omnibus Plan), as amended and restated from time-to-time, under which 1,850,739 shares of common stock are currently authorized for issuance. The Omnibus Plan provides for the grant of options and/or other stock-based or stock-denominated awards to our non-employee directors, officers, and employees. As of December 31, 2024, there were 841,714 shares available for future grant under the Omnibus Plan. In May 2021, we adopted the 2021 Inducement Plan (Inducement Plan), under which 125,000 shares of common stock are authorized for issuance. On June 9, 2023, our Board approved an amendment and restatement of the Inducement Plan to increase the aggregate number of shares of common stock authorized for issuance by 92,000 shares. The Inducement Plan is intended to assist us in attracting and retaining selected individuals to serve as employees who are expected to contribute to our success, by providing an inducement for such individuals to enter into employment with us, and to achieve long-term objectives that will benefit our stockholders. As of December 31, 2024, there were 157,146 shares available for future grant under the Inducement Plan.During the three and six months ended December 31, 2024 due to the Strategic Alternatives RIF, as discussed in Note 5. Employee Termination Benefits, we reversed share-based compensation in excess of that recorded. Total share-based compensation for all stock awards consisted of the following for the periods presented (in thousands): Â Â For the Three Months Ended December 31, Â Â For the Six Months Ended December 31, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Research and development Â $ (53) Â $ 129 Â Â $ (159) Â $ 60 Â General and administrative Â Â (50) Â Â 721 Â Â Â (79) Â Â 1,153 Â Total share-based compensation Â $ (103) Â $ 850 Â Â $ (238) Â $ 1,213 Â Stock OptionsStock options granted to employees vest 25% one year from the date of grant and ratably each month thereafter on the first day of the month following the one-year anniversary of the grant date for a period of 36 months and generally expire ten years from the date of grant. Stock options granted to directors vest ratably each month for a period of 12 months from the date of grant and generally expire ten years from the date of grant. Upon separation from the Company, without cause, our Board members have three years to 17 Table of Contents exercise their vested stock options. As of December 31, 2024, there were 954,723 total options outstanding of which 894,869 were granted under the Omnibus Plan and 59,854 were granted under the Inducement Plan.A summary of our stock option activity and related data follows: Â Â Number ofOptions Â Â Weighted-AverageExercise Price Â Â Weighted-AverageRemaining ContractualTerm (in years) Â Â AggregateIntrinsic Value Â Outstanding at June 30, 2024 Â Â 1,357,213 Â Â $ 31.60 Â Â Â Â Â Â Â Forfeited Â Â (402,490) Â $ 25.14 Â Â Â Â Â Â Â Â Outstanding at December 31, 2024 Â Â 954,723 Â Â $ 34.32 Â Â Â 6.3 Â Â $ â€” Â Vested and expected to vest at December 31, 2024 Â Â 954,723 Â Â $ 34.32 Â Â Â 6.3 Â Â $ â€” Â As of December 31, 2024, the aggregate intrinsic value of outstanding options was calculated as the difference between the exercise price of the underlying options and the closing price of our common stock of $2.46 on that date.Unrecognized compensation expense related to non-vested stock options totaled $0.1 million as of December 31, 2024. Such compensation expense is expected to be recognized over a weighted-average period of 1.43 years.We use the Black-Scholes valuation model to estimate the grant date fair value of stock options. During the six months ended December 31, 2024, we did not grant any stock options. To calculate these fair values, the following weighted-average assumptions were used for the period presented: Â Â For the Six Months Ended December 31, Â Â Â 2023 Â Risk-free interest rate Â Â 4.5 % Expected life (years) Â Â 5.7 Â Volatility Â Â 90.0 % Dividend yield Â Â â€” Â % Weighted-average grant date fair value Â $ 5.18 Â Â 12. Disposition of a Non-financial AssetOn October 22, 2024 (the Closing Date), MEI and Aardvark Therapeutics, Inc. (the Purchaser), entered into an Asset Purchase Agreement (the Asset Purchase Agreement), whereby we sold to the Purchaser our rights, title and interest in and to certain assets related to ME-344, including relevant intellectual property rights, technology and contracts (the ME-344 Sale). Pursuant to the Asset Purchase Agreement, the Purchaser paid us an initial payment of $0.5 million in cash plus a reimbursement amount of $55,000 at the closing of the transaction. The Purchaser may also make future milestone payments up to $62.0 million after the Closing Date, payable upon the achievement of certain regulatory and revenue milestones. The Purchaser also assumed certain of our liabilities after the Closing Date, including liabilities arising under the contracts transferred under the Asset Purchase Agreement.The ME-344 sale did not trigger a discontinued operation as the intellectual property sold did not represent a component of our business. Additionally, we concluded the ME-344 Sale met all the criteria to be derecognized on the Closing Date. Variable consideration, such as future potential regulatory and revenue milestones have been fully constrained. As such, as of the Closing Date and December 31, 2024, we determined the transaction price to be the initial payment of $0.5 million. Accordingly, we recognized a gain, upon satisfaction of our obligations under the Asset Purchase Agreement, of $0.5 million as a separate component of other income (expense), net in the consolidated statements of operations. The $55,000 reimbursement by the Purchaser represented work performed at the Purchaser's request prior to the Closing Date, which they agreed to reimburse. The reimbursement did not represent a liability assumed or relieved by the Purchaser and was, therefore, not included in the calculation of the gain on the disposition of the ME-344 asset. The $55,000 reimbursement was recognized as contra research and development expense in accordance with our reimbursement policy for pass through services. Â 18 Table of Contents Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations This Quarterly Report on Form 10-Q (Quarterly Report) includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act) and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act). All statements other than statements of historical facts contained in this Quarterly Report, including statements regarding the future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. The words â€œmay,â€ â€œwill,â€ â€œintend,â€ â€œplan,â€ â€œbelieve,â€ â€œanticipate,â€ â€œexpect,â€ â€œestimate,â€ "predict," "potential," â€œcontinue,â€ "likely," or â€œopportunity,â€ the negative of these words or similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, without limitation, those described in Risk Factors in our 2024 Annual Report on Form 10-K (2024 Annual Report), as filed with the Securities and Exchange Commission (SEC) on September 19, 2024. Unless the context requires otherwise, references in this Annual Report to â€œMEI Pharma,â€ â€œMEI,â€ â€œwe,â€ â€œusâ€ and â€œourâ€ refer to MEI Pharma, Inc. Overview MEI Pharma, Inc. (Nasdaq: MEIP) is a pharmaceutical company that has been developing novel and differentiated cancer therapies. We built our pipeline by acquiring promising cancer agents and creating value in programs through clinical development, strategic partnerships, and out-licensing or commercialization, as appropriate. Our approach to oncology drug development has been to evaluate our drug candidates in combinations with standard-of-care therapies to overcome known resistance mechanisms and address clear medical needs to provide improved patient benefit. Our drug candidate pipeline includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and prior to its sale (as discussed below), ME-344, an intravenous small molecule mitochondrial inhibitor targeting the oxidative phosphorylation pathway. Strategic Alternatives On July 22, 2024, we announced that our Board of Directors (Board) had determined unanimously to begin the evaluation of our strategic alternatives, including potential transactions as well as an orderly wind down of operations, if appropriate, to maximize the value of our assets for our stockholders. We commenced a reduction-in-force (the Strategic Alternatives RIF) beginning August 1, 2024, which will continue in stages as our operational and strategic direction evolves. We have discontinued the clinical development of voruciclib, while certain nonclinical activities related to MEIâ€™s drug candidate assets will continue to be conducted by us. As part of the review of strategic alternatives, we may consider options such as out-licensing opportunities for existing programs and merger and acquisition opportunities. Consistent with our intention to preserve cash, David M. Urso, our former President and Chief Executive Officer, and Richard Ghalie, M.D., our former Chief Medical Officer, stepped down effective August 1, 2024. Mr. Urso also left the Board at that date. We have entered into consulting agreements with both Mr. Urso and Dr. Ghalie under which they will remain available to assist us in our strategic efforts. Charles V. Baltic III, the former Chairperson of the Board, also stepped down from the Board contemporaneously with the announcement on July 22, 2024. Our Board appointed Justin J. File, our Chief Financial Officer, to assume the position of Acting Chief Executive Officer and appointed Frederick W. Driscoll as our Chairperson of the Board. Sale of ME-344 On October 22, 2024 (the Closing Date), MEI and Aardvark Therapeutics, Inc. (the Purchaser), entered into an Asset Purchase Agreement (the Asset Purchase Agreement), whereby we sold to the Purchaser our rights, title and interest in and to certain assets related to ME-344, including relevant intellectual property rights, technology and contracts (the ME-344 Sale). Pursuant to the Asset Purchase Agreement, the Purchaser paid us an initial payment of $0.5 million in cash plus a reimbursement amount of $55,000 at the closing of the transaction. The Purchaser may also make future milestone payments up to $62.0 million after the Closing Date, payable upon the achievement of certain regulatory and revenue milestones. The Purchaser also assumed certain of our liabilities after the Closing Date, including liabilities arising under the contracts transferred under the Asset Purchase Agreement. Clinical Development Programs Our clinical-stage drug candidate pipeline includes voruciclib, an oral CDK9 inhibitor, and prior to its sale, ME-344, an intravenous small molecule mitochondrial inhibitor targeting the oxidative phosphorylation pathway in the mitochondria. 19 Table of Contents Voruciclib: Potent Orally Administered CDK9 Inhibitor in Phase 1 Studies Following the announcement of the exploration of strategic alternatives on July 22, 2024, all ongoing clinical trial efforts for voruciclib have ceased, while certain nonclinical activities have continued. Voruciclib is a selective orally administered CDK9 inhibitor. Voruciclib recently completed a Phase 1 trial evaluating dose and schedule in patients with acute myeloid leukemia (AML) in combination with the B-cell lymphoma 2 (BCL-2) inhibitor venetoclax (marketed as VenclextaÂ®). Voruciclib is also being evaluated in pre-clinical studies to explore potential activity in various solid tumor cancers including in combination with therapies that target the RAS signaling pathway, such as KRAS inhibitors. Voruciclib Scientific Overview: Cell Cycle Signaling CDK9 has important functions in cell cycle regulation, including the modulation of two therapeutic targets in cancer: â€¢CDK9 is a transcriptional regulator of the myeloid leukemia cell differentiation protein (Mcl-1), a member of the family of anti-apoptotic proteins which, when elevated, may prevent the cell from undergoing cell death and result in poor prognosis in cancer. Inhibition of CDK9 blocks the production of Mcl-1, which is also an established resistance mechanism to the BCL-2 inhibitor venetoclax. â€¢CDK9 is a transcriptional regulator of the MYC proto-oncogene protein (MYC) which regulates cell proliferation and growth. Upregulation of MYC is implicated in many human cancers and is frequently associated with poor prognosis and unfavorable patient survival. CDK9, in addition to being a transcription factor for MYC, also decreases phosphorylation of MYC protein that is implicated in stabilizing MYC in KRAS mutant cancers. Directly inhibiting MCL1 and MYC has historically been difficult, but CDK9 is a promising approach to indirectly target these oncogenes. Voruciclib: Inhibition of MCL1 CDK9 is a known transcriptional regulator of MCL1. Over expression of MCL1 is frequently observed in many tumor types and is closely associated with tumorigenesis, poor prognosis and drug resistance. In AML, MCL1 is upregulated in about half of patients with relapsed and refractory (R/R) disease and is associated with poor prognosis in these patients. Also important, high levels of MCL1 expression are associated with resistance to venetoclax. In pre-clinical studies, voruciclib shows dose-dependent suppression of MCL1; in December 2017, a study of voruciclib published in the journal Nature Scientific Reports reported that the combination of voruciclib plus the BCL-2 inhibitor venetoclax was capable of inhibiting two master regulators of cell survival, MCL-1 and BCL-2, and achieved synergistic antitumor effect in an aggressive subset of DLBCL cells. In a peer reviewed manuscript published in 2020, it was reported that the inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the BCL-2 inhibitor venetoclax in preclinical models of AML. The data demonstrated that voruciclib synergizes with venetoclax to induce programmed cell death, or apoptosis, in both AML cell lines and primary patient samples. It was also demonstrated that voruciclib downregulates MCL1, which is relevant for the synergy between voruciclib and venetoclax, and further that voruciclib downregulates MYC, which also contributes to the synergies with venetoclax. Subsequently, and consistent with the reported pre-clinical studies, data from an ongoing Phase 1 study evaluating voruciclib as a single agent and in combination with venetoclax in patients with relapsed or refractory (R/R) AML have also demonstrated the anticipated decreases in Mcl-1 protein. The research suggests that voruciclib is potentially an attractive therapeutic agent for treating cancers in combination with venetoclax or other BCL-2 inhibitors, to address potential resistance associated with MCL1, and is supportive of our ongoing clinical evaluation of voruciclib in AML. 20 Table of Contents Voruciclib: Inhibition of MYC Many cancers are associated with over expression of MYC, a transcription factor regulating cell proliferation and growth. CDK9 is a known regulator of MYC transcription and a modulator of MYC protein phosphorylation. Data reported at the American Association for Cancer Research (AACR) Annual Meeting 2021 in preclinical models demonstrated that voruciclib: â€¢Results in a rapid decrease in the phosphorylation of proteins that promote MYC transcription; â€¢Rapidly decreases phosphorylation of MYC protein on Ser62, a site implicated in stabilizing MYC in KRAS mutant cancers; â€¢Possesses single agent activity against multiple KRAS mutant cancer cell lines both in vitro and in vivo; and â€¢Synergistically inhibits KRAS G12C mutant cancer cell lines in combination with KRAS G12C inhibitors, both in vitro and in vivo. The research presented suggests that voruciclib could be an attractive therapeutic agent for both hematological cancers, as well as solid tumors, dependent on the activity of MYC. Clinical Programs In a recent Phase 1 clinical trial, we evaluated the dose and schedule of voruciclib in combination with venetoclax, a BCL-2 inhibitor, in patients with R/R AML. The trial started with the evaluation of dose and schedule of voruciclib as a monotherapy in patients with relapsed and refractory B-cell malignancies and AML after failure of prior standard therapies to determine the safety, preliminary efficacy and maximum tolerated dose. The primary objectives of the study were to determine the safety and biologic effective dose of voruciclib monotherapy or voruciclib in combination with venetoclax. Secondary objectives of the study included assessing the preliminary efficacy, pharmacokinetics, pharmacodynamics, and biomarkers of voruciclib monotherapy or voruciclib in combination with venetoclax. As we reported in a poster presented at the American Society of Hematology (ASH) Annual Meeting in December 2023, the voruciclib monotherapy dose escalation/expansion stage of the study enrolled a total of 40 patients and is complete. The majority of patients (n=21) had AML and the remaining patients (n=19) had B-cell malignancies. Of the 40 patients enrolled, the first 16 were dosed daily continuously at 50 and 100 mg and the following 24 patients were dosed on an intermittent schedule (14 consecutive days on therapy in a 28-day cycle) at 100, 150 and 200 mg. All patients were heavily pre-treated with a median of three prior therapies (range 1-9), and five patients had prior hematopoietic stem cell transplant. Voruciclib at doses up to 200 mg administered on 14 consecutive days in a 28-day cycle (Cohort 2) was well tolerated with no dose limiting toxicities (DLT) reported. The most common adverse events (â‰¥20% of patients) were diarrhea, nausea, anemia and fatigue. The large majority of adverse events were Grade 1-2; of note, the only Grade 3-4 adverse events in Cohort 2 were diarrhea (n=1) and anemia (n=5). Pharmacokinetics were dose proportional and a mean half-life of approximately 24 hours supports once daily dosing. On the intermittent dosing schedule selected for further development, no DLTs were observed, there were no Grade 3 or higher drug related toxicities, and dose escalation was stopped at 200 mg before reaching the maximum tolerated dose because

plasma concentrations reached levels considered sufficient for target inhibition. In the 21 patients enrolled with AML, one patient at 100 mg achieved a morphologic leukemia-free state and nine patients had disease stabilization, which lasted at least three months in two patients. In the 19 patients enrolled with B-cell malignancies, four patients had stable disease with a decrease in tumor size. Initial results from correlative studies assessing myeloid leukemia cell differentiation protein (Mcl-1) and RNA Pol II phosphorylation on Ser2 (RNA Pol II p-S2) demonstrated reduction in expression consistent with the anticipated on-target pharmacodynamic effect of voruciclib on Mcl-1 and RNA Pol II p-S2. The next stage of the study evaluated seven voruciclib dose levels from 50 mg every other day to 300 mg daily for 14 consecutive days in a 28-day cycle in combination with standard dose venetoclax in patients with R/R AML. A total of 41 patients with R/R AML, median age 67 years (range 34-89), enrolled in this dose escalation stage of the study evaluating voruciclib in combination with venetoclax. These patients were generally heavily pretreated; the median number of prior therapies was 2 (range 1-7), and 18 (44%) patients had â‰¥3 prior lines. Almost all patients (39/41) were treated with venetoclax in an earlier line of therapy. Additionally, 30 (73%) patients were noted as being in an adverse 2017 ELN Risk Category due to adverse cytogenetics and molecular mutations. Of the 32 patients administered voruciclib at doses â‰¥ 100 mg in combination with venetoclax 10 (31%) achieved disease control. Three patients achieved a response, including two patients that achieved a complete response with incomplete hematologic recovery (CRi) and one patient that achieved a morphologic leukemia-free state (MLFS), in each case having received venetoclax in an earlier line of treatment. Responses lasted 6 months in one patient, 9 months and ongoing in the second patient, and the third patient was referred to stem cell transplant. Further, an additional 7 patients had stable disease which lasted more than 90 days and 13 had stable disease < 3 months. 21 Table of Contents In the 28 patients administered voruciclib in combination with venetoclax and with blood samples available for analysis, initial results from correlative biomarker assay studies demonstrated anticipated decreases of Mcl-1, including a greater decrease in Mcl-1 in responding patients. This supports our hypothesis that voruciclib, as an inhibitor or CDK9, regulates Mcl-1 and therefore may address the upregulation of MCL1 associated with venetoclax. Additional evidence of anti-leukemic activity was also demonstrated including decreases in bone marrow blast counts post voruciclib/venetoclax administration versus pre drug administration in ~50% (11/21) of evaluable patients. Voruciclib at doses up to 300 mg administered on 14 consecutive days in a 28-day cycle in combination with standard dose venetoclax was well tolerated with no dose limiting toxicities observed. The maximum tolerated dose of voruciclib administered on this schedule with venetoclax has not been established. There were no discontinuations due to drug-related adverse events and no evidence of overlapping toxicity has been observed to date. The most common (â‰¥5% of patients) grade 3 adverse events were myelosuppression associated with AML. Only 1 patient was observed as having a non-hematologic grade 3 drug-related adverse event (diarrhea). Before ending the study, three patients were administered 150 mg voruciclib over 21 consecutive days in a 28-day cycle in combination with venetoclax to increase dose intensity and potentially optimize patient response based upon the rebound of peripheral blast counts in 44% (8/18) of the patients between Day 14 and Day 28 when voruciclib was stopped while continuing venetoclax. Voruciclib was also previously evaluated in more than 70 patients with solid tumors in multiple Phase 1 studies. The totality of the clinical data, along with data from pre-clinical studies, suggests voruciclibâ€™s ability to inhibit its molecular target at a projected dose as low as 150 mg daily. In one clinical study, voruciclib was evaluated in combination with vemurafenib (marketed as ZelborafÂ®) in nine patients with BRAF mutated advanced/ inoperable malignant melanoma. All three BRAF/MEK naive patients achieved a response: two partial responses and one complete response. In this study voruciclib was dosed at 150 mg daily plus vemurafenib 720 mg or 960 mg twice daily in 28-day cycles. The most common adverse events were fatigue, constipation, diarrhea, arthralgia and headache. One instance of grade 3 fatigue was dose limiting and no serious adverse events related to voruciclib were reported. Other clinical studies evaluated voruciclib at doses up to 850 mg in patients with solid tumors, demonstrating additional evidence of potential biologic activity and an adverse event profile generally consistent with other drugs in its class. ME-344: Mitochondrial Inhibitor with Combinatorial Potential Nonclinical activities related to ME-344 continued following the announcement of the exploration of strategic alternatives on July 22, 2024 and ended with the closing of its sale, as discussed under Sale of ME-344, elsewhere in this Quarterly Report on Form 10-Q. MEI-344 is a novel drug candidate that inhibits mitochondrial OXPHOS, a fundamental metabolic pathway involved in the production of adenosine triphosphate (ATP) in the mitochondria. ATP provides energy to drive many metabolic cell processes, including division, proliferation, and growth. By disrupting the production of ATP, ME-344 has been shown to induce cancer cell death in nonclinical models and was associated with antitumor activity in clinical studies. ME-344 has also demonstrated clinical activity in multiple clinical studies in combinations, including with bevacizumab (AvastinÂ®). Recently, we were advancing ME-344 via development of a new formulation with the goal of increasing biological activity, improving patient convenience of administration and increasing commercial opportunity. We believe a new formulation represents the optimal approach to pursue the potential of the program after observing encouraging data in two clinical studies evaluating the prior ME-344 formulation in combination with bevacizumab (AvastinÂ®). ME-344 Scientific Overview: Cancer Metabolism Energy supplied in the form of ATP fuels tumor metabolism supporting cell division and growth. Accordingly, tumor cells often display a high metabolic rate to support tumor cell survival and proliferation. This heightened metabolism requires a continual supply of energy in the form of ATP. Anti-angiogenics, such as the vascular endothelial growth factor (VEGF) inhibitor bevacizumab, have the potential to normalize vasculature and decrease reliance on glycolysis for ATP. The resulting reduction in glycolysis may trigger an increased dependence on mitochondrial ATP production for energy to support continued tumor proliferation. In such cases of tumor plasticity, the combination of ME-344 and bevacizumab may induce metabolic synthetic lethality, providing a novel therapeutic strategy. Specifically, leveraging the ability of antiangiogenics like bevacizumab to reduce glycolysis and force tumor cells to switch to mitochondrial respiration via OXPHOS, which is inhibited by ME-344, may reduce access to ATP needed for cell division and growth in tumors. We obtained initial clinical data on this approach in a completed investigator-initiated, multi-center, randomized, controlled, window of opportunity clinical trial evaluating ME-344 in combination with bevacizumab that enrolled a total of 42 patients with human epidermal growth factor receptor 2 (HER2) negative breast cancer. Further clinical support for the combination of ME-344 in combination with bevacizumab was reported in April 2024 from a Phase 1b study of patients with relapsed metastatic colorectal cancer (mCRC) after failure of standard therapies. This study demonstrated clinical activity, including an effect on progression free survival in a cohort of 23 patients. 22 Table of Contents An earlier Phase 1 clinical study evaluating ME-344 as a single-agent in patients with refractory solid tumors also demonstrated anti-tumor activity, further validating the potential of mitochondrial inhibition as a promising therapeutic modality. Clinical Program ME-344 has been evaluated pre-clinically and clinically as a single agent and in combination with anti-angiogenics such as bevacizumab. When evaluated as a single agent, ME-344 demonstrated evidence of activity against refractory solid tumors in a Phase 1b trial, and in pre-clinical studies tumor cells treated with ME-344 resulted in a rapid loss of ATP and cancer cell death. In addition to single agent activity, ME-344 has also demonstrated significant potential in combination with anti-angiogenic therapeutics. Pre-clinical studies have shown that one outcome of anti-angiogenics is a reduced rate of glycolysis in tumors as a mechanism to slow tumor growth. However, when faced with reduced glycolysis and reduced ATP production, tumor metabolism was able to shift to mitochondrial metabolism for energy production to support continued tumor proliferation. In such cases of tumor plasticity in the presence of treatment with anti-angiogenics, contemporaneously targeting the mitochondria as an alternative metabolic source of ATP with ME-344 may open an important development opportunity. Support for this combinatorial use of ME-344 was first published in the June 2016 edition of Cell Reports; pre-clinical data from a collaboration with the Spanish National Cancer Research Centre in Madrid demonstrated mitochondria-specific effects of ME-344 in cancer cells, including substantially enhanced anti-tumor activity when combined with agents that inhibit the activity of VEGF. These data demonstrating the potential anti-cancer effects of combining ME-344 with a VEGF inhibitor due to an inhibition of both mitochondrial and glycolytic metabolism provided a basis for commencement of an investigator-initiated trial of ME-344 in combination with bevacizumab in HER2 negative breast cancer patients. Results published in the November 2019 issue of Clinical Cancer Research from a multi-center, investigator-initiated, randomized, controlled, clinical trial that evaluated the combination of ME-344 and bevacizumab in 42 women with early HER2-negative breast cancer provided evidence for the combinatorial use of ME-344 with anti-angiogenic therapeutics. The primary objective of the trial was to show proof of ME-344 biologic activity as measured by reductions in the nuclear protein Ki67 (expression of which is strongly associated with tumor cell proliferation and growth) from days 0 to 28 compared to the control group who received bevacizumab alone. Secondary objectives included determining whether ME-344 biologic activity correlates with vascular normalization. The data demonstrated significant biologic activity in the ME-344 treatment group: â€¢In ME-344 treated patients, mean absolute Ki67 decreases were 13.3 compared to an increase of 1.1 in the bevacizumab monotherapy group (P=0.01). â€¢In ME-344 treated patients, mean relative Ki67 decreases were 23% compared to an increase of 186% in the bevacizumab monotherapy group (P < 0.01). â€¢The mean relative Ki67 reduction in patients experiencing vascular normalization in the ME-344 treated patients was 33%, compared to an increase of 11.8% in normalized patients from the bevacizumab monotherapy group (P=0.09). Approximately one-third of patients in each arm had vascular normalization. Treatment was generally well tolerated; three grade 3 adverse events of high blood pressure were reported, two in the ME-344 arm and one in the bevacizumab monotherapy arm. Building on the clinical study evaluating patients with breast cancer, a Phase 1b study evaluating ME-344 in combination with bevacizumab in patients with relapsed metastatic colorectal cancer (mCRC) after failure of standard therapies was initiated. The study was designed to evaluate ME-344 plus bevacizumab in up to two cohorts of approximately 20 patients each. The option to enroll the second cohort was conditioned upon Cohort 1 reaching a predetermined non-progression threshold of at least 20% at four months. Patients in the study were treated until disease progression or intolerability. The primary endpoint of the study was 16-week progression free survival (PFS), and secondary endpoints included overall PFS, duration of response, overall survival and safety. ME-344 was administered once weekly on Days 1, 8 and 15 combined with bevacizumab on Days 1 and 15 of each 28-day cycle. Cohort 1 enrolled a total of 23 patients with relapsed mCRC. Patients were generally heavily pretreated; the median number of prior lines of therapy was 4 (range 1-8), 18 (78%) patients had â‰¥3 prior lines, and all patients had previously received bevacizumab and standard chemotherapy. As reported in April 2024, the combination was generally well tolerated with no overlapping toxicities observed. Two patients (9%) discontinued therapy due to an adverse event: fatigue considered related to study drugs and sepsis considered unrelated. The most common (â‰¥10% of patients) drug-related adverse events (all grades/grade â‰¥3) were fatigue in 8 (35%) / 3 (13%) patients and abdominal pain in 3 (13%) / 2 (9%) patients. It was further reported that in the first cohort, 5 of 20 (25%) evaluable patients completed 16 weeks of therapy without evidence of disease progression, exceeding the 20% predetermined threshold as set forth in the Clinical Study Protocol to proceed to Cohort 2. The median PFS was 1.9 months, the 4-month PFS rate was 31.2%, and the median overall survival was 6.7 months with 15 patients 23 Table of Contents censored at the time of analysis. Nine (45%) of the 20 evaluable patients had stable disease. Although Cohort 1 exceeded the predetermined PFS threshold, we decided not to initiate enrollment in a second cohort. Results from an earlier, first-in-human, single-agent Phase 1 clinical trial of ME-344 in patients with refractory solid tumors were published in the April 1, 2015 edition of Cancer. The results indicated that eight of 21 evaluable patients (38%) treated with ME-344 achieved stable disease or better, including five who experienced progression-free survival that was at least twice the duration of their last prior treatment before entry into the trial. In addition, one of these patients, a heavily pre-treated patient with small cell lung cancer, achieved a confirmed partial response and remained on study for two years. ME-344 was generally well tolerated at doses equal to or less than 10 mg/kg delivered on a weekly schedule for extended durations. Treatment-related adverse events included nausea, dizziness and fatigue. Dose-limiting toxicities were observed at both the 15 mg/kg and 20 mg/kg dose levels, consisting primarily of grade 3 peripheral neuropathy. Through October 22, 2024, we were pursuing ME-344 via development of a new formulation to advance our novel approach to inducing synthetic lethality in tumors in combination with VEGF inhibitors such as bevacizumab (AvastinÂ®). We had already initiated research and development activity of the new formulation, with the goal of increasing biological activity, improving patient convenience of administration and increasing commercial opportunity. Also, through October 22, 2024, we were advancing ME-344 in combination with the anti-angiogenic antibody bevacizumab in a Phase 1b study evaluating patients with relapsed colorectal cancer. The study enrolled patients with progressive disease after failure of standard therapies with patients treated until disease progression or intolerance. The primary objective was progression free survival. Secondary endpoints included overall response rate, duration of response, overall survival and safety. Additionally, ME-344 may also have clinical potential against hematological malignancies. At the AACR Annual Meeting 2022, a poster presentation reported results from preclinical studies exploring the ability of ME-344 to enhance the activity of venetoclax against AML. Data from the in vitro and in vivo preclinical studies evaluating the combination of ME-344 with venetoclax in standard-of-care-resistant AML cell lines and relapsed or refractory AML patient samples suggest that ME-344, both alone and in combination with venetoclax, inhibits purine biosynthesis, suppresses oxidative phosphorylation, induces apoptosis and decreases MCL-1, which together target metabolic vulnerabilities of AML cells. The data demonstrated that ME-344 and venetoclax prolong survival in MV4-11 and MV4-11/AraC-R-derived xenograft AML models. The poster concluded that ME-344 enhances venetoclax activity against AML cells including resistant AML. Zandelisib: PI3KÎ´ Inhibitor Overview Zandelisib is an oral, once-daily, selective PI3KÎ´ inhibitor that we were jointly developing with Kyowa Kirin Co., Ltd. (KKC) under a global license, development and commercialization agreement entered into in April 2020. In March 2022, we and KKC jointly decided to discontinue global development of zandelisib for indolent forms of non-Hodgkin lymphoma outside of Japan. The discontinuation of zandelisib development outside of Japan was a business decision based on the most recent regulatory guidance from the FDA and was not related to the zandelisib clinical data generated to date. After making the joint decision to terminate development outside of Japan, we and KKC began closing all ongoing zandelisib clinical studies outside of Japan, including the Phase 3 COASTAL trial, the Phase 2 TIDAL trial, and the Phase 2 CORAL trial. Subsequently, in May 2023, KKC decided to discontinue development of zandelisib in Japan. The discontinuation of zandelisib in Japan was a business decision by KKC based on the most recent regulatory guidance from the Pharmaceuticals and Medical Devices Agency in Japan and was not related to the zandelisib clinical data generated to date. KKC License, Development and Commercialization Agreement In April 2020, we entered into the April 2020, License, Development and Commercialization Agreement with KKC (the KKC Commercialization Agreement) under which we granted to KKC a co-exclusive, sublicensable, payment-bearing license under certain patents and know-how controlled by us to develop and commercialize zandelisib and any pharmaceutical product containing zandelisib for all human indications in the U.S. (the U.S. License), and an exclusive (subject to certain retained rights to perform obligations under the KKC Commercialization Agreement), sublicensable, payment- bearing, license under certain patents and know-how controlled by us to develop and commercialize zandelisib and any pharmaceutical product containing zandelisib for all human indications in countries outside of the U.S. (the Ex-U.S. and the Ex-U.S. License). Also, under the KKC Commercialization Agreement, we were granted a co-exclusive, sublicensable, license under certain patents and know-how controlled by KKC to develop and commercialize zandelisib for all human indications in the U.S., and a co-exclusive, sublicensable, royalty-free, fully paid license under certain patents and know-how controlled by KKC to perform our obligations in the Ex-U.S. and were paid an initial non-refundable payment of $100.0 million. Additionally, in Japan, the KKC Commercialization Agreement included potential regulatory and commercialization milestone payments plus royalties on net sales of zandelisib in Japan, which are tiered beginning in the teens. Prior to the execution of the Termination Agreement as discussed below, KKC was responsible for the development and commercialization of zandelisib in the Ex-U.S. and, subject to certain exceptions, solely responsible for all costs related thereto. We 24 Table of Contents also provided to KKC certain drug supplies necessary for the development and commercialization of zandelisib in the Ex-U.S., with the understanding that KKC would have assumed responsibility for manufacturing for the Ex-U.S. as soon as practicable. On July 14, 2023, we entered into a Termination Agreement with KKC (the Termination Agreement) to mutually terminate the KKC Commercialization Agreement and all other related agreements between the parties. Pursuant to the Termination Agreement: â€¢we regained full, global rights to develop, manufacture and commercialize zandelisib, subject to KKC's limited rights to use zandelisib for compassionate use (as more specifically defined in the Termination Agreement) in certain expanded access programs for the existing patients who have been enrolled in Japanese clinical trial sponsored by KKC until November 30, 2027, and for which KKC is fully liable; â€¢each party released the other party from any and all claims, demands, etc. arising from the KKC Commercialization Agreement, excluding certain surviving claims; and â€¢we are obligated to deliver a discrete quantity of materials to facilitate KKC's compassionate use activities. As of June 30, 2023, we had $64.9 million of aggregate deferred revenue associated with the KKC Commercialization Agreement, of which $64.5 million was allocated to the U.S. License and $0.3 million was allocated to the Development Services performance obligations which were recognized based on the proportional performance of these development activities through wind-down of the associated trials. As further discussed in Note 7. License Agreements, in connection with the execution of the Termination Agreement during the three months ended September 30, 2023, we recognized the $64.5 million of noncash long-term deferred revenue associated with the U.S. License as well as the remaining $0.3 million noncash deferred revenue associated with the completion of the underlying proportional performance activities. As of September 30, 2023, all deferred revenue associated with the KKC Commercialization Agreement had been recognized. Results of Operations Comparison of Three Months Ended December 31, 2024 and 2023 The following table summarizes certain components of our results of operations (in thousands): Â Â For the Three Months Ended December 31, Â Â Â Â Â Â Â 2024 Â Â 2023 Â Â $ Change Â Â

% Change Â Research and development Â $ 308 Â Â $ 3,912 Â Â $ (3,604) Â Â (92.1)% General and administrative Â Â 3,143 Â Â Â 8,018 Â Â Â (4,875) Â Â (60.8)% Other income, net Â Â 774 Â Â Â 867 Â Â Â (93) Â Â (10.7)% Research and Development: The following is a summary of our research and development expenses to supplement the more detailed discussion below (in thousands). Â Â For the Three Months Ended December 31, Â Â Â 2024 Â Â 2023 Â zandelisib Â $ (109) Â $ (58) voruciclib Â Â 81 Â Â Â 523 Â ME-344 Â Â (104) Â Â 1,385 Â Other Â Â 440 Â Â Â 2,062 Â Total research and development expenses Â $ 308 Â Â $ 3,912 Â Research and development costs decreased by $3.6 million to $0.3 million for the three months ended December 31, 2024 compared to $3.9 million for the three months ended December 31, 2023. Research and development costs decreased compared to the same period in 2023 as a result of our announcement in July 2024 to explore strategic alternatives, at which time all clinical studies were ceased resulting in a reduction of close out costs and we initiated reductions in our workforce. General and Administrative: General and administrative expenses decreased by $4.9 million to $3.1 million for the three months ended December 31, 2024 compared to $8.0 million for the three months ended December 31, 2023. General and administrative costs decreased compared to the same period in 2023 primarily as a result of our announcement in July 2024 to explore strategic alternatives, at which time all administrative support activities related to clinical studies were ceased, including reduced payroll and related costs from further reductions in our workforce totaling approximately $1.2 million, and the reduction in legal and professional 25 Table of Contents fees of approximately $2.6 million associated with various stockholder related items from the prior fiscal year with no current period recurrence. Other Income, net: Other income, net, decreased by $0.1 million to $0.8 million for the three months ended December 31, 2024 compared to $0.9 million for the three months ended December 31, 2023. The decrease in other income, net was due to lower average investment balances partially offset by a gain recognized on the sale of our ME-344 asset. Comparison of Six Months Ended December 31, 2024 and 2023 The following table summarizes certain components of our results of operations (in thousands): Â Â For the Six Months Ended December 31, Â Â Â Â Â Â Â 2024 Â Â 2023 Â Â $ Change Â Â % Change Â Revenues Â $ â€” Â Â $ 65,297 Â Â $ (65,297) Â Â (100.0)% Research and development Â Â 3,471 Â Â Â 7,397 Â Â Â (3,926) Â Â (53.1)% General and administrative Â Â 8,332 Â Â Â 14,549 Â Â Â (6,217) Â Â (42.7)% Other income, net Â Â 1,119 Â Â Â 1,960 Â Â Â (841) Â Â (42.9)% Revenue: During the six months ended December 31, 2024, we recognized no revenue due to all deferred revenue associated with the KKC Commercialization Agreement having been recognized in fiscal year 2024, upon entry into the Termination Agreement. During the six months ended December 31, 2023, we recognized revenue of $65.3 million from the KKC Commercialization Agreement. Research and Development: The following is a summary of our research and development expenses to supplement the more detailed discussion below (in thousands). Â Â For the Six Months Ended December 31, Â Â Â Â 2024 Â Â 2023 Â zandelisib Â $ (55) Â $ 391 Â voruciclib Â Â 798 Â Â Â 188 Â ME-344 Â Â 253 Â Â Â 2,605 Â Other Â Â 2,475 Â Â Â Â 4,213 Â Total research and development expenses Â $ 3,471 Â Â $ 7,397 Â Research and development costs decreased by $3.9 million to $3.5 million for the six months ended December 31, 2024 compared to $7.4 million for the six months ended December 31, 2023. Research and development costs primarily decreased compared to the same period in 2023 as a result of our announcement in July 2024 to explore strategic alternatives, at which time all clinical studies were ceased and we initiated reductions in our workforce. These decreases were partially offset by increased costs associated with voruciclib mainly due to greater recognized manufacturing and clinical costs in the Phase 1 study prior to the July 2024 announcement to explore strategic alternatives and increased costs associated with nonclinical studies costs. General and Administrative: General and administrative expenses decreased by $6.2 million to $8.3 million for the six months ended December 31, 2024 compared to $14.5 million for the six months ended December 31, 2023. General and administrative costs decreased compared to the same period in 2023 primarily as a result of our announcement in July 2024 to explore strategic alternatives, at which time all administrative support activities related to clinical studies were ceased, including reduced payroll and related costs from further reductions in our workforce totaling approximately $0.7 million, and the reduction in legal and professional fees of approximately $4.2 million associated with various stockholder related items from the prior fiscal year with no current period recurrence. Other Income, net: Other income, net, decreased by approximately $0.8 million to $1.1 million for the six months ended December 31, 2024 compared to $2.0 million for the six months ended December 31, 2023. The decrease in other income, net was due to lower average investment balances partially offset by a gain recognized on the sale of our ME-344 asset. Liquidity and Capital Resources To date, we have obtained cash and funded our operations primarily through equity financings and license agreements. There can be no assurance that we will be able to continue to raise additional capital in the future. We have accumulated losses of $398.9 million since inception and expect to incur operating losses and generate negative cash flows from operations for the foreseeable 26 Table of Contents future. As of December 31, 2024, we had $23.7 million in cash and cash equivalents. On July 22, 2024, we announced that our Board had determined unanimously to begin the evaluation of our strategic alternatives, including potential transactions as well as an orderly wind down of operations, if appropriate, to maximize the value of our assets for our stockholders. In connection with the exploration of strategic alternatives, we initiated the Strategic Alternatives RIF to reduce headcount on August 1, 2024 and discontinued the clinical development of voruciclib. As a result of this announcement, we expect our research and development expenses to decrease significantly as we discontinued our clinical research and development activities along with decreased general and administrative costs as we reduce headcount and other operational expenses that supported research and development activities. We will continue to incur research and development expenses in connection with clinical trial closing costs and the completion of certain ongoing nonclinical activities. We believe our cash balance is sufficient to fund operations for at least the next 12 months. Sources and Uses of Our Cash Net cash used in operating activities for the six months ended December 31, 2024 of $15.1 million consisted of our net loss of $10.7 million, $4.3 million in changes in our operating assets and $0.1 million for noncash items. Net cash used in operating activities for the six months ended December 31, 2023 of $29.5 million consisted of our net income of $45.3 million and $2.1 million in noncash items offset by changes in our operating assets and liabilities of $77.0 million primarily due to recognition of $64.9 million in deferred revenue. Net cash provided by investing activities for the six months ended December 31, 2024 was $35.2 million as compared to $29.5 million net cash provided by investing activities for the six months ended December 31, 2023. The change in net cash provided by investing activities was primarily due to more net short-term investment activity during the six months ended December 31, 2024 and the proceeds recognized on the disposition of a non-financial asset with no similar transaction in the prior period. During the six months ended December 31, 2024, we had no financing activities. Net cash used in financing activities for the six months ended December 31, 2023 was $11.7 million due to the payment of dividends agreed to under the Cooperation Agreement. Capital Resource Requirements On June 18, 2024, we entered into a lease termination agreement (Agreement) with our landlord for our offices at 11455 El Camino Real, Suite 200 and Suite 250, San Diego, California. Under the Agreement, the lease terminated on September 30, 2024, rather than its scheduled expiration date of November 30, 2029. During the fiscal year ended June 30, 2024, we paid the landlord a termination fee totaling approximately $11.1 million in addition to prepaying the remaining rent under the Agreement in the amount of approximately $0.2 million. We have no further financial obligations under the Agreement. As of December 31, 2024, we have the following potential purchase obligations for which the timing and/or likelihood of occurrence is unknown; however, if such claims arise in the future, they could have a material effect on our financial position, results of operations, and cash flows. â€¢Under our remaining license agreements, we have payment obligations, which are contingent upon future events such as our achievement of specified development, regulatory and commercial milestones and are required to make royalty payments in connection with the sales of products developed under those agreements. For additional details regarding these agreements, see the section titled Note 8. Other License Agreements and Note 6. Commitments and Contingencies to our condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report; â€¢Obligations under contracts which are cancelable without significant penalty; â€¢Purchase orders issued in the ordinary course of business as they represent authorizations to purchase the items rather than binding agreements; and â€¢Contracts in the normal course of business with clinical supply manufacturers and with vendors for preclinical studies, research supplies and other services and products for operating purposes. These contracts are cancelable and generally provide for termination after a notice period. Our future capital requirements will depend on many factors, including: â€¢the Board's decision regarding strategic alternatives; â€¢the scope, progress, results and costs of drug discovery, preclinical development, laboratory testing and clinical trials for our product candidates; â€¢the costs, timing and outcome of regulatory review of our product candidates; â€¢the costs of establishing or contracting for sales, marketing and distribution capabilities if we obtain regulatory approvals to market our product candidates; 27 Table of Contents â€¢the costs of securing and producing drug substance and drug product material for use in preclinical studies, clinical trials and for use as commercial supply; â€¢the costs of securing manufacturing arrangements for development activities and commercial production; â€¢the scope, prioritization and number of our research and development programs; â€¢the extent to which we are obligated to reimburse, or entitled to reimbursement of, clinical trial costs under future collaboration agreements, if any; and â€¢the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims. Estimate Considerations Related to Macroeconomic Conditions and other Geopolitical Conditions Due to recent disruptions in access to bank deposits and lending commitments associated with macroeconomic and geopolitical conditions, there has been uncertainty and disruption in the global economy and financial markets. We are not aware of any specific event or circumstance that would require an update to our estimates or judgments or a revision of the carrying value of our assets or liabilities as of December 31, 2024. While there was no material impact to our condensed consolidated financial statements as of and for the three months ended December 31, 2024, these estimates may change, as new events occur and additional information is obtained, which could materially impact our condensed consolidated financial statements in future reporting periods. Critical Accounting Estimates We describe our significant accounting policies in Note 2. Summary of Significant Accounting Policies, of the notes to the financial statements included in our 2024 Annual Report. We discuss our critical accounting estimates in Item 7. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations, in our 2024 Annual Report. There have been no changes in our significant accounting policies or critical accounting estimates since June 30, 2024. Recent Accounting Pronouncement See Note 2. Summary of Significant Accounting Policies in the Notes to Condensed Consolidated Financial Statements in this Quarterly Report. Item 3. Quantitative and Qualitative Disclosures about Market Risk As a smaller reporting company, the Company is not required to provide the information otherwise required by this Item. Item 4. Controls and Procedures Evaluation of Disclosure Controls and Procedures Disclosure controls and procedures are controls and other procedures of a company that are designed to ensure that information required to be disclosed by the company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SECâ€™s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the companyâ€™s management, including its principal executive and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. As of the end of the period covered by this Quarterly Report, or December 31, 2024, our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on such evaluation, our principal executive officer and principal financial officer have concluded that, as of such date, our disclosure controls and procedures were effective. Changes in Internal Control over Financial Reporting Under the supervision and with the participation of our management, including our principal executive and principal financial officer, we carried out an evaluation of any potential changes in our internal control over financial reporting during the fiscal quarter ended December 31, 2024. There were no changes in our internal control over financial reporting (as defined in Rule 13aâ€‘15(f) of the Exchange Act) that occurred during the fiscal quarter ended December 31, 2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. 28 Table of Contents Inherent Limitations of Internal Controls Our management does not expect that our disclosure controls and procedures or our internal controls over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Due to the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. 29 Table of Contents PART II OTHER INFORMATION Item 1. Legal Proceedings None. Item 1A. Risk Factors There have been no material changes in our risk factors from those included in our 2024 Annual Report. Item 2. Unregistered Sales of Equity Securities and Use of Proceeds None. Item 3. Defaults upon Senior Securities None. Item 4. Mine Safety Disclosures Not applicable. Item 5. Other Information None of our executive officers or directors have adopted, modified or terminated any contract, instruction, or written plan for the purchase or sale of the Company's securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1 (c) or any "non-Rule 10b5-1 trading arrangement" (as defined in Item 408(c) of Regulation S-K) during the six months ended December 31, 2024. 30 Table of Contents Item 6. Exhibits Exhibit Index Â Â Incorporated by Reference Herein ExhibitNumber Description Schedule/Form File No. Exhibit Filing Date 2.1 Â Asset Purchase Agreement, by and between MEI Pharma, Inc. and Aardvark Therapeutics, Inc., dated as of October 22, 2024. Â 8-K Â 001-41827 Â 2.1 Â October 25, 2024 3.1 Â Amended and Restated Certificate of Incorporation of MEI Pharma, Inc. Â 10-Q Â 001-41827 Â 3.2 Â February 13, 2024 3.2 Â Sixth Amended and Restated Bylaws of MEI Pharma, Inc. adopted as of December 18, 2023 Â 8-K Â 001-41827 Â 3.1 Â December 22, 2023 3.3 Â Certificate of Designation of Series A Convertible Preferred Stock of Marshall Edwards, Inc. Â 8-K Â 000-50484 Â 3.1 Â May 11, 2011 3.4 Â Certificate of Designation of Series B Preferred Stock of Marshall Edwards, Inc. Â 8-K Â 000-50484 Â 10.1 Â March 18, 2011 3.5 Â Certification of Designation of Series A Junior Participating Preferred Stock Â 8-K Â 000-50484 Â 3.1 Â October 3, 2023 4.1 Â Specimen Stock Certificate Â S-1 Â 333-109129 Â 4.1 Â October 31, 2023 4.2 Â Form of Warrant Â 8-K Â 000-50484 Â 10.1 Â May 16, 2018 31.1* Â Certification of Principal Executive and Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Â Â Â Â Â Â Â Â Â Â 32.1** Â Certification of Principal Executive Officer and Principal Financial Officer required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C 1350). Â Â Â Â Â Â Â Â Â Â 101INS Â Inline XBRL Instance Document â€” the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document. Â Â Â Â Â Â Â Â Â Â 104 Â Cover Page Interactive Data File â€“ the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the XBRL document. Â Â Â Â Â Â Â Â Â * Â Filed herewith Â Â Â Â Â Â Â Â Â ** Â Furnished herewith Â Â Â Â Â Â Â Â Â Â Â 31 Table of Contents SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Quarterly Report to be signed on its behalf by the undersigned, thereunto duly authorized. Â Â MEI Pharma, Inc. Â Â Â /s/ Justin J. File Â Justin J. FileActing Chief Executive Officer, Chief Financial Officer and SecretaryÂ Â Â Â Date: February 12, 2025 Â 32 EX-31.1 2 meip-ex31_1.htm EX-31.1 EX-31.1 Â Exhibit 31.1 CERTIFICATION I, Justin J. File, certify that: 1.I have reviewed this Quarterly Report on Form 10-Q of MEI Pharma, Inc.; 2.Based on my knowledge, this Quarterly Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Quarterly Report; 3.Based on my knowledge, the financial statements, and other financial information included in this Quarterly Report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this Quarterly Report; 4.The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: (a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this Quarterly Report is being prepared; (b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c)evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in the Quarterly Report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this Quarterly Report based on such evaluation; and (d)disclosed in this Quarterly

Report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting, and 5.The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors: (a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and (b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Date: February 12, 2025 /s/ Justin J. File Justin J. FileActing Chief Executive Officer, Chief Financial Officer and Secretary(Principal Executive Officer and Principal Financial Officer) Â EX-32.1 3 meip-ex32_1.htm EX-32.1 EX-32.1 Â Exhibit 32.1 CERTIFICATION The undersigned hereby certifies, for the purposes of Section 1350 of Chapter 63 of Title 18 of the U.S. Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, in his capacity as Acting Chief Executive Officer and Chief Financial Officer of MEI Pharma, Inc. (â€œMEI Pharmaâ€) that, to his knowledge, this Quarterly Report on Form 10-Q of MEI Pharma, for the quarter ended December 31, 2024, fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of MEI Pharma. Dated: February 12, 2025 Â /s/ Justin J. File Â Justin J. File Â Acting Chief Executive Officer, Chief Financial Officer and Secretary(Principal Executive Officer and Principal Financial Officer) Â These certifications accompanying the report to which they relate, are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of MEI Pharma under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent MEI Pharma specifically incorporates it by reference. A signed original of this written statement required by Section 906 has been provided to MEI Pharma and will be retained by MEI Pharma and furnished to the Securities and Exchange Commission or its staff upon request. Â GRAPHIC 4 img105009805_0.jpg GRAPHIC begin 644 img105009805_0.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# ," @," @,# P,$ P,$!0@%!00$ M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_ MVP!#0,$! 4$!0D%!0D4#0L-%!04%!04%!04

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

*A_]JH_X:N_ZE;_RH?\ VJOG^BN#_6K./^?_ /Y+'_Y$+L^@/^&K MO^I6_P#*A_\ :J/^&KO^I6_\J'_VJOG^BC_6K./^?_\ Y+'_ .1"[/H#_AJ[M_J5O_*A_]JH_X:N_ZE;_ ,J'_P!JKY_HH_UJSC_G_P#^2Q_^1"[/H#_AJ[_J M5O\ RH?_ &JC_AJ[_J5O_*A_]JKY_HH_UJSC_G__
.2Q_P#D0NSZ _X:N_ZE M;_RH?_:J/^&KO^I6_P#*A_\ :J^?Z*/]:LX_Y_\ _DL?_D0NSZ _X:N_ZE;_ M ,J'_P!JH_X:N_ZE;_RH?_:J^?Z*/]:LX_Y__P#DL?_\ Y$+L^@/^&KO^I6_\ MJ'_VJC_AJ[_J5O\ RH?_ &JOG^BC_6K./^?_ /Y+'_Y$+L^@/^&KO^I6_P#* MA_\
:J/^&KO^I6_\J'_VJOG^BC_6K./^?_\ Y+'_ .1"[/H#_AJ[_J5O_*A_ M]JH_X:N_ZE;_ ,J'_P!JKY_HH_UJSC_G_P#^2Q_^1"[/H#_AJ[_J5O\ RH?_ M &JO8/ /BS_A./"=CK?V7[%]J\S]QYGF;=LC)][SG;GIWKX?K[^ G_ "2? M0O\ MO\
^CY*^QX6SK'YEC9TL54YHJ+>T5K>*Z)=RDST"BBBOU$H**** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH *^;O@S_R>E^T5_UZ^'/_ $C>OI&OF[X,_P#)Z7[17_7KX<_] M(WH ^D:*** /(?B%_P
G$_"7_KAJW_I.M>O5Y#\0O^3B?A+_ -<-6_\ 2=:] M>H&%>:>.?C-_P@?Q"T/P[>:0'LM4\O;J?VK:(]SE#E-G8X/WNAKTNO$?VL/" MS:O\/[?68 WVG1[@2;E/(B?"M[_>\L\>AKR,UJ5Z&$G6P[M*.OJENON)9Z/\ M2/'$'PY\'WVNSP_:OL^U8[?S-AE=F"A0<''7/0\
T_X=^++CQQX/T_7+C3AI M9O%,B6WG&4A-Q"DMM7J!GIT(KYX^*?C2?XMZ)\-?#EG)_I6L".YN^1@2;C#D MX[!A,?P%7?$>DS_%7XS/\/UU*XTKPMH5HJ+;0,%+JB(#QT+98 9!PHSCK7BR MSF;Q+E17-
#W8Q6BO.2YKWZ66XKGT]17S/X9L[WX%_'33/"5GJ=SJ/A_6(5=; M>X;)CW%U4D 8W!H^H R#^7,^%/AI;?%'XU>/],U"_NK/38;^ZN)8[-@K2L+A ME3[P(P-Q/0_KFMWG53W:<:/[QR<"FV:5][:H=SZ^HKYPL=+@T3]]J_2=/M@W MV>UTQ8(]YRVU;5@,GN>.M6KA@?
VQ+8 Y(LB#_P" S5T+-W;6GK[7V>_X[?A^ M(7/H6L?Q=K5UX=\-W^I66F3:S:S;X[&WSOF.0,#"L>^>AZ5\V^&?",W[27C M;Q9>Z_K%Y;6&FS>3:6MNP_=ABX3@@@ !.<#+$GFNJU3P'X@^'OP#\8:9K6M1 MZO!Y8:T5 Q\A=XR-SE.M3HM4[3M*Z^S?=6TNUIOZ!
<]F M\&Z]=^)O#-CJ=_I4VAW=PK&33[C/F0X8@ Y53R #T'6MJOE'7/&>I>&?V:?! M=AI=P]G-JLDDT,EQ&VUA&)')4'J,DCD@=@?6NKL_V8]3\)ZQHVJ^%O%4MK?PMN MOI;L$K(>^U5 RIY!5CWZU-'-J]10A2HNHU&#D[I-SVQ]ZK.C_$+5M0\1>);"*7FFV.DI(\&HSL
MXBO=K$#9F, 9'/!:O-+C_D\2U_Z\3_Z3-5#X:?\ )8_BY_URNO\ T::YHYCB M/:\DI?\ +V<>FRC=+;_@^8'J/P;^+/\ PMO2+^^_LK^ROLLXA\O[1YV[*@YS ML7'6O0J^.?@5\%8/BIX5U6:_UJ\LK6"Y,4%K:LNWS=BDR.ISD8(';.#SQ7IW M[*?B34[_
$KQ%H>H74EY'H]Q&D$DA+$*V\%03V!CR!VS5Y3FV(K1H4\5#6HG M:5UJUJ]$E;0$SWBBBBOKR@HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@#R/X+_"/6/ASX_^*^N:EN?TO]G?4?"OQJ\7ZEHLVG_\ "L?'5A(OB/0)I9$ECOF5E-Q;*$*XD4X<
M%EY8GG"@>^44 ?+>F_!+XZ^'OA_:_"_1_&WAVQ\'VH6QMO%D7VF/7[?3U;Y8 MTC4>5YJIA!('' Z \UT?BK]FW5?%'CKXA7AUM;31O$O@B'PK!=":22^CF4R[MI9,J RD.,G?EOFSC.:^@:* /CKQ1^S\;\:O&/P-M/AK-?_#[P]I.F+:>4NBK= M+_:C6\D;()R8@(?
+#ML60EU7H,U9TVU^)'_ V#\;KWX?W'AUI(;'0(K[3? M$9G2";?;2F.1)859E:,HXP5(82'H0#7UY6?9^'M*T_5]1U6UTRSMM4U$1+>W MT,")/=",$1B5P-SA S!=Q. 3CK0!_Z;^S?XZ\,^ 9+G0_'D=O\ $R[\2MXK MU2_\N6/3=2F8;6LI8U;=]F"!5'4C8#@9P*VC?LNZOXXX\
<>)_%'Q(@\,:2^L> M')_#+:7X+24)+%,P:2XGGD1&>48 7Y,+@')(KZ9HH ^9+/X0_'N3PCHOP^N? M&_AW3?"VGM!;R>*M&:ZAUVXLX67;&$QY<#DYZ#7/A+\1? _Q2 M\3^+_A;J'AN6V\50V_\ :FD>*CGO=% ' MRU\)??V7_
!OX7F\/Q>+==TC6;:S\;ZIXRU">S:5'O)I8=EJ?+:/ (D>21EW8 M4JF"_4>IZ/\ "W5=/_:0\1_$"2XLVT;4O#UII,,"N_VA98II'9F7;M"D.,$, M3G/ KU*B@#YX?X1_%/X7^+O&MW\+-2*W.@>++^369K*#Q2;E'TZ_E $TL+0J MPD1R Y1@O/ (Y)FU3]GOQ5>>"?
A)I5UXL/B;6?"_B^U\2:QJ^M32;[I46X\Q M(1A\8,RJB$A0J]0>OT#10!YA\._A?JOA+XT?%GQ=>7%G)IOBV?2Y;&*!W,T8 MMK-8)/-!4 $L,C:6XZX/%>.>$_V;_BSX%%\(>*/ &AZSX-M/#>LW-Z[>*I(+A M]<:&X=F821[1&TH#E1(7.!CY3BOK*B@#Y?
T7]FKQQX)\._"C6_#.IZ!#\0O! MFAMX?O;>^:9],U.T;:2AE5!(A#*'5@AY)!!%6O&7[/GQ)^*OPG^)^F>+_%NG M?\))XNAMX;'3;"2X;1M)2!@RK'O^\2>$-!\96M MO:^(-$T[;:WG6ZAAU*TCN$BF4$+(JN" X#-AAR,GUK7H \'_:STN;2]\$_ M$.W1I%\!^(;?5E]]8\EO[.8-
#=E0.I6.3S/I&U6WN(DG@ ME4I)%(H974C!4@\$$=JCT_3[72-/MK&QMH;*QM8E@@MK>,1QQ1J JHB@850 M . !0!X'XQ^'WQE^+WP3^(?@_QG_P (+8:GJ]E';:1+H-S>M"&+$RFX,L60 M.(]NQ6_BSVJ3P]#^TSIJZ99W5I\)SI]OY44KPWFIF7REP&*YB W8!QGC-?0%
M% ''_$3X7Z5\3)O"DFJ7%Y WAO7;?Q!:?9'10]Q"DB*LFY6RA$K9 P>!R.^? M\?/&R?#[X/>*M8V-/>"R>VL;:;9>XNYOW5O$H[EI71?QKT"J>HZ/I^L-:&_L M;:]-I.MU;FXA63R9E!"R)D?*X!..&R: .-^ ?PZD^$OP7&^$V5[K2=-B@@ MN6CQM,Q&Z4CVWLU=]110 4444
%%%% !1110 4444 %%%% !1110 4444 >3 M:I\=+32?&WBL7L]O8^"?"<=K9ZKJ;6LT\K:CUUKXC>&_#OB.+0M3U6&RU*33KC5S',K".*S@*":>63&R)%+J,NRYSQG!QX MU\/?]IXH/[1/PYUR,J=7U^XNI2Z [K2^L8%AE7GG!CD4'/!AX((X\G\/_"O MXH?&#X+_
!2OO$FCW6G>.9=%LO".EV>H'R6NX[%5DN9$,@";;N=I KM\I 7. M%R2 ?4G@_P".7@WQU-/#I6HW:S16 U01:CI=W8//9DX^T0+<1(9X@< O'N4; MTR1O7-#P=^TA\/?'VH:)::'K<]T=UT6&P>XM_+%LL2:=" M]V[$#(BX'X\!QXL/AW^V)?+J TAKH:?)H_)1Y'
MDED144[WPJ [F4!UW*P-> Z9\-?$]C\-;GX8:K/\1KW76UN5&T?3=,LK?1;E M&OC$_C-X1\:37L%AJ-Q: M75G:K?SVNLZ?WEECC2YC&4),+M\K!@<'->9?%WPSKO[26N MZA<>$=-'U;1+2U\"ZUI#7^O:7:<6]W>7PB$5GLN$1V51 6:0*8U\T8+-'('6ZK
MX^D\8?!O5/"5AX%\70ZR?"M[!/#'M-\(>$[SQ'/<_P!NZMH%OKES8:%I%[J+6\3QJ6E>.WCE:&+> M656DP&V, 6*-CI=/^,G@S5-8TK3;;7K>2?5M);7+*"78ZV]U9J0'DCG*^6Q7(M+(&WJI#%0#FOF+3]$UZQ:+3O$$&E^.-6&L7Z'Z#%@6K1Y(9=:N(K:17M[^_A
MA\^!XY6"!9)[>-5.6.&MZWIU MU;16*JL\'V%7'EEFNF?RW57.("[X;*9 /IVX^.UI<2> ?$.DR1ZC\/\ Q3> MV0+^2SGMYXKJ0D6LP\P+N@D=#$/DY:6)E8J>?6:^9?BMKDGDQ(^!?P\TE/#MY MX0US6?$VC6*:'>6C0/82V]RD\X12HW11Q6TI5T&THH(X-?35 !1110 4444
M%%%% !1110 4444 %%%% !7P[\=/^3H/%O\ V!=,_G/7W%7P[\=/^3H/%O\ MV!=,_G/7SW$'_(JK_P"$3V,&BBBOYS,PHHHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "NR^#_ /R433/]RX_]$25QM36=]<:=<+<6D\MM.N=LL+E& M&00<$<\@D?
C77@ZRPV)IUVKJ,D_N=P.O^#EQ;6_Q TYKDJ"PD2$LVT>84(7G MWS@>Y%=;I8&G6_B65/!]QI2K92QWEQJ.IR%'#<8&8SO8GD8_/FO'02.1P:T+ M[Q'JVJ6XM[S5+R[@4Y$4]P[J/P)Q7K8+-(X6@J3CJG)K2+^)):W3:VZ;K09T MWQ*N)&M/!\)8F)-
#@=5]"2P)_P#'1^5=G)V2?S M->.7-]<7GD_:)Y9_)C$4?F.6V(.BKGH!:D\#UJ;^VM1_M+^T?M]U_:&<_:_.; MSG'7I50S6,:WM7%_'3E\H)JWSOH%SL_!;-?>"?'[SDRN\,$C,W)+> M8QS]<\UV5U#VD1AU#! 0?SKQ6WU"ZM+>>""YFAAN %FCCD M*K(!T# =?QJ9ME:8?-
XT:-.FXN\;: M_P#;TW_[<%SJO">ZX^'/C" R!$\ZPQYC81296!;VZ#)]J[NQ\-P:5\0K&U&C MZOK5]#+$\NN7UTZQJ =RX&& ' !;G %>)Q7UQ#;3V\<\L=O/M\V)7(23:* ZM?&"(J8XC6Y\)_$)(8GE8:R&VQJ2<"1B3QV K?\ $RVU]XDT
M6>T*7>KI)!;FQU"UO7CB50!@8"$)M.<\^]>-P>(-4M9KJ6'4KN*6ZS]H>.= ME:;.<[R#\W4]?6G6?B35M-M3;6FJ7MK;GK##<.B<^P.*WCG-)1Y7!].D7M*4 ME;F36O-KU32L%SU#Q3]J\0:#XP@TZ&(WR:O%+>6MBYFW1",+P=H+?O!D\#&# M^.+XRL;
[3_A3X4AU".6&87$Y6.8$,J$Y48/3CM7 6&I7>EW GLKJ:SGQCS+> M0HV/3(-2W^N:CJJ*E[J%U>(K%PMQ,S@,>IY/6N>MFM.O"I*47SSCR[JWQ\U] MOEVZ^07*5%%%?-""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^ MP/@)_P DGT+_ +;_
/H^2OC^OL#X"?\ ))]"_P"V_P#Z/DK]!X)_Y&-3_ __ M $J)4=ST"BBBOVPL**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH *^;O@S_R>E^T5_UZ^'/_ $C> MOI&OF[X,_P#)Z7[17_7KX<_](WH ^D:*** /(?B%_P
G$_"7_KAJW_I.M>O5 MY#\0O^3B?A+_ -<-6_\ 2=:]>H&%9WB+1+?Q)H.H:5=#-O>P/ _&WB4O)+*P5$4=22> *F45.+C):,1X'\%?V<]6^'_C M1=;UV\T^\CMH'2T2TD=RLC<;B&08&TOT/5JZ#XE_!35]:\9Q>,/!^MIHGB#8 M$E_/ER87:#D!OX0 05((_'MO#/Q8\$>-
M2ET_P[XR\/Z]?P@F2UTS5(+F5 M,=L:=XV?QAXTUJ+7-= M52L"P ^7&2,;N57H"0 % & M8R#>"@ X/8GFO6*S]6\0Z5X?:Q75-3L]-:_NDLK07ZURGB3XL^!_!NJQ:7K_C+P_H>I2X\NSU+5(+>9\XQA'<$] M1V[UG+)\+*O[?6_-S6N[VP6/,]<^!?
BW0/&&J:W\/O$=MI$>J,7N+:\!P MK$DD#Y'!&22,@$9ZU;T;X#ZOI7PQ\3:+-K@U'7-; +23RR"VB8-GC@G)Y);; MD\#'%>J>(/&&@^$M#;6M/_"^M:C*<1VFGZS;3RO\ 1$M]+NRYM[+97" MQR=Q\!6UOX+Z3X0U.[AAU73BTL-Y;9>-9"[G'(!*E7P>!SSVYYR'X%_$3Q%?
M:3!XJ\:0RZ/IKAHOL+OY^![[$^8CC<2Q&>]>ZWWB'2M-U33=,O-3L[34M2,B MV-G/.B371C7?((D)RY5?F.T' Y/%5O$?C+P_X.6R;7]=TW0UO9UM;4ZE=QVX MGF/2--Y&YSV49-$\FPE3ENGHDM&U=1VO;>P6.$?X5:K_ ,+XM_&JW%G_ &3'
M;>086D3_>JOX0^$>L>'_'WCG7+BYL7M-=29;9(I',B;W+#>"@ M X]":[?Q%\3/!_@_5+73->\5Z'HFI78!M[/4=1AMYILG V([MSQP*Z6MEEF M'4N>SOS.>_5JS_ +'S/X4_9]^)?@?3;I="\6Z=IUQ>,4N(8V<#)Y/))/TKK MK7Q-H]_KE]HMMJUC<:S8)')=Z=%XD.
(X4W$;G8\!1R>P MKVQFA16=IWB+2M8OM1LK#4[.]O--D6&]M[>X222U=E#*DJ@Y1BI! ;!PA:F;5'!.I45Y;X@^ %CXAT_1;23QAXRLQI=M]E26RUEH MI+@9SOF;;\[\XSZ4>(/@!8^(=/T6TD\8>,K,:7;?94ELM9:*2X&<[YFV_._. M,^E 'J5%>6^(/@!8^(=/T6TD\8>,K,:7;?
94ELM9:*2X&<[YFV_._.,^E'B# MX 6/B'3]%M)/&'C*S&EVWV5);+66BDN!G.^9MOSOSC/I0!ZE17EOB#X 6/B' M3]%M)/&'C*S&EVWV5);+66BDN!G.^9MOSOSC/I1X@^ %CXAT_1;23QAXRLQI M=M]E26RUEHI+@9SOF;;\[\XSZ4 >I45Y;X@^
%CXAT_1;23QAXRLQI=M]E26 MRUEHI+@9SOF;;\[\XSZ4>(/@!8^(=/T6TD\8>,K,:7;?94ELM9:*2X&<[YFV M_._.,^E 'J5%>6^(/@!8^(=/T6TD\8>,K,:7;?94ELM9:*2X&<[YFV_._.,^ ME'B#X 6/B'3]%M)/&'C*S&EVWV5);+66BDN!G.^9MOSOSC/I0!ZE17EOB#X
M6/B'3]%M)/&'C*S&EVWV5);+66BDN!G.^9MOSOSC/I1X@^ %CXAT_1;23QAX MRLQI=M]E26RUEHI+@9SOF;;\[\XSZ4 >I45Y;X@^ %CXAT_1;23QAXRLQI=M M]E26RUEHI+@9SOF;;\[\XSZ4>(/@!8^(=/T6TD\8>,K,:7;?94ELM9:*2X&< M[YFV_._.,^E
'J5%>6^(/@!8^(=/T6TD\8>,K,:7;?94ELM9:*2X&<[YFV_. M_.,^E'B#X 6/B'3]%M)/&'C*S&EVWV5);+66BDN!G.^9MOSOSC/I0!ZE17EO MB#X 6/B'3]%M)/&'C*S&EVWV5);+66BDN!G.^9MOSOSC/I1X@^ %CXAT_1;2 M3QAXRLQI=M]E26RUEHI+@9SOF;;\[\XSZ4
>I45Y;X@^ %CXAT_1;23QAXRL MQI=M]E26RUEHI+@9SOF;;\[\XSZ4>(/@!8^(=/T6TD\8>,K,:7;?94ELM9:* M2X&<[YFV_._.,^E 'J5%>6^(/@!8^(=/T6TD\8>,K,:7;?94ELM9:*2X&<[Y MFV_._.,^E'B#X 6/B'3]%M)/&'C*S&EVWV5);+66BDN!G.^9MOSOSC/I0!ZE
M17EOB#X 6/B'3]%M)/&'C*S&EVWV5);+66BDN!G.^9MOSOSC/I1X@^ %CXAT M_1;23QAXRLQI=M]E26RUEHI+@9SOF;;\[\XSZ4 >I45Y;X@^ %CXAT_1;23Q MAXRLQI=M]E26RUEHI+@9SOF;;\[\XSZ4>(/@!8^(=/T6TD\8>,K,:7;?94EL MM9:*2X&<[YFV_._.,^E
'J5%>6^(/@!8^(=/T6TD\8>,K,:7;?94ELM9:*2X M&<[YFV_._.,^E'B#X 6/B'3]%M)/&'C*S&EVWV5);+66BDN!G.^9MOSOSC/I M0!ZE17EOB#X 6/B'3]%M)/&'C*S&EVWV5);+66BDN!G.^9MOSOSC/I1X@^ % MCXAT_1;23QAXRLQI=M]E26RUEHI+@9SOF;;\[\XSZ4
>I45Y;X@^ %CXAT_1 M;23QAXRLQI=M]E26RUEHI+@9SOF;;\[\XSZ4>(/@!8^(=/T6TD\8>,K,:7;? M94ELM9:*2X&<[YFV_._.,^E 'J5%>6^(/@!8^(=/T6TD\8>,K,:7;?94ELM9 M:*2X&<[YFV_._.,^E'B#X 6/B'3]%M)/&'C*S&EVWV5);+66BDN!G.^9MOSO
MSC/I0!ZE17EOB#X 6/B'3]%M)/&'C*S&EVWV5);+66BDN!G.^9MOSOSC/I1X M@^ %CXAT_1;23QAXRLQI=M]E26RUEHI+@9SOF;;\[\XSZ4 >I45Y;X@^ %CX MAT_1;23QAXRLQI=M]E26RUEHI+@9SOF;;\[\XSZ4>(/@!8^(=/T6TD\8>,K, M:7;?94ELM9:*2X&
<[YFV_._.,^E 'J5%>6^(/@!8^(=/T6TD\8>,K,:7;?94 MELM9:*2X&<[YFV_._.,^E'B#X 6/B'3]%M)/&'C*S&EVWV5);+66BDN!G.^9 MMOSOSC/I0!ZE17EOB#X 6/B'3]%M)/&'C*S&EVWV5);+66BDN!G.^9MOSOSC M/I1X@^
%CXAT_1;23QAXRLQI=M]E26RUEHI+@9SOF;;\[\XSZ4 =RWA#27\7 M1^*/LI77$LCIWVI)77?;E]X1T#;7PV2I8$KN?:1N;.S7EOB#X 6/B'3]%M)/ M&'C*S&EVWV5);+66BDN!G.^9MOSOSC/I7DWQB\7?!KP=J6D^%?$_Q?\ %6DZ MOHUH()(-
(O[F>XVD[@]T8(7P^".7V\$4 ?5=%?-_B2'X9Z]\(M'\;GXK>*$\ M&:3#'8C6M'U:5S,SSK$OG".-G:3S)%4Y4$9YP 37?>(/@!8^(=/T6TD\8>,K M,:7;?94ELM9:*2X&<[YFV_._.,^E 'J5%>6^(/@!8^(=/T6TD\8>,K,:7;?9 M4ELM9:*2X&<[YFV_._.,^E'B#X
6/B'3]%M)/&'C*S&EVWV5);+66BDN!G.^ M9MOSOSC/I0!ZE17ANB_#_P)_&KPEH][H'C_ ,92Z9I0FTM;RRU.:UDGDBE9 M)#-OC#.X<,N[&"!QD>$=)O\ MQ1IWB*YM3/J^GV\UM:322N4@24J9"L>=@<[%&_;NVY7.&(.Q7EOB#X 6/B'3
M]%M)/&'C*S&EVWV5);+66BDN!G.^9MOSOSC/I1X@^ %CXAT_1;23QAXRLQI= MM]E26RUEHI+@9SOF;;\[\XSZ4 >I45Y;X@^ %CXAT_1;23QAXRLQI=M]E26R MUEHI+@9SOF;;\[\XSZ4>(/@!8^(=/T6TD\8>,K,:7;?94ELM9:*2X&<[YFV_ M._.,^E 'J5%>6^*^(_A?
X8U[7] \%3?$#Q99Z_8Z.]S%:66LM'<7%HDJHT\Q"_ M,=\BJ&."><9P<:OB;X#Z;K&DZ3#=>-/%G0:/:&#[3:ZT86E0$L9)VV_,P_O M" H]5HKYBT#4_A/\,/&5F-+MOLJ2V6LM%)<#.=\S;?G?G&?2@#U*BO+?$'P L?$.GZ+:2> M,/&5F-+MOLJ2V6LM%)<#.=\S;?G?G&?
2CQ!\ +'Q#I^BVDGC#QE9C2[;[*DM MEK+127 SG?,VWYWYQGTH]2HKRWQ!\ +'Q#I^BVDGC#QE9C2[;[*DMEK+127 M SG?,VWYWYQGTH\0? "Q\0Z?HMI)XP\968TNV^RI+9:RT4EP,YWS-M^=^<9] M* /4J^<='T;3]<_;7\=0:E8VVH0+X5T]UCNH5E4-YK#(#
C.">? M)?$UG#I?A2P9-0L]3,5Y/^\88FEV_..?3K4RC&:Y9*Z ^H?^%>^%?^A9T?\ M\ (O_B:/^%>^%?\ H6=' 7_ XFN-\0? "Q\0Z?HMI)XP\968TNV^RI+9: MRT4EP,YWS-M^=^<9]*/$'P L?$.GZ+:2>,/&5F-+MOLJ2V6LM%)<#.=\S;?G M?G&?2N;ZIA_^?(/@!8^(=
94ELM9:*2X&<[YFV_._.,^E'B# MX 6/B'3]%M)/&'C*S&EVWV5);+66BDN!G.^9MOSOSC/I1]4P_P#S[C]R [+_ M (5[X5_Z%G1__ "+_P")H_X5[X5_Z%G1_P#P B_^)KC?$'P L?$.GZ+:2>,/ M&5F-+MOLJ2V6LM%)<#.=\S;?G?G&?2CQ!\ +'Q#I^BVDGC#QE9C2[;[*DMEK

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

X8OTUMS%I;H$FD4-EGSRPVT%HJ>-(U=XT5 L:3#:" M1T5=QQV&37JVF^&='T6X:?3]]L;"9EV&2VMDC8KD'&5 XR!Q[4Y_#NE2->%M M,LV-YC[26MT/GXZ;^/F_&@#R_P_;7[V_B3QJ]M,R/%IUC',T+8:-#,/,Y'0^ M6Q/T.:=KFDZ-
H_CA(M'AM[9'\/W;O%:X"8*@*^!QD@=>^!7I]CX?TO3%9;/3 M;.T5D\MA! B KDG:<#IDDX]S45GX5T33_9='L+;*LI\FU1,A@ PX'0@#/K@ M4 >5^'K6;7+O3;.[TW3]5@M_#MD]M:ZID:A:V M]M=:597-O;KMAAFMT=(A@#"@C &
!QZ4[4/#^EZM###?:;9WD,/^JCN($D5. M,?*"../2@#*^'>I6^J>$;*2UM9;*"/? MO+,9MFQRI57/WE!& ?0>U>=>&-+ MM=8?P%;7L"W-LS:PS0R#*/B<$!AT(R <'C@5[-;V\5K;QP01I##&H1(XU"JJ M@8 '0 =JKP:-I]JUNT-C;0FWW^28X57R]YR^W XW'DXZ]Z
.:^&:K;V.MV< M0V6UGJ]S!!%DD1Q@@A5] ,GBO/\ QM&+W2?%FL106<1M;V2#^T-0D,MZLL;(M$C@PJB%0".#S9#+)Y.!=[GJQQU)]:I7'AG1[J^ MDO)])L9KR12CW$ELC2,I7806(R05^7'IQTH R_%48U/X;ZH;E$G,FF22$.H(M+B,L#CID, 1Z$"N3T/2=.OM>\.Z5?
VEO)IB:!'G+:PK;"W$48MPGEB(*-FW&-N.F,<8K/D*Z++816+Z/8/91,7CMFM M4,:,3S[T >56-C;ZGJ'A430I?:?%K5[:V2>;J3RK.J*B%500@*K';E_E[#DU[5= M:+IU]9PVES86MQ:PE3%!+"K(A484JI&!@<#'2JTWA+0[BXFN)=%T^6>;/FRO M:QEL]=Q(R<^]
&+X5_Y'SQQ_P!=[3_TF6N>FLM-U>7QW=:\$DOK"4K"\W#V MEN(@T+Q$_<)8N!'=,'(P2,CGGB@#SSPG8IJ'CC0KW4K.%]2D\-QW,L MLD2ES,)$7>3UW;>,]>U=5\2]1N+'PE<16;E+Z^DCL;=@,D/*X3/Y$_E71_8[M?[8+OR(_M7E^5Y^P;]F<[=W7&><47-
G;WGE"X@CG\J198_,0-L<=&&>A'8T M8>MW$'@/P+=R6B^7%IMF5@7 /(7"9^IQGZU-X*T/_A'?"^GV39-P(Q)<,WWG MF;YG)_X$36M>6=OJ%N]O=01W-N_#13('5N<\@\'FIJ /,VT;0=8^('C/^VH[M>80VENP%P1B*/RCOD4'H1@?,.1QR,\Y&FM=^)H_#]K?
6UOJ.H1Z.+MFUR3=; M(AEVB8Q;,R2;!U++P1SDYKO?^$#TZY\1ZIJNH6]KJ7VP0^7#N1V'3O6OJF@:9KGE?VEIUIJ'E9\O[5 LNS.,XW XS@?D* /&/"]K!K%KX$- MW%;W\<>J7ELCO&&7RE5V11G/R@C(&3C]!5E?.NM6@T]K>WO+&Y\1:H9+6]G
M,,$TBL#&KD(V>2Q"D8)45Z[-X=TJYA:&;3+.6%IC3:E8L]G)IGCQ) M90K9Z?-(Z6A/'NF6EG!!8KIMM>);QQJL: M2@LI=5QA6(Y&.E>N1Z)IT-I;VL=A:I:V[B6&%85"1N#D,JXP""GR:79 M32W$DEG;O)<1^3,[1*3)'S\C''*\G@\;:YX6M5NI[FWL]%UFSM],59M'
MNI/)DLU"LP:$J&$9?)))5>5!#>GH'AG48]7\.Z;>PI,D5Q;QR(MP29,%1C<3 MU/OWZU%/X.T"ZB@BFT/398X%V1)):1L(USG"@C@9)/'K6E]CM_MGVOR(_M7E M^5Y^P;]F<[=W7&><4 4-<\+Z9XD$0U*U^TB)75,NR[=P)&".<#@]1VQ22>% M=+DU9-
3:V+:@C(RW'FON&U64 <],.V1T.8?#S3M;U#P?<16>]6= ME:RW-V@WV+R2IF5P2&\X#/*]%L[&WT^'R;6WBMHMQ;RX4"+DG).!W)..7[';_&S[7Y$?VKR_M*_8-^S.=N[KC/.* /'M'D?5M"\(Z5]E34K@K?\ D0:E.19D12-&GF+L8R%% MQM7C'7/0A-%TUM;\.W^G1:EI3?
9?$DHM+.X&RQN@J*WDK&&)";G9PHW#(Z'J M/5;CPSH]W9Q6D^DV,UK$$/'!);(R(Q))(4C)).3[FAO"^C/:RVS:38M;RE3 M)";9-CE1A21C!P /3% 'E6JZ@JV:Z';Z1;Z;:QZ\D%_:B^)LWWH75!($^5& M8#*[>"!FNO\$6\NF^*M=LEBT^QMEB@D;3=/DDDCMY""-
PS$B+O7!*CGY<] MZZJ+0=,@TU].CTZTCT]L[K58%$1SRPL[>Q@W;O*MHEC M7)ZG &: .7TNXCTWXB^*OM?3-+\.-/%U\-= M/M;F)A#IZ'INM>4-1T^UOQ$28_M4"R;,]<;@<=!^ M57J /"H=;O;%-&U"X9O*\'LMC> 8ZN\D+Y]<(D1S_M5))I\FGKI[7&/M=WX>
MU*\N&YR9)<.V<]_FQ^%>QR:'ILT%U#)I]J\-T_F7$;0J5F;CYG&/F/ Y/H*D MN=+LKR;S;BT@GE\MH=\D2LVQOO+DCH>XZ&@#S+2]-@T&Z^'\^EVL<-[>VE2>&/ FJXC.N7.L6HN+EL>?-(9LRJYZMAA MT/3 Z5[(--LU:U86D -H,6Y\M?W(*[<)Q\O''';BJO\
PB^C&^:].DV)O&<2 M&X^S)YA8$$,6QG((!SZB@#S">WLKCP?XPUK4 !XCM;VX5+H',]M(KXMTC;JJ MYV =0QZYJ#7K/4+JXU?PH@,-QK1BU0*.,?N6:7&.G[Z%!C_&_>O69O#^EW M&HIJ$NFVU M'$?#'4&\5W&I>)I>3.D%G%NZJL<8:3Z R.WY52-
AIFM^)/&K^(TCE:Q11#YI M!:VMO)#>9%G[ASN.XB65C;:;;);VEO%:VZY*Q0H$09))P!QR23^-5M M0\/Z7]\T4U]IMG>S1?ZN2X@21DYSP2..: /,?"=K_;GB_P (7NJ6D4NHR:$T M\DTT0,C.KH$D)(SNVXYZ\UTWC"&+4O"AG3M31)='FCN"\B7F.:=0NU64\-@ M$D
^_7%=BUC;M>)=M;Q&Z1#&LY0,PI.2H;KC('%,U#2[/5[MWTR'QK8Z?LM=%BBT]Y8K?"1P3F90VQ1PI**I./8GDUZ-KW@JRUJQTJQCC@M+ M&QNTN?LJVZF*10&!CV\ [CV/THUWP59:EX7N=$L(X-(@F='_P!'MU"@JZN3 MM&!D[<4 <1XFA7PSJEW'X1CCMLZ!/-
/%9D!?E(\J7 ZOR^&Y)QWQ5NWL=,T: MZ\"SZ"B)=WSE9GM\$W4'E%I7E/5R&V')Z$GUKT#2]#T[1$D33M/M,!9#EUM8 M5C#$=".=H&:;I_A_2])N)9[+3;.SGE_UDMO B,_.>2!D\T >-0>&],D^&'AZ] M?3K:6[GU6%9KB2)6D=?
M!3:6(SMV@#'3%=/@MHFG/HTYK"U;3SUM#"OE==WW,8Z\].M0W/A?1KR2*2XTFQGDAC M$,;R6R,4C&<("1PO)X'')H \[T#0=/\ $'BC28=2M([V!?"MHPAF&Y-V]QNQ MTR 3@]LG%9%BO]K:/X)CNE^U Z;JT>V;Y\A0J]#GT"C\]]E@TVSM9EEAM((I
M5B6!9(XU5A&#D("!]T=ATIEOHVGVIMC#8VT)M@P@\N%5\H-]X+@?+GOCK0!Y M/I[6_@GPGX+\4PVR101VGV>_$(V&194RK-@<_O%7GK\U>@_#_2Y=+*60NLF M^N0UW)8#))[^M#^&])DCNXWTNR:.\<27*-;H1.P.0SC'S'/.3 MWH \O\17Z_\ "0>,-
LY6P>_TNWU"6%ON0$;902.@['ZD52O&%6>20DN2F2 ,8&/0#K6O##';PQQ11K M%%&H5(T "JH& !T% 'BOP[T:RUR^*0W]M'=V\?A^63R9E#1LWVD ;E/!QN M)Y[X/:IM)NAH6@:'X@.?L^CZG1D&3UPAV8%>MVFC:?I[1-:V-M M;-
%&88VAA5"D9.XH,#A<\XZ9I/[%T_[#+9?8+7['*2TEOY*^6Y)R25Q@DGF@ M#R..UNKJ/PN]U:6]PGB"\NM2N;.]F,,$DA"F"-SM?("\A2""5%7O['GOM/U7 M2HKW1[**'5H3;:7)+)+9F79N:T)*(&4MA]B [3QBO4+S2K+4+'['=6=O M/L\T2O'QT^4C'&*C_L'3#I?]F'3K0Z;_
,^?D+Y/WMWW,8Z\].O- 'DFO6^G M7&GW&F'0K?3IK'7;,36\4HN+;$K#)CRHVAAPR!0.G')]?7(XD\6:S9.%BTJ; M6M-M[I =B&+[+PA XVE@@QT[5ZE'X&\T^:WT];/3WF:/S=]E'-%.B *(Y$.-R[1@8((P,' P0#S34UTS MPWJWCU+ /!:):6:-
#I\HA\IG=@55L$1C+9.!QN8].1M*.F>-+C2WM-(LXKG1 M;@S:;IJ9CVJM>@>&_ MIH9U-YH[.9M058I8+:S6"V6)01L6 M++<$LQ;).2WX5K6/AO2-+:)K/2K*T:)F:,P6Z(4+ !B,#@D*H/K@>E 'F'A' M3;*[D\$:;?6T)T]?2'NDM6C'DW-WA Q=
<8=@A9N>G6H)+>&\ALM."^?HD/B] M;>VC8[D\H0ONC'J@8L,=,9%>J'PMHIT_["=(L#9;_-^S?9D\O?\ WMN,9]ZL MKI%@MO:P+96XAM6#V\8B7;"P! *#'RD GD>IH YOXD6L%C\,]2WN88[B"0;7BE4,K#T(/!%1)I=E&9REG IN%"3;8E'F*!M ;CD <8/:
M@#QK6@VM:\UTHNII/ ZW#--AB7#!]^3W!YSUS5O5;BW\-W#RPK-9PQ^$TP- M/*PNI:<#*M@A,ELEL$C)/6O5UT73TP%L+90(/LHQ"O$/_//I]S_9Z4RW\.Z5 M:Q^7#IEG#'Y+6^V.W11Y1))3 'W2221TR: /+;?1?[-^(&G:8;+1[.&^TVY5 M]/TU2R/$%'EF9F
\PDAL$J.AZUG:#:&31_A_IZZ?8W%C=P3W$EM=2^3!=7 P M!YF$?DV-I)&S,C06R(5)&"00."1P?:C_A%]&^ MPO9?V38_8WD\U[?[,GEL_P#>*XP3QUH \O0R0M!I=TUJ- ;Q$()K6UDDDDA@S M&6%L6=$4Q^: =H! SM/I6[X/T71U\;>.--M[6VDT[99*]GL#0JO$I9=O0#)S
MCL2:[G^Q=/&F_P!G"PMAI^-OV3R5\K&H:;9V-GI\= MY#Y,C0VJ ;><' QDC<2,]")M M"$27EZK?:GA8;KF$PEI&E/5L.%QNZ'@8KT;7-- MG1=0T_S/)^UV\D'F;=VW M8@#+,1R'M-O) MDNM DUF]A91Q;2[%+01X)/R%LE4)(.!UQ7K5QX5T6\M8+:?1[">W@W&*&2U1
MDCRS.G6AM+A_,FMS OER-Q\S+C!/ Y/H* ///%-AI] MCJFBZ-H\5E)IEQJ#F]TV2[,=KYXCWQQ. K[Q!81[<,5'%8>OP10:;J6G7DE MG9:1%K5COL]/GD>.RW',H5S&@7/WMJ_=)/3//KR^'M*CTQM-73+-=.8Y:T%N M@B/.>4QCJ
>E"^'M*CL([%=,LULHW\Q+80((U;.=P7& <\YH \S\7*_A>^\3 MP^&E_L^V31TFNHK!=JP2F4+O"KPC^4'.1@X4'MFMR+3],\/^-O#$'AZ.&V@O M+:8W4=F1LF@5 8Y'Q]X[CPYY.X\G-=KIND6.BV[0:?96]A"S;S';1+&I; &<
M*!S@#GVJ/2]!TS1/-.G:=:6!EQYGV6!8]^,XSM SC)_,T W-O?6D%[;DAC%<1K(N1T.",5#)X=TJ M734TY],LWT]#E;1K=#$ISGA,8')/;O0!Y1J5K#<2R:5&&;0HO%=O;P1YPJ9C M/G1)CH@.PN8;:- (XI&R&=%Z*2%&2.M>
MN)HVGQVUM;I8VRV]LXD@B6%0D3#.&48PI&3R/6EETFQG-T9+.WD-T@CN"T2G MSE ("OQ\P)X/J: /.SH=HOQ$UW[-I]N\ECI,$EC#Y*E(I07*%%Q@,"!@CID M^M9]I;6-IX5\%ZQIVUM?O+RW66[4_O[EW;_24D;JZ@[\@]-HZ8KU*QT73],; M=9V-M:-
L$6Z"%4.P9(7@=!D\>],M_#^EVNH27\.FV<-]G?=1P(LK9ZY8#)S M0!Y-9230^(K.2V3S+A=>UMHEQG+"%\#\Z7P_;RH/A'5HXM,M;VZO(O,U/[9 M*]W>,['SHI L'))W##,0FTI[U'!X?TNUU%]0ATRSBOW)+W4<"+*V>N6 R/Z_9Z;?_#/5-7U%(SXC
M_M)HI;B3B=91ZNM)L;FY< ---;(IL! MC +$9/0?E5V*SMX;B>XC@CCGGV^;*J -)M&%W'J<#IF@":BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ H MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB 0B@ HHHH **** "BBB@#_V0$! end EX-101.SCH 5 meip-20241231.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 -
Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 100010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 100020 - Statement -
CONDENSED CONSOLIDATED BALANCE SHEETS (parenthetical) link:presentationLink link:calculationLink link:definitionLink 100030 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink
link:calculationLink link:definitionLink 100040 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 100050 - Statement - CONDENSED CONSOLIDATED
STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100060 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink
link:definitionLink 995455 - Disclosure - Description of Business and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - Summary of Significant Accounting Policies link:presentationLink
link:calculationLink link:definitionLink 995475 - Disclosure - Balance Sheet Details link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink
link:definitionLink 995495 - Disclosure - Employee Termination Benefits link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink
995515 - Disclosure - License Agreements link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Other License Agreements link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Leases
link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Share-based Compensation link:presentationLink
link:calculationLink link:definitionLink 995565 - Disclosure - Disposition of a Non-financial Asset link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - Subsequent Events link:presentationLink link:calculationLink
link:definitionLink 995585 - Disclosure - Description of Business and Basis of Presentation (Policies) link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - Summary of Significant Accounting Policies (Policies)
link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - Balance Sheet Details (Tables)
link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - Employee Termination Benefits (Tables)
link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - Share-based Compensation (Tables) link:presentationLink
link:calculationLink link:definitionLink 995665 - Disclosure - Description of Business and Basis of Presentation - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - Summary of Significant
Accounting Policies - Schedule of Revenue Associated with License Agreement (Detail) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Summary of Significant Accounting Policies - Schedule of Changes in Unbilled
Receivables and Contract Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Securities (Detail) link:presentationLink link:calculationLink
link:definitionLink 995705 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - Balance Sheet Details - Schedule of Prepaid and
Other Current Assets (Detail) link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - Balance Sheet Details - Schedule of Property and Equipment (Detail) link:presentationLink link:calculationLink link:definitionLink 995735 -
Disclosure - Balance Sheet Details - Schedule of Property and Equipment - (Parenthetical) (Detail) link:presentationLink link:calculationLink link:definitionLink 995745 - Disclosure - Balance Sheet Details - Additional Information (Detail)
link:presentationLink link:calculationLink link:definitionLink 995755 - Disclosure - Balance Sheet Details - Accrued Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink 995765 - Disclosure - Balance Sheet Details - Accrued
Liabilities (Parenthetical) (Detail) link:presentationLink link:calculationLink link:definitionLink 995775 - Disclosure - Fair Value Measurements - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995785 -
Disclosure - Fair Value Measurements - Schedule of Assumptions Used to Calculate Fair Value of Warrant Liability (Detail) link:presentationLink link:calculationLink link:definitionLink 995795 - Disclosure - Fair Value Measurements - Schedule of
Changes in Estimated Fair Value of Warrant Liability (Detail) link:presentationLink link:calculationLink link:definitionLink 995805 - Disclosure - Employee Termination Benefits - Additional Information (Detail) link:presentationLink link:calculationLink
link:definitionLink 995815 - Disclosure - Employee Termination Benefits - Summary of Activity Related to Employee Benefits Included in Accrued Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink 995825 - Disclosure -
Commitments and Contingencies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995835 - Disclosure - License Agreements - Additional Information (Detail) link:presentationLink link:calculationLink
link:definitionLink 995845 - Disclosure - Other License Agreements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995855 - Disclosure - Leases - Additional Information (Detail) link:presentationLink
link:calculationLink link:definitionLink 995865 - Disclosure - Leases - Schedule of Total Operating Costs (Detail) link:presentationLink link:calculationLink link:definitionLink 995875 - Disclosure - Leases - Schedule of Supplemental Cash Flow
Information Related to Operating Leases (Detail) link:presentationLink link:calculationLink link:definitionLink 995885 - Disclosure - Net Income (Loss) Per Share - Additional Information (Detail) link:presentationLink link:calculationLink
link:definitionLink 995895 - Disclosure - Stockholders' Equity - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995905 - Disclosure - Share-based Compensation - Additional Information (Detail)
link:presentationLink link:calculationLink link:definitionLink 995915 - Disclosure - Share-based Compensation - Share-based Compensation Expense for Stock Awards (Detail) link:presentationLink link:calculationLink link:definitionLink 995925 -
Disclosure - Share-based Compensation - Summary of Stock Option Activity (Detail) link:presentationLink link:calculationLink link:definitionLink 995935 - Disclosure - Share-based Compensation - Fair Value of Stock Options Weighted-Average
Assumptions Used (Detail) link:presentationLink link:calculationLink link:definitionLink 995945 - Disclosure - Disposition of a Non-financial Asset - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995955 -
Disclosure - Subsequent Events - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink Statement [Line Items]Statement [Line Items]Transaction Type [Axis]Plan Name [Domain]Plan Name [Domain]Entity Address,
Postal Zip CodeEntity Address, Postal Zip CodeRevenue related to non-refundable payments for performance obligationsRevenue, Remaining Performance Obligation, AmountFair Value, Recurring and Nonrecurring [Table]Entity Incorporation, State or
Country CodeEntity Incorporation, State or Country CodeCosts and Expenses [Abstract]Operating expenses:Fair Value Hierarchy and NAV [Axis]Fair Value Hierarchy and NAV [Axis]Incremental Payment.Incremental Payment [Member]Incremental
PaymentShare-Based Compensation Arrangement by Share-Based Payment Award [Line Items]Share-based Compensation Arrangement by Share-based Payment Award [Line Items]Closing agreement dateClosing AgreementClosing agreement.Lessee,
Operating Leases [Text Block]LeasesCommitments and Contingencies Disclosure [Text Block]Commitments and ContingenciesRestructuring Cost [Table]Stock Issued During Period, Value, Restricted Stock Award, Net of ForfeituresStock Issued During
Period, Value, Restricted Stock Award, Net of Forfeitures, TotalIssuance of common stock for vested restricted stock unitsStock, Class of Stock [Table]Schedule of Stock by Class [Table]Product and Service [Axis]Depreciation expenseDepreciation,
Depletion and Amortization, TotalDepreciation, Depletion and AmortizationFurniture And EquipmentFurniture And Equipment [Member]Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, PercentageStock
option vested percentageCollaborative Arrangement and Arrangement Other than Collaborative [Domain]Arrangements and Non-arrangement Transactions [Domain]Disclosure Of Supplemental Cash Flow Information Related To Operating Leases
[Abstract]Disclosure of supplemental cash flow information related to operating leases.Related Party Transaction [Line Items]Related Party Transaction [Line Items]Concentration Risk Benchmark [Axis]Increase in accrued restructuringRestructuring
Reserve, Period Increase (Decrease)Restructuring Reserve, Period Increase (Decrease), TotalEquity [Text Block]Stockholders' EquityTitle and Position [Axis]Title of Individual [Axis]License AgreementsRevenue from Contract with Customer [Text
Block]Termination BenefitsOne-time Termination Benefits [Member]One -Time Termination BenefitsSale of Stock [Domain]Sale of Stock [Domain]The Disclosure In Its Entirety Pertaining to the Accounting Policy In Respect Of Liquid Resources Held By
The Entity.Liquidity [Policy Text Block]LiquidityFair Value Measurement Inputs and Valuation Techniques [Line Items]Fair Value Measurement Inputs and Valuation Techniques [Line Items]Entity Central Index KeyEntity Central Index KeyDisclosure of
Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]Summary of Stock Option Activity and Related DataWarrantsWarrant [Member]WarrantsShare-Based Compensation Arrangement by Share-Based Payment
Award, Options, Forfeitures in PeriodForfeitedIncrease (Decrease) in Operating Capital [Abstract]Changes in operating assets and liabilities:Common Stock, Shares, Issued, TotalCommon Stock, Shares, IssuedCommon stock, shares issuedShare-Based
Payment Arrangement, Expensed and Capitalized, Amount [Table]Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]Fair Value Measurement Inputs and Valuation Techniques [Table]Fair Value
Measurement Inputs and Valuation Techniques [Table]Measurement Input, Expected Dividend Rate [Member]Dividend YieldIncrease (Decrease) in Prepaid Expense and Other Assets, TotalIncrease (Decrease) in Prepaid Expense and Other AssetsPrepaid
expenses and other current assetsEntity public float, thresholdEntity public float threshold.Entity Public Float ThresholdTargeted or Tracking Stock, Stock [Table]Targeted or Tracking Stock, Stock [Table]Income Statement [Abstract]Two Thousand And
Twenty At The Market Sale Agreement MemberTwo thousand and twenty at the market sale agreement memberTwo Thousand And Twenty At The Market Sale Agreement MemberEntity Address, State or ProvinceEntity Address, State or
ProvinceDescription of Business and Basis of PresentationOrganization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]Potential payments on achievement of development regulatory
and commercial milestones.Potential Payments on Achievement of Development Regulatory and Commercial Milestones [Member]Potential Payments on Achievement of Development Regulatory and Commercial MilestonesPayments to Acquire Short-
Term InvestmentsPurchases of short-term investmentsFair value, measurement with unobservable inputs reconciliation, recurring basis, liability, transfersFair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability,
Transfers, NetFair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net, TotalUnderwritten Registered OfferingUnderwritten Registered Offering [Member]Underwritten registered offering.Revenue
recognizedContract with Customer, Liability, Revenue RecognizedContract with Customer, Liability, Revenue RecognizedCover [Abstract]Subsequent Event [Line Items]Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period
Increase (Decrease), Excluding Exchange Rate EffectNet increase (decrease) in cash and cash equivalentsEarnings Per Share, Basic, TotalEarnings Per Share, BasicBasicAccrued milestone payments.Accrued Milestone PaymentsAccrued payment for
potential future paymentsTiming of Transfer of Good or Service [Axis]Other liabilitiesOther LiabilitiesOther Liabilities, TotalLease termination dateLease termination date.Lease Termination DateAccrued Liabilities [Line Items]Accrued Liabilities [Line
Items]Retained Earnings (Accumulated Deficit), Ending BalanceRetained Earnings (Accumulated Deficit), Beginning BalanceRetained Earnings (Accumulated Deficit), TotalRetained Earnings (Accumulated Deficit)Accumulated deficitAccumulated Losses
Since InceptionAccumulated losses since inceptionPurchaser initial paymentPurchaser initial payment.Purchaser Initial PaymentAssets and Liabilities Eliminated upon Consolidation [Abstract]Assets and Liabilities Eliminated upon Consolidation
[Abstract]Plan Name [Axis]Plan Name [Axis]Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, NumberEnding balanceBeginning BalanceOptions outstandingOutstanding OptionsPrepaid clinical costsPrepaid
Clinical CostsPrepaid clinical costsPayment for license agreement.Payment For License AgreementPayment for licenseAssets, Current [Abstract]Current assets:EventEvent [Domain]Net Cash Provided by (Used in) Operating ActivitiesNet cash used in
operating activitiesProduct and Service [Domain]Lease termination fee.Lease Termination FeeTermination feeProperty and equipment, netProperty, Plant and Equipment, Net, Ending BalanceProperty, Plant and Equipment, Net, Beginning
BalanceProperty, Plant and Equipment, NetProperty and equipment, netShort-term InvestmentsInvestment, Policy [Policy Text Block]Contract with Customer, Liability, NoncurrentContract with customer liability non currentNet Cash Provided by (Used
in) Operating Activities [Abstract]Cash flows from operating activities:Type of Restructuring [Domain]Fair Value, Recurring [Member]Fair Value, Measurements, Recurring [Member]Closing price of common
stock.ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsClosingStockPriceClosing price of common stockDisposition of Non-Financial AssetsDisposition of Non-Financial Assets Policy Text BlockDisposition of non-financial assets
policy text block.Vesting [Axis]Common Stock, Par or Stated Value Per ShareCommon stock, par valueStock optionRevenue from collaboration agreementsRevenue From Collaboration Agreements [Member]Revenue from collaboration
agreements.Measurement Input Type [Domain]Measurement Input Type [Domain]Contract liabilities, end of periodContract liabilities, beginning of periodContract with Customer, Liability, TotalContract with Customer, LiabilityDisposal Groups,
Including Discontinued Operations [Table]US License [Member]Us License MemberUs License [Member]Timing of Transfer of Good or Service [Domain]Statement of Cash Flows [Abstract]Antidilutive Securities, Name [Domain]Antidilutive Securities,
Name [Domain]Termination AgreementTermination AgreementTermination agreement.Entity [Domain]Entity [Domain]Balance Sheet Related Disclosures [Abstract]Equity Components [Axis]Equity Components [Axis]Other License AgreementsOther
Licensing Arrangements [Text Block]Other licensing agreements.Services performed over timeServices Performed Over Time [Member]Services Performed Over Time [Member]Entity Address, Address Line OneEntity Address, Address Line OneAccrued
compensation and benefitsEmployee-related Liabilities, CurrentEmployee-related Liabilities, Current, TotalRelated Party Transaction [Table]Schedule of Related Party Transactions, by Related Party [Table]Schedule Of Changes In Fair Value Of Warrant
Liability [Table Text Block]Schedule Of Changes In Fair Value Of Warrant Liability [Table Text Block]Schedule of Changes in Estimated Fair Value of Warrant LiabilityProperty, Plant and Equipment [Line Items]Subsequent Event Type [Axis]Fair Value of
Warrant Liability Assumptions [Table Text Block]Fair Value of Warrant Liability Assumptions [Table Text Block]Schedule of Assumptions Used to Calculate Fair Value of Warrant LiabilityIncrease (Decrease) in Accounts Payable, TradeAccounts
payableTotal other income, netNonoperating Income (Expense)Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]Antidilutive SecuritiesShare-Based Compensation Arrangement by Share-Based
Payment Award, Fair Value Assumptions, Risk Free Interest RateRisk-free interest rateDevelopment Services [Member]Development ServicesAmendment FlagAmendment FlagAccounting Standards Update 2016-02 [Member]Accounting Standards Update
2016-02 [Member]Event [Axis]EventOperating lease liabilityIncrease (Decrease) in Operating Lease LiabilityPotentially Dilutive Securities Outstanding [Line Items]Potentially Dilutive Securities Outstanding [Line Items]Potentially Dilutive Securities
Outstanding [Line Items]Additional Paid in Capital, Common Stock, Ending BalanceAdditional Paid in Capital, Common Stock, Beginning BalanceAdditional Paid in Capital, Common StockAdditional paid-in capitalNet income lossNet (loss)
incomeResearch and DevelopmentResearch and Development Expense [Member]Research and developmentEquity Component [Domain]Equity Component [Domain]Statistical Measurement [Domain]Range [Domain]General and Administrative Expense,
TotalGeneral and Administrative ExpenseGeneral and administrativeProceeds from sale of property and equipmentProceeds from Sale of Property, Plant, and Equipment, TotalProceeds from Sale of Property, Plant, and EquipmentBalance Sheet
DetailsSupplemental Balance Sheet Disclosures [Text Block]Other Nonoperating Income (Expense), TotalOther Nonoperating Income (Expense)Other expense, netOther expense, netShare-Based Compensation Arrangement by Share-Based Payment
Award, Expiration PeriodShare-based compensation arrangement by share-based payment award, expiration periodFurniture and Fixtures [Member]Furniture and equipmentNon rule 10b51 arrangement modified.Non Rule 10b51 Arr Modified [Flag]Non
Rule 10b51 Arr ModifiedNet Income (Loss), Including Portion Attributable to Noncontrolling Interest, TotalNet Income (Loss), Including Portion Attributable to Noncontrolling InterestNet (loss) incomeSchedule of Other Current Assets [Table Text
Block]Schedule of Prepaid and Other Current AssetsPreferred Stock, Shares IssuedPreferred stock, shares issuedOperating cash flows from operating leasesOperating Lease, PaymentsSupplemental cash flowUpdation Of Initial AssessmentUpdation Of
Initial Assessment [Member]Updation of Initial AssessmentTransaction price of deferred revenue remaining performance obligationsLicense Obligation Account Transaction Price Allocated Deferred RevenueLicense obligation account transaction price
allocated deferred revenue.Short-term Investments, TotalShort-Term InvestmentsShort-term investmentsPrepaid Expense and Other Assets, CurrentPrepaid expenses and other current assetsTotal prepaid and other current assetsShare-Based
Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise PriceForfeitedO 2024 Q2 Dividends.O 2024 Q2 Dividends [Member]O 2024 Q2 DividendsTransferred over Time [Member]Services
performed over timeLease expiration amended date.Lease Expiration Amended DateLease expiration amended dateCollaborative Arrangement and Arrangement Other than Collaborative [Axis]Type of Arrangement and Non-arrangement Transactions
[Axis]Federal Home Loan Banks [Abstract]Severance CostsSeverance costsCommon Stock, Shares, Outstanding, Ending BalanceCommon Stock, Shares, Outstanding, Beginning BalanceCommon Stock, Shares, OutstandingCommon stock, shares
outstandingShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]Number of OptionsPreferred Stock, Par or Stated Value Per SharePreferred stock, par valueAntidilutive Securities
[Axis]Antidilutive Securities [Axis]Discontinued Operations and Disposal Groups [Abstract]Entity Interactive Data CurrentEntity Interactive Data CurrentLease expire dateLease Expiration DateAccounting Standards Update [Domain]Document Quarterly
ReportRelated Party Transaction [Domain]Related Party Transaction [Domain]Range [Axis]Statistical Measurement [Axis]RangeOperating Lease, CostOperating lease costEx US License [Member]Ex US LicenseAssetsAssets, Fair Value DisclosureAssets,
Fair Value Disclosure, TotalRelated and Nonrelated Parties [Domain]Related Party [Domain]Total lease costs included in general and administrative expensesLease, CostLease costSchedule of Revenue Associated with License AgreementDisaggregation of
Revenue [Table Text Block]Schedule of Future Minimum Rental PaymentsLessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]Research and Development Arrangement [Member]Research And Development ArrangementDirector
[Member]DirectorsShare-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for GrantShares available for future grantShare-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period
for RecognitionExpected weighted average period for recognition of compensation expenseLoss Contingency, Nature [Domain]Statement of Income Location, Balance [Axis]Income Statement Location [Axis]AssetsTotal assetsShare-Based Compensation
Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected TermExpected life (years)Restructuring Type [Axis]Recent Accounting PronouncementNew Accounting Pronouncements, Policy [Policy Text Block]Entity Address, City or
TownEntity Address, City or TownEquity [Abstract]Operating Leases, Future Minimum Payments DueRemaining future minimum rental paymentsDividends [Axis]Cash paymentsCash paymentsPayments for RestructuringRevenue recognized upon
satisfaction of performance obligationsContract with customer liability revenue recognized upon satisfaction of performance obligations.Contract With Customer Liability Revenue Recognized Upon Satisfaction of Performance ObligationsRestructuring
Cost and Reserve [Line Items]Depreciation, TotalDepreciationDepreciationNet Income (Loss) Attributable to Parent [Abstract]Net loss:Torreya partnersTorreya Partners [Member]Torreya partners.Share-Based Payment Arrangement [Text Block]Share-
based CompensationShare-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares AuthorizedCommon stock authorizedFair Value Disclosures [Abstract]Entity Public FloatEntity public floatLiabilities, Current
[Abstract]Current liabilities:Fair Value, Liability, Recurring Basis, Still Held, Unrealized Gain (Loss)Change in estimated fair value of liability classified warrantsChange in fair value of warrant liabilityChange in fair value of warrant liabilityChange in
estimated fair value of liability classified warrantsDocument TypeDocument TypeAccounting Standards Update [Axis]Deferred Revenue Arrangement Type [Axis]Deferred Revenue Arrangement Type [Axis]Asset Impairment Charges, TotalAsset Impairment
ChargesImpairment chargesTitle of 12(b) SecurityTitle of 12(b) SecurityCash and Cash Equivalents, at Carrying Value, TotalCash and Cash Equivalents, at Carrying ValueCash and cash equivalents at end of the periodCash and cash equivalents at
beginning of the periodCash and cash equivalentsLease, Cost [Table Text Block]Schedule of Total Operating CostsDividends [Domain]Statement of Stockholders' Equity [Abstract]Document Fiscal Period FocusDocument Fiscal Period FocusResearch and
Development Expense, TotalResearch and Development ExpenseResearch and developmentDividend paidPayments of Dividends, TotalPayments of DividendsPayment of cash dividendAsset Class [Domain]Recognized Revenue Associated with The Following
License Agreements [Abstract]Property, Plant and Equipment, GrossProperty, Plant and Equipment, Gross, Ending BalanceProperty, Plant and Equipment, Gross, Beginning BalanceProperty, Plant and Equipment, Gross, TotalProperty and equipment,
grossSubsequent Event Type [Domain]Measurement Input, Expected Term [Member]Expected life yearsSchedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]Fair Value of Stock Options Weighted-Average
Assumptions UsedEmployee Termination BenefitsEmployee termination benefits.Employee Termination Benefits [Member]Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]Disposition of a Non-financial AssetClass of Warrant
or Right, Exercise Price of Warrants or RightsExercise priceEstimated development cost sharing reoverable through earnings.Estimated Development Cost Sharing Recoverable Through EarningsEstimated development cost sharing recovered through
earningsContract with customer asset and liability Line items.Contract with Customer Asset and Liability [Line Items]Contract with Customer Asset and Liability [Line Items]Sale of Stock [Axis]Sale of Stock [Axis]Net Cash Provided by (Used in) Investing
Activities [Abstract]Cash flows from investing activities:Category of Item Purchased [Axis]Unpaid common stock dividendCommon Stock, Dividends, Per Share, DeclaredCash dividends declared, per shareFair Value Measurements, Significant
Unobservable Inputs [Line Items]Fair Value Measurements, Significant Unobservable Inputs [Line Items]Fair value measurements Significant unobservable inputs [Line Items]Earnings Per Share, Diluted, by Common Class, Including Two-Class Method
[Table]Aggregate offering priceMaximum amount of common stock offering priceMaximum Amount Of Common Stock Offering PriceSchedule of fair value measurements significant unobservable inputs.Fair Value Measurements, Significant Unobservable
Inputs [Table]Fair value measurements Significant unobservable inputs [Table]OtherOther Accrued Liabilities, CurrentEntity Address, Address Line TwoLiabilities and Equity [Abstract]LIABILITIES AND STOCKHOLDERS' EQUITYDocument Period End
DateDocument Period End DateNet Cash Provided by (Used in) Financing ActivitiesNet cash used in financing activitiesRecognized Revenue Associated with The Following License Agreements [Table]Total anti-dilutive sharesAntidilutive Securities
Excluded from Computation of Earnings Per Share, AmountAccrued reimbursement to KKCAccrued Reimbursement to Related PartyAccrued reimbursement to related party.One-time termination employee benefitsRestructuring ReserveRestructuring
Reserve, Ending BalanceRestructuring Reserve, Beginning BalanceRestructuring Reserve, TotalAPIC, Share-based Payment Arrangement, Increase for Cost Recognition, TotalAPIC, Share-Based Payment Arrangement, Increase for Cost RecognitionShare-
based compensation expenseAccrued liabilitiesTotal accrued liabilitiesAccrued Liabilities, CurrentDeferred Revenue, TotalDeferred RevenueDeferred revenueLoss on disposal of property and equipmentGain (Loss) on Disposition of Property Plant
Equipment, TotalGain (Loss) on Disposition of Property Plant EquipmentLoss on disposal of property and equipmentTrading SymbolTrading SymbolEquity, Attributable to ParentEnding BalanceBeginning BalanceTotal stockholders' equityPurchase
Commitment, Excluding Long-Term Purchase Commitment [Table]Purchase Commitment, Excluding Long-term Commitment [Table]Software licensesSoftware licenses.Software LicensesLong-Lived Tangible Asset [Axis]Infinity's Stockholders.Infinity's
Stockholders [Member]Infinitys StockholdersRestricted Stock Units (RSUs) [Member]Restricted Stock Units (RSUs)Number of shares issued and soldSale of Stock, Number of Shares Issued in TransactionRelated Party Transactions [Abstract]Variable
lease costsVariable Lease, CostKyowa Kirin Co. LtdKyowa Kirin Co [Member]Kyowa Kirin Co [Member]Contract with Customer, Contract Asset, Contract Liability, and Receivable [Abstract]Share-Based Payment Arrangement, Expensed and Capitalized,
Amount [Table Text Block]Share-Based Compensation Expense for Stock AwardsTotal authorized share capitalCapital Units, AuthorizedSecurity depositSecurity DepositMeasurement Input Type [Axis]Measurement Input Type [Axis]Geographical
[Axis]Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, AmountUnrecognized compensation expense related to unvested stock optionsLeases [Abstract]Restructuring and Related Costs [Table Text Block]Summary of
Activity Related to Employee Benefits Included in Accrued LiabilitiesNumber of square feet under leaseArea of LandEquipment [Member]EquipmentUse of EstimatesUse of Estimates, Policy [Policy Text Block]Class of Stock [Line Items]Class of Stock
[Line Items]Expected VolatilityMeasurement Input, Price Volatility [Member]Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend RateDividend yieldSchedule of Changes in Unbilled

~~Receivables and Contract LiabilitiesContract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]Security Exchange NameSecurity Exchange NameLicense obligation account transaction price allocated.License Obligation Account Transaction Price AllocatedLicense Obligation Account Transaction Price AllocatedBusiness Acquisition, Acquiree [Domain]Measurement Input, Risk Free Interest Rate [Member]Risk Free Interest RateUnbilled receivablesUnbilled Receivables, CurrentLong-Lived Tangible Asset [Domain]Loss Contingency Nature [Axis]Less: accumulated depreciationAccumulated Depreciation, Depletion and Amortization, Property, Plant, and EquipmentAccumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending BalanceAccumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning BalanceAccumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, TotalLegal Entity [Axis]Legal Entity [Axis]San Diego California [Member]San Diego California [Member]Fair Value Disclosures [Text Block]Fair Value MeasurementsGrantedShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair ValueWeighted-average grant date fair valueSubsequent EventSubsequent Event [Member]Maximum [Member]MaximumRestructuring and Related Activities Disclosure [Text Block]Employee Termination BenefitsLiabilities and EquityTotal liabilities and stockholders' equityNumber of workforce reduction percentageRestructuring and Related Cost, Number of Positions Eliminated, Period PercentOperating Lease, Right-of-Use AssetOperating lease right-of-use assetRight-of-use asset balanceNumber Of Warrants ExercisedNumber Of Warrants ExercisedNumber of warrants exercisedDilutedEarnings Per Share, Diluted, TotalEarnings Per Share, DilutedKKC License AgreementKkc Agreements [Member]Kkc Agreements [Member]KKC License Agreement [Member]Leasehold Improvements [Member]Total liabilitiesLiabilitiesCommon stock voting rightsCommon Stock, Voting RightsFair Value Hierarchy and NAV [Domain]Fair Value Hierarchy and NAV [Domain]Assets, CurrentTotal current assetsNet cash provided by investing activitiesNet Cash Provided by (Used in) Investing ActivitiesShare-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures [Abstract]Aggregate Intrinsic ValueShare-based Compensation Arrangement by Share-Based Payment Award, Award Vesting PeriodShare-based compensation arrangement by share-based payment award, award vesting periodReimbursement amountReimbursement AmountReimbursement amountEntity Filer CategoryEntity Filer CategoryClass of Warrant or Right, Number of Securities Called by Each Warrant or RightWarrants outstandingProceeds from the disposition of a non-financial assetProceeds from Sale of Other Assets, Investing ActivitiesPurchaser initial paymentOther income (expense) [Abstract]Nonoperating Income (Expense) [Abstract]Current Fiscal Year End DateCurrent Fiscal Year End DateFair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]Total upfront payment receivable for grant of rightsTotal upfront payment receivable for grant of rights,Total Upfront Payment Receivable For Grant Of RightsTotal upfront payment receivable for grant of rightsRule 10b51 Arr Modified [Flag]Rule 10b51 Arr Modified [Flag]Rule 10b51 Arr ModifiedPurchase Commitment, Excluding Long-Term Commitment [Line Items]Purchase Commitment, Excluding Long-term Commitment [Line Items]Share-based compensationShare-based Payment Arrangement, Noncash Expense, TotalShare-Based Payment Arrangement, Noncash ExpenseShare-based compensationTargeted or Tracking Stock, Stock [Line Items]Targeted or Tracking Stock, Stock [Line Items]Related Party Transaction [Axis]Related Party TransactionsShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic ValueOutstanding at end of periodRelated and Nonrelated Parties [Axis]Related PartyPass Through Services [Member]Pass through services member.Pass Through Services [Member]Two thousand and eight omnibus plan.Two Thousand And Eight Omnibus Plan [Member]2008 Omnibus PlanEntity Registrant NameEntity Registrant NameWeighted-average grant date fair valueMeasurement Input Weighted-Average Grant Date Fair Value [Member]Measurement input weighted-average grant date fair value.Proceeds from Sale of Furniture and FixturesProceeds from sale of furniture and fixturesSchedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]Entity Emerging Growth CompanyEntity Emerging Growth CompanyTransaction [Domain]Presage License Agreement.Presage License Agreement [Member]Presage License AgreementShares used in calculating basic net income (loss) per shareWeighted Average Number of Shares Outstanding, Basic, TotalWeighted Average Number of Shares Outstanding, BasicBasicWeighted average shares used in calculating basic net loss per shareVesting [Domain]Number of workforce reductionRestructuring and Related Cost, Number of Positions EliminatedEnding balanceBeginning balanceWarrants Not Settleable in Cash, Fair Value DisclosureFair value of warrantsWarrant liabilityWarrant liabilityEnding balanceBeginning balanceIncome Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]Common Stock, Shares AuthorizedCommon stock, shares authorizedSale of shares and warrants under agreement.Sale Of Shares And Warrants Under AgreementSale of shares and warrants under agreementShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise PriceVested and expected to vest at end of periodExpenses related to an agreementCosts and Expenses, Related PartyShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual TermOutstanding at end of periodEarnings Per Share, Policy [Policy Text Block]Net Income (Loss) Per ShareLong-Term Purchase Commitment, Category of Item Purchased [Domain]Contract with customer asset and liability.Contract with Customer Asset and Liability [Table]Contract with Customer Asset and Liability [Table]General and Administrative Expense [Member]General and Administrative Expense [Member]General and administrativeImpairment, Long-Lived Asset, Held-for-Use, TotalImpairment, Long-Lived Asset, Held-for-UseImpairment chargeRevenue [Policy Text Block]Revenue RecognitionShare-Based Payment Arrangement [Abstract]Licensing Arrangements [Abstract]Licensing arrangements [Abstract].Unbilled receivablesIncrease Decrease In Unbilled ReceivableIncrease Decrease In Unbilled ReceivableDilutive Securities, Effect on Basic Earnings Per Share [Abstract]Accounting Policies [Abstract]Equity, Attributable to Parent [Abstract]Stockholders' equity.Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]Noncash investing activities:Recovery of Direct CostsReimbursements costsMeasurement Input, Exercise Price [Member]Black-Scholes Fair ValueStatement [Table]Statement [Table]Schedule of Property and EquipmentProperty, Plant and Equipment [Table Text Block]Transaction price relating to the performance obligationTotal transaction price in respect of colloboration revenue.Total Transaction Price In Respect Of Colloboration RevenueTransaction price relating to the performance obligationShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual TermVested and expected to vest at end of periodSubsequent Event [Table]Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]Weighted- Average Exercise PricePreferred Stock, Shares AuthorizedPreferred stock, shares authorizedAdopted agreement dateAdopted AgreementAdopted agreementPercentage Of Reimbursement Of Pass Through Costs As RevenuePercentage Of Reimbursement Of Pass Through Costs As RevenuePercentage of reimbursement of pass through costs as revenueSecurities Act File NumberEntity File NumberMilestone PaymentMilestone PaymentMilestone paymentEarnings Per Share [Abstract]Net (loss) income per share - basic and diluted:Transferred at Point in Time [Member]Pass through Services at a Point in TimeStatement of Financial Position [Abstract]Operating Income (Loss)(Loss) income from operationsShare-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected VolatilityRateVolatilityEntity Shell CompanyEntity Shell CompanyAccrued legal and professional servicesAccrued Professional Fees, CurrentEntity Tax Identification NumberEntity Tax Identification NumberAssets [Abstract]ASSETSEntity Current Reporting StatusEntity Current Reporting StatusReturn of capital authorizedDividends, CashDividends, Cash, TotalSubsequent Events [Abstract]Increase (Decrease) in Contract with Customer, LiabilityDeferred revenueIncrease (Decrease) in Deferred RevenueGeographical [Domain]Document Fiscal Year FocusDocument Fiscal Year FocusCash and cash equivalents and short term investmentsCash, Cash Equivalents, and Short-Term InvestmentsTotal cash, cash equivalents and short-term investmentsDirect costs.Direct CostsDirect costsShare-Based Payment Arrangement, Tranche Two [Member]Share-based Payment Arrangement Tranche TwoPreferred Stock, Value, Issued, Ending BalancePreferred Stock, Value, Issued, Beginning BalancePreferred Stock, Value, Issued, TotalPreferred Stock, Value, IssuedPreferred stock, $0.01 par value; 100 shares authorized; none outstandingIncrease in right of use asset balanceIncrease in right of use asset balance.Increase in Right of Use Asset BalanceInducement PlanInducement Plan [Member]Inducement Plan [Member]Cash and cash equivalents at end of the periodCash and cash equivalents at beginning of the periodCash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, TotalCash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued OperationsBusiness Acquisition [Axis]City Area CodeCity Area CodeBeiGene, LtdBeiGene, Ltd [Member]BeiGene, LtdWarrants and rights outstanding, measurement inputWarrants and Rights Outstanding, Measurement InputSchedule of Supplemental Cash Flow Information Related to Operating LeasesSchedule of Cash Flow, Supplemental Disclosures [Table Text Block]Liabilities, CurrentTotal current liabilitiesTorreya partners llc memberTorreya Partners LLC [Member]Torreya Partners LLCGain (Loss) on Disposition of Other AssetsGain on disposition of a non-financial assetGain on disposition of a non-financial assetGain of dispositionOrganization, Consolidation and Presentation of Financial Statements [Abstract]Local Phone NumberAnticipated dividendInvestment Company, Dividend DistributionInvestment Company, Dividend Distribution, TotalPreferred Stock, Shares Outstanding, Ending BalancePreferred Stock, Shares Outstanding, Beginning BalancePreferred Stock, Shares OutstandingPreferred stock, shares outstandingShare-based compensation arrangement by share-based payment award, options, weighted average remaining contractual term.Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]Weighted Average Remaining Contractual Term (in years)Presage Biosciences Inc [Member]Presage Biosciences Inc.Presage Biosciences, Inc.Prepayment of remaining rent.Prepayment of Remaining RentPrepayment of remaining rentDisclosure Text Block [Abstract]Commitments and Contingencies Disclosure [Abstract]Amount on reduction in remaining right of use asset and lease liability.Amount on Reduction in Remaining Right of Use Asset and Lease LiabilityAmount on reduction in remaining right of use asset and lease liabilityAccrued pre-clinical and clinical trial expensesAccrued Preclinical And Clinical CostsAccrued pre-clinical and clinical trial expenses.Retained Earnings [Member]Accumulated DeficitPurchases of property and equipmentPayments to Acquire Property, Plant, and EquipmentPayments to Acquire Property, Plant, and Equipment, TotalDocument Transition ReportDeferred Revenue [Domain]Deferred Revenue [Domain]Antidilutive Security, Excluded EPS Calculation [Table]Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]Potential milestone payments receivable.Potential Milestone Payments ReceivableMilestone payment receivable amountConcentrations of Credit RiskConcentration Risk, Credit Risk, Policy [Policy Text Block]MinimumMinimum [Member]Common Stock [Member]Common SharesShare-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]Vested and expected to vest at end of periodShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic ValueOperating Lease, Right-of-Use Asset, Periodic ReductionDecrease in ROU asset balanceAdditional Paid in Capital [Member]Additional paid in capitalDevelopment services performance obligations member.Development Services Performance Obligations [Member]Development Services Performance ObligationsAdjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]Adjustments to reconcile net (loss) income to net cash used in operating activities:Property, Plant and Equipment [Member]Property and EquipmentAdjustments to Additional Paid in Capital, Dividends in Excess of Retained EarningsCash dividends declaredExpected milestone payment receivable.Expected Milestone Payment ReceivableExpected milestone payment receivableHelsinn license agreement.Helsinn License Agreement [Member]Helsinn License AgreementStatement of Income Location, Balance [Domain]Income Statement Location [Domain]Description of BusinessBusiness Description and Accounting Policies [Text Block]Other Prepaid Expense, CurrentOtherProceeds from Maturities, Prepayments and Calls of Short-Term InvestmentsProceeds from maturity of short-term investmentsTermination BenefitsContract Termination [Member]Entity Common Stock, Shares OutstandingEntity Common Stock, Shares OutstandingBasis of Accounting, Policy [Policy Text Block]Basis of Presentation and ConsolidationTitle and Position [Domain]Relationship to Entity [Domain]Investment Income, Interest and Dividend, TotalInvestment Income, Interest and DividendInterest and dividend incomeCommon stock valueCommon Stock, Value, Issued, Ending BalanceCommon Stock, Value, Issued, Beginning BalanceCommon Stock, Value, Issued, TotalCommon Stock, Value, IssuedCommon stock, $0.00000002 par value; 226,000 shares authorized; 6,662 shares issued and outstanding at December 31, 2024 and June 30, 2024.InsurancePrepaid InsuranceAsset Purchase Agreement [Member]Asset Purchase Agreement [Member]Revenue from customersRevenue from Contract with Customer Benchmark [Member]Weighted Average Number of Shares, Common Stock Subject to Repurchase or CancellationCommon stock subject to repurchase or forfeitureDisclosure of supplemental cash flow information related to operating leases.Disclosure Of Supplemental Cash Flow Information Related To Operating Leases [Table Text Block]Schedule of Supplemental Cash Flow Information Related to Operating LeasesOperating lease liabilitiesOperating Lease, LiabilityTotal operating lease liabilityTotal operating lease liabilityMeasurement Frequency [Axis]Measurement Frequency [Axis]Accrued LiabilitiesSchedule of Accrued Liabilities [Table Text Block]Commitments and contingencies (Note 6)Commitments and ContingenciesNew Accounting Pronouncements or Change in Accounting Principle [Line Items]Recognized Revenue Associated with The Following License Agreements [Line Items]Shares used in calculating diluted net income (loss) per shareWeighted Average Number of Shares Outstanding, DilutedDilutedWeighted-average shares used in calculating diluted net loss per shareWeighted-average shares used in calculating diluted net loss per shareSummary of Significant Accounting PoliciesSignificant Accounting Policies [Text Block]Non cash lease expense.Non Cash Lease ExpenseNoncash lease expensesAccounts receivableAccounts Receivable, after Allowance for Credit Loss, CurrentAccounts Receivable, after Allowance for Credit Loss, Current, TotalShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, NumberVested and expected to vest at end of periodRestructuring Reserve [Abstract]Employees.Employees [Member]EmployeesWeighted Average Number of Shares Outstanding, Diluted [Abstract]Weighted-average shares used in computing net (loss) income per share - basic and diluted:At-the-market offering agreement description.At-the-Market Offering Agreement DescriptionAt-the-market offering agreement, descriptionConcentration Risk Benchmark [Domain]Entity Small BusinessEntity Small BusinessUp Front PaymentUp Front PaymentUpfront paymentRights and the rights agreement expiration description.Rights and the Rights Agreement Expiration DescriptionRights and the rights agreement expiration descriptionEntity Bankruptcy Proceedings, Reporting CurrentRevenuesRevenues, TotalRevenuesAccounting Standards Update and Change in Accounting Principle [Table]Net Cash Provided by (Used in) Financing Activities [Abstract]Cash flows from financing activities:Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise PriceEnding balanceBeginning BalanceAsset Class [Axis]Measurement Frequency [Domain]Fair Value, Measurement Frequency [Domain]Fair Value, Inputs, Level 3 [Member]Level 3Subsequent EventsSubsequent Events [Text Block]Accounts Payable, Current, TotalAccounts Payable, CurrentAccounts payableCosts and ExpensesTotal operating expensesLiabilitiesLiabilities, Fair Value Disclosure,Liabilities, Fair Value Disclosure, TotalAt The Market Sale Agreement [Member]ATM Sales AgreementAt-the-market equity offering sales agreement.Increase (Decrease) in Accrued Liabilities, TotalIncrease (Decrease) in Accrued LiabilitiesAccrued liabilities XML 7 R1.htm IDEA: XBRL DOCUMENT~~

Cover Page - shares	6 Months Ended Dec. 31, 2024	Feb. 07, 2025
Cover [Abstract]		
Document Type	10-Q	
Amendment Flag	false	
Document Quarterly Report	true	
Document Transition Report	false	
Document Period End Date	Dec. 31, 2024	
Document Fiscal Year Focus	2025	
Document Fiscal Period Focus	Q2	
Securities Act File Number	001-41827	
Trading Symbol	MEIP	
Entity Registrant Name	MEI Pharma, Inc.	
Entity Tax Identification Number	51-0407811	
Entity Central Index Key	0001262104	
Current Fiscal Year End Date	--06-30	
Entity Filer Category	Non-accelerated Filer	
Entity Current Reporting Status	Yes	
Entity Emerging Growth Company	false	
Entity Shell Company	false	
City Area Code	858	
Local Phone Number	369-7100	
Entity Small Business	true	
Title of 12(b) Security	Common Stock, $0.00000002 par value	
Security Exchange Name	NASDAQ	
Entity Incorporation, State or Country Code	DE	
Entity Address, Address Line One	9920 Pacific Heights Blvd	
Entity Address, Address Line Two	Suite 150	
Entity Address, City or Town	San Diego	
Entity Address, State or Province	CA	
Entity Address, Postal Zip Code	92121	
Entity Interactive Data Current	Yes	
Entity Common Stock, Shares Outstanding		6,662,857

~~XML 8 R2.htm IDEA: XBRL DOCUMENT~~

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2024	Jun. 30, 2024
Current assets:		
Cash and cash equivalents	$ 23,739	$ 3,705
Short-term investments	0	34,640
Prepaid expenses and other current assets	646	2,424
Total current assets	24,385	40,769
Operating lease right-of-use asset	0	214
Property and equipment, net	0	392
Total assets	24,385	41,375
Current liabilities:		
Accounts payable	596	3,168
Accrued liabilities	1,691	5,187
Total current liabilities	2,287	8,355

Total liabilities	2,287	8,355
Commitments and contingencies (Note 6)		
Stockholders' equity:		
Preferred stock, $0.01 par value; 100 shares authorized; none outstanding	0	0
Common stock, $0.00000002 par value; 226,000 shares authorized; 6,663 shares issued and outstanding at December 31, 2024 and June 30, 2024.	0	0
Additional paid-in capital	421,001	421,239
Accumulated deficit	(398,903)	(388,219)
Total stockholders' equity	22,098	33,020
Total liabilities and stockholders' equity	$ 24,385	$ 41,375

XML 9 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (parenthetical) - $ / shares

	Dec. 31, 2024	Jun. 30, 2024
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	100,000	100,000
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.00000002	$ 0.00000002
Common stock, shares authorized	226,000,000	226,000,000
Common stock, shares issued	6,663,000	6,663,000
Common stock, shares outstanding	6,663,000	6,663,000

XML 10 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands

	3 Months Ended		6 Months Ended	
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Revenues	$ 0	$ 0	$ 0	$ 65,297
Operating expenses:				
Research and development	308	3,912	3,471	7,397
General and administrative	3,143	8,018	8,332	14,549
Total operating expenses	3,451	11,930	11,803	21,946
(Loss) income from operations	(3,451)	(11,930)	(11,803)	43,351
Other income (expense):				
Interest and dividend income	279	869	634	1,963
Gain on disposition of a non-financial asset	500	0	500	0
Other expense, net	(5)	(2)	(15)	(3)
Total other income, net	774	867	1,119	1,960
Net (loss) income	$ (2,677)	$ (11,063)	$ (10,684)	$ 45,311
Net (loss) income per share - basic and diluted:				
Basic	$ (0.4)	$ (1.66)	$ (1.6)	$ 6.8
Diluted	$ (0.4)	$ (1.66)	$ (1.6)	$ 6.8
Weighted-average shares used in computing net (loss) income per share - basic and diluted:				
Basic	6,663	6,663	6,663	6,663
Diluted	6,663	6,663	6,663	6,663
Revenue from customers				
Revenues	$ 0	$ 0	$ 0	$ 752
Revenue from collaboration agreements				
Revenues	$ 0	$ 0	$ 0	$ 64,545

XML 11 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands

	Total	Common Shares	Additional paid in capital	Accumulated Deficit
Beginning Balance at Jun. 30, 2023	$ 24,624	$ 6,663	$ 430,621	$ (405,997)
Net Income (Loss)	56,374			56,374
Share-based compensation expense	363		363	
Ending Balance at Sep. 30, 2023	81,361	6,663	430,984	(349,623)
Beginning Balance at Jun. 30, 2023	24,624	6,663	430,621	(405,997)
Net Income (Loss)	45,311			
Ending Balance at Dec. 31, 2023	59,488	6,663	420,174	(360,686)
Beginning Balance at Sep. 30, 2023	81,361	6,663	430,984	(349,623)
Net Income (Loss)	(11,063)			(11,063)
Cash dividends declared	(11,660)		(11,660)	
Share-based compensation expense	850		850	
Ending Balance at Dec. 31, 2023	59,488	6,663	420,174	(360,686)
Beginning Balance at Jun. 30, 2024	33,020	6,663	421,239	(388,219)
Net Income (Loss)	(8,007)			(8,007)
Share-based compensation expense	(135)		(135)	
Ending Balance at Sep. 30, 2024	24,878	6,663	421,104	(396,226)
Beginning Balance at Jun. 30, 2024	33,020	6,663	421,239	(388,219)
Net Income (Loss)	(10,684)			
Ending Balance at Dec. 31, 2024	22,098	6,663	421,001	(398,903)
Beginning Balance at Sep. 30, 2024	24,878	6,663	421,104	(396,226)
Net Income (Loss)	(2,677)			(2,677)
Share-based compensation expense	(103)		(103)	
Ending Balance at Dec. 31, 2024	$ 22,098	$ 6,663	$ 421,001	$ (398,903)

XML 12 R6.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)

	3 Months Ended
	Dec. 31, 2023 $ / shares
Statement of Stockholders' Equity [Abstract]	
Cash dividends declared, per share	$ 1.75

XML 13 R7.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands

	6 Months Ended	
	Dec. 31, 2024	Dec. 31, 2023
Cash flows from operating activities:		
Net (loss) income	$ (10,684)	$ 45,311
Adjustments to reconcile net (loss) income to net cash used in operating activities:		
Share-based compensation	(238)	1,213
Noncash lease expense	214	750

Depreciation expense	368	172
Loss on disposal of property and equipment	14	0
Gain on disposition of a non-financial asset	(500)	0
Changes in operating assets and liabilities:		
Unbilled receivables	0	85
Prepaid expenses and other current assets	1,778	58
Accounts payable	(2,572)	(4,756)
Accrued liabilities	(3,496)	(6,816)
Deferred revenue	0	(64,862)
Operating lease liability	0	(701)
Net cash used in operating activities	(15,116)	(29,546)
Cash flows from investing activities:		
Purchases of short-term investments	0	(33,938)
Proceeds from maturity of short-term investments	34,640	63,419
Proceeds from sale of property and equipment	10	0
Proceeds from the disposition of a non-financial asset	500	0
Purchases of property and equipment	0	(7)
Net cash provided by investing activities	35,150	29,474
Cash flows from financing activities:		
Payment of cash dividend	0	(11,660)
Net cash used in financing activities	0	(11,660)
Net increase (decrease) in cash and cash equivalents	20,034	(11,732)
Cash and cash equivalents at beginning of the period	3,705	16,906
Cash and cash equivalents at end of the period	$ 23,739	$ 5,174

~~XML 14 R8.htm IDEA: XBRL DOCUMENT~~

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		6 Months Ended			
	Dec. 31, 2024	Sep. 30, 2024	Dec. 31, 2023	Sep. 30, 2023	Dec. 31, 2024	Dec. 31, 2023
Pay vs Performance Disclosure						
Net Income (Loss)	$ (2,677)	$ (8,007)	$ (11,063)	$ 56,374	$ (10,684)	$ 45,311

~~XML 15 R9.htm IDEA: XBRL DOCUMENT~~

Insider Trading Arrangements	3 Months Ended Dec. 31, 2024
Trading Arrangements, by Individual	
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Non Rule 10b51 Arr Modified	false
Rule 10b51 Arr Modified	false

~~XML 16 R10.htm IDEA: XBRL DOCUMENT~~

Description of Business and Basis of Presentation	6 Months Ended Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]	

Description of Business and Basis of Presentation

1. Description of Business and Basis of Presentation

Description of Business

MEI Pharma, Inc. (Nasdaq: MEIP) is a pharmaceutical company that has been developing novel and differentiated cancer therapies. We built our pipeline by acquiring promising cancer agents and creating value in programs through development, strategic partnerships, and out-licensing or commercialization, as appropriate. Our approach to oncology drug development has been to evaluate our drug candidates in combinations with standard-of-care therapies to overcome known resistance mechanisms and address clear medical needs to provide improved patient benefit. Our pipeline includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and prior to its sale, ME-344 as more fully discussed in *Note 12. Disposition of a Non-financial Asset*, an intravenous small molecule mitochondrial inhibitor targeting the oxidative phosphorylation pathway.

Strategic Alternatives

On July 22, 2024, we announced that our Board of Directors (Board) had determined unanimously to begin the evaluation of our strategic alternatives, including potential transactions as well as an orderly wind down of operations, if appropriate, to maximize the value of our assets for our stockholders. We commenced a reduction-in-force (the Strategic Alternatives RIF) beginning August 1, 2024, which will continue in stages as our operational and strategic direction evolves. We have discontinued the clinical development of voruciclib, while certain nonclinical activities related to MEI's drug candidate assets will continue to be conducted by us. As part of the review of strategic alternatives, we may consider options such as out-licensing opportunities for existing programs and merger and acquisition opportunities.

Consistent with our intention to preserve cash, David M. Urso, our former President and Chief Executive Officer, and Richard Ghalie, M.D., our former Chief Medical Officer, stepped down effective August 1, 2024. Mr. Urso also left the Board at that date. We have entered into consulting agreements with both Mr. Urso and Dr. Ghalie under which they will remain available to assist us in our strategic efforts. Charles V. Baltic III, the former Chairperson of the Board, also stepped down from the Board contemporaneously with the announcement on July 22, 2024. Our Board appointed Justin J. File, our Chief Financial Officer, to assume the position of Acting Chief Executive Officer and appointed Frederick W. Driscoll as our Chairperson of the Board.

Basis of Presentation and Consolidation

Unaudited Interim Financial Information

The interim condensed consolidated financial statements are unaudited. These interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. (U.S. GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the accompanying interim condensed financial statements do not include all of the information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying condensed interim consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) that are necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. These statements do not include all disclosures required by U.S. GAAP and should be read in conjunction with the Company's audited consolidated financial statements and notes for the fiscal year ended June 30, 2024.

Consolidation Principles

The accompanying unaudited condensed consolidated financial statements include the accounts of MEI Pharma, Inc. and our wholly owned subsidiary, Meadow Merger Sub, Inc. We have eliminated all intercompany accounts and transactions in consolidation.

The accompanying unaudited interim condensed consolidated financial statements for the quarterly and six month periods ended December 31, 2024 should be read in conjunction with the audited financial statements and notes thereto as of and for the fiscal year ended June 30, 2024, included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on September 19, 2024 (2024 Annual Report). Interim results are not necessarily indicative of results for a full year.

Subsequent Events

The Company has evaluated subsequent events through the date the condensed consolidated financial statements were issued.

Liquidity

To date, we have obtained cash and funded our operations primarily through equity financings and license agreements. We have accumulated losses of $398.9 million since inception and expect to incur operating losses and generate negative cash flows from operations for the foreseeable future. As of December 31, 2024, we had $23.7 million in cash and cash equivalents. In connection with our July 2024 announcement regarding the evaluation of our strategic alternatives, we discontinued the clinical development of voruciclib, while certain nonclinical research and development activities continued. As a result, we continue to incur research and development expenses in connection with clinical trial closing costs and the completion of our nonclinical projects. We believe that our cash balance, will be sufficient to meet our obligations and fund operations for at least the next 12 months from the issuance of these condensed consolidated financial statements.

~~XML 17 R11.htm IDEA: XBRL DOCUMENT~~

Summary of Significant Accounting Policies	6 Months Ended Dec. 31, 2024
Accounting Policies [Abstract]	

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

There have been no material changes to our significant accounting policies from those described in the notes to our audited consolidated financial statements contained in the 2024 Annual Report.

Risks and Uncertainties

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to the valuation of share-based awards, the discount rate used in estimating the present value of the right-of-use assets and lease liabilities, the useful lives of property and equipment, the recoverability of long-lived assets, clinical trial accruals, periods over which revenue should be recognized, relative stand-alone selling price, deferred income taxes and related valuation allowances, and the assessment of our ability to fund our operations for at least the next 12 months from the date of issuance of these condensed consolidated financial statements. We base our estimates on historical experience and other market-specific or other relevant assumptions that we believe to be reasonable under the circumstances. Estimates are assessed each reporting period and updated to reflect current information. As future events and their effects cannot be determined with precision, actual results may materially differ from those estimates or assumptions.

Short-term Investments

Short-term investments are marketable securities with maturities greater than three months but less than one year from date of purchase. As of December 31, 2024 we had no short-term investments. As of June 30, 2024, our short-term investments consisted of $34.6 million, in United States government securities. The short-term investments held as of June 30, 2024 were considered to be held to maturity and are carried at amortized cost. As of December 31, 2024, we had no unrealized gains and losses. As of June 30, 2024, gross unrealized gains and losses were immaterial.

Revenue Recognition

Revenues from Customers

In accordance with ASC Topic 606, *Revenue from Contracts with Customers* (Topic 606), we recognized revenue when control of the promised goods or services was transferred to our customers, in an amount that reflects the consideration we expected to be entitled to in exchange for those goods or services. For enforceable contracts with our customers, we first identified the distinct performance obligations – or accounting units – within the contract. Performance obligations are commitments in a contract to transfer a distinct good or service to the customer.

Payments received under commercial arrangements, such as licensing technology rights, may include non-refundable fees at the inception of the arrangements, milestone payments for specific achievements designated in the agreements, and royalties on the sale of products. At the inception of arrangements that include milestone payments, we used judgment to evaluate whether the milestones were probable of being achieved, and we estimated the amount, if any, to include in the transaction price using the most likely method. If it were probable that a significant revenue reversal would not occur, the estimated amount was included in the transaction price. Milestone payments that were not within our or the licensee's control, such as regulatory approvals, were not included in the transaction price until those approvals were received. At the end of each reporting period, we re-evaluated the probability of achievement of development milestones and any related constraint and, as necessary, we adjusted our estimate of the overall transaction price.

To the extent a contract included multiple promised deliverables, we applied judgment to determine whether promised deliverables were capable of being distinct and were distinct within the context of the contract. If these criteria were not met, the promised deliverables were accounted for as a combined performance obligation. For arrangements with multiple distinct performance obligations, we allocated variable consideration related to our 50-50 cost share for development services directly to the associated performance obligation and then allocated the remaining consideration among the performance obligations based on their relative stand-alone selling price.

When not directly observable, we typically estimated the stand-alone selling price for each distinct performance obligation. Variable consideration that related specifically to our efforts to satisfy specific performance obligations was allocated entirely to those performance obligations. Other components of the transaction price were allocated based on the relative stand-alone selling price, over which management has applied significant judgment. We developed assumptions that required judgment to determine the stand-alone selling price for license-related performance obligations, which may have included forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical, regulatory and commercial success. We estimated stand-alone selling price for research and development performance obligations by forecasting the expected costs of satisfying a performance obligation plus an appropriate margin.

In the case of a license that is a distinct performance obligation, we recognized revenue allocated to the license from non-refundable, up-front fees at the point in time when the license was transferred to the licensee and the licensee can use and benefit from the license. For licenses that are bundled with other distinct or combined obligations, we used judgment to assess the nature of the performance obligation to determine whether the performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. If the performance obligation is satisfied over time, we evaluated the measure of progress in each reporting period and, if necessary, adjusted the measure of performance and related revenue recognition.

The selection of the method to measure progress towards completion requires judgment and is based on the nature of the products or services to be provided. Revenue is recorded proportionally as costs are incurred. We generally used the cost-to-cost measure of progress because it best depicted the transfer of control to the customer which occurred as we incurred costs. Under the cost-to-cost measure of progress, the extent of progress towards completion was measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation (an input method under Topic 606). We used judgment to estimate the total cost expected to complete the research and development performance obligations, which included subcontractors' costs, labor, materials, other direct costs and an allocation of indirect costs. We evaluated these cost estimates and the progress each reporting period and, as necessary, we adjusted the measure of progress and related revenue recognition.

In connection with our, now terminated, April 2020 License, Development and Commercialization Agreement with Kyowa Kirin Co., Ltd. (KKC) (the KKC Commercialization Agreement) described in *Note 7. License Agreements,* we performed development services related to our 50-50 cost sharing arrangement for which revenue was recognized over time. Additionally, we performed services for KKC at their request, the costs of which were fully reimbursed to us. We recorded the reimbursement for such pass through services as revenue at 100% of reimbursed costs, as control of the additional services for KKC was transferred at the time we incurred such costs. The costs of these services were recognized in the condensed consolidated statements of operations as research and development expense.

During the three and six months ended December 31, 2024 and the three months ended December 31, 2023, we did not recognize any revenue associated with the KKC Commercialization Agreement. During the six months ended December 31, 2023, we recognized revenue associated with the KKC Commercialization Agreement as follows (in thousands):

Timing of Revenue Recognition:	
Services performed over time	$ 743
Pass through services at a point in time	9
	$ 752

Contract Balances

Contract liabilities were included in deferred revenue and deferred revenue, long-term in our condensed consolidated balance sheets. Our contract liabilities accounted for under Topic 606 related to the amount of initial upfront consideration allocated to the development services performance obligations.

As of June 30, 2024 and December 31, 2024, we had no accounts receivable, unbilled receivable balances or contract liabilities. A reconciliation of the beginning and ending amount of contract liabilities as of June 30, 2024, which was primarily related to the combined performance obligation for the transfer of development services under the KKC Commercialization Agreement and was a separate performance obligation in our contracts pursuant to research plans under the agreements, was as follows:

Beginning balance	$ 317
Recognized as revenue:	
Revenue recognized upon satisfaction of performance obligations	(317)
Ending balance	$ —

The timing of revenue recognition, invoicing and cash collections results in billed accounts receivable and unbilled receivables (contract assets) and deferred revenue (contract liabilities). We invoiced our customers in accordance with agreed-upon contractual terms, typically at periodic intervals or upon achievement of contractual milestones. Invoicing may have occurred subsequent to revenue recognition, resulting in unbilled receivables. Advanced payments from our customers before revenue was recognized resulted in contract liabilities.

Revenues from Collaborators

At contract inception, we assessed whether the collaboration arrangements were within the scope of ASC Topic 808 *Collaborative Agreements (Topic 808)*, to determine whether such arrangements involved joint operating activities performed by parties that were both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment was performed based on the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of Topic 808 that contain multiple units of account, we first determined which units of account within the arrangement were within the scope of Topic 808 and which elements were within the scope of Topic 606. For units of account within collaboration arrangements that were accounted for pursuant to Topic 808, an appropriate recognition method was determined and applied consistently, by analogy to authoritative accounting literature. For elements of collaboration arrangements that were accounted for pursuant to Topic 606, we recognized revenue as discussed above. Consideration received that did not meet the requirements to satisfy Topic 606 revenue recognition criteria was recorded as deferred revenue and classified as either current or long-term deferred revenue based on our best estimate of when such amounts would be recognized.

Disposition of Non-Financial Assets

The Company accounts for infrequent dispositions of assets in its product pipeline in accordance with ASC 610-20, *Other Income - Gains and Losses from the Derecognition of Nonfinancial Assets*, which requires dispositions of long-lived assets that are not a discontinued operation be accounted for on a net basis and included in income from continuing operations before income taxes in accordance with ASC 350, *Intangible Assets - Goodwill and Other*. Proceeds from sales designated as dispositions of non-financial assets are classified as cash flows from investing activities in the condensed consolidated statements of cash flows.

Net (Loss) Income Per Share

Basic and diluted net (loss) income per share is computed using the weighted-average number of shares of common stock outstanding during the period, less any shares subject to repurchase or forfeiture. There were no shares of common stock subject to repurchase or forfeiture for the three and six months ended December 31, 2024 and 2023. Diluted net (loss) income per share is computed based on the sum of the weighted-average number of common shares and potentially dilutive common shares outstanding during the period determined using the treasury-stock and if-converted methods.

For purposes of the diluted net (loss) income per share calculation for the three and six months ended December 31, 2024 and 2023, potentially dilutive securities are excluded from the calculation of diluted net (loss) income per share because their weighted-average exercise prices were above our weighted-average share price as of December 31, 2024 and 2023, respectively, therefore, basic and diluted net (loss) income per share were the same for the three and six months ended December 31, 2024 and 2023.

The following table presents potentially dilutive shares that have been excluded from the calculation of net (loss) income per share because of their anti-dilutive effect (in thousands):

	For the Three Months Ended December 31,		For the Six Months Ended December 31,	
	2024	**2023**	**2024**	**2023**
Stock options	955	1,398	955	1,398
Warrants	103	103	103	103
Total anti-dilutive shares	1,058	1,501	1,058	1,501

Recent Accounting Pronouncement

Recently Issued

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standards setting bodies that are adopted as of the specified effective date. The Company believes the impact of recently issued standards and any issued but not yet effective standards will not have a material impact on its condensed consolidated financial statements upon adoption.

In November 2023, the FASB issued Accounting Standard Update (ASU) No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires a public entity to disclose significant segment expenses and other segment items on an annual and interim basis and provide in interim periods all disclosures about a reportable segment's profit or loss and assets that are currently required annually. Additionally, it requires a public entity to disclose the title and position of the Chief Operating Decision Maker. This ASU does not change how a public entity identifies its operating segments, aggregates them, or applies the quantitative thresholds to determine its reportable segments. The new standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. We expect this ASU to only impact our disclosures with no impact to our results of operations, cash flows, and financial condition.

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which focuses on the rate reconciliation and income taxes paid. ASU No. 2023-09 requires a public business entity (PBE) to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local, and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. For PBEs, the new standard is effective for annual periods beginning after December 15, 2024, with early adoption permitted. An entity may apply the amendments in this ASU prospectively by providing the revised disclosures for the period ending December 31, 2025 and continuing to provide the pre-ASU disclosures for the prior periods, or may apply the amendments retrospectively by providing the revised disclosures for all periods presented. We expect this ASU to only impact our disclosures with no impact to our results of operations, cash flows, and financial condition.

In November 2024, the FASB issued ASU No. 2024-03, *Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40)* (ASU 2024-03). The amendments in this update require disclosure, in the notes to the financial statements, of specific expense categories present within expense captions presented on the face of the statement of operations within continuing operations of PBEs. The amendments in this update are effective for annual periods beginning after December 15, 2026 and interim periods beginning after December 15, 2027. Early adoption is permitted. The amendments should be applied either prospectively to financial statements issued for reporting periods after the effective date of this ASU or retrospectively to any and all prior periods presented in the financial statements. The impact of adoption of this ASU on the Company's disclosures is currently being evaluated.

In January 2025, the FASB issued ASU No. 2025-01, *Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date.*

The amendment in this update clarifies the effective date of ASU 2024-03, which is that PBEs are required to adopt the guidance in annual reporting periods beginning after December 15, 2026 and in interim periods within annual reporting periods beginning after December 15, 2027. The impact of adoption of this ASU on the Company's disclosures is currently being evaluated.

~~XML 18 R12.htm IDEA: XBRL DOCUMENT~~

Balance Sheet Details

6 Months Ended
Dec. 31, 2024

Balance Sheet Related Disclosures [Abstract]

Balance Sheet Details

3. Balance Sheet Details

Prepaid and Other Current Assets

Prepaid and other current assets consisted of the following, in thousands:

	December 31, 2024	June 30, 2024
Insurance	$ 350	$ 460
Software licenses	225	442
Security deposit	—	263
Prepaid clinical costs	—	1,050
Other	71	209
Total prepaid and other current assets	$ 646	$ 2,424

Property and Equipment

As of December 31, 2024, we had no property and equipment. Property and equipment consisted of the following as of June 30, 2024, in thousands:

Furniture and equipment	$ 1,000
Equipment	187
Leasehold improvements	969
	2,156
Less: accumulated depreciation [(1)]	(1,764)
Property and equipment, net	$ 392

[(1)] Includes impairment charge of $0.5 million, see below discussion on *Impact of the Agreement* (as discussed in *Note 9. Leases*).

Depreciation expense of property and equipment for the six months ended December 31, 2024 and 2023 are presented in the condensed consolidated statements of cash flows. During the three months ended December 31, 2024, we did not record depreciation expense. During the three months ended December 31, 2023, depreciation expense was approximately $0.1 million.

Impact of the Agreement (as discussed in Note 9. Leases)

As noted in *Note 9. Leases*, we agreed to sell our furniture and fixtures to the landlord for $1.00 on our lease termination date of September 30, 2024. We completed an evaluation of the impact of the Agreement, as defined in *Note 9. Leases*, on the carrying value of our property and equipment (Other Long-Lived Assets). This process included evaluating the remaining estimated useful lives, significant changes in the use and potential impairment charges related to the Other Long-Lived Assets. Based upon our evaluation, we recorded an impairment charge during our fiscal year ended June 30, 2024 of approximately $0.5 million for the furniture and fixtures sold to the landlord on September 30, 2024, which was included in the impairment of long-lived assets in the condensed consolidated statements of operations for the fiscal year ended June 30, 2024. We also changed our estimate of the remaining useful lives of our leasehold improvements resulting in an acceleration of depreciation of approximately $0.1 million during our fiscal year ended June 30, 2024.

Accrued Liabilities

Accrued liabilities consisted of the following, in thousands:

	December 31, 2024	June 30, 2024
Accrued compensation and benefits [(1)]	$ 1,476	$ 2,821
Accrued pre-clinical and clinical trial expenses	151	1,407
Accrued legal and professional services	6	33
Accrued reimbursement to KKC	—	892
Other	58	34
Total accrued liabilities	$ 1,691	$ 5,187

[(1)] Includes employee termination benefits of approximately $1.3 million and $21,000 as of December 31, 2024 and June 30, 2024, respectively, as more fully described in *Note 5. Employee Termination Benefits*.

~~XML 19 R13.htm IDEA: XBRL DOCUMENT~~

Fair Value Measurements

6 Months Ended
Dec. 31, 2024

Fair Value Disclosures [Abstract]

Fair Value Measurements

4. Fair Value Measurements

The carrying amounts of financial instruments such as cash equivalents, short-term investments and accounts payable approximate the related fair values due to the short-term maturities of these instruments. We invest our excess cash in financial instruments which are readily convertible into cash, such as money market funds and U.S. government securities. Cash equivalents and short-term investments are classified as Level 1 as defined by the fair value hierarchy. As of December 31, 2024 and June 30, 2024, we had no assets or liabilities measured on a recurring or non-recurring basis.

~~XML 20 R14.htm IDEA: XBRL DOCUMENT~~

Employee Termination Benefits

6 Months Ended
Dec. 31, 2024

Restructuring Reserve [Abstract]

Employee Termination Benefits

5. Employee Termination Benefits

In connection with our joint decision to discontinue development of zandelisib outside of Japan in December 2022, we announced a realignment of our clinical development efforts that streamlined our organization towards the continued clinical development of our two earlier clinical-stage assets, voruciclib and ME-344. As a result, our Board approved a staggered workforce reduction (the 2023 RIF), which was completed during fiscal year 2024.

In August 2024, we commenced the Strategic Alternatives RIF, as discussed in our strategic alternatives announcement described in *Note 1. Description of Business and Basis of Presentation*. Including contractual pro-rata fiscal year 2025 bonuses, we expect to incur charges not to exceed a total of $6.5 million in retention, severance and COBRA costs related to the termination of our employees due to our related wind down activities. The charges that we expect to incur in connection with the Strategic Alternatives RIF are subject to a number of assumptions, and actual results may differ materially. We may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the Strategic Alternatives RIF.

For the three months ended December 31, 2024, we recorded employee termination benefits of $0.3 million and $0.9 million within research and development and general and administrative expense, respectively. For the three months ended December 31, 2023, we recorded employee termination benefits of $0.1 million and $0.2 million within research and development expense and general and administrative expense, respectively.

For the six months ended December 31, 2024, we recorded employee termination benefits of $1.6 million and $2.7 million within research and development and general and administrative expense, respectively. For the six months ended December 31, 2023, we recorded employee termination benefits of $0.2 million in both research and development expense and general and administrative expense.

The following table summarizes our activity related to employee benefits included in accrued liabilities (in thousands):

	December 31, 2024	June 30, 2024
Beginning balance	$ 21	$ 993
Increase in accrued restructuring	4,333	556
Cash payments	(3,069)	(1,528)
Ending Balance	$ 1,285	$ 21

~~XML 21 R15.htm IDEA: XBRL DOCUMENT~~

Commitments and Contingencies

6 Months Ended
Dec. 31, 2024

Commitments and Contingencies

6. Commitments and Contingencies

We have contracted with various consultants and third parties to assist us in pre-clinical research and development and clinical trials work for our leading drug compounds and general and administrative activities. The contracts are terminable at any time but obligate us to reimburse the providers for any time or costs incurred through the date of termination. See the discussion of the sale of ME-344 within *Note 12. Disposition of a Non-financial Asset* for additional information regarding contracts associated with ME-344 assumed by the Purchaser (as defined in *Note 12. Disposition of a Non-financial Asset*). We also have an employment agreement with our acting chief executive officer and chief financial officer that provides for severance payments and accelerated vesting for share-based awards if their employment is terminated under specified circumstances.

Litigation

From time to time, we may be involved in various lawsuits, legal proceedings, or claims that arise in the ordinary course of business. Management believes there are no claims or actions pending against us as of December 31, 2024, which will have, individually or in the aggregate, a material adverse effect on its business, liquidity, financial position, or results of operations. Litigation, however, is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business.

Indemnification

In accordance with our amended and restated certificate of incorporation and sixth amended and restated bylaws, we have indemnification obligations to our officers and directors for certain events or occurrences, subject to certain limits, while they are serving in such capacity. There have been no claims to date, and we have a directors and officers liability insurance policy that may enable it to recover a portion of any amounts paid for future claims.

Presage License Agreement

As discussed in *Note 8. Other License Agreements*, we are party to a license agreement with Presage Biosciences, Inc. (Presage) under which we may be required to make future payments upon the achievement of certain development, regulatory and commercial milestones, as well as potential future royalties based upon net sales. As of December 31, 2024, we had no accruals for potential future payments as achievement of the milestones had not been met.

~~XML 22 R16.htm IDEA: XBRL DOCUMENT~~

License Agreements

6 Months Ended
Dec. 31, 2024

Related Party Transactions [Abstract]

License Agreements

7. License Agreements

Kyowa Kirin Co., Ltd. License, Development and Commercialization Agreement

In April 2020, we entered into the KKC Commercialization Agreement under which we granted to KKC a co-exclusive, sublicensable, payment-bearing license under certain patents and know-how controlled by us to develop and commercialize zandelisib and any pharmaceutical product containing zandelisib for all human indications in the U.S. (the U.S. License), and an exclusive (subject to certain retained rights to perform obligations under the KKC Commercialization Agreement), sublicensable, payment-bearing, license under certain patents and know-how controlled by us to develop and commercialize zandelisib and any pharmaceutical product containing zandelisib for all human indications in countries outside of the U.S. KKC granted to us a co-exclusive, sublicensable, license under certain patents and know-how controlled by KKC to develop and commercialize zandelisib for all human indications in the U.S., and a co-exclusive, sublicensable, royalty-free, fully paid license under certain patents and know-how controlled by KKC to perform our obligations in the Ex-U.S. under the KKC Commercialization Agreement. KKC paid us an initial nonrefundable payment of $100.0 million.

In July 2023, we entered into a termination agreement with KKC to mutually terminate the KKC Commercialization Agreement and all other related agreements between the parties (Termination Agreement) and jointly decided to discontinue zandelisib development in the U.S. Prior to the execution of the Termination Agreement, KKC was responsible for the development and commercialization of zandelisib in Ex-U.S. and, subject to certain exceptions, was solely responsible for all costs related thereto. We also provided to KKC certain drug supplies necessary for the development and commercialization of zandelisib in the Ex-U.S., with the understanding that KKC would have assumed responsibility for manufacturing for the Ex-U.S. as soon as practicable.

During fiscal year 2023, we updated our assessment of the total transaction price from the KKC Commercialization Agreement to reflect the upfront payment, milestone payments, estimated development cost-sharing, and deferred revenue. After announcing our plan to discontinue the global development of zandelisib outside of Japan, in December 2022, we decreased our estimate for variable consideration related to development cost sharing.

With the execution of the Termination Agreement, we regained full, global rights (subject to KKC's limited rights for compassionate use) and KKC has no further rights to develop, use or commercialize zandelisib in the U.S., nor do we have any remaining performance obligations with all consideration received from KKC being nonrefundable. Therefore, the remaining long-term deferred revenue as of June 30, 2023, of $64.5 million that was allocated to the U.S. License obligation accounted for under Topic 808 at inception of the KKC Commercialization Agreement was recognized as revenue from collaboration agreements in the three months ended September 30, 2023, utilizing contract termination analogous to guidance provided in Topic 606.

The $64.5 million transaction price allocated to the U.S. License obligation accounted for under Topic 808 was included as noncurrent deferred revenue as of June 30, 2023. As of June 30, 2023, we also had deferred revenue of approximately $0.3 million related to the transaction price allocated to the Development Services performance obligations and recognized the remaining revenue based on the proportional performance of these development activities. The KKC Agreement was terminated on July 14, 2023 and all remaining amounts of deferred revenue were recognized during the fiscal year ended June 30, 2024.

~~XML 23 R17.htm IDEA: XBRL DOCUMENT~~

Other License Agreements

6 Months Ended
Dec. 31, 2024

Licensing Arrangements [Abstract]

Other License Agreements

8. Other License Agreements

Presage License Agreement

In September 2017, we, as licensee, entered into a license agreement with Presage. Under the terms of the license agreement, Presage granted us exclusive worldwide rights to develop, manufacture and commercialize voruciclib, a clinical-stage, oral and selective CDK inhibitor, and related compounds. In exchange, we paid $2.9 million to Presage. With respect to the first indication, an incremental $2.0 million payment, due upon dosing of the first subject in the first registration trial, will be owed to Presage, for total payments of $4.9 million prior to receipt of marketing approval of the first indication in the U.S., EU or Japan. Additional potential payments of up to $179.0 million will be due upon the achievement of certain development, regulatory and commercial milestones. We will also pay mid-single digit tiered royalties on the net sales of any product successfully developed. As an alternative to milestone and royalty payments related to countries in which we sublicense product rights, we will pay to Presage a tiered percentage (which decreases as product development progresses) of amounts received from such sublicensees. During the three and six months ended December 31, 2024 and 2023, we made no payments under the Presage license agreement.

BeiGene Collaboration

In October 2018, we entered into a clinical collaboration with BeiGene, Ltd. (BeiGene) to evaluate the safety and efficacy of zandelisib in combination with BeiGene's zanubrutinib (marketed as Brukinsa®), an inhibitor of Bruton's tyrosine kinase, for the treatment of patients with B-cell malignancies. Under the terms of the clinical collaboration agreement, we amended our ongoing Phase 1b trial to include evaluation of zandelisib in combination with zanubrutinib in patients with B-cell malignancies. Study costs are being shared equally by the parties, and we agreed to supply zandelisib and BeiGene agreed to supply zanubrutinib. We record the costs reimbursed by BeiGene as a reduction of our research and development expenses. We retained full commercial rights for

zandelisib and BeiGene retained full commercial rights for zanubrutinib. With the discontinuation of the zandelisib program outside of Japan, this clinical collaboration was terminated on September 28, 2023. The Company did not recognize any cost reimbursement reductions within research and development during the three and six months ended December 31, 2024 and three months ended December 31, 2023. Cost reimbursements recorded as a reduction of research and development costs, in the condensed consolidated statements of operations, during the six months ended December 31, 2023 were approximately $0.1 million.

~~XML 24 R18.htm IDEA: XBRL DOCUMENT~~

Leases

6 Months Ended
Dec. 31, 2024

Disclosure Text Block [Abstract]

Leases

9. Leases

In July 2020, we entered into a lease agreement for approximately 32,800 square feet of office space in San Diego, California. The lease agreement was scheduled to expire in March 2028. We accounted for the lease agreement as an operating lease. The lease agreement contained an option to renew and extend the lease term, which was not included in the determination of the right-of-use (ROU) asset and operating lease liability, as it was not reasonably certain to be exercised. In July 2022, we amended the lease to extend the lease termination date from March 2028 to November 30, 2029 and to add an additional 12,300 square feet of office space adjacent to our current office in San Diego (the Amended Lease). Upon commencement of the Amended Lease, we recognized an additional ROU asset and a corresponding operating lease liability of $4.3 million. The Amended Lease includes variable non-lease components (e.g., common area maintenance, maintenance, etc.) that are not included in the ROU asset and operating lease liability and are reflected as an expense in the period incurred as a component of the lease cost.

Lease Termination

On June 18, 2024 (the Agreement Date), we entered into a lease termination agreement (Agreement) with our landlord pursuant to which the parties agreed to terminate the lease for our existing office space as of September 30, 2024. The original (as amended) scheduled expiration date was November 30, 2029. As consideration for the Agreement, we agreed to pay the landlord a termination fee of approximately $11.1 million (the Termination Fee) and to prepay the remaining rent due under the Agreement in the amount of approximately $0.2 million (the Remaining Rent) and sell all the furniture and fixtures to the landlord for $1.00 (see *Property and Equipment* within *Note 3. Balance Sheet Details* for further discussion on the impact of the Agreement on our property and equipment). We received our security deposit, which is classified as a component of prepaid and other current assets, from the landlord in October 2024.

The Agreement was accounted for as a lease modification of the original contract. As a result of the Agreement, we reduced both the remaining ROU asset and lease liability by approximately $22,000, resulting in no impact to our consolidated statements of operations for the fiscal year ended June 30, 2024. We reassessed the lease classification, as of the Agreement Date, noting the current classification as an operating lease remained appropriate. Both the Termination Fee and the Remaining Rent were paid prior to June 30, 2024. Subsequent to the payment of both the Termination Fee and the Remaining Rent, our lease liability was relieved and the balance was reduced to zero.

We incurred direct costs of approximately $0.2 million in connection with the Agreement which accordingly was recorded to the ROU assets as a direct cost of modifying the Agreement. As of the Agreement Date, we determined a triggering event, in accordance with ASC 360, had occurred and therefore completed an impairment analysis on its ROU asset resulting in an impairment charge of approximately $10.4 million being recorded in our consolidated statements of operations for the fiscal year ended June 30, 2024.

During the three months ended December 31, 2024 we did not recognize lease costs. The total operating lease costs for the Amended Lease were as follows for the periods presented (in thousands):

	For the Three Months Ended December 31, 2023	For the Six Months Ended December 31, 2024	For the Six Months Ended December 31, 2023
Operating lease cost	$ 609	$ 214	$ 1,217
Variable lease costs	12	—	24
Total lease costs included in operating expenses	$ 621	$ 214	$ 1,241

During the three and six months ended December 31, 2024, we had no supplemental cash flow activity. Supplemental cash flow information related to our operating leases was as follows for the periods presented (in thousands):

	For the Three Months Ended December 31, 2023	For the Six Months Ended December 31, 2023
Cash paid for amount included in the measurement of lease liabilities:		
Operating cash flows from operating leases	$ 583	$ 1,167

As of June 30, 2024, we had no remaining future minimum rental payments for our operating leases and the remaining ROU asset balance was $0.2 million. As of September 30, 2024, we had vacated the facility and the leased property reverted to the landlord. In addition, the ROU asset has been fully amortized. During fiscal year 2024, the ROU asset balance was increased by approximately $0.2 million related to direct costs associated with the Agreement. Additionally, the ROU asset balance was decreased by: (1) approximately $22,000 associated with our reassessment of the lease liability as of the Agreement Date and (2) $10.4 million associated with the impairment of the ROU asset, as discussed above.

~~XML 25 R19.htm IDEA: XBRL DOCUMENT~~

Stockholders' Equity

6 Months Ended
Dec. 31, 2024

Federal Home Loan Banks [Abstract]

Stockholders' Equity

10. Stockholders' Equity

Equity Transactions

Shelf Registration Statement

We have a shelf registration statement (February 2024 Shelf Registration Statement) that permits us to sell, from time to time, up to $100.0 million of common stock, preferred stock, warrants, rights and units, subject to the "Baby Shelf Limitation" described below. The February 2024 Shelf Registration Statement was filed February 20, 2024 and declared effective February 28, 2024.

At-The-Market Equity Offering

On February 20, 2024, we entered into a capital on demand sales agreement with JonesTrading Institution Services LLC, pursuant to which we can offer and sell shares having an aggregate offering price of up to $25.0 million (the ATM Program). In no event will we sell securities registered on this registration statement in a public primary offering with a value exceeding more than one-third of our public float in any 12-month period so long as our public float remains below $75.0 million (Baby Shelf Limitation) As of January 2, 2024, the date used under applicable rules of the SEC to determine our public float at the commencement of the offering, one-third of our public float was equal to approximately $9.9 million. As of December 31, 2024, no shares have been issued and sold under our ATM Program.

Cooperation Agreement and Cash Dividend

On October 31, 2023, we announced our entry into a cooperation agreement with Anson Funds Management LP and Cable Car Capital LLC, which, among other non-financial related items provided for a capital return to stockholders in the form of a dividend in the amount of $1.75 per share of common stock that was declared on November 6, 2023 to stockholders of record at the close of business on November 17, 2023 (Cooperation Agreement). The total dividend of $11.7 million was paid on December 6, 2023 and was recorded as a reduction of additional paid-in capital in the condensed consolidated statements of stockholders' equity, as we have an accumulated deficit, rather than retained earnings.

Rights Agreement

On October 1, 2023, our Board approved and adopted a rights agreement (Rights Agreement) by and between us and Computershare, Inc., as Rights Agent (as defined in the Rights Agreement). Pursuant to the Rights Agreement, the Board declared a dividend of one preferred share purchase right (each, a Right) for each outstanding share of our common stock, par value $0.00000002 (each a Common Share and collectively, the Common Shares). The Rights are distributable to stockholders of record as of the close of business on October 12, 2023. One Right also will be issued together with each Common Share issued by us after October 12, 2023, but before the Distribution Date, as defined in the Rights Agreement (or the earlier of the redemption or expiration of the Rights) and, in certain circumstances, after the Distribution Date. The Rights and the Rights Agreement expired at the close of business on September 30, 2024. No rights were redeemed or exchanged under the Rights Agreement.

Warrants

As of December 31, 2024, we have outstanding warrants to purchase 102,513 shares of our common stock issued to Torreya Partners LLC. The warrants are fully vested, exercisable at a price of $6.80 per share and expire in October 2027. No warrants were exercised as of December 31, 2024.

Description of Capital Stock

Our total authorized share capital is 226,100,000 shares consisting of 226,000,000 shares of common stock, $0.00000002 par value per share, and 100,000 shares of preferred stock, $0.01 par value per share.

Common Stock

The holders of common stock are entitled to one vote per share. In the event of a liquidation, dissolution or winding up of our affairs, holders of the common stock will be entitled to share ratably in all our assets that are remaining after payment of our liabilities and the liquidation preference of any outstanding shares of preferred stock. All outstanding shares of common stock are fully paid and non-assessable. The rights, preferences and privileges of holders of common stock are subject to any series of preferred stock that we have issued or that we may issue in the future. The holders of common stock have no preemptive rights and are not subject to future calls or assessments by us.

Preferred Stock

Our Board has the authority to issue up to 100,000 shares of preferred stock with a par value of $0.01 per share in one or more series and to fix the rights, preferences, privileges and restrictions in respect of that preferred stock, including dividend rights, dividend rates, conversion rights, voting rights, terms of redemption (including sinking fund provisions), redemption prices and liquidation preferences, and the number of shares constituting such series and the designation of any such series, without future vote or action by the stockholders. Therefore, the Board, without the approval of the stockholders, could authorize the issuance of preferred stock with voting, conversion and other rights that could affect the voting power, dividend and other rights of the holders of shares or that could have the effect of delaying, deferring or preventing a change of control. There were no shares of preferred stock outstanding as of December 31, 2024 and June 30, 2024.

~~XML 26 R20.htm IDEA: XBRL DOCUMENT~~

Share-based Compensation	6 Months Ended Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]	
Share-based Compensation	

11. Share-based Compensation

We use equity-based compensation programs to provide long-term performance incentives for our employees. These incentives consist primarily of stock options and RSUs. In December 2008, we adopted the MEI Pharma, Inc. 2008 Stock Omnibus Equity Compensation Plan (Omnibus Plan), as amended and restated from time-to-time, under which 1,850,739 shares of common stock are currently authorized for issuance. The Omnibus Plan provides for the grant of options and/or other stock-based or stock-denominated awards to our non-employee directors, officers, and employees. As of December 31, 2024, there were 841,714 shares available for future grant under the Omnibus Plan.

In May 2021, we adopted the 2021 Inducement Plan (Inducement Plan), under which 125,000 shares of common stock are authorized for issuance. On June 9, 2023, our Board approved an amendment and restatement of the Inducement Plan to increase the aggregate number of shares of common stock authorized for issuance by 92,000 shares. The Inducement Plan is intended to assist us in attracting and retaining selected individuals to serve as employees who are expected to contribute to our success, by providing an inducement for such individuals to enter into employment with us, and to achieve long-term objectives that will benefit our stockholders. As of December 31, 2024, there were 157,146 shares available for future grant under the Inducement Plan.

During the three and six months ended December 31, 2024 due to the Strategic Alternatives RIF, as discussed in *Note 5. Employee Termination Benefits,* we reversed share-based compensation in excess of that recorded. Total share-based compensation for all stock awards consisted of the following for the periods presented (in thousands):

	For the Three Months Ended December 31,		For the Six Months Ended December 31,	
	2024	2023	2024	2023
Research and development	$ (53)	$ 129	$ (159)	$ 60
General and administrative	(50)	721	(79)	1,153
Total share-based compensation	$ (103)	$ 850	$ (238)	$ 1,213

Stock Options

Stock options granted to employees vest 25% one year from the date of grant and ratably each month thereafter on the first day of the month following the one-year anniversary of the grant date for a period of 36 months and generally expire ten years from the date of grant. Stock options granted to directors vest ratably each month for a period of 12 months from the date of grant and generally expire ten years from the date of grant. Upon separation from the Company, without cause, our Board members have three years to

exercise their vested stock options. As of December 31, 2024, there were 954,723 total options outstanding of which 894,869 were granted under the Omnibus Plan and 59,854 were granted under the Inducement Plan.

A summary of our stock option activity and related data follows:

	Number of Options	Weighted-Average Exercise Price	Weighted-Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Outstanding at June 30, 2024	1,357,213	$ 31.60		
Forfeited	(402,490)	$ 25.14		
Outstanding at December 31, 2024	954,723	$ 34.32	6.3	$ —
Vested and expected to vest at December 31, 2024	954,723	$ 34.32	6.3	$ —

As of December 31, 2024, the aggregate intrinsic value of outstanding options was calculated as the difference between the exercise price of the underlying options and the closing price of our common stock of $2.46 on that date.

Unrecognized compensation expense related to non-vested stock options totaled $0.1 million as of December 31, 2024. Such compensation expense is expected to be recognized over a weighted-average period of 1.43 years.

We use the Black-Scholes valuation model to estimate the grant date fair value of stock options. During the six months ended December 31, 2024, we did not grant any stock options. To calculate these fair values, the following weighted-average assumptions were used for the period presented:

	For the Six Months Ended December 31, 2023
Risk-free interest rate	4.5 %
Expected life (years)	5.7
Volatility	90.0 %
Dividend yield	— %
Weighted-average grant date fair value	$ 5.18

~~XML 27 R21.htm IDEA: XBRL DOCUMENT~~

Disposition of a Non-financial Asset	6 Months Ended Dec. 31, 2024
Discontinued Operations and Disposal Groups [Abstract]	
Disposition of a Non-financial Asset	

12. Disposition of a Non-financial Asset

On October 22, 2024 (the Closing Date), MEI and Aardvark Therapeutics, Inc. (the Purchaser), entered into an Asset Purchase Agreement (the Asset Purchase Agreement), whereby we sold to the Purchaser our rights, title and interest in and to certain assets related to ME-344, including relevant intellectual property rights, technology and contracts (the ME-344 Sale). Pursuant to the Asset Purchase Agreement, the Purchaser paid us an initial payment of $0.5 million in cash plus a reimbursement amount of $55,000 at the closing of the transaction. The Purchaser may also make future milestone payments up to $62.0 million after the Closing Date, payable upon the achievement of certain regulatory and revenue milestones. The Purchaser also assumed certain of our liabilities after the Closing Date, including liabilities arising under the contracts transferred under the Asset Purchase Agreement.

The ME-344 sale did not trigger a discontinued operation as the intellectual property sold did not represent a component of our business. Additionally, we concluded the ME-344 Sale met all the criteria to be derecognized on the Closing Date. Variable consideration, such as future potential regulatory and revenue milestones have been fully constrained. As such, as of the Closing Date and December 31, 2024, we determined the transaction price to be the initial payment of $0.5 million. Accordingly, we recognized a gain, upon satisfaction of our obligations under the Asset Purchase Agreement, of $0.5 million as a separate component of other income (expense), net in the consolidated statements of operations. The $55,000 reimbursement by the Purchaser represented work performed at the Purchaser's request prior to the Closing Date, which they agreed to reimburse. The reimbursement did not represent a liability assumed or relieved by the Purchaser and was, therefore, not included in the calculation of the gain on the disposition of the ME-344 asset. The $55,000 reimbursement was recognized as contra research and development expense in accordance with our reimbursement policy for pass through services.

~~XML 28 R22.htm IDEA: XBRL DOCUMENT~~

Description of Business and Basis of Presentation (Policies)	6 Months Ended Dec. 31, 2024
Description of Business	

Description of Business

MEI Pharma, Inc. (Nasdaq: MEIP) is a pharmaceutical company that has been developing novel and differentiated cancer therapies. We built our pipeline by acquiring promising cancer agents and

creating value in programs through development, strategic partnerships, and out-licensing or commercialization, as appropriate. Our approach to oncology drug development has been to evaluate our drug candidates in combinations with standard-of-care therapies to overcome known resistance mechanisms and address clear medical needs to provide improved patient benefit. Our pipeline includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and prior to its sale, ME-344 as more fully discussed in *Note 12. Disposition of a Non-financial Asset*, an intravenous small molecule mitochondrial inhibitor targeting the oxidative phosphorylation pathway.

Strategic Alternatives

On July 22, 2024, we announced that our Board of Directors (Board) had determined unanimously to begin the evaluation of our strategic alternatives, including potential transactions as well as an orderly wind down of operations, if appropriate, to maximize the value of our assets for our stockholders. We commenced a reduction-in-force (the Strategic Alternatives RIF) beginning August 1, 2024, which will continue in stages as our operational and strategic direction evolves. We have discontinued the clinical development of voruciclib, while certain nonclinical activities related to MEI's drug candidate assets will continue to be conducted by us. As part of the review of strategic alternatives, we may consider options such as out-licensing opportunities for existing programs and merger and acquisition opportunities.

Consistent with our intention to preserve cash, David M. Urso, our former President and Chief Executive Officer, and Richard Ghalie, M.D., our former Chief Medical Officer, stepped down effective August 1, 2024. Mr. Urso also left the Board at that date. We have entered into consulting agreements with both Mr. Urso and Dr. Ghalie under which they will remain available to assist us in our strategic efforts. Charles V. Baltic III, the former Chairperson of the Board, also stepped down from the Board contemporaneously with the announcement on July 22, 2024. Our Board appointed Justin J. File, our Chief Financial Officer, to assume the position of Acting Chief Executive Officer and appointed Frederick W. Driscoll as our Chairperson of the Board.

Basis of Presentation and Consolidation

Basis of Presentation and Consolidation

Unaudited Interim Financial Information

The interim condensed consolidated financial statements are unaudited. These interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. (U.S. GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the accompanying interim condensed financial statements do not include all of the information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying condensed interim consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) that are necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. These statements do not include all disclosures required by U.S. GAAP and should be read in conjunction with the Company's audited consolidated financial statements and notes for the fiscal year ended June 30, 2024.

Consolidation Principles

The accompanying unaudited condensed consolidated financial statements include the accounts of MEI Pharma, Inc. and our wholly owned subsidiary, Meadow Merger Sub, Inc. We have eliminated all intercompany accounts and transactions in consolidation.

The accompanying unaudited interim condensed consolidated financial statements for the quarterly and six month periods ended December 31, 2024 should be read in conjunction with the audited financial statements and notes thereto as of and for the fiscal year ended June 30, 2024, included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on September 19, 2024 (2024 Annual Report). Interim results are not necessarily indicative of results for a full year.

Subsequent Events

The Company has evaluated subsequent events through the date the condensed consolidated financial statements were issued.

Liquidity

Liquidity

To date, we have obtained cash and funded our operations primarily through equity financings and license agreements. We have accumulated losses of $398.9 million since inception and expect to incur operating losses and generate negative cash flows from operations for the foreseeable future. As of December 31, 2024, we had $23.7 million in cash and cash equivalents. In connection with our July 2024 announcement regarding the evaluation of our strategic alternatives, we discontinued the clinical development of voruciclib, while certain nonclinical research and development activities continued. As a result, we continue to incur research and development expenses in connection with clinical trial closing costs and the completion of our nonclinical projects. We believe that our cash balance, will be sufficient to meet our obligations and fund operations for at least the next 12 months from the issuance of these condensed consolidated financial statements.

~~XML 29 R23.htm IDEA: XBRL DOCUMENT~~

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Dec. 31, 2024

Accounting Policies [Abstract]

Use of Estimates

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to the valuation of share-based awards, the discount rate used in estimating the present value of the right-of-use assets and lease liabilities, the useful lives of property and equipment, the recoverability of long-lived assets, clinical trial accruals, periods over which revenue should be recognized, relative stand-alone selling price, deferred income taxes and related valuation allowances, and the assessment of our ability to fund our operations for at least the next 12 months from the date of issuance of these condensed consolidated financial statements. We base our estimates on historical experience and other market-specific or other relevant assumptions that we believe to be reasonable under the circumstances. Estimates are assessed each reporting period and updated to reflect current information. As future events and their effects cannot be determined with precision, actual results may materially differ from those estimates or assumptions.

Short-term Investments

Short-term Investments

Short-term investments are marketable securities with maturities greater than three months but less than one year from date of purchase. As of December 31, 2024 we had no short-term investments. As of June 30, 2024, our short-term investments consisted of $34.6 million, in United States government securities. The short-term investments held as of June 30, 2024 were considered to be held to maturity and are carried at amortized cost. As of December 31, 2024, we had no unrealized gains and losses. As of June 30, 2024, gross unrealized gains and losses were immaterial.

Revenue Recognition

Revenue Recognition

Revenues from Customers

In accordance with ASC Topic 606, *Revenue from Contracts with Customers* (Topic 606), we recognized revenue when control of the promised goods or services was transferred to our customers, in an amount that reflects the consideration we expected to be entitled to in exchange for those goods or services. For enforceable contracts with our customers, we first identified the distinct performance obligations – or accounting units – within the contract. Performance obligations are commitments in a contract to transfer a distinct good or service to the customer.

Payments received under commercial arrangements, such as licensing technology rights, may include non-refundable fees at the inception of the arrangements, milestone payments for specific achievements designated in the agreements, and royalties on the sale of products. At the inception of arrangements that include milestone payments, we used judgment to evaluate whether the milestones were probable of being achieved, and we estimated the amount, if any, to include in the transaction price using the most likely method. If it were probable that a significant revenue reversal would not occur, the estimated amount was included in the transaction price. Milestone payments that were not within our or the licensee's control, such as regulatory approvals, were not included in the transaction price until those approvals were received. At the end of each reporting period, we re-evaluated the probability of achievement of development milestones and any related constraint and, as necessary, we adjusted our estimate of the overall transaction price.

To the extent a contract included multiple promised deliverables, we applied judgment to determine whether promised deliverables were capable of being distinct and were distinct within the context of the contract. If these criteria were not met, the promised deliverables were accounted for as a combined performance obligation. For arrangements with multiple distinct performance obligations, we allocated variable consideration related to our 50-50 cost share for development services directly to the associated performance obligation and then allocated the remaining consideration among the performance obligations based on their relative stand-alone selling price.

When not directly observable, we typically estimated the stand-alone selling price for each distinct performance obligation. Variable consideration that related specifically to our efforts to satisfy specific performance obligations was allocated entirely to those performance obligations. Other components of the transaction price were allocated based on the relative stand-alone selling price, over which management has applied significant judgment. We developed assumptions that required judgment to determine the stand-alone selling price for license-related performance obligations, which may have included forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical, regulatory and commercial success. We estimated stand-alone selling price for research and development performance obligations by forecasting the expected costs of satisfying a performance obligation plus an appropriate margin.

In the case of a license that is a distinct performance obligation, we recognized revenue allocated to the license from non-refundable, up-front fees at the point in time when the license was transferred to the licensee and the licensee can use and benefit from the license. For licenses that are bundled with other distinct or combined obligations, we used judgment to assess the nature of the performance obligation to determine whether the performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. If the performance obligation is satisfied over time, we evaluated the measure of progress in each reporting period and, if necessary, adjusted the measure of performance and related revenue recognition.

The selection of the method to measure progress towards completion requires judgment and is based on the nature of the products or services to be provided. Revenue is recorded proportionally as costs are incurred. We generally used the cost-to-cost measure of progress because it best depicted the transfer of control to the customer which occurred as we incurred costs. Under the cost-to-cost measure of progress, the extent of progress towards completion was measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation (an input method under Topic 606). We used judgment to estimate the total cost expected to complete the research and development performance obligations, which included subcontractors' costs, labor, materials, other direct costs and an allocation of indirect costs. We evaluated these cost estimates and the progress each reporting period and, as necessary, we adjusted the measure of progress and related revenue recognition.

In connection with our, now terminated, April 2020 License, Development and Commercialization Agreement with Kyowa Kirin Co., Ltd. (KKC) (the KKC Commercialization Agreement) described in *Note 7. License Agreements,* we performed development services related to our 50-50 cost sharing arrangement for which revenue was recognized over time. Additionally, we performed services for KKC at their request, the costs of which were fully reimbursed to us. We recorded the reimbursement for such pass through services as revenue at 100% of reimbursed costs, as control of the additional services for KKC was transferred at the time we incurred such costs. The costs of these services were recognized in the condensed consolidated statements of operations as research and development expense.

During the three and six months ended December 31, 2024 and the three months ended December 31, 2023, we did not recognize any revenue associated with the KKC Commercialization Agreement. During the six months ended December 31, 2023, we recognized revenue associated with the KKC Commercialization Agreement as follows (in thousands):

Timing of Revenue Recognition:	
Services performed over time	$ 743
Pass through services at a point in time	9
	$ 752

Contract Balances

Contract liabilities were included in deferred revenue and deferred revenue, long-term in our condensed consolidated balance sheets. Our contract liabilities accounted for under Topic 606 related to the amount of initial upfront consideration allocated to the development services performance obligations.

As of June 30, 2024 and December 31, 2024, we had no accounts receivable, unbilled receivable balances or contract liabilities. A reconciliation of the beginning and ending amount of contract liabilities as of June 30, 2024, which was primarily related to the combined performance obligation for the transfer of development services under the KKC Commercialization Agreement and was a separate performance obligation in our contracts pursuant to research plans under the agreements, was as follows:

Beginning balance	$ 317
Recognized as revenue:	
Revenue recognized upon satisfaction of performance obligations	(317)
Ending balance	$ —

The timing of revenue recognition, invoicing and cash collections results in billed accounts receivable and unbilled receivables (contract assets) and deferred revenue (contract liabilities). We invoiced our customers in accordance with agreed-upon contractual terms, typically at periodic intervals or upon achievement of contractual milestones. Invoicing may have occurred subsequent to revenue recognition, resulting in unbilled receivables. Advanced payments from our customers before revenue was recognized resulted in contract liabilities.

Revenues from Collaborators

At contract inception, we assessed whether the collaboration arrangements were within the scope of ASC Topic 808 *Collaborative Agreements (Topic 808)*, to determine whether such arrangements involved joint operating activities performed by parties that were both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment was performed based on the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of Topic 808 that contain multiple units of account, we first determined which units of account within the arrangement were within the scope of Topic 808 and which elements were within the scope of Topic 606. For units of account within collaboration arrangements that were accounted for pursuant to Topic 808, an appropriate recognition method was determined and applied consistently, by analogy to authoritative accounting literature. For elements of collaboration arrangements that were accounted for pursuant to Topic 606, we recognized revenue as discussed above. Consideration received that did not meet the requirements to satisfy Topic 606 revenue recognition criteria was recorded as deferred revenue and classified as either current or long-term deferred revenue based on our best estimate of when such amounts would be recognized.

Disposition of Non-Financial Assets

Disposition of Non-Financial Assets

The Company accounts for infrequent dispositions of assets in its product pipeline in accordance with ASC 610-20, *Other Income - Gains and Losses from the Derecognition of Nonfinancial Assets*, which requires dispositions of long-lived assets that are not a discontinued operation be accounted for on a net basis and included in income from continuing operations before income taxes in accordance with ASC 350, *Intangible Assets - Goodwill and Other*. Proceeds from sales designated as dispositions of non-financial assets are classified as cash flows from investing activities in the condensed consolidated statements of cash flows.

Net Income (Loss) Per Share

Net (Loss) Income Per Share

Basic and diluted net (loss) income per share is computed using the weighted-average number of shares of common stock outstanding during the period, less any shares subject to repurchase or forfeiture. There were no shares of common stock subject to repurchase or forfeiture for the three and six months ended December 31, 2024 and 2023. Diluted net (loss) income per share is computed based on the sum of the weighted-average number of common shares and potentially dilutive common shares outstanding during the period determined using the treasury-stock and if-converted methods.

For purposes of the diluted net (loss) income per share calculation for the three and six months ended December 31, 2024 and 2023, potentially dilutive securities are excluded from the calculation of diluted net (loss) income per share because their weighted-average exercise prices were above our weighted-average share price as of December 31, 2024 and 2023, respectively, therefore, basic and diluted net (loss) income per share were the same for the three and six months ended December 31, 2024 and 2023.

The following table presents potentially dilutive shares that have been excluded from the calculation of net (loss) income per share because of their anti-dilutive effect (in thousands):

	For the Three Months Ended December 31,		For the Six Months Ended December 31,	
	2024	2023	2024	2023
Stock options	955	1,398	955	1,398
Warrants	103	103	103	103
Total anti-dilutive shares	1,058	1,501	1,058	1,501

Recent Accounting Pronouncement

Recent Accounting Pronouncement

Recently Issued

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standards setting bodies that are adopted as of the specified effective date. The Company believes the impact of recently issued standards and any issued but not yet effective standards will not have a material impact on its condensed consolidated financial statements upon adoption.

In November 2023, the FASB issued Accounting Standard Update (ASU) No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires a public entity to disclose significant segment expenses and other segment items on an annual and interim basis and provide in interim periods all disclosures about a reportable segment's profit or loss and assets that are currently required annually. Additionally, it requires a public entity to disclose the title and position of the Chief Operating Decision Maker. This ASU does not change how a public entity identifies its operating segments, aggregates them, or applies the quantitative thresholds to determine its reportable segments. The new standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. We expect this ASU to only impact our disclosures with no impact to our results of operations, cash flows, and financial condition.

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which focuses on the rate reconciliation and income taxes paid. ASU No. 2023-09 requires a public business entity (PBE) to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local, and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. For PBEs, the new standard is effective for annual periods beginning after December 15, 2024, with early adoption permitted. An entity may apply the amendments in this ASU prospectively by providing the revised disclosures for the period ending December 31, 2025 and continuing to provide the pre-ASU disclosures for the prior periods, or may apply the amendments retrospectively by providing the revised disclosures for all periods presented. We expect this ASU to only impact our disclosures with no impact to our results of operations, cash flows, and financial condition.

In November 2024, the FASB issued ASU No. 2024-03, *Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40)* (ASU 2024-03). The amendments in this update require disclosure, in the notes to the financial statements, of specific expense categories present within expense captions presented on the face of the statement of operations within continuing operations of PBEs. The amendments in this update are effective for annual periods beginning after December 15, 2026 and interim periods beginning after December 15, 2027. Early adoption is permitted. The amendments should be applied either prospectively to financial statements issued for reporting periods after the effective date of this ASU or retrospectively to any and all prior periods presented in the financial statements. The impact of adoption of this ASU on the Company's disclosures is currently being evaluated.

In January 2025, the FASB issued ASU No. 2025-01, *Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date.* The amendment in this update clarifies the effective date of ASU 2024-03, which is that PBEs are required to adopt the guidance in annual reporting periods beginning after December 15, 2026 and in interim periods within annual reporting periods beginning after December 15, 2027. The impact of adoption of this ASU on the Company's disclosures is currently being evaluated.

~~XML 30 R24.htm IDEA: XBRL DOCUMENT~~

Summary of Significant Accounting Policies (Tables)

6 Months Ended
Dec. 31, 2024

Accounting Policies [Abstract]

Schedule of Revenue Associated with License Agreement

we recognized revenue associated with the KKC Commercialization Agreement as follows (in thousands):

Timing of Revenue Recognition:	
Services performed over time	$ 743
Pass through services at a point in time	9
	$ 752

Schedule of Changes in Unbilled Receivables and Contract Liabilities

A reconciliation of the beginning and ending amount of contract liabilities as of June 30, 2024, which was primarily related to the combined performance obligation for the transfer of development services under the KKC Commercialization Agreement and was a separate performance obligation in our contracts pursuant to research plans under the agreements, was as follows:

Beginning balance	$ 317
Recognized as revenue:	
Revenue recognized upon satisfaction of performance obligations	(317)
Ending balance	$ —

Antidilutive Securities

The following table presents potentially dilutive shares that have been excluded from the calculation of net (loss) income per share because of their anti-dilutive effect (in thousands):

	For the Three Months Ended December 31,		For the Six Months Ended December 31,	
	2024	2023	2024	2023
Stock options	955	1,398	955	1,398
Warrants	103	103	103	103
Total anti-dilutive shares	1,058	1,501	1,058	1,501

~~XML 31 R25.htm IDEA: XBRL DOCUMENT~~

Balance Sheet Details (Tables)

6 Months Ended
Dec. 31, 2024

Balance Sheet Related Disclosures [Abstract]

Schedule of Prepaid and Other Current Assets

Prepaid and other current assets consisted of the following, in thousands:

	December 31, 2024	June 30, 2024
Insurance	$ 350	$ 460
Software licenses	225	442
Security deposit	—	263
Prepaid clinical costs	—	1,050
Other	71	209
Total prepaid and other current assets	$ 646	$ 2,424

Schedule of Property and Equipment

Property and equipment consisted of the following as of June 30, 2024, in thousands:

Furniture and equipment	$ 1,000
Equipment	187
Leasehold improvements	969
	2,156
Less: accumulated depreciation [1]	(1,764)
Property and equipment, net	$ 392

[1] Includes impairment charge of $0.5 million, see below discussion on *Impact of the Agreement* (as discussed in *Note 9. Leases*).

Accrued Liabilities

Accrued liabilities consisted of the following, in thousands:

	December 31, 2024	June 30, 2024
Accrued compensation and benefits [1]	$ 1,476	$ 2,821
Accrued pre-clinical and clinical trial expenses	151	1,407
Accrued legal and professional services	6	33

Accrued reimbursement to KKC	—	892
Other	58	34
Total accrued liabilities	$ 1,691	$ 5,187

(1) Includes employee termination benefits of approximately $1.3 million and $21,000 as of December 31, 2024 and June 30, 2024, respectively, as more fully described in *Note 5. Employee Termination Benefits*.

~~XML 32 R26.htm IDEA: XBRL DOCUMENT~~

Employee Termination Benefits (Tables)

6 Months Ended
Dec. 31, 2024

Restructuring Reserve [Abstract]

Summary of Activity Related to Employee Benefits Included in Accrued Liabilities

The following table summarizes our activity related to employee benefits included in accrued liabilities (in thousands):

	December 31, 2024	June 30, 2024
Beginning balance	$ 21	$ 993
Increase in accrued restructuring	4,333	556
Cash payments	(3,069)	(1,528)
Ending Balance	$ 1,285	$ 21

~~XML 33 R27.htm IDEA: XBRL DOCUMENT~~

Leases (Tables)

6 Months Ended
Dec. 31, 2024

Leases [Abstract]

Schedule of Total Operating Costs

The total operating lease costs for the Amended Lease were as follows for the periods presented (in thousands):

	For the Three Months Ended December 31, 2023	For the Six Months Ended December 31, 2024	For the Six Months Ended December 31, 2023
Operating lease cost	$ 609	$ 214	$ 1,217
Variable lease costs	12	—	24
Total lease costs included in operating expenses	$ 621	$ 214	$ 1,241

Schedule of Supplemental Cash Flow Information Related to Operating Leases

Supplemental cash flow information related to our operating leases was as follows for the periods presented (in thousands):

	For the Three Months Ended December 31, 2023	For the Six Months Ended December 31, 2023
Cash paid for amount included in the measurement of lease liabilities:		
Operating cash flows from operating leases	$ 583	$ 1,167

~~XML 34 R28.htm IDEA: XBRL DOCUMENT~~

Share-based Compensation (Tables)

6 Months Ended
Dec. 31, 2024

Share-Based Compensation Expense for Stock Awards

Total share-based compensation for all stock awards consisted of the following for the periods presented (in thousands):

	For the Three Months Ended December 31,		For the Six Months Ended December 31,	
	2024	2023	2024	2023
Research and development	$ (53)	$ 129	$ (159)	$ 60
General and administrative	(50)	721	(79)	1,153
Total share-based compensation	$ (103)	$ 850	$ (238)	$ 1,213

Summary of Stock Option Activity and Related Data

A summary of our stock option activity and related data follows:

	Number of Options	Weighted-Average Exercise Price	Weighted-Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Outstanding at June 30, 2024	1,357,213	$ 31.60		
Forfeited	(402,490)	$ 25.14		
Outstanding at December 31, 2024	954,723	$ 34.32	6.3	$ —
Vested and expected to vest at December 31, 2024	954,723	$ 34.32	6.3	$ —

Fair Value of Stock Options Weighted-Average Assumptions Used following weighted-average assumptions were used for the period presented:

	For the Six Months Ended December 31, 2023
Risk-free interest rate	4.5%
Expected life (years)	5.7
Volatility	90.0%
Dividend yield	— %
Weighted-average grant date fair value	$ 5.18

~~XML 35 R29.htm IDEA: XBRL DOCUMENT~~

Description of Business and Basis of Presentation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands

	3 Months Ended		
	Dec. 31, 2023	Dec. 31, 2024	Jun. 30, 2024
Targeted or Tracking Stock, Stock [Line Items]			
Unpaid common stock dividend	$ 1.75		
Accumulated losses since inception		$ 398,903	$ 388,219
Cash and cash equivalents and short term investments		$ 23,700	

~~XML 36 R30.htm IDEA: XBRL DOCUMENT~~

Summary of Significant Accounting Policies - Schedule of Revenue Associated with License Agreement (Detail) - USD ($) $ in Thousands

	3 Months Ended		6 Months Ended	
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Recognized Revenue Associated with The Following License Agreements [Line Items]				
Revenues	$ 0	$ 0	$ 0	$ 65,297
Revenue from customers				
Recognized Revenue Associated with The Following License Agreements [Line Items]				
Revenues	$ 0	$ 0	$ 0	752
Services performed over time | Revenue from customers				
Recognized Revenue Associated with The Following License Agreements [Line Items]				
Revenues				743
Pass through Services at a Point in Time | Revenue from customers				
Recognized Revenue Associated with The Following License Agreements [Line Items]				
Revenues				$ 9

~~XML 37 R31.htm IDEA: XBRL DOCUMENT~~

Summary of Significant Accounting Policies - Schedule of Changes in Unbilled Receivables and Contract Liabilities (Detail)

	12 Months Ended
	Jun. 30, 2024
	USD ($)

$ in Thousands	
Contract with Customer Asset and Liability [Line Items]	
Contract liabilities, beginning of period	$ 317
Revenue recognized upon satisfaction of performance obligations	(317)
Contract liabilities, end of period	$ 0

XML 38 R32.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Antidilutive Securities (Detail) - shares shares in Thousands	3 Months Ended		6 Months Ended	
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Potentially Dilutive Securities Outstanding [Line Items]				
Total anti-dilutive shares	1,058	1,501	1,058	1,501
Stock option				
Potentially Dilutive Securities Outstanding [Line Items]				
Total anti-dilutive shares	955	1,398	955	1,398
Warrants				
Potentially Dilutive Securities Outstanding [Line Items]				
Total anti-dilutive shares	103	103	103	103

XML 39 R33.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Jun. 30, 2024
New Accounting Pronouncements or Change in Accounting Principle [Line Items]					
Short-term investments	$ 0		$ 0		$ 34,640
Accounts receivable	$ 0		$ 0		$ 0
Common stock subject to repurchase or forfeiture	0	0	0	0	
Pass Through Services [Member]					
New Accounting Pronouncements or Change in Accounting Principle [Line Items]					
Percentage of reimbursement of pass through costs as revenue			100.00%		

XML 40 R34.htm IDEA: XBRL DOCUMENT

Balance Sheet Details - Schedule of Prepaid and Other Current Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2024	Jun. 30, 2024
Insurance	$ 350	$ 460
Software licenses	225	442
Security deposit	0	263
Prepaid clinical costs	0	1,050
Other	71	209
Total prepaid and other current assets	$ 646	$ 2,424

XML 41 R35.htm IDEA: XBRL DOCUMENT

Balance Sheet Details - Schedule of Property and Equipment (Detail) - USD ($) $ in Thousands		Dec. 31, 2024	Jun. 30, 2024
Property, Plant and Equipment [Line Items]			
Property and equipment, gross			$ 2,156
Less: accumulated depreciation	[1]		(1,764)
Property and equipment, net		$ 0	392
Furniture and equipment			
Property, Plant and Equipment [Line Items]			
Property and equipment, gross			1,000
Equipment			
Property, Plant and Equipment [Line Items]			
Property and equipment, gross			187
Leasehold Improvements			
Property, Plant and Equipment [Line Items]			
Property and equipment, gross			$ 969

[1] Includes impairment charge of $0.5 million, see below discussion on *Impact of the Agreement* (as discussed in *Note 9. Leases*).

XML 42 R36.htm IDEA: XBRL DOCUMENT

Balance Sheet Details - Schedule of Property and Equipment - (Parenthetical) (Detail) $ in Millions	12 Months Ended
	Jun. 30, 2024 USD ($)
Furniture and equipment	
Property, Plant and Equipment [Line Items]	
Impairment charges	$ 0.5

XML 43 R37.htm IDEA: XBRL DOCUMENT

Balance Sheet Details - Additional Information (Detail) - USD ($)		3 Months Ended		12 Months Ended
	Jun. 18, 2024	Dec. 31, 2024	Dec. 31, 2023	Jun. 30, 2024
Proceeds from sale of furniture and fixtures	$ 1			
Depreciation				$ 100,000
Property and Equipment				
Depreciation		$ 0	$ 100,000	
Furniture and equipment				
Impairment charges				$ 500,000

XML 44 R38.htm IDEA: XBRL DOCUMENT

Balance Sheet Details - Accrued Liabilities (Detail) - USD ($) $ in Thousands		Dec. 31, 2024	Jun. 30, 2024
Accrued Liabilities [Line Items]			
Accrued compensation and benefits	[1]	$ 1,476	$ 2,821
Accrued pre-clinical and clinical trial expenses		151	1,407
Accrued legal and professional services		6	33
Accrued reimbursement to KKC		0	892
Other		58	34

Total accrued liabilities	$ 1,691	$ 5,187

[1] Includes employee termination benefits of approximately $1.3 million and $21,000 as of December 31, 2024 and June 30, 2024, respectively, as more fully described in *Note 5. Employee Termination Benefits*.

~~XML 45 R39.htm IDEA: XBRL DOCUMENT~~

Balance Sheet Details - Accrued Liabilities (Parenthetical) (Detail) - USD ($)		Dec. 31, 2024	Jun. 30, 2024
Accrued compensation and benefits	[1]	$ 1,476,000	$ 2,821,000
Termination Benefits			
Accrued compensation and benefits		$ 1,300,000	$ 21,000

[1] Includes employee termination benefits of approximately $1.3 million and $21,000 as of December 31, 2024 and June 30, 2024, respectively, as more fully described in *Note 5. Employee Termination Benefits*.

~~XML 46 R40.htm IDEA: XBRL DOCUMENT~~

Fair Value Measurements - Additional Information (Detail) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands	Dec. 31, 2024	Jun. 30, 2024
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Liabilities	$ 0	$ 0
Assets	$ 0	$ 0

~~XML 47 R41.htm IDEA: XBRL DOCUMENT~~

Employee Termination Benefits - Additional Information (Detail) - USD ($) $ in Millions	1 Months Ended	3 Months Ended		6 Months Ended	
	Aug. 31, 2024	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]					
Severance costs	$ 6.5				
Research and Development					
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]					
Severance costs		$ 0.3	$ 0.1	$ 1.6	$ 0.2
General and administrative					
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]					
Severance costs		$ 0.9	$ 0.2	$ 2.7	$ 0.2

~~XML 48 R42.htm IDEA: XBRL DOCUMENT~~

Employee Termination Benefits - Summary of Activity Related to Employee Benefits Included in Accrued Liabilities (Detail) - One -Time Termination Benefits - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Dec. 31, 2024	Jun. 30, 2024
Restructuring Cost and Reserve [Line Items]		
Restructuring Reserve, Beginning Balance	$ 21	$ 993
Increase in accrued restructuring	4,333	556
Cash payments	(3,069)	(1,528)
Restructuring Reserve, Ending Balance	$ 1,285	$ 21

~~XML 49 R43.htm IDEA: XBRL DOCUMENT~~

Commitments and Contingencies - Additional Information (Detail) $ in Thousands	Dec. 31, 2024 USD ($)
Presage License Agreement	
Purchase Commitment, Excluding Long-term Commitment [Line Items]	
Accrued payment for potential future payments	$ 0

~~XML 50 R44.htm IDEA: XBRL DOCUMENT~~

License Agreements - Additional Information (Detail) - Kyowa Kirin Co. Ltd - USD ($) $ in Millions	12 Months Ended		
	Jul. 14, 2023	Jun. 30, 2023	Apr. 30, 2020
Related Party Transaction [Line Items]			
Termination Agreement	Jul. 14, 2023		
Total upfront payment receivable for grant of rights			$ 100.0
Kkc Agreements [Member] | US License [Member]			
Related Party Transaction [Line Items]			
Deferred revenue		$ 64.5	
Kkc Agreements [Member] | Development Services			
Related Party Transaction [Line Items]			
Transaction price of deferred revenue remaining performance obligations		$ 0.3	

~~XML 51 R45.htm IDEA: XBRL DOCUMENT~~

Other License Agreements - Additional Information (Details) - USD ($) $ in Millions	1 Months Ended	6 Months Ended	
	Sep. 30, 2017	Dec. 31, 2023	Dec. 31, 2024
BeiGene, Ltd			
Related Party Transaction [Line Items]			
Reimbursements costs		$ 0.1	
Presage License Agreement | Presage Biosciences, Inc.			
Related Party Transaction [Line Items]			
Payment for license	$ 2.9		
Other liabilities			$ 4.9
Presage License Agreement | Presage Biosciences, Inc. | Incremental Payment			
Related Party Transaction [Line Items]			
Other liabilities			2.0
Presage License Agreement | Presage Biosciences, Inc. | Potential Payments on Achievement of Development Regulatory and Commercial Milestones			
Related Party Transaction [Line Items]			
Milestone payment receivable amount			$ 179.0

~~XML 52 R46.htm IDEA: XBRL DOCUMENT~~

Leases - Additional Information (Detail)	Jun. 18,	1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
		Jul. 31, 2022	Dec. 31,	Dec. 31,	Dec. 31,	Dec. 31,	Jul. 31,

	2024 USD ($)	USD ($) ft²	2024 USD ($)	2023 USD ($)	2024 USD ($)	2023 USD ($)	Jun. 30, 2024 USD ($)	2020 ft²
Number of square feet under lease | ft²								32,800
Lease expire date		Mar. 31, 2028			Mar. 31, 2028			
Lease termination date		Nov. 30, 2029			Nov. 30, 2029			
Operating lease liabilities	$ 0							
Lease expiration amended date	Sep. 30, 2024							
Termination fee	$ 11,100,000							
Prepayment of remaining rent	200,000							
Proceeds from sale of furniture and fixtures	1							
Amount on reduction in remaining right of use asset and lease liability	22,000							
Direct costs	200,000						$ 200,000	
Impairment charge	$ 10,400,000							
Lease cost			$ 0					
Supplemental cash flow			0	$ 583,000	$ 0	$ 1,167,000		
Remaining future minimum rental payments							0	
Right-of-use asset balance			$ 0		$ 0		214,000	
Decrease in ROU asset balance							$ 22,000	
San Diego California [Member]								
Operating lease liabilities		$ 4,300,000						
Accounting Standards Update 2016-02 [Member]								
Number of square feet under lease | ft²		12,300						

~~XML 53 R47.htm IDEA: XBRL DOCUMENT~~

Leases - Schedule of Total Operating Costs (Detail) - USD ($)	3 Months Ended		6 Months Ended	
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Total lease costs included in general and administrative expenses	$ 0			
General and Administrative Expense [Member]				
Operating lease cost		$ 609,000	$ 214,000	$ 1,217,000
Variable lease costs		12,000	0	24,000
Total lease costs included in general and administrative expenses		$ 621,000	$ 214,000	$ 1,241,000

~~XML 54 R48.htm IDEA: XBRL DOCUMENT~~

Leases - Schedule of Supplemental Cash Flow Information Related to Operating Leases (Detail) - USD ($)	3 Months Ended		6 Months Ended	
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Disclosure Of Supplemental Cash Flow Information Related To Operating Leases [Abstract]				
Operating cash flows from operating leases	$ 0	$ 583,000	$ 0	$ 1,167,000

~~XML 55 R49.htm IDEA: XBRL DOCUMENT~~

Net Income (Loss) Per Share - Additional Information (Detail) - shares shares in Thousands	3 Months Ended		6 Months Ended	
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Potentially Dilutive Securities Outstanding [Line Items]				
Common stock subject to repurchase or forfeiture	0	0	0	0

~~XML 56 R50.htm IDEA: XBRL DOCUMENT~~

Stockholders' Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Oct. 22, 2024	Feb. 20, 2024	Dec. 06, 2023	Oct. 31, 2023	Oct. 01, 2023	3 Months Ended Dec. 31, 2023	6 Months Ended Dec. 31, 2024	Dec. 31, 2023	Jun. 30, 2024	Jan. 02, 2024
Class of Stock [Line Items]										
Total authorized share capital							226,100,000			
Common stock, shares authorized							226,000,000			226,000,000
Common stock, par value							$ 0.00000002			$ 0.00000002
Preferred stock, shares authorized							100,000			100,000
Preferred stock, par value					$ 0.00000002		$ 0.01			$ 0.01
Rights and the rights agreement expiration description							The Rights and the Rights Agreement expired at the close of business on September 30, 2024. No rights were redeemed or exchanged under the Rights Agreement.			
Preferred stock, shares issued							100,000			
Common stock voting rights							one vote per share			
Preferred stock, shares outstanding							0			0
Number of warrants exercised							0			
Cash dividends declared, per share						$ 1.75				
Closing agreement date				Nov. 17, 2023						
Dividend paid			$ 11,700				$ 0		$ 11,660	
Adopted agreement date	Oct. 22, 2024				Oct. 01, 2023					
Warrants | Torreya Partners LLC										
Class of Stock [Line Items]										
Exercise price							$ 6.80			
Warrants outstanding							102,513			
O 2024 Q2 Dividends										
Class of Stock [Line Items]										
Cash dividends declared, per share							$ 1.75			
ATM Sales Agreement										
Class of Stock [Line Items]										
At-the-market offering agreement, description							In no event will we sell securities registered on this registration statement in a public primary offering with a value exceeding more than one-third of our public float in any 12-			

		month period so long as our public float remains below $75.0 million (Baby Shelf Limitation) As of January 2, 2024, the date used under applicable rules of the SEC to determine our public float at the commencement of the offering, one-third of our public float was equal to approximately $9.9 million.
Aggregate offering price	$ 25,000	
Entity public float, threshold	$ 75,000	
Entity public float		$ 9,900
Number of shares issued and sold		0
Maximum		
Class of Stock [Line Items]		
Sale of shares and warrants under agreement		$ 100,000

~~XML 57 R51.htm IDEA: XBRL DOCUMENT~~

Share-based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	6 Months Ended			
	Dec. 31, 2024	Jun. 30, 2024	Jun. 09, 2023	May 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]				
Options outstanding	954,723	1,357,213		
Unrecognized compensation expense related to unvested stock options	$ 0.1			
Expected weighted average period for recognition of compensation expense	1 year 5 months 4 days			
Employee Stock Option				
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]				
Share-based compensation arrangement by share-based payment award, award vesting period	3 years			
Options outstanding	954,723			
Closing price of common stock	$ 2.46			
Employee Stock Option | Directors				
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]				
Share-based compensation arrangement by share-based payment award, award vesting period	12 months			
Share-based compensation arrangement by share-based payment award, expiration period	10 years			
Employee Stock Option | Employees				
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]				
Stock option vested percentage	25.00%			
Share-based compensation arrangement by share-based payment award, award vesting period	36 months			
2008 Omnibus Plan				
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]				
Common stock authorized	1,850,739			
Shares available for future grant	841,714			
2008 Omnibus Plan | Employee Stock Option				
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]				
Options outstanding	894,869			
Inducement Plan [Member]				
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]				
Common stock authorized			92,000	125,000
Shares available for future grant	157,146			
Inducement Plan [Member] | Employee Stock Option				
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]				
Options outstanding	59,854			

~~XML 58 R52.htm IDEA: XBRL DOCUMENT~~

Share-based Compensation - Share-based Compensation Expense for Stock Awards (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended	
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]				
Share-based compensation	$ (103)	$ 850	$ (238)	$ 1,213
Research and development				
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]				
Share-based compensation	(53)	129	(159)	60
General and administrative				
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]				
Share-based compensation	$ (50)	$ 721	$ (79)	$ 1,153

~~XML 59 R53.htm IDEA: XBRL DOCUMENT~~

Share-based Compensation - Summary of Stock Option Activity (Detail) $ / shares in Units, $ in Thousands	6 Months Ended
	Dec. 31, 2024 USD ($) $ / shares shares
Number of Options	
Beginning Balance | shares	1,357,213
Forfeited | shares	(402,490)
Ending balance | shares	954,723
Vested and expected to vest at end of period | shares	954,723
Weighted- Average Exercise Price	
Beginning Balance | $ / shares	$ 31.60
Forfeited | $ / shares	25.14
Ending balance | $ / shares	34.32
Vested and expected to vest at end of period | $ / shares	$ 34.32
Weighted Average Remaining Contractual Term (in years)	
Outstanding at end of period	6 years 3 months 18 days
Vested and expected to vest at end of period	6 years 3 months 18 days
Aggregate Intrinsic Value	
Outstanding at end of period | $	$ 0
Vested and expected to vest at end of period | $	$ 0

~~XML 60 R54.htm IDEA: XBRL DOCUMENT~~

Share-based Compensation - Fair Value of Stock Options Weighted-Average Assumptions	6 Months Ended
	Dec. 31, 2023 $ / shares

Used (Detail)

Share-based Compensation Arrangement by Share-based Award [Line Items]

Risk-free interest rate	4.50%
Expected life (years)	5 years 8 months 12 days
Volatility	90.00%
Dividend yield	0.00%
Weighted-average grant date fair value	$ 5.18

~~XML 61 R55.htm IDEA: XBRL DOCUMENT~~

Disposition of a Non-financial Asset - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended	
	Oct. 22, 2024	Oct. 01, 2023	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Income Statement, Balance Sheet and Additional Disclosures by Financial Statement Group, Including Discontinued Operations [Line Items]						
Adopted agreement date	Oct. 22, 2024	Oct. 01, 2023				
Reimbursement amount			$ 55,000		$ 55,000	
Purchaser initial payment					500,000	$ 0
Gain of disposition			500,000	$ 0	500,000	$ 0
Research And Development Arrangement						
Income Statement, Balance Sheet and Additional Disclosures by Financial Statement Group, Including Discontinued Operations [Line Items]						
Reimbursement amount			$ 55,000		$ 55,000	
Purchaser initial payment			500,000			
Asset Purchase Agreement						
Income Statement, Balance Sheet and Additional Disclosures by Financial Statement Group, Including Discontinued Operations [Line Items]						
Reimbursement amount			$ 55,000			
Purchaser initial payment			500,000			
Asset Purchase Agreement | Maximum						
Income Statement, Balance Sheet and Additional Disclosures by Financial Statement Group, Including Discontinued Operations [Line Items]						
Milestone payment			$ 62,000,000			

~~EXCEL 62 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 (> 3%H'04UB@0 +$ 0 9&]C4'\)O<',O8?!P+GAM M;$V,/0L"1!$)QQ;=(P4)B0 !2L+((>QLQD&1#LD)^OCG!CVX>;QA&WPIG M*N*!#BV&5(C@((/47BK9.7:=N')=HI6 Y #OGDK7A-YGG4FZ4A!0W_I=0UIR;UEA_6\#MI7E!+ P04 M "`@0;0)%NL*`K & @ $6 I08U!R:WS!+V-OGLIL59+! M:L,P#(9??B>M+!"H:BJU96.6%@8K.QF;!+4UBV-C.R1!"SE9FS%V!IC1TN)/ MGT"MB=*$A,U15D--,>ONNS`"#3D11 F1S0JS71):1V"\HK?,QTA:O.A MCPB"\WOP2-HTC !I[@0F6IMD2;AH N>&L6?Q,W0RS!K!#CSUE:,H&F)HF MQQ/8M7 #3##"Y/-W >U"G^M_8N<.L$MRS&Y)#< -0#ZIY5W9HX&VW?9G7K5R? M2?<&RZ_L)!TC;MAU\NQX7' -O)3@8EUQ435B+OK)N>3K]\GUAJ\VZK#NX? M&U\%5ON_]D)1 5!+ P04 "`@$Q:F5R<0&D+"<)P $P`AL+W1D M96UE+W1H96UE,2VX;6SM8EMXGO4?N^O7AGIFT+0C:!MK03623A\^ 1S80R9!8-09)-NH\\"SI^\Y%!^7R.!HH_8@ MGV1*V84BTN%;@5*)5P!D9Y7+,>^VCIK\"%!C

MT"@6ONAIY2T4HI1LB=\,&> 524<"G,*^8Y0N8K_#%,6.1h\0+62F67?.OH* M02.0Y; Y'+.A2?T`1 B@%-6-ZEY.#WMO<9FSF?@8Z.UE2;1\%KO/U*GTHc?PTL MB&Q1\6^WD@Y25'<^>N-U!t;_/4I<9*5VG2^IFX)M9> T98A2H&L#BP=UL)"W-MSA\
};*,4X/,%/"\"32&$81YQ$K*K8:#@<T=Q,%C:RCOL,*.4PTQ3>$;+O$)-MHE+(Z 21<2-4'=0;/V6WUP,N9IHL]'WNZ6;/!&W"%FV:\""P2"3R<[MT.8N M=,E\>TF#4.;T=LK5$IFTK)920#-^ONBR%FX378,\XO%36N>CF$%M<5$KZLDW
M:*8"Y";4"VJSH4+!)=5=N0$[" QV%>L4H=]4M*6=@=A=1H-4M*6=@=A=1H-4M*6=@=A=1H-

B#K?ZP MCU"%CU#R&E#ELKLQ)O6(<\V^H 9=;H?OLUN,P0?F!%Q=`$'Y_Z"?NO'IK- M7/9(7TW'4MV-<16"\E69D]98+,2:8U5X, XEI G2^8 MNB_U0BMH_I40_0502P,$% @ !X!.6FL,:NW= P O1$!D !X,"]W M:W)K&ULQ5A=;!L\%/TKA%8,+=!&LBTKB6<;2"P+ MRI_.1KUN#\4>:.K:XB*1&DG9W; ?I;2H=[(R2I6 !9(>9Q#'EY=-?9P/4CWH M\,"0+ UDI],O(;BGKJM9 AG5%S(<@^V4F748%*M?)FKH'$)REJWZ'EIFU$N MG/FTK%N[^506)N4*5HKH(I4N^OL64GF8.0/GJ>(CWR7&5KC5:4YWL ;S*5\I M+!+D-2\P5$)!+01I9\ [-8!)=V 9E@]X'/3I,[$CV4CY8 MW\YIQ47W3+14/]4P#D:0<+,#P'OGE'=$(50K@=OR:RT%3$'CUYN@;]M,WOALKJOMU57A\,T=43N13*))DL10]R"#]OQ00?>1=\\%/YMT..PE#8]=D M'A/AM0[,^GN?7P4=MPODU]^6WJ43*UI/@WK&M3_^RX 3BL0,#]TI#:0? 9%?9(M^R2+>B(H0>_B0>_BWV^3M'R PRH#*=\#]I4>= YLQ5/4;+8=70_]Z,N_GBZ.I5>.UUGY99IRD7_EAOY@?15 M\3 <<6/NN-/<^@O2N#5@P/~TDT*,I^.55G,"O-.9LW+!-/N6B+KD35X/&U:#3 MU87,_EP.<05?52UP4ZAGRRM%<8?E9UN$ M9ULLSI:(.D? Z'S]R\;'RTX75U1KW" @ /0< M !D !X;"]W;)K&ULQ5=;YLP%(; BH5ZT4I; M(^QE]PA2FVA);TV+FG:[=N50K1],V-9I _UL0Q6-)-M-L/'[^C G0#X0>RZ> M90#'6I7&M^5'PZ15+UM>O*K0(*RQFO@>F5=HL"*S75.U'6 <3HH0 MV]2):;<1:<;(:10F<4"RI2HLWFZ\\0W2F3N"%=D5RKSPDV3&N@^`]QW@=#1<.LH.:Z <@9$E L6QOY16IA%/PD\!>#,/L(9/+$^;.9W.5+!OS- @"%3)@+6 MCQ=8 .4FD;XW<5I^BV-<3@<7)/B<1<]>V&$)*TY D5R52^>3@WH<$/5/=]_ MA2Z? R,3+;)7\%^]K>-]<>6K)&^5YU9$U2$M4 \VM5A8B'B)^PQ^9 # _UQ!TAL F MVI+ 0M-98X301(^<$4>MH9FIK8ITZ&<\,/0JA50\]25/I+:.898"V[LBL06%" M)?[MQ]XV T%Q NT$<!DK8/,F M[^ZN4%FOR~3;^,%)^+=,=D4ZBI3%IK;*WFUKBRD>0E!LL0=ZP)X[^:=TQ! MSQ2<9=KR0NVQ s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

Trading ArrangementsNotes9 falsefalseR10.htm995455 - Disclosure - Description of Business and Basis of PresentationSheethttp://www.meipharma.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationDescription of
Business and Basis of PresentationNotes10 falsefalseR11.htm995465 - Disclosure - Summary of Significant Accounting PoliciesSheethttp://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummary of
Significant Accounting PoliciesNotes11 falsefalseR12.htm995475 - Disclosure - Balance Sheet DetailsSheethttp://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsBalance Sheet DetailsNotes12 falsefalseR13.htm995485 -
Disclosure - Fair Value MeasurementsSheethttp://www.meipharma.com/20241231/taxonomy/role/FairValueMeasurementsFair Value MeasurementsNotes13 falsefalseR14.htm995495 - Disclosure - Employee Termination
BenefitsSheethttp://www.meipharma.com/20241231/taxonomy/role/DisclosureEmployeeTerminationBenefits1Employee Termination BenefitsNotes14 falsefalseR15.htm995505 - Disclosure - Commitments and
ContingenciesSheethttp://www.meipharma.com/20241231/taxonomy/role/CommitmentsAndContingenciesCommitments and ContingenciesNotes15 falsefalseR16.htm995515 - Disclosure - License
AgreementsSheethttp://www.meipharma.com/20241231/taxonomy/role/LicenseAgreementsLicense AgreementsNotes16 falsefalseR17.htm995525 - Disclosure - Other License
AgreementsSheethttp://www.meipharma.com/20241231/taxonomy/role/DisclosureOtherLicenseAgreementsOther License AgreementsNotes17 falsefalseR18.htm995535 - Disclosure -
LeasesSheethttp://www.meipharma.com/20241231/taxonomy/role/LeasesLeasesNotes18 falsefalseR19.htm995545 - Disclosure - Stockholders' EquitySheethttp://www.meipharma.com/20241231/taxonomy/role/StockholdersEquityStockholders'
EquityNotes19 falsefalseR20.htm995555 - Disclosure - Share-based CompensationSheethttp://www.meipharma.com/20241231/taxonomy/role/ShareBasedCompensationShare-based CompensationNotes20 falsefalseR21.htm995565 - Disclosure - Disposition
of a Non-financial AssetSheethttp://www.meipharma.com/20241231/taxonomy/role/DisclosureDispositionOfANonfinancialAssetDisposition of a Non-financial AssetNotes21 falsefalseR22.htm995585 - Disclosure - Description of Business and Basis of
Presentation (Policies)Sheethttp://www.meipharma.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationPoliciesDescription of Business and Basis of Presentation
(Policies)Policieshttp://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies22 falsefalseR23.htm995595 - Disclosure - Summary of Significant Accounting Policies
(Policies)Sheethttp://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciesSummary of Significant Accounting Policies
(Policies)Policieshttp://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies23 falsefalseR24.htm995605 - Disclosure - Summary of Significant Accounting Policies
(Tables)Sheethttp://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTablesSummary of Significant Accounting Policies
(Tables)Tableshttp://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies24 falsefalseR25.htm995615 - Disclosure - Balance Sheet Details
(Tables)Sheethttp://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsTablesBalance Sheet Details (Tables)Tableshttp://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetails25 falsefalseR26.htm995635
- Disclosure - Employee Termination Benefits (Tables)Sheethttp://www.meipharma.com/20241231/taxonomy/role/DisclosureEmployeeTerminationBenefitsTablesEmployee Termination Benefits
(Tables)Tableshttp://www.meipharma.com/20241231/taxonomy/role/DisclosureEmployeeTerminationBenefits126 falsefalseR27.htm995645 - Disclosure - Leases (Tables)Sheethttp://www.meipharma.com/20241231/taxonomy/role/LeasesTablesLeases
(Tables)Tableshttp://www.meipharma.com/20241231/taxonomy/role/Leases27 falsefalseR28.htm995655 - Disclosure - Share-based Compensation (Tables)Sheethttp://www.meipharma.com/20241231/taxonomy/role/ShareBasedCompensationTablesShare-
based Compensation (Tables)Tableshttp://www.meipharma.com/20241231/taxonomy/role/ShareBasedCompensation28 falsefalseR29.htm995665 - Disclosure - Description of Business and Basis of Presentation - Additional Information
(Detail)Sheethttp://www.meipharma.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetailDescription of Business and Basis of Presentation - Additional Information (Detail)Details29
falsefalseR30.htm995675 - Disclosure - Summary of Significant Accounting Policies - Schedule of Revenue Associated with License Agreement
(Detail)Sheethttp://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenueAssociatedWithLicenseAgreementDetailSummary of Significant Accounting Policies - Schedule of Revenue
Associated with License Agreement (Detail)Details30 falsefalseR31.htm995685 - Disclosure - Summary of Significant Accounting Policies - Schedule of Changes in Unbilled Receivables and Contract Liabilities
(Detail)Sheethttp://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInUnbilledReceivablesAndContractLiabilitiesDetailSummary of Significant Accounting Policies - Schedule of
Changes in Unbilled Receivables and Contract Liabilities (Detail)Details31 falsefalseR32.htm995695 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Securities
(Detail)Sheethttp://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAntidilutiveSecuritiesDetailSummary of Significant Accounting Policies - Antidilutive Securities (Detail)Details32
falsefalseR33.htm995705 - Disclosure - Summary of Significant Accounting Policies - Additional Information
(Detail)Sheethttp://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetailSummary of Significant Accounting Policies - Additional Information (Detail)Details33
falsefalseR34.htm995715 - Disclosure - Balance Sheet Details - Schedule of Prepaid and Other Current Assets
(Detail)Sheethttp://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidAndOtherCurrentAssetsDetailBalance Sheet Details - Schedule of Prepaid and Other Current Assets (Detail)Details34
falsefalseR35.htm995725 - Disclosure - Balance Sheet Details - Schedule of Property and Equipment (Detail)Sheethttp://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetailBalance Sheet
Details - Schedule of Property and Equipment (Detail)Details35 falsefalseR36.htm995735 - Disclosure - Balance Sheet Details - Schedule of Property and Equipment - (Parenthetical)
(Detail)Sheethttp://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentParentheticalDetailBalance Sheet Details - Schedule of Property and Equipment - (Parenthetical) (Detail)Details36
falsefalseR37.htm995745 - Disclosure - Balance Sheet Details - Additional Information (Detail)Sheethttp://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetailBalance Sheet Details - Additional
Information (Detail)Details37 falsefalseR38.htm995755 - Disclosure - Balance Sheet Details - Accrued Liabilities (Detail)Sheethttp://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetailBalance Sheet
Details - Accrued Liabilities (Detail)Details38 falsefalseR39.htm995765 - Disclosure - Balance Sheet Details - Accrued Liabilities (Parenthetical)
(Detail)Sheethttp://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesParentheticalDetailBalance Sheet Details - Accrued Liabilities (Parenthetical) (Detail)Details39 falsefalseR40.htm995775 - Disclosure -
Fair Value Measurements - Additional Information (Detail)Sheethttp://www.meipharma.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetailFair Value Measurements - Additional Information (Detail)Details40
falsefalseR41.htm995805 - Disclosure - Employee Termination Benefits - Additional Information (Detail)Sheethttp://www.meipharma.com/20241231/taxonomy/role/DisclosureEmployeeTerminationBenefitsAdditionalInformationDetailEmployee
Termination Benefits - Additional Information (Detail)Details41 falsefalseR42.htm995815 - Disclosure - Employee Termination Benefits - Summary of Activity Related to Employee Benefits Included in Accrued Liabilities
(Detail)Sheethttp://www.meipharma.com/20241231/taxonomy/role/DisclosureEmployeeTerminationBenefitsSummaryOfActivityRelatedToEmployeeBenefitsIncludedInAccruedLiabilitiesDetailEmployee Termination Benefits - Summary of Activity Related to
Employee Benefits Included in Accrued Liabilities (Detail)Details42 falsefalseR43.htm995825 - Disclosure - Commitments and Contingencies - Additional Information
(Detail)Sheethttp://www.meipharma.com/20241231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetailCommitments and Contingencies - Additional Information (Detail)Details43 falsefalseR44.htm995835 - Disclosure - License
Agreements - Additional Information (Detail)Sheethttp://www.meipharma.com/20241231/taxonomy/role/LicenseAgreementsAdditionalInformationDetailLicense Agreements - Additional Information (Detail)Details44 falsefalseR45.htm995845 - Disclosure -
Other License Agreements - Additional Information (Details)Sheethttp://www.meipharma.com/20241231/taxonomy/role/DisclosureOtherLicenseAgreementsAdditionalInformationDetailsOther License Agreements - Additional Information (Details)Details45
falsefalseR46.htm995855 - Disclosure - Leases - Additional Information (Detail)Sheethttp://www.meipharma.com/20241231/taxonomy/role/LeasesAdditionalInformationDetailLeases - Additional Information (Detail)Details46 falsefalseR47.htm995865 -
Disclosure - Leases - Schedule of Total Operating Costs (Detail)Sheethttp://www.meipharma.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfTotalOperatingCostsDetailLeases - Schedule of Total Operating Costs (Detail)Details47
falsefalseR48.htm995875 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information Related to Operating Leases
(Detail)Sheethttp://www.meipharma.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetailLeases - Schedule of Supplemental Cash Flow Information Related to Operating Leases
(Detail)Details48 falsefalseR49.htm995885 - Disclosure - Net Income (Loss) Per Share - Additional Information (Detail)Sheethttp://www.meipharma.com/20241231/taxonomy/role/DisclosureNetIncomeLossPerShareAdditionalInformationDetailNet Income
(Loss) Per Share - Additional Information (Detail)Details49 falsefalseR50.htm995895 - Disclosure - Stockholders' Equity - Additional Information
(Detail)Sheethttp://www.meipharma.com/20241231/taxonomy/role/StockholdersEquityAdditionalInformationDetailStockholders' Equity - Additional Information (Detail)Details50 falsefalseR51.htm995905 - Disclosure - Share-based Compensation -
Additional Information (Detail)Sheethttp://www.meipharma.com/20241231/taxonomy/role/ShareBasedCompensationAdditionalInformationDetailShare-based Compensation - Additional Information (Detail)Details51 falsefalseR52.htm995915 - Disclosure -
Share-based Compensation - Share-based Compensation Expense for Stock Awards (Detail)Sheethttp://www.meipharma.com/20241231/taxonomy/role/DisclosureSharebasedCompensationSharebasedCompensationExpenseForStockAwardsDetailShare-based
Compensation - Share-based Compensation Expense for Stock Awards (Detail)Details52 falsefalseR53.htm995925 - Disclosure - Share-based Compensation - Summary of Stock Option Activity
(Detail)Sheethttp://www.meipharma.com/20241231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetailShare-based Compensation - Summary of Stock Option Activity (Detail)Details53 falsefalseR54.htm995935 -
Disclosure - Share-based Compensation - Fair Value of Stock Options Weighted-Average Assumptions Used
(Detail)Sheethttp://www.meipharma.com/20241231/taxonomy/role/DisclosureSharebasedCompensationFairValueOfStockOptionsWeightedaverageAssumptionsUsedDetailShare-based Compensation - Fair Value of Stock Options Weighted-Average
Assumptions Used (Detail)Details54 falsefalseR55.htm995945 - Disclosure - Disposition of a Non-financial Asset - Additional Information
(Detail)Sheethttp://www.meipharma.com/20241231/taxonomy/role/DisclosureDispositionOfANonfinancialAssetAdditionalInformationDetailDisposition of a Non-financial Asset - Additional Information (Detail)Details55 falsefalseAll ReportsBookAll Reports
meip-20241231.htmmeip-20241231.xsd img105009805_0.jpg http://fasb.org/us-gaap/2024http://xbrl.sec.gov/dei/2024http://xbrl.sec.gov/ecd/2024falsefalse JSON 69 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "meip-
20241231.htm": { "nsprefix": "meip", "nsuri": "http://www.meipharma.com/20241231", "dts": { "inline": { "local": ["meip-20241231.htm"] }, "schema": { "local": ["meip-20241231.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-
31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
"http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
"https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
"https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-
gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
"https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] } }, "keyStandard": 190, "keyCustom": 36, "axisStandard": 25, "axisCustom": 0, "memberStandard": 20, "memberCustom": 19, "hidden": { "total": 10,
"http://xbrl.sec.gov/dei/2024": 6, "http://fasb.org/us-gaap/2024": 4 }, "contextCount": 123, "entityCount": 1, "segmentCount": 41, "elementCount": 563, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 403, "http://xbrl.sec.gov/dei/2024":
31, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://www.meipharma.com/20241231/taxonomy/role/CoverPage", "longName": "100000 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document",
"subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_8b13b7d8-6b0a-4271-af1c-3ff3ecfd58a8", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p",
"body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8b13b7d8-6b0a-4271-af1c-3ff3ecfd58a8", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-
US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true } }, "R2": { "role":
"http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets", "longName": "100010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE
SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "C_827a0adf-d22d-45ae-9e03-2a61bf80b070", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
"unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef":
"C_827a0adf-d22d-45ae-9e03-2a61bf80b070", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1,
"baseRef": "meip-20241231.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "longName": "100020 - Statement - CONDENSED
CONSOLIDATED BALANCE SHEETS (parenthetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3",
"firstAnchor": { "contextRef": "C_827a0adf-d22d-45ae-9e03-2a61bf80b070", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [
"span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_827a0adf-d22d-45ae-9e03-2a61bf80b070", "name": "us-gaap:CommonStockSharesIssued", "unitRef":
"U_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "unique": true } }, "R4": { "role":
"http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations", "longName": "100030 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "shortName": "CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "C_06e799d5-eae5-4d69-b078-1af7ccbcba94", "name": "us-
gaap:Revenues", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef":
"C_06e799d5-eae5-4d69-b078-1af7ccbcba94", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1,
"baseRef": "meip-20241231.htm", "unique": true } }, "R5": { "role": "http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "longName": "100040 - Statement - CONDENSED
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements",
"order": "5", "firstAnchor": { "contextRef": "C_3894aeee-6315-4317-9591-6c66f232315e", "name": "us-gaap:StockholdersEquity", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"
], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_fd17fea5-e971-478e-801e-c7e4004776bb", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3",
"ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "unique": true } }, "R6": { "role":
"http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical", "longName": "100050 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
(Parenthetical)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6",
"firstAnchor": { "contextRef": "C_6051305e-d87f-406f-a717-4b38aa3284ee", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [
"span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true }, "uniqueAnchor": null }, "R7": { "role":
"http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows", "longName": "100060 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "C_8b13b7d8-6b0a-4271-af1c-3ff3ecfd58a8", "name": "us-
gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": {
"contextRef": "C_8b13b7d8-6b0a-4271-af1c-3ff3ecfd58a8", "name": "us-gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "meip-
20241231.htm", "first": true, "unique": true } }, "R8": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false",
"groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "C_06e799d5-eae5-4d69-b078-1af7ccbcba94", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals":
"-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true }, "uniqueAnchor": null }, "R9": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 -
Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "C_06e799d5-eae5-4d69-b078-
1af7ccbcba94", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true },
"uniqueAnchor": { "contextRef": "C_06e799d5-eae5-4d69-b078-1af7ccbcba94", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1,
"baseRef": "meip-20241231.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.meipharma.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentation", "longName": "995455 - Disclosure - Description of
Business and Basis of Presentation", "shortName": "Description of Business and Basis of Presentation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "C_8b13b7d8-
6b0a-4271-af1c-3ff3ecfd58a8", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [
"div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8b13b7d8-6b0a-4271-af1c-3ff3ecfd58a8", "name": "us-
gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1,
"baseRef": "meip-20241231.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies", "longName": "995465 - Disclosure - Summary of Significant
Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "C_8b13b7d8-6b0a-4271-af1c-
3ff3ecfd58a8", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique":
true }, "uniqueAnchor": { "contextRef": "C_8b13b7d8-6b0a-4271-af1c-3ff3ecfd58a8", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"],
"reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetails", "longName": "995475 - Disclosure - Balance Sheet Details",
"shortName": "Balance Sheet Details", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C_8b13b7d8-6b0a-4271-af1c-3ff3ecfd58a8", "name": "us-
gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true },
"uniqueAnchor": { "contextRef": "C_8b13b7d8-6b0a-4271-af1c-3ff3ecfd58a8", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"],
"reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.meipharma.com/20241231/taxonomy/role/FairValueMeasurements", "longName": "995485 - Disclosure - Fair Value Measurements",
"shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "C_8b13b7d8-6b0a-4271-af1c-3ff3ecfd58a8", "name": "us-
gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": {
"contextRef": "C_8b13b7d8-6b0a-4271-af1c-3ff3ecfd58a8", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "meip-
20241231.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.meipharma.com/20241231/taxonomy/role/DisclosureEmployeeTerminationBenefits1", "longName": "995495 - Disclosure - Employee Termination Benefits", "shortName":
"Employee Termination Benefits", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "C_8b13b7d8-6b0a-4271-af1c-3ff3ecfd58a8", "name": "us-
gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true },
"uniqueAnchor": { "contextRef": "C_8b13b7d8-6b0a-4271-af1c-3ff3ecfd58a8", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"
], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.meipharma.com/20241231/taxonomy/role/CommitmentsAndContingencies", "longName": "995505 - Disclosure - Commitments and
Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "C_8b13b7d8-6b0a-4271-af1c-3ff3ecfd58a8", "name":
"us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true },
"uniqueAnchor": { "contextRef": "C_8b13b7d8-6b0a-4271-af1c-3ff3ecfd58a8", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"],
"reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.meipharma.com/20241231/taxonomy/role/LicenseAgreements", "longName": "995515 - Disclosure - License Agreements", "shortName":
"License Agreements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "C_8b13b7d8-6b0a-4271-af1c-3ff3ecfd58a8", "name": "us-
gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true },
"uniqueAnchor": { "contextRef": "C_8b13b7d8-6b0a-4271-af1c-3ff3ecfd58a8", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"],
"reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.meipharma.com/20241231/taxonomy/role/DisclosureOtherLicenseAgreements", "longName": "995525 - Disclosure - Other License
Agreements", "shortName": "Other License Agreements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "C_8b13b7d8-6b0a-4271-af1c-3ff3ecfd58a8", "name":
"meip:OtherLicensingArrangementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": {
"contextRef": "C_8b13b7d8-6b0a-4271-af1c-3ff3ecfd58a8", "name": "meip:OtherLicensingArrangementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "meip-
20241231.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.meipharma.com/20241231/taxonomy/role/Leases", "longName": "995535 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "C_8b13b7d8-6b0a-4271-af1c-3ff3ecfd58a8", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null,
"ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8b13b7d8-6b0a-4271-af1c-3ff3ecfd58a8", "name": "us-gaap:LesseeOperatingLeasesTextBlock",
"unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true } }, "R19": { "role":
"http://www.meipharma.com/20241231/taxonomy/role/StockholdersEquity", "longName": "995545 - Disclosure - Stockholders' Equity", "shortName": "Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat":
"Notes", "order": "19", "firstAnchor": { "contextRef": "C_8b13b7d8-6b0a-4271-af1c-3ff3ecfd58a8", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div",
"body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8b13b7d8-6b0a-4271-af1c-3ff3ecfd58a8", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef":
null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true } }, "R20": { "role":
"http://www.meipharma.com/20241231/taxonomy/role/ShareBasedCompensation", "longName": "995555 - Disclosure - Share-based Compensation", "shortName": "Share-based Compensation", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "C_8b13b7d8-6b0a-4271-af1c-3ff3ecfd58a8", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false",
"lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8b13b7d8-6b0a-4271-af1c-3ff3ecfd58a8", "name": "us-
gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true,
"unique": true } }, "R21": { "role": "http://www.meipharma.com/20241231/taxonomy/role/DisclosureDispositionOfANonfinancialAsset", "longName": "995565 - Disclosure - Disposition of a Non-financial Asset", "shortName": "Disposition of a Non-financial
Asset", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "C_8b13b7d8-6b0a-4271-af1c-3ff3ecfd58a8", "name": "us-
gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique":
true }, "uniqueAnchor": { "contextRef": "C_8b13b7d8-6b0a-4271-af1c-3ff3ecfd58a8", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [
"div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.meipharma.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationPolicies",
"longName": "995585 - Disclosure - Description of Business and Basis of Presentation (Policies)", "shortName": "Description of Business and Basis of Presentation (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies",
"menuCat": "Policies", "order": "22", "firstAnchor": { "contextRef": "C_8b13b7d8-6b0a-4271-af1c-3ff3ecfd58a8", "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null,
"ancestors": ["div", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true
}, "uniqueAnchor": { "contextRef": "C_8b13b7d8-6b0a-4271-af1c-3ff3ecfd58a8", "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-
gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true } }, "R23": { "role":

"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "longName": "995595 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "23", "firstAnchor": { "contextRef": "C_8b13b7d8-6b0a-4271-af1c-3ff3ecfd58a8", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8b13b7d8-6b0a-4271-af1c-3ff3ecfd58a8", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "longName": "995605 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "C_8b13b7d8-6b0a-4271-af1c-3ff3ecfd58a8", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8b13b7d8-6b0a-4271-af1c-3ff3ecfd58a8", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsTables", "longName": "995615 - Disclosure - Balance Sheet Details (Tables)", "shortName": "Balance Sheet Details (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "C_8b13b7d8-6b0a-4271-af1c-3ff3ecfd58a8", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8b13b7d8-6b0a-4271-af1c-3ff3ecfd58a8", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.meipharma.com/20241231/taxonomy/role/DisclosureEmployeeTerminationBenefitsTables", "longName": "995635 - Disclosure - Employee Termination Benefits (Tables)", "shortName": "Employee Termination Benefits (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "C_8b13b7d8-6b0a-4271-af1c-3ff3ecfd58a8", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8b13b7d8-6b0a-4271-af1c-3ff3ecfd58a8", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.meipharma.com/20241231/taxonomy/role/LeasesTables", "longName": "995645 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "C_8b13b7d8-6b0a-4271-af1c-3ff3ecfd58a8", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8b13b7d8-6b0a-4271-af1c-3ff3ecfd58a8", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.meipharma.com/20241231/taxonomy/role/ShareBasedCompensationTables", "longName": "995655 - Disclosure - Share-based Compensation (Tables)", "shortName": "Share-based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "C_8b13b7d8-6b0a-4271-af1c-3ff3ecfd58a8", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8b13b7d8-6b0a-4271-af1c-3ff3ecfd58a8", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.meipharma.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "longName": "995665 - Disclosure - Description of Business and Basis of Presentation - Additional Information (Detail)", "shortName": "Description of Business and Basis of Presentation - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "C_6051305e-d87f-406f-a717-4b38aa3284ee", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_827a0adf-d22d-45ae-9e03-2a61bf80b070", "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "meip:LiquidityPolicyTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "unique": true } }, "R30": { "role": "http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenueAssociatedWithLicenseAgreementDetail", "longName": "995675 - Disclosure - Summary of Significant Accounting Policies - Schedule of Revenue Associated with License Agreement (Detail)", "shortName": "Summary of Significant Accounting Policies - Schedule of Revenue Associated with License Agreement (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "C_06e799d5-eae5-4d69-b078-1af7ccbcba94", "name": "us-gaap:Revenues", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_152fe244-5eb6-4737-b76a-731c608811d9", "name": "us-gaap:Revenues", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "unique": true } }, "R31": { "role": "http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInUnbilledReceivablesAndContractLiabilitiesDetail", "longName": "995685 - Disclosure - Summary of Significant Accounting Policies - Schedule of Changes in Unbilled Receivables and Contract Liabilities (Detail)", "shortName": "Summary of Significant Accounting Policies - Schedule of Changes in Unbilled Receivables and Contract Liabilities (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "C_3894aeee-6315-4317-9591-6c66f232315e", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3894aeee-6315-4317-9591-6c66f232315e", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAntidilutiveSecuritiesDetail", "longName": "995695 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Securities (Detail)", "shortName": "Summary of Significant Accounting Policies - Antidilutive Securities (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "C_06e799d5-eae5-4d69-b078-1af7ccbcba94", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerSharePolicyTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_06e799d5-eae5-4d69-b078-1af7ccbcba94", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerSharePolicyTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "longName": "995705 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)", "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "C_827a0adf-d22d-45ae-9e03-2a61bf80b070", "name": "us-gaap:ShortTermInvestments", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_3686c8cb-bff3-4c7c-9a58-553cc5c2ba5d", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "unique": true } }, "R34": { "role": "http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidAndOtherCurrentAssetsDetail", "longName": "995715 - Disclosure - Balance Sheet Details - Schedule of Prepaid and Other Current Assets (Detail)", "shortName": "Balance Sheet Details - Schedule of Prepaid and Other Current Assets (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "C_827a0adf-d22d-45ae-9e03-2a61bf80b070", "name": "us-gaap:PrepaidInsurance", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_827a0adf-d22d-45ae-9e03-2a61bf80b070", "name": "us-gaap:PrepaidInsurance", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetail", "longName": "995725 - Disclosure - Balance Sheet Details - Schedule of Property and Equipment (Detail)", "shortName": "Balance Sheet Details - Schedule of Property and Equipment (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "C_3686c8cb-bff3-4c7c-9a58-553cc5c2ba5d", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3686c8cb-bff3-4c7c-9a58-553cc5c2ba5d", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentParentheticalDetail", "longName": "995735 - Disclosure - Balance Sheet Details - Schedule of Property and Equipment - (Parenthetical) (Detail)", "shortName": "Balance Sheet Details - Schedule of Property and Equipment - (Parenthetical) (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "C_58fea88c-9a67-4d49-a096-ad2680d6b19e", "name": "us-gaap:AssetImpairmentCharges", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "link:footnote", "p", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true }, "uniqueAnchor": null }, "R37": { "role": "http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetail", "longName": "995745 - Disclosure - Balance Sheet Details - Additional Information (Detail)", "shortName": "Balance Sheet Details - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "C_fe619927-b7fb-4791-adb2-59ebab6ac138", "name": "us-gaap:ProceedsFromSaleOfFurnitureAndFixtures", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_3d0bd768-8dec-4c2e-9891-bb85a5302fc8", "name": "us-gaap:Depreciation", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "unique": true } }, "R38": { "role": "http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetail", "longName": "995755 - Disclosure - Balance Sheet Details - Accrued Liabilities (Detail)", "shortName": "Balance Sheet Details - Accrued Liabilities (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "C_827a0adf-d22d-45ae-9e03-2a61bf80b070", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_827a0adf-d22d-45ae-9e03-2a61bf80b070", "name": "meip:AccruedPreclinicalAndClinicalCosts", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "unique": true } }, "R39": { "role": "http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesParentheticalDetail", "longName": "995765 - Disclosure - Balance Sheet Details - Accrued Liabilities (Parenthetical) (Detail)", "shortName": "Balance Sheet Details - Accrued Liabilities (Parenthetical) (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "C_827a0adf-d22d-45ae-9e03-2a61bf80b070", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_1958d545-b7bc-4c99-8c72-cd9039c72752", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "link:footnote", "ix:continuation", "span", "ix:continuation", "span", "p", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "unique": true } }, "R40": { "role": "http://www.meipharma.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "longName": "995775 - Disclosure - Fair Value Measurements - Additional Information (Detail)", "shortName": "Fair Value Measurements - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "C_509db951-a0b1-4acd-9db3-fbe2a5d5ac0b", "name": "us-gaap:LiabilitiesFairValueDisclosure", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_509db951-a0b1-4acd-9db3-fbe2a5d5ac0b", "name": "us-gaap:LiabilitiesFairValueDisclosure", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.meipharma.com/20241231/taxonomy/role/DisclosureEmployeeTerminationBenefitsAdditionalInformationDetail", "longName": "995805 - Disclosure - Employee Termination Benefits - Additional Information (Detail)", "shortName": "Employee Termination Benefits - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "C_de3f223a-00a5-496e-af4c-d83f26721a7b", "name": "us-gaap:SeveranceCosts1", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_de3f223a-00a5-496e-af4c-d83f26721a7b", "name": "us-gaap:SeveranceCosts1", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.meipharma.com/20241231/taxonomy/role/DisclosureEmployeeTerminationBenefitsSummaryOfActivityRelatedToEmployeeBenefitsIncludedInAccruedLiabilitiesDetail", "longName": "995815 - Disclosure - Employee Termination Benefits - Summary of Activity Related to Employee Benefits Included in Accrued Liabilities (Detail)", "shortName": "Employee Termination Benefits - Summary of Activity Related to Employee Benefits Included in Accrued Liabilities (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "C_2b9e7311-1870-4182-a2a6-2837de8f0594", "name": "us-gaap:RestructuringReserve", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_19ab83b1-b833-4654-8ccf-fd92e95a2999", "name": "us-gaap:RestructuringReserve", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "unique": true } }, "R43": { "role": "http://www.meipharma.com/20241231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail", "longName": "995825 - Disclosure - Commitments and Contingencies - Additional Information (Detail)", "shortName": "Commitments and Contingencies - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "C_93c10f6d-279e-4986-8ce3-9c573b9d36e9", "name": "meip:AccruedMilestonePayments", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_93c10f6d-279e-4986-8ce3-9c573b9d36e9", "name": "meip:AccruedMilestonePayments", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.meipharma.com/20241231/taxonomy/role/LicenseAgreementsAdditionalInformationDetail", "longName": "995835 - Disclosure - License Agreements - Additional Information (Detail)", "shortName": "License Agreements - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "C_5f7f7190-434c-4608-8699-7b97315c4cd6", "name": "meip:TerminationAgreement", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_5f7f7190-434c-4608-8699-7b97315c4cd6", "name": "meip:TerminationAgreement", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.meipharma.com/20241231/taxonomy/role/DisclosureOtherLicenseAgreementsAdditionalInformationDetails", "longName": "995845 - Disclosure - Other License Agreements - Additional Information (Details)", "shortName": "Other License Agreements - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "C_87410c57-0fd3-4dff-8a12-2b823d480b03", "name": "us-gaap:RecoveryOfDirectCosts", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_87410c57-0fd3-4dff-8a12-2b823d480b03", "name": "us-gaap:RecoveryOfDirectCosts", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.meipharma.com/20241231/taxonomy/role/LeasesAdditionalInformationDetail", "longName": "995855 - Disclosure - Leases - Additional Information (Detail)", "shortName": "Leases - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "C_1595c842-d16c-45ba-9283-3328fad25c7b", "name": "us-gaap:AreaOfLand", "unitRef": "U_sqft", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_1595c842-d16c-45ba-9283-3328fad25c7b", "name": "us-gaap:AreaOfLand", "unitRef": "U_sqft", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.meipharma.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfTotalOperatingCostsDetail", "longName": "995865 - Disclosure - Leases - Schedule of Total Operating Costs (Detail)", "shortName": "Leases - Schedule of Total Operating Costs (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "C_06e799d5-eae5-4d69-b078-1af7ccbcba94", "name": "us-gaap:LeaseCost", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_f8694ef2-e709-4ca9-bab6-953c014f745b", "name": "us-gaap:OperatingLeaseCost", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "unique": true } }, "R48": { "role": "http://www.meipharma.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetail", "longName": "995875 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information Related to Operating Leases (Detail)", "shortName": "Leases - Schedule of Supplemental Cash Flow Information Related to Operating Leases (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "C_06e799d5-eae5-4d69-b078-1af7ccbcba94", "name": "us-gaap:OperatingLeasePayments", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true }, "uniqueAnchor": null }, "R49": { "role": "http://www.meipharma.com/20241231/taxonomy/role/DisclosureNetIncomeLossPerShareAdditionalInformationDetail", "longName": "995885 - Disclosure - Net Income (Loss) Per Share - Additional Information (Detail)", "shortName": "Net Income (Loss) Per Share - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "C_06e799d5-eae5-4d69-b078-1af7ccbcba94", "name": "us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "us-gaap:EarningsPerSharePolicyTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true }, "uniqueAnchor": null }, "R50": { "role": "http://www.meipharma.com/20241231/taxonomy/role/StockholdersEquityAdditionalInformationDetail", "longName": "995895 - Disclosure - Stockholders' Equity - Additional Information (Detail)", "shortName": "Stockholders' Equity - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "C_827a0adf-d22d-45ae-9e03-2a61bf80b070", "name": "us-gaap:CapitalUnitsAuthorized", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_827a0adf-d22d-45ae-9e03-2a61bf80b070", "name": "us-gaap:CapitalUnitsAuthorized", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.meipharma.com/20241231/taxonomy/role/ShareBasedCompensationAdditionalInformationDetail", "longName": "995905 - Disclosure - Share-based Compensation - Additional Information (Detail)", "shortName": "Share-based Compensation - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "C_827a0adf-d22d-45ae-9e03-2a61bf80b070", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_827a0adf-d22d-45ae-9e03-2a61bf80b070", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "unique": true } }, "R52": { "role": "http://www.meipharma.com/20241231/taxonomy/role/DisclosureSharebasedCompensationSharebasedCompensationExpenseForStockAwardsDetail", "longName": "995915 - Disclosure - Share-based Compensation - Share-based Compensation Expense for Stock Awards (Detail)", "shortName": "Share-based Compensation - Share-based Compensation Expense for Stock Awards (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "C_06e799d5-eae5-4d69-b078-1af7ccbcba94", "name": "us-gaap:ShareBasedCompensation", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_a16564fa-bbad-4856-8c7a-45bec790c2b6", "name": "us-gaap:ShareBasedCompensation", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "unique": true } }, "R53": { "role": "http://www.meipharma.com/20241231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetail", "longName": "995925 - Disclosure - Share-based Compensation - Summary of Stock Option Activity (Detail)", "shortName": "Share-based Compensation - Summary of Stock Option Activity (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "C_3686c8cb-bff3-4c7c-9a58-553cc5c2ba5d", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_8b13b7d8-6b0a-4271-af1c-3ff3ecfd58a8", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "unique": true } }, "R54": { "role": "http://www.meipharma.com/20241231/taxonomy/role/DisclosureSharebasedCompensationFairValueOfStockOptionsWeightedaverageAssumptionsUsedDetail", "longName": "995935 - Disclosure - Share-based Compensation - Fair Value of Stock Options Weighted-Average Assumptions Used (Detail)", "shortName": "Share-based Compensation - Fair Value of Stock Options Weighted-Average Assumptions Used (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "C_6c2a2a4e-83ce-45ab-84b5-1e49f751dc2c", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_6c2a2a4e-83ce-45ab-84b5-1e49f751dc2c", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.meipharma.com/20241231/taxonomy/role/DisclosureDispositionOfANonfinancialAssetAdditionalInformationDetail", "longName": "995945 - Disclosure - Disposition of a Non-financial Asset - Additional Information (Detail)", "shortName": "Disposition of a Non-financial Asset - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "C_93de1be9-2d8a-451f-9a30-284114c11078", "name": "meip:AdoptedAgreement", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "body", "html"],

"reportCount": 1, "baseRef": "meip-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_d8fa8949-e191-4d11-ac1d-08c78994c008", "name": "meip:ReimbursementAmount", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "meip-20241231.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountingStandardsUpdate201602Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingStandardsUpdate201602Member", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/LeasesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Accounting Standards Update 2016-02 [Member]", "label": "Accounting Standards Update 2016-02 [Member]", "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842)." } } }, "auth_ref": ["r414"] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Accounts Payable, Current, Total", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r56", "r672"] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Current, Total", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": ["r811"] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetail", "http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Accrued liabilities", "totalLabel": "Total accrued liabilities", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r58"] }, "meip_AccruedLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "AccruedLiabilitiesLineItems", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetail"], "lang": { "en-us": { "role": { "label": "Accrued Liabilities [Line Items]", "documentation": "Accrued Liabilities [Line Items]" } } }, "auth_ref": [] }, "meip_AccruedMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "AccruedMilestonePayments", "crdr": "credit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Accrued milestone payments.", "label": "Accrued Milestone Payments", "terseLabel": "Accrued payment for potential future payments" } } }, "auth_ref": [] }, "meip_AccruedPreclinicalAndClinicalCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "AccruedPreclinicalAndClinicalCosts", "crdr": "credit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Accrued pre-clinical and clinical trial expenses", "label": "Accrued Preclinical And Clinical Costs", "documentation": "Accrued pre-clinical and clinical trial expenses." } } }, "auth_ref": [] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Accrued legal and professional services", "label": "Accrued Professional Fees, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r58"] }, "meip_AccruedReimbursementToRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "AccruedReimbursementToRelatedParty", "crdr": "credit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Accrued reimbursement to KKC", "label": "Accrued Reimbursement to Related Party", "documentation": "Accrued reimbursement to related party." } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetail"], "lang": { "en-us": { "role": { "negatedLabel": "Less: accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance", "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance", "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": ["r26", "r136", "r493"] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": ["r735"] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance", "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": ["r66"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional paid in capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r538", "r801", "r802", "r803", "r804", "r853", "r910"] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": ["r748"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": ["r748"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": ["r748"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": ["r748"] }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/LeasesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Accounting Standards Update [Axis]", "documentation": "Information by amendment to accounting standards." } } }, "auth_ref": ["r125", "r126", "r127", "r128", "r129", "r130", "r159", "r160", "r161", "r162", "r172", "r198", "r199", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r217", "r218", "r221", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r404", "r405", "r415", "r416", "r417", "r428", "r429", "r430", "r431", "r432", "r433", "r447", "r448", "r449", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings", "crdr": "debit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings", "negatedTerseLabel": "Cash dividends declared", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from dividends legally declared (or paid) in excess of retained earnings balance." } } }, "auth_ref": ["r7", "r101"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "verboseLabel": "Share-based compensation expense", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r36", "r37", "r293"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Adjustments to reconcile net (loss) income to net cash used in operating activities:" } } }, "auth_ref": [] }, "meip_AdoptedAgreement": { "xbrltype": "dateItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "AdoptedAgreement", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureDispositionOfANonfinancialAssetAdditionalInformationDetail", "http://www.meipharma.com/20241231/taxonomy/role/StockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Adopted agreement date", "label": "Adopted Agreement", "documentation": "Adopted agreement" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": ["r781"] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r707", "r717", "r727", "r759"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": ["r710", "r720", "r730", "r762"] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": ["r782"] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": ["r748"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": ["r755"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": ["r711", "r721", "r731", "r755", "r763", "r767", "r775"] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": ["r773"] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "meip_AmountOnReductionInRemainingRightOfUseAssetAndLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "AmountOnReductionInRemainingRightOfUseAssetAndLeaseLiability", "crdr": "debit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/LeasesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Amount on reduction in remaining right of use asset and lease liability.", "label": "Amount on Reduction in Remaining Right of Use Asset and Lease Liability", "terseLabel": "Amount on reduction in remaining right of use asset and lease liability" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAntidilutiveSecuritiesDetail"], "lang": { "en-us": { "role": { "verboseLabel": "Total anti-dilutive shares", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r181"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAntidilutiveSecuritiesDetail"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r16"] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAntidilutiveSecuritiesDetail"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r16"] }, "us-gaap_AreaOfLand": { "xbrltype": "areaItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AreaOfLand", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/LeasesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Number of square feet under lease", "label": "Area of Land", "documentation": "Area of land held." } } }, "auth_ref": [] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.meipharma.com/20241231/taxonomy/role/DisclosureOtherLicenseAgreementsAdditionalInformationDetails", "http://www.meipharma.com/20241231/taxonomy/role/LicenseAgreementsAdditionalInformationDetail", "http://www.meipharma.com/20241231/taxonomy/role/StockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r351"] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetImpairmentCharges", "crdr": "debit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetail", "http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentParentheticalDetail"], "lang": { "en-us": { "role": { "totalLabel": "Asset Impairment Charges, Total", "label": "Asset Impairment Charges", "terseLabel": "Impairment charges", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": ["r3", "r24"] }, "meip_AssetPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "AssetPurchaseAgreementMember", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureDispositionOfANonfinancialAssetAdditionalInformationDetail", "http://www.meipharma.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Asset Purchase Agreement [Member]", "label": "Asset Purchase Agreement [Member]", "terseLabel": "Asset Purchase Agreement" } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r105", "r115", "r137", "r154", "r184", "r187", "r192", "r193", "r201", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r353", "r357", "r406", "r484", "r565", "r637", "r638", "r672", "r697", "r821", "r822", "r868"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "auth_ref": [] }, "meip_AssetsAndLiabilitiesEliminatedUponConsolidationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "AssetsAndLiabilitiesEliminatedUponConsolidationAbstract", "lang": { "en-us": { "role": { "documentation": "Assets and Liabilities Eliminated upon Consolidation [Abstract]", "label": "Assets and Liabilities Eliminated upon Consolidation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r132", "r141", "r154", "r201", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r353", "r357", "r406", "r672", "r821", "r822", "r868"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets, Fair Value Disclosure", "totalLabel": "Assets, Fair Value Disclosure, Total", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r383", "r384", "r663"] }, "meip_AtTheMarketOfferingAgreementDescription": { "xbrltype": "stringItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "AtTheMarketOfferingAgreementDescription", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "At-the-market offering agreement description.", "label": "At-the-Market Offering Agreement Description", "terseLabel": "At-the-market offering agreement, description" } } }, "auth_ref": [] }, "meip_AtTheMarketSaleAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "AtTheMarketSaleAgreementMember", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "At The Market Sale Agreement [Member]", "terseLabel": "ATM Sales Agreement", "documentation": "At-the-market equity offering sales agreement." } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": ["r770"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": ["r771"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": ["r766"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": ["r766"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": ["r766"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": ["r766"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": ["r766"] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": ["r766"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/ShareBasedCompensationAdditionalInformationDetail", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": ["r769"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r768"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": ["r767"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": ["r767"] }, "us-gaap_BalanceSheetRelatedDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetRelatedDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Balance Sheet Related Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationPolicies"], "lang": { "en-us": { "role": { "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation and Consolidation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "meip_BeigeneLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "BeigeneLtdMember", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureOtherLicenseAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "BeiGene, Ltd", "label": "BeiGene, Ltd [Member]", "terseLabel": "BeiGene, Ltd" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": ["r212", "r213", "r214", "r215", "r216", "r342", "r655", "r656"] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": ["r38", "r39", "r212", "r213", "r214", "r215", "r216", "r342", "r655", "r656"] }, "us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessDescriptionAndAccountingPoliciesTextBlock", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Description of Business", "label": "Business Description and Accounting Policies [Text Block]", "documentation": "The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r86", "r87"] }, "us-gaap_CapitalUnitsAuthorized": { "xbrltype": "sharesItemType",

"nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalUnitsAuthorized", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Total authorized share capital", "label": "Capital Units, Authorized", "documentation": "Number of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash and cash equivalents at end of the period", "periodStartLabel": "Cash and cash equivalents at beginning of the period", "terseLabel": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r12", "r134", "r630"] }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsAndShortTermInvestments", "crdr": "debit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents and short term investments", "label": "Cash, Cash Equivalents, and Short-Term Investments", "totalLabel": "Total cash, cash equivalents and short-term investments", "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable." } } }, "auth_ref": ["r794"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "periodEndLabel": "Cash and cash equivalents at end of the period", "periodStartLabel": "Cash and cash equivalents at beginning of the period", "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r12", "r83", "r151"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "crdr": "debit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r0", "r83"] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Noncash investing activities:" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r746"] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": ["r743"] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": ["r741"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r138", "r139", "r140", "r186", "r252", "r253", "r254", "r256", "r259", "r264", "r266", "r530", "r531", "r532", "r533", "r648", "r785", "r799"] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "verboseLabel": "Exercise price", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r267"] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "terseLabel": "Warrants outstanding", "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares." } } }, "auth_ref": [] }, "meip_ClosingAgreement": { "xbrltype": "dateItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "ClosingAgreement", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Closing agreement date", "label": "Closing Agreement", "documentation": "Closing agreement." } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": ["r747"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": ["r747"] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "verboseLabel": "Commitments and contingencies (Note 6)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r62", "r107", "r487", "r552"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/CommitmentsAndContingencies"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r96", "r233", "r234", "r614", "r814", "r816"] }, "us-gaap_CommonStockDividendsPerShareDeclared": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockDividendsPerShareDeclared", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical", "http://www.meipharma.com/20241231/taxonomy/role/StockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "verboseLabel": "Unpaid common stock dividend", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Cash dividends declared, per share", "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding." } } }, "auth_ref": ["r101"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Shares", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r687", "r688", "r689", "r691", "r692", "r693", "r694", "r801", "r802", "r804", "r853", "r908", "r910"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.meipharma.com/20241231/taxonomy/role/StockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r65"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.meipharma.com/20241231/taxonomy/role/StockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r65", "r553"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "totalLabel": "Common Stock, Shares, Issued, Total", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r65"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance", "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r7", "r65", "r553", "r571", "r910", "r911"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Common stock value", "periodEndLabel": "Common Stock, Value, Issued, Ending Balance", "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance", "totalLabel": "Common Stock, Value, Issued, Total", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock, $0.00000002 par value; 226,000 shares authorized; 6,663 shares issued and outstanding at December 31, 2024 and June 30, 2024.", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r65", "r489", "r672"] }, "us-gaap_CommonStockVotingRights": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockVotingRights", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Common stock voting rights", "label": "Common Stock, Voting Rights", "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights." } } }, "auth_ref": ["r30"] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": ["r752"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": ["r751"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": ["r753"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": ["r750"] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenueAssociatedWithLicenseAgreementDetail", "http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": ["r19", "r20", "r40", "r41", "r197", "r613"] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenueAssociatedWithLicenseAgreementDetail", "http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": ["r19", "r20", "r40", "r41", "r197", "r524", "r613"] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRisk", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Concentrations of Credit Risk", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": ["r44", "r120"] }, "us-gaap_ContractTerminationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractTerminationMember", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureEmployeeTerminationBenefitsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Termination Benefits", "label": "Contract Termination [Member]", "documentation": "Termination of a contract associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": ["r641", "r642", "r643", "r644"] }, "us-gaap_ContractWithCustomerAssetAndLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetAndLiabilityAbstract", "lang": { "en-us": { "role": { "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Abstract]" } } }, "auth_ref": [] }, "meip_ContractWithCustomerAssetAndLiabilityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "ContractWithCustomerAssetAndLiabilityLineItems", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInUnbilledReceivablesAndContractLiabilitiesDetail"], "lang": { "en-us": { "role": { "documentation": "Contract with customer asset and liability Line items.", "label": "Contract with Customer Asset and Liability [Line Items]", "terseLabel": "Contract with Customer Asset and Liability [Line Items]" } } }, "auth_ref": [] }, "meip_ContractWithCustomerAssetAndLiabilityTable": { "xbrltype": "stringItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "ContractWithCustomerAssetAndLiabilityTable", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInUnbilledReceivablesAndContractLiabilitiesDetail"], "lang": { "en-us": { "role": { "documentation": "Contract with customer asset and liability.", "label": "Contract with Customer Asset and Liability [Table]", "terseLabel": "Contract with Customer Asset and Liability [Table]" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes in Unbilled Receivables and Contract Liabilities", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability." } } }, "auth_ref": ["r824"] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInUnbilledReceivablesAndContractLiabilitiesDetail"], "lang": { "en-us": { "role": { "periodEndLabel": "Contract liabilities, end of period", "periodStartLabel": "Contract liabilities, beginning of period", "totalLabel": "Contract with Customer, Liability, Total", "label": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r269", "r270", "r279"] }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityNoncurrent", "crdr": "credit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/LicenseAgreementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability, Noncurrent", "terseLabel": "Contract with customer liability non current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": ["r269", "r270", "r279"] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/LicenseAgreementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Revenue recognized", "label": "Contract with Customer, Liability, Revenue Recognized", "verboseLabel": "Contract with Customer, Liability, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": ["r280"] }, "meip_ContractWithCustomerLiabilityRevenueRecognizedUponSatisfactionOfPerformanceObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "ContractWithCustomerLiabilityRevenueRecognizedUponSatisfactionOfPerformanceObligations", "crdr": "credit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInUnbilledReceivablesAndContractLiabilitiesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Revenue recognized upon satisfaction of performance obligations", "documentation": "Contract with customer liability revenue recognized upon satisfaction of performance obligations.", "label": "Contract With Customer Liability Revenue Recognized Upon Satisfaction of Performance Obligations" } } }, "auth_ref": [] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpenses", "crdr": "debit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Costs and Expenses", "totalLabel": "Total operating expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": ["r78"] }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpensesAbstract", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_CostsAndExpensesRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpensesRelatedParty", "crdr": "debit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Expenses related to an agreement", "label": "Costs and Expenses, Related Party", "documentation": "Costs of sales and operating expenses for the period incurred from transactions with related parties." } } }, "auth_ref": ["r71"] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenue", "crdr": "credit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/LicenseAgreementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "totalLabel": "Deferred Revenue, Total", "label": "Deferred Revenue", "terseLabel": "Deferred revenue", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r791"] }, "us-gaap_DeferredRevenueArrangementTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenueArrangementTypeAxis", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Deferred Revenue Arrangement Type [Axis]", "terseLabel": "Deferred Revenue Arrangement Type [Axis]", "documentation": "Information by type of deferred revenue arrangement." } } }, "auth_ref": [] }, "us-gaap_DeferredRevenueArrangementTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenueArrangementTypeDomain", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Deferred Revenue [Domain]", "terseLabel": "Deferred Revenue [Domain]", "documentation": "Category of obligation arising when an entity receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized." } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "totalLabel": "Depreciation, Total", "label": "Depreciation", "terseLabel": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": ["r3", "r25"] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Depreciation expense", "totalLabel": "Depreciation, Depletion and Amortization, Total", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": ["r3", "r184", "r190", "r193", "r637", "r638"] }, "meip_DevelopmentServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "DevelopmentServicesMember", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/LicenseAgreementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Development Services [Member]", "terseLabel": "Development Services" } } }, "auth_ref": [] }, "meip_DevelopmentServicesPerformanceObligationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "DevelopmentServicesPerformanceObligationsMember", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Development services performance obligations member.", "label": "Development Services Performance Obligations [Member]", "terseLabel": "Development Services Performance Obligations" } } }, "auth_ref": [] }, "us-gaap_DilutiveSecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DilutiveSecuritiesAbstract", "lang": { "en-us": { "role": { "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "meip_DirectCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "DirectCosts", "crdr": "debit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/LeasesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Direct costs.", "label": "Direct Costs", "terseLabel": "Direct costs" } } }, "auth_ref": [] }, "srt_DirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "DirectorMember", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/ShareBasedCompensationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Director [Member]", "terseLabel": "Directors" } } }, "auth_ref": ["r810", "r909"] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Revenue Associated with License Agreement", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": ["r825"] }, "us-

gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"presentation": ["http://www.meipharma.com/20241231/taxonomy/role/ShareBasedCompensation"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Share-based Compensation", "documentation":
"The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r291", "r295", "r322", "r323", "r325", "r658"] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/ShareBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Disclosure of
Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]", "terseLabel": "Summary of Stock Option Activity and Related Data", "documentation": "Tabular disclosure of share-based payment arrangement." } } },
"auth_ref": ["r5", "r34"] }, "meip_DisclosureOfSupplementalCashFlowInformationRelatedToOperatingLeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.meipharma.com/20241231", "localname":
"DisclosureOfSupplementalCashFlowInformationRelatedToOperatingLeasesAbstract", "lang": { "en-us": { "role": { "label": "Disclosure Of Supplemental Cash Flow Information Related To Operating Leases [Abstract]", "documentation": "Disclosure of
supplemental cash flow information related to operating leases." } } }, "auth_ref": [] }, "meip_DisclosureOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://www.meipharma.com/20241231", "localname": "DisclosureOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/LeasesTables"], "lang": { "en-us":
{ "role": { "documentation": "Disclosure of supplemental cash flow information related to operating leases.", "label": "Disclosure Of Supplemental Cash Flow Information Related To Operating Leases [Table Text Block]", "terseLabel": "Schedule of
Supplemental Cash Flow Information Related to Operating Leases" } } }, "auth_ref": [] }, "us-gaap_DisclosureTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureTextBlockAbstract", "lang":
{ "en-us": { "role": { "label": "Disclosure Text Block [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DiscontinuedOperationsAndDisposalGroupsAbstract", "lang": { "en-us": { "role": { "label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock":
{ "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureDispositionOfANonfinancialAsset"], "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "terseLabel": "Disposition of a Non-
financial Asset", "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually
significant component." } } }, "auth_ref": ["r46", "r89"] }, "meip_DispositionOfNon-FinancialAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "DispositionOfNon-
FinancialAssetsPolicyTextBlock", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Disposition of Non-Financial Assets",
"label": "Disposition of Non-Financial Assets Policy Text Block", "documentation": "Disposition of non-financial assets policy text block." } } }, "auth_ref": [] }, "us-gaap_DividendsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "DividendsAxis", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Dividends [Axis]", "documentation": "Information
by distribution of earnings to shareholder. Includes, but is not limited to, distribution paid and declared." } } }, "auth_ref": [] }, "us-gaap_DividendsCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DividendsCash", "crdr": "debit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Return of capital
authorised", "label": "Dividends, Cash", "totalLabel": "Dividends, Cash, Total", "documentation": "Amount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred." } } }, "auth_ref": ["r1",
"r101"] }, "us-gaap_DividendsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsDomain", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/StockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Dividends [Domain]", "documentation": "Distributions of earnings to shareholders including but not limited to
cash, property or capital stock." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st,
2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "terseLabel": "Document
Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example:
2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/CoverPage"
], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR
submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation":
"Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r702"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport",
"presentation": ["http://www.meipharma.com/20241231/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } },
"auth_ref": ["r734"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/CoverPage"], "lang": {
"en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission
type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise
Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": ["r745"] }, "us-
gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "verboseLabel": "Net (loss) income per share - basic and diluted:" }
} }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "totalLabel": "Earnings Per Share, Basic, Total", "label": "Earnings Per Share, Basic", "terseLabel": "Basic",
"documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r148", "r163", "r164", "r165", "r166", "r167", "r168", "r173", "r175", "r178", "r179",
"r180", "r183", "r340", "r350", "r380", "r381", "r481", "r498", "r634"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "terseLabel": "Diluted", "totalLabel": "Earnings Per Share, Diluted, Total", "label": "Earnings Per Share,
Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the
issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r148", "r163", "r164", "r165", "r166", "r167", "r168", "r175", "r178", "r179", "r180", "r183", "r340", "r350",
"r380", "r381", "r481", "r498", "r634"] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Income (Loss) Per Share",
"documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have
been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": ["r16", "r17",
"r182"] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetail", "http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesParentheticalDetail"], "lang": { "en-
us": { "role": { "terseLabel": "Accrued compensation and benefits", "label": "Employee-related Liabilities, Current", "totalLabel": "Employee-related Liabilities, Current, Total", "documentation": "Total of the carrying values as of the balance sheet date of
obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one
year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r58"] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureEmployeeTerminationBenefitsAdditionalInformationDetail",
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSharebasedCompensationSharebasedCompensationExpenseForStockAwardsDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized,
Amount [Line Items]", "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose
reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-
gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/ShareBasedCompensationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
"terseLabel": "Expected weighted average period for recognition of compensation expense", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement,
in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r324"] }, "us-
gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/ShareBasedCompensationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
"terseLabel": "Unrecognized compensation expense related to unvested stock options", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": ["r852"] }, "us-
gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAntidilutiveSecuritiesDetail", "http://www.meipharma.com/20241231/taxonomy/role/ShareBasedCompensationAdditionalInformationDetail",
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "verboseLabel": "Stock option", "documentation": "Share-based payment arrangement
granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "meip_EmployeeTerminationBenefitsMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "EmployeeTerminationBenefitsMember", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureEmployeeTerminationBenefitsAdditionalInformationDetail",
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureEmployeeTerminationBenefitsSummaryOfActivityRelatedToEmployeeBenefitsIncludedInAccruedLiabilitiesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Employee Termination
Benefits", "documentation": "Employee termination benefits.", "label": "Employee Termination Benefits [Member]" } } }, "auth_ref": [] }, "meip_EmployeesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.meipharma.com/20241231",
"localname": "EmployeesMember", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/ShareBasedCompensationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Employees.", "label": "Employees
[Member]", "terseLabel": "Employees" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name,
Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] },
"dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/CoverPage"], "lang": {
"en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel":
"Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityAddressStateOrProvince", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province",
"documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityBankruptcyProceedingsReportingCurrent", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For
registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934
subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } },
"auth_ref": ["r701"] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that
have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r699"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityCommonStockSharesOutstanding", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares
Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or
units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] },
"dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/CoverPage"], "lang": { "en-
us": { "role": { "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the
registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/CommitmentsAndContingencies", "http://www.meipharma.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationPolicies", "http://www.meipharma.com/20241231/taxonomy/role/DisclosureNetIncomeLossPerShareAdditionalInformationDetail",
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSharebasedCompensationFairValueOfStockOptionsWeightedaverageAssumptionsUsedDetail",
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetail",
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInUnbilledReceivablesAndContractLiabilitiesDetail",
"http://www.meipharma.com/20241231/taxonomy/role/LicenseAgreementsAdditionalInformationDetail", "http://www.meipharma.com/20241231/taxonomy/role/ShareBasedCompensationTables",
"http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets", "http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows",
"http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations", "http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-
us": { "role": { "label": "Entity [Domain]", "terseLabel": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such
structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } },
"auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging
growth company criteria." } } }, "auth_ref": ["r699"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters.
The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype":
"filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "label": "Entity Filer Category",
"terseLabel": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act.
This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r699"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country
Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "terseLabel":
"Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months
(or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r784"] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr":
"credit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Entity Public Float", "terseLabel": "Entity public float", "documentation": "The
aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day
of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "meip_EntityPublicFloatThreshold": { "xbrltype": "monetaryItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "EntityPublicFloatThreshold",
"crdr": "credit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Entity public float, threshold", "documentation": "Entity public float
threshold.", "label": "Entity Public Float Threshold" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its
charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r699"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "terseLabel": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as
defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r699"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company
(SRC)." } } }, "auth_ref": ["r699"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also
known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r699"] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": [
"r739"] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in
Compensation Table" } } }, "auth_ref": ["r780"] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"
], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": ["r780"] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award
Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": ["r780"] }, "us-gaap_EquipmentMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquipmentMember", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetail"],
"lang": { "en-us": { "role": { "label": "Equipment [Member]", "verboseLabel": "Equipment", "documentation": "Tangible personal property used to produce goods and services." } } }, "auth_ref": [] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity",
"http://www.meipharma.com/20241231/taxonomy/role/StockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]", "documentation": "Components of
equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r7", "r127", "r144", "r145", "r146", "r155", "r156", "r157", "r160", "r167", "r169", "r171",
"r185", "r205", "r211", "r218", "r268", "r328", "r329", "r336", "r337", "r338", "r341", "r349", "r350", "r362", "r364", "r365", "r366", "r367", "r369", "r379", "r407", "r408", "r409", "r410", "r411", "r412", "r416", "r419", "r433", "r497", "r513", "r514", "r515",
"r538", "r594"] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": ["r749"] },
"ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": {
"label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": ["r707", "r717", "r727", "r759"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel":
"Erroneously Awarded Compensation Recovery" } } }, "auth_ref": ["r704", "r714", "r724", "r756"] }, "meip_EstimatedDevelopmentCostSharingRecoverableThroughEarnings": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.meipharma.com/20241231", "localname": "EstimatedDevelopmentCostSharingRecoverableThroughEarnings", "crdr": "debit", "presentation": [

"http://www.meipharma.com/20241231/taxonomy/role/LicenseAgreementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Estimated development cost sharing reoverable through earnings.", "label": "Estimated Development
Cost Sharing Recoverable Through Earnings", "terseLabel": "Estimated development cost sharing recovered through earnings" } } }, "auth_ref": [] }, "meip_EventAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.meipharma.com/20241231",
"localname": "EventAxis", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/LicenseAgreementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Event [Axis]", "documentation": "Event" } } }, "auth_ref": [] },
"meip_EventDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "EventDomain", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/LicenseAgreementsAdditionalInformationDetail"
], "lang": { "en-us": { "role": { "documentation": "Event", "label": "Event [Domain]" } } }, "auth_ref": [] }, "meip_ExUsLicenseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "ExUsLicenseMember",
"presentation": ["http://www.meipharma.com/20241231/taxonomy/role/LicenseAgreementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Ex US License [Member]", "terseLabel": "Ex US License" } } }, "auth_ref": [] },
"ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Executive
Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": ["r755"] }, "meip_ExpectedMilestonePaymentReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.meipharma.com/20241231", "localname":
"ExpectedMilestonePaymentReceivable", "crdr": "debit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/LicenseAgreementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Expected milestone
payment receivable.", "label": "Expected Milestone Payment Receivable", "terseLabel": "Expected milestone payment receivable" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r383", "r384",
"r397", "r663"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"], "lang": { "en-us": { "role": {
"label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": ["r383", "r384", "r397", "r663"] }, "us-
gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssumptionsUsedToCalculateFairValueOfWarrantLiabilityDetail"], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation
Techniques [Line Items]", "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information
associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r385", "r386", "r387", "r667"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssumptionsUsedToCalculateFairValueOfWarrantLiabilityDetail"], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation
Techniques [Table]", "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and
technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": ["r385", "r386", "r387", "r667"] }, "us-
gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetail"], "lang": { "en-us": {
"role": { "label": "Asset Class [Domain]", "documentation": "Class of asset." } } }, "auth_ref": ["r388", "r389", "r390", "r391", "r392", "r393", "r398", "r665"] }, "us-gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "FairValueByAssetClassAxis", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Asset
Class [Axis]", "documentation": "Information by class of asset." } } }, "auth_ref": ["r388", "r389", "r390", "r391", "r392", "r393", "r398", "r665"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfChangesInEstimatedFairValueOfWarrantLiabilityDetail"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair
Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r250", "r283", "r284", "r285", "r286", "r287", "r288",
"r382", "r384", "r385", "r386", "r387", "r396", "r397", "r399", "r439", "r440", "r441", "r646", "r647", "r652", "r653", "r654", "r663", "r667"] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfChangesInEstimatedFairValueOfWarrantLiabilityDetail"], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "terseLabel":
"Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": ["r383", "r384", "r385", "r387", "r663", "r857", "r862"] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/FairValueMeasurements"], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text
Block]", "terseLabel": "Fair Value Measurements", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those
instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying
amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons
why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed
to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative
information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the
financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the
election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": ["r392",
"r394", "r395", "r396", "r399", "r400", "r401", "r402", "r403", "r480", "r663", "r668"] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member",
"presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfChangesInEstimatedFairValueOfWarrantLiabilityDetail"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]",
"terseLabel": "Level 3", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r250", "r283", "r284", "r285", "r286", "r287", "r288", "r384",
"r385", "r386", "r387", "r397", "r441", "r646", "r647", "r652", "r653", "r654", "r663", "r667"] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss", "crdr": "credit", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfChangesInEstimatedFairValueOfWarrantLiabilityDetail"], "lang": { "en-us": { "role": { "label": "Fair Value, Liability, Recurring Basis, Still Held,
Unrealized Gain (Loss)", "terseLabel": "Change in estimated fair value of liability classified warrants", "verboseLabel": "Change in fair value of warrant liability", "negatedLabel": "Change in fair value of warrant liability", "negatedTerseLabel": "Change in
estimated fair value of liability classified warrants", "documentation": "Amount of unrealized gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3) and still held." } } }, "auth_ref": [
"r393", "r398"] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfChangesInEstimatedFairValueOfWarrantLiabilityDetail"], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]", "terseLabel": "Fair
Value, Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": ["r383", "r384", "r385", "r387", "r663", "r857", "r862"] }, "us-
gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet", "crdr": "credit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
], "lang": { "en-us": { "role": { "terseLabel": "Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, transfers", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability,
Transfers, Net", "totalLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net, Total", "documentation": "Amount of transfers of financial instrument classified as a liability into (out of) level 3
of the fair value hierarchy." } } }, "auth_ref": ["r859", "r861"] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueMeasurementsFairValueHierarchyDomain", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfChangesInEstimatedFairValueOfWarrantLiabilityDetail"], "lang": { "en-us": {
"role": { "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": ["r250",
"r283", "r284", "r285", "r286", "r287", "r288", "r382", "r384", "r385", "r386", "r387", "r396", "r397", "r399", "r439", "r440", "r441", "r646", "r647", "r652", "r653", "r654", "r663", "r667"] }, "us-gaap_FairValueMeasurementsRecurringMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfChangesInEstimatedFairValueOfWarrantLiabilityDetail"], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair
Value, Measurements, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [
"r663", "r854", "r855", "r856", "r857", "r858", "r862"] }, "meip_FairValueMeasurementsSignificantUnobservableInputsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.meipharma.com/20241231", "localname":
"FairValueMeasurementsSignificantUnobservableInputsLineItems", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfChangesInEstimatedFairValueOfWarrantLiabilityDetail"], "lang": {
"en-us": { "role": { "documentation": "Fair Value Measurements, Significant Unobservable Inputs [Line Items]", "label": "Fair Value Measurements, Significant Unobservable Inputs [Line Items]", "terseLabel": "Fair value measurements Significant
unobservable inputs [Line Items]" } } }, "auth_ref": [] }, "meip_FairValueMeasurementsSignificantUnobservableInputsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.meipharma.com/20241231", "localname":
"FairValueMeasurementsSignificantUnobservableInputsTable", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfChangesInEstimatedFairValueOfWarrantLiabilityDetail"], "lang": { "en-
us": { "role": { "documentation": "Schedule of fair value measurements significant unobservable inputs.", "label": "Fair Value Measurements, Significant Unobservable Inputs [Table]", "terseLabel": "Fair value measurements Significant unobservable
inputs [Table]" } } }, "auth_ref": [] }, "meip_FairValueOfWarrantLiabilityAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.meipharma.com/20241231", "localname":
"FairValueOfWarrantLiabilityAssumptionsTableTextBlock", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/FairValueMeasurementsTables"], "lang": { "en-us": { "role": { "documentation": "Fair Value of Warrant Liability
Assumptions [Table Text Block]", "label": "Fair Value of Warrant Liability Assumptions [Table Text Block]", "terseLabel": "Schedule of Assumptions Used to Calculate Fair Value of Warrant Liability" } } }, "auth_ref": [] }, "us-
gaap_FederalHomeLoanBanksAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FederalHomeLoanBanksAbstract", "lang": { "en-us": { "role": { "label": "Federal Home Loan Banks [Abstract]" } } }, "auth_ref":
[] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } },
"auth_ref": ["r711", "r721", "r731", "r763"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
"presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } },
"auth_ref": ["r711", "r721", "r731", "r763"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel":
"Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r711", "r721", "r731", "r763"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of
Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": ["r711", "r721", "r731", "r763"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "ForgoneRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r711", "r721", "r731",
"r763"] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year
that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": [
"r744"] }, "meip_FurnitureAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "FurnitureAndEquipmentMember", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetail"], "lang": { "en-us": { "role": { "terseLabel": "Furniture And Equipment", "label": "Furniture And Equipment [Member]" } } },
"auth_ref": [] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FurnitureAndFixturesMember", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetail", "http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetail",
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentParentheticalDetail"], "lang": { "en-us": { "role": { "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and
equipment", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref":
[] }, "us-gaap_GainLossOnSaleOfOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSaleOfOtherAssets", "crdr": "credit", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureDispositionOfANonfinancialAssetAdditionalInformationDetail", "http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows",
"http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Disposition of Other Assets", "negatedLabel": "Gain on disposition of a non-financial
asset", "terseLabel": "Gain on disposition of a non-financial asset", "verboseLabel": "Gain of disposition", "documentation": "Amount of gain (loss) on sale or disposal of other assets." } } }, "auth_ref": ["r798"] }, "us-
gaap_GainLossOnSaleOfPropertyPlantEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSaleOfPropertyPlantEquipment", "crdr": "credit", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Loss on disposal of property and equipment", "totalLabel": "Gain (Loss) on Disposition of
Property Plant Equipment, Total", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedLabel": "Loss on disposal of property and equipment", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and
equipment assets, including oil and gas property and timber property." } } }, "auth_ref": ["r3"] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"GeneralAndAdministrativeExpense", "crdr": "debit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "totalLabel": "General and
Administrative Expense, Total", "label": "General and Administrative Expense", "terseLabel": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of
the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r73", "r575"] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureEmployeeTerminationBenefitsAdditionalInformationDetail", "http://www.meipharma.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfTotalOperatingCostsDetail",
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSharebasedCompensationSharebasedCompensationExpenseForStockAwardsDetail"], "lang": { "en-us": { "role": { "verboseLabel": "General and Administrative Expense [Member]", "label":
"General and Administrative Expense [Member]", "terseLabel": "General and administrative", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": ["r73"] },
"meip_HelsinnLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "HelsinnLicenseAgreementMember", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/LicenseAgreementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Helsinn license agreement.", "label": "Helsinn License Agreement [Member]", "terseLabel": "Helsinn
License Agreement" } } }, "auth_ref": [] }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "crdr": "debit",
"presentation": ["http://www.meipharma.com/20241231/taxonomy/role/LeasesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "totalLabel": "Impairment, Long-Lived Asset, Held-for-Use, Total", "label": "Impairment, Long-Lived Asset, Held-for-
Use", "terseLabel": "Impairment charge", "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)." } } },
"auth_ref": ["r3", "r24", "r91", "r664"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement
[Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureDispositionOfANonfinancialAssetAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups,
Including Discontinued Operations [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to
the table." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureDispositionOfANonfinancialAssetAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations [Table]", "documentation":
"Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref":
["r6", "r8", "r10", "r47", "r48", "r49", "r50", "r51", "r52", "r53", "r54", "r55", "r92"] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis",
"presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureEmployeeTerminationBenefitsAdditionalInformationDetail", "http://www.meipharma.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfTotalOperatingCostsDetail",
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSharebasedCompensationFairValueOfStockOptionsWeightedaverageAssumptionsUsedDetail",
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSharebasedCompensationSharebasedCompensationExpenseForStockAwardsDetail"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "terseLabel":
"Income Statement Location [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r219", "r220", "r226", "r389", "r393", "r398", "r508", "r510", "r578", "r626",
"r666", "r879"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureEmployeeTerminationBenefitsAdditionalInformationDetail", "http://www.meipharma.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfTotalOperatingCostsDetail",
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSharebasedCompensationFairValueOfStockOptionsWeightedaverageAssumptionsUsedDetail",
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSharebasedCompensationSharebasedCompensationExpenseForStockAwardsDetail"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Domain]", "terseLabel":
"Income Statement Location [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r220", "r226", "r389", "r393", "r398", "r508", "r510", "r578", "r626", "r666", "r879"] }, "us-
gaap_IncreaseDecreaseInAccountsPayableTrade": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableTrade", "crdr": "debit", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Payable, Trade", "terseLabel": "Accounts payable", "documentation":
"Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services." } } }, "auth_ref": ["r2"] }, "us-
gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Accrued Liabilities, Total", "label": "Increase (Decrease) in Accrued
Liabilities", "terseLabel": "Accrued liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": ["r2"] }, "us-
gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Deferred revenue",
"verboseLabel": "Increase (Decrease) in Deferred Revenue", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r445",
"r797"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and
liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "presentation":
["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liability", "label": "Increase (Decrease) in Operating Lease Liability",
"documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": ["r788", "r797"] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total", "label": "Increase (Decrease)
in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": ["r2"] },
"meip_IncreaseDecreaseInUnbilledReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "IncreaseDecreaseInUnbilledReceivable", "crdr": "credit", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "negatedLabel": "Unbilled receivables", "label": "Increase Decrease In Unbilled Receivable", "documentation":
"Increase Decrease In Unbilled Receivable" } } }, "auth_ref": [] }, "meip_IncreaseInRightOfUseAssetBalance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "IncreaseInRightOfUseAssetBalance", "crdr":
"debit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/LeasesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Increase in right of use asset balance", "documentation": "Increase in right of use asset

balance.", "label": "Increase in Right of Use Asset Balance" } } }, "auth_ref": [] }, "meip_IncrementalPaymentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "IncrementalPaymentMember",
"presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureOtherLicenseAgreementsAdditionalInformationDetails", "http://www.meipharma.com/20241231/taxonomy/role/LicenseAgreementsAdditionalInformationDetail"], "lang": {
"en-us": { "role": { "documentation": "Incremental Payment.", "label": "Incremental Payment [Member]", "terseLabel": "Incremental Payment" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": ["r711", "r721", "r731", "r755", "r763", "r767", "r775"] }, "meip_InducementPlanMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "InducementPlanMember", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/ShareBasedCompensationAdditionalInformationDetail"], "lang": { "en-
us": { "role": { "terseLabel": "Inducement Plan", "label": "Inducement Plan [Member]", "documentation": "Inducement Plan [Member]" } } }, "auth_ref": [] }, "meip_InfinitysStockholdersMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.meipharma.com/20241231", "localname": "InfinitysStockholdersMember", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail"], "lang":
{ "en-us": { "role": { "documentation": "Infinity's Stockholders.", "label": "Infinity's Stockholders [Member]", "terseLabel": "Infinitys Stockholders" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": ["r773"] },
"ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line
Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": ["r703", "r779"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and
Procedures Adopted" } } }, "auth_ref": ["r703", "r779"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
"presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } }
}, "auth_ref": ["r703", "r779"] }, "us-gaap_InvestmentCompanyDividendDistribution": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentCompanyDividendDistribution", "crdr": "debit", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Anticipated dividend", "label": "Investment Company, Dividend
Distribution", "totalLabel": "Investment Company, Dividend Distribution, Total", "documentation": "Amount of dividend distribution from ordinary income and capital gain. Excludes distribution for tax return of capital." } } }, "auth_ref": ["r535", "r537",
"r538", "r593"] }, "us-gaap_InvestmentIncomeInterestAndDividend": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterestAndDividend", "crdr": "credit", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "totalLabel": "Investment Income, Interest and Dividend, Total", "label": "Investment Income, Interest and
Dividend", "terseLabel": "Interest and dividend income", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities." } } }, "auth_ref": ["r74", "r75"] },
"us-gaap_InvestmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentPolicyTextBlock", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Short-term Investments", "label": "Investment, Policy [Policy Text Block]", "documentation":
"Disclosure of accounting policy for investment in financial asset." } } }, "auth_ref": ["r499", "r526", "r527", "r528", "r529", "r602", "r603"] }, "meip_KkcAgreementsMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.meipharma.com/20241231", "localname": "KkcAgreementsMember", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/LicenseAgreementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "verboseLabel": "KKC
License Agreement", "documentation": "Kkc Agreements [Member].", "label": "Kkc Agreements [Member]", "terseLabel": "KKC License Agreement [Member]" } } }, "auth_ref": [] }, "meip_KyowaKirinCoMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.meipharma.com/20241231", "localname": "KyowaKirinCoMember", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
"http://www.meipharma.com/20241231/taxonomy/role/LicenseAgreementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "verboseLabel": "Kyowa Kirin Co. Ltd", "terseLabel": "Kyowa Kirin Co [Member]", "label": "Kyowa Kirin Co [Member]" }
} }, "auth_ref": [] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crdr": "debit", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfTotalOperatingCostsDetail", "http://www.meipharma.com/20241231/taxonomy/role/LeasesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "totalLabel": "Total
lease costs included in general and administrative expenses", "label": "Lease, Cost", "verboseLabel": "Lease cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": ["r423", "r671"] }, "us-
gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/LeasesTables"], "lang": { "en-
us": { "role": { "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of Total Operating Costs", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-
of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": ["r864"] }, "meip_LeaseExpirationAmendedDate": { "xbrltype": "dateItemType", "nsuri":
"http://www.meipharma.com/20241231", "localname": "LeaseExpirationAmendedDate", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/LeasesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Lease
expiration amended date.", "label": "Lease Expiration Amended Date", "terseLabel": "Lease expiration amended date" } } }, "auth_ref": [] }, "us-gaap_LeaseExpirationDate1": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LeaseExpirationDate1", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/LeasesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Lease expire date", "label": "Lease Expiration Date",
"documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "meip_LeaseTerminationDate": { "xbrltype": "dateItemType", "nsuri": "http://www.meipharma.com/20241231", "localname":
"LeaseTerminationDate", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/LeasesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Lease termination date", "documentation": "Lease termination date.",
"label": "Lease Termination Date" } } }, "auth_ref": [] }, "meip_LeaseTerminationFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "LeaseTerminationFee", "crdr": "credit", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/LeasesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Lease termination fee.", "label": "Lease Termination Fee", "terseLabel": "Termination fee" } } }, "auth_ref": [] },
"us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetail"], "lang": { "en-us": { "role": { "terseLabel": "Leasehold Improvements", "label": "Leasehold Improvements [Member]",
"documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": ["r90", "r427"] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/CommitmentsAndContingencies", "http://www.meipharma.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationPolicies", "http://www.meipharma.com/20241231/taxonomy/role/DisclosureNetIncomeLossPerShareAdditionalInformationDetail",
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSharebasedCompensationFairValueOfStockOptionsWeightedaverageAssumptionsUsedDetail",
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetail",
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInUnbilledReceivablesAndContractLiabilitiesDetail",
"http://www.meipharma.com/20241231/taxonomy/role/LicenseAgreementsAdditionalInformationDetail", "http://www.meipharma.com/20241231/taxonomy/role/ShareBasedCompensationTables",
"http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets", "http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows",
"http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations", "http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-
us": { "role": { "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/LeasesTables"], "lang": { "en-us": { "role": {
"terseLabel": "Schedule of Future Minimum Rental Payments", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability.
Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": ["r865"] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/Leases"], "lang": { "en-us": { "role": { "label": "Lessee, Operating
Leases [Text Block]", "terseLabel": "Leases", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": ["r418"]
}, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present
obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r9", "r57", "r58", "r59", "r60", "r61", "r62", "r63", "r154", "r201", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r354", "r357",
"r358", "r406", "r551", "r635", "r697", "r821", "r868", "r869"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit",
"presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity",
"documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r70", "r108", "r491", "r672", "r800", "r812", "r863"] }, "us-
gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } },
"auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as
part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r59", "r133", "r154", "r201", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249",
"r354", "r357", "r358", "r406", "r672", "r821", "r868", "r869"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "auth_ref": [] }, "us-
gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Liabilities", "label": "Liabilities, Fair Value Disclosure", "totalLabel": "Liabilities, Fair
Value Disclosure, Total", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": ["r384", "r854"] }, "meip_LicenseObligationAccountTransactionPriceAllocated": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.meipharma.com/20241231", "localname": "LicenseObligationAccountTransactionPriceAllocated", "crdr": "credit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/LicenseAgreementsAdditionalInformationDetail"],
"lang": { "en-us": { "role": { "documentation": "License obligation account transaction price allocated.", "label": "License Obligation Account Transaction Price Allocated", "terseLabel": "License Obligation Account Transaction Price Allocated" } } },
"auth_ref": [] }, "meip_LicenseObligationAccountTransactionPriceAllocatedDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.meipharma.com/20241231", "localname":
"LicenseObligationAccountTransactionPriceAllocatedDeferredRevenue", "crdr": "credit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/LicenseAgreementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel":
"Transaction price of deferred revenue remaining performance obligations", "label": "License Obligation Account Transaction Price Allocated Deferred Revenue", "documentation": "License obligation account transaction price allocated deferred revenue."
} } }, "auth_ref": [] }, "meip_LicensingArrangementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "LicensingArrangementsAbstract", "lang": { "en-us": { "role": { "label": "Licensing Arrangements
[Abstract]", "documentation": "Licensing arrangements [Abstract]." } } }, "auth_ref": [] }, "meip_LiquidityPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "LiquidityPolicyTextBlock",
"presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationPolicies"], "lang": { "en-us": { "role": { "documentation": "The Disclosure In Its Entirety Pertaining to the Accounting Policy
In Respect Of Liquid Resources Held By The Entity.", "label": "Liquidity [Policy Text Block]", "terseLabel": "Liquidity" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "LocalPhoneNumber", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] },
"us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureDispositionOfANonfinancialAssetAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Category of Item Purchased [Axis]", "documentation": "Information by category of
items purchased under a long-term purchase commitment." } } }, "auth_ref": [] }, "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureDispositionOfANonfinancialAssetAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label":
"Long-Term Purchase Commitment, Category of Item Purchased [Domain]", "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment." } } }, "auth_ref": [] }, "us-
gaap_LossContingenciesByNatureOfContingencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesByNatureOfContingencyAxis", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Loss Contingency Nature [Axis]", "documentation": "Information by type of existing
condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur." } } }, "auth_ref": ["r235", "r236", "r237", "r240", "r326", "r523",
"r645", "r817", "r818"] }, "us-gaap_LossContingencyNatureDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyNatureDomain", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Loss Contingency, Nature [Domain]", "documentation": "An existing condition, situation, or
set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an
asset or the incurrence of a liability." } } }, "auth_ref": ["r235", "r236", "r237", "r240", "r326", "r523", "r645", "r817", "r818"] }, "meip_MaximumAmountOfCommonStockOfferingPrice": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.meipharma.com/20241231", "localname": "MaximumAmountOfCommonStockOfferingPrice", "crdr": "credit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StockholdersEquityAdditionalInformationDetail"], "lang": {
"en-us": { "role": { "terseLabel": "Aggregate offering price", "documentation": "Maximum amount of common stock offering price", "label": "Maximum Amount Of Common Stock Offering Price" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureDispositionOfANonfinancialAssetAdditionalInformationDetail",
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail", "http://www.meipharma.com/20241231/taxonomy/role/LicenseAgreementsAdditionalInformationDetail",
"http://www.meipharma.com/20241231/taxonomy/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.meipharma.com/20241231/taxonomy/role/StockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label":
"Maximum [Member]", "terseLabel": "Maximum" } } }, "auth_ref": ["r236", "r237", "r238", "r239", "r290", "r326", "r387", "r444", "r507", "r509", "r523", "r543", "r544", "r600", "r604", "r606", "r607", "r609", "r624", "r625", "r639", "r648", "r657", "r667",
"r668", "r669", "r670", "r682", "r823", "r870", "r871", "r872", "r873", "r874", "r875"] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": ["r747"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": ["r747"] }, "us-
gaap_MeasurementInputExercisePriceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputExercisePriceMember", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssumptionsUsedToCalculateFairValueOfWarrantLiabilityDetail"], "lang": { "en-us": { "role": { "label": "Measurement Input, Exercise Price [Member]",
"terseLabel": "Black-Scholes Fair Value", "documentation": "Measurement input using agreed upon price for exchange of underlying asset." } } }, "auth_ref": ["r856", "r857", "r858"] }, "us-gaap_MeasurementInputExpectedDividendRateMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputExpectedDividendRateMember", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssumptionsUsedToCalculateFairValueOfWarrantLiabilityDetail"], "lang": { "en-us": { "role": { "label": "Measurement Input, Expected Dividend Rate
[Member]", "terseLabel": "Dividend Yield", "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year." } } }, "auth_ref": ["r856", "r857", "r858"] }, "us-gaap_MeasurementInputExpectedTermMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputExpectedTermMember", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssumptionsUsedToCalculateFairValueOfWarrantLiabilityDetail"], "lang": { "en-us": { "role": { "label": "Measurement Input, Expected Term [Member]",
"terseLabel": "Expected life years", "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date." } } }, "auth_ref": ["r856", "r857", "r858"] }, "us-
gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputPriceVolatilityMember", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssumptionsUsedToCalculateFairValueOfWarrantLiabilityDetail"], "lang": { "en-us": { "role": { "terseLabel": "Expected Volatility", "label": "Measurement
Input, Price Volatility [Member]", "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns." } } }, "auth_ref": ["r667", "r856", "r857", "r858"] }, "us-
gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssumptionsUsedToCalculateFairValueOfWarrantLiabilityDetail"], "lang": { "en-us": { "role": { "label": "Measurement Input, Risk Free Interest Rate
[Member]", "terseLabel": "Risk Free Interest Rate", "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss." } } }, "auth_ref": ["r856", "r857", "r858"] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeAxis", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssumptionsUsedToCalculateFairValueOfWarrantLiabilityDetail"], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]", "terseLabel":
"Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": ["r385", "r386", "r387", "r667"] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeDomain", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssumptionsUsedToCalculateFairValueOfWarrantLiabilityDetail"], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Domain]",
"terseLabel": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": ["r385", "r386", "r387", "r667"] },
"meip_MeasurementInputWeightedAverageGrantDateFairValueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "MeasurementInputWeightedAverageGrantDateFairValueMember", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssumptionsUsedToCalculateFairValueOfWarrantLiabilityDetail"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average grant date fair value",
"label": "Measurement Input Weighted-Average Grant Date Fair Value [Member]", "documentation": "Measurement input weighted-average grant date fair value." } } }, "auth_ref": [] }, "meip_MilestonePayment": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.meipharma.com/20241231", "localname": "MilestonePayment", "crdr": "credit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureDispositionOfANonfinancialAssetAdditionalInformationDetail"], "lang": { "en-
us": { "role": { "documentation": "Milestone Payment", "label": "Milestone Payment", "terseLabel": "Milestone payment" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"MinimumMember", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/LicenseAgreementsAdditionalInformationDetail", "http://www.meipharma.com/20241231/taxonomy/role/ShareBasedCompensationAdditionalInformationDetail"],
"lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": ["r236", "r237", "r238", "r239", "r290", "r326", "r387", "r444", "r507", "r509", "r523", "r543", "r544", "r600", "r604", "r606", "r607", "r609", "r624",
"r625", "r639", "r648", "r657", "r667", "r668", "r669", "r682", "r823", "r870", "r871", "r872", "r873", "r874", "r875"] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for
Compensation Value" } } }, "auth_ref": ["r766"] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": ["r774"] },
"ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": {
"role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": ["r748"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": {
"en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations.
Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for
other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r150"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by
(Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "totalLabel":
"Net cash provided by investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include
making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r150"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from
investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating
activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing
activities." } } }, "auth_ref": ["r83", "r84", "r85"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by
(Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss",
"crdr": "credit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations",
"http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income
(Loss)", "verboseLabel": "Net income loss", "totalLabel": "Net (loss) income", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r72", "r85", "r111", "r131", "r142",
"r143", "r146", "r154", "r159", "r163", "r164", "r165", "r166", "r167", "r170", "r171", "r177", "r201", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r340", "r350", "r381", "r406", "r496", "r573", "r591", "r592", "r695", "r821"] }, "us-
gaap_NetIncomeLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAbstract", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Parent [Abstract]", "verboseLabel": "Net loss:" } } }, "auth_ref": []

}, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r125", "r126", "r127", "r128", "r129", "r130", "r158", "r159", "r160", "r161", "r162", "r165", "r172", "r183", "r198", "r199", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r217", "r218", "r221", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r404", "r405", "r415", "r416", "r417", "r428", "r429", "r430", "r431", "r432", "r433", "r447", "r448", "r449", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r525"] }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Accounting Standards Update and Change in Accounting Principle [Table]", "documentation": "Disclosure of information about change in accounting principle or amendment to accounting standards or both. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards and other change in accounting principle." } } }, "auth_ref": ["r13", "r125", "r126", "r127", "r128", "r129", "r130", "r158", "r159", "r160", "r161", "r162", "r165", "r172", "r183", "r198", "r199", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r217", "r218", "r221", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r404", "r405", "r415", "r416", "r417", "r428", "r429", "r430", "r431", "r432", "r433", "r447", "r448", "r449", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r525"] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Recent Accounting Pronouncement", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "meip_NonCashLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "NonCashLeaseExpense", "crdr": "debit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Non cash lease expense.", "label": "Non Cash Lease Expense", "terseLabel": "Noncash lease expense" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": ["r747"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": ["r711", "r721", "r731", "r755", "r763"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r738"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r737"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": ["r755"] }, "meip_NonRule10B51ArrModifiedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "NonRule10B51ArrModifiedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "documentation": "Non rule 10b51 arrangement modified.", "label": "Non Rule 10b51 Arr Modified [Flag]", "terseLabel": "Non Rule 10b51 Arr Modified" } } }, "auth_ref": [] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r774"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r774"] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "totalLabel": "Total other income, net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": ["r76"] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "terseLabel": "Other income (expense):", "label": "Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "meip_NumberOfWarrantsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "NumberOfWarrantsExercised", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Number Of Warrants Exercised", "label": "Number Of Warrants Exercised", "terseLabel": "Number of warrants exercised" } } }, "auth_ref": [] }, "meip_O2024Q2DividendsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "O2024Q2DividendsMember", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "O 2024 Q2 Dividends.", "label": "O 2024 Q2 Dividends [Member]", "terseLabel": "O 2024 Q2 Dividends" } } }, "auth_ref": [] }, "us-gaap_OneTimeTerminationBenefitsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OneTimeTerminationBenefitsMember", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesParentheticalDetail", "http://www.meipharma.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://www.meipharma.com/20241231/taxonomy/role/DisclosureEmployeeTerminationBenefitsSummaryOfActivityRelatedToEmployeeBenefitsIncludedInAccruedLiabilitiesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Termination Benefits", "label": "One-time Termination Benefits [Member]", "verboseLabel": "One -Time Termination Benefits", "documentation": "A lump sum payment to an involuntarily terminated employee in conjunction with exit or disposal activities." } } }, "auth_ref": ["r641", "r642", "r643", "r644"] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "(Loss) income from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r114", "r636", "r805", "r806", "r807", "r808", "r809"] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfTotalOperatingCostsDetail"], "lang": { "en-us": { "role": { "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": ["r424", "r671"] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/LeasesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Operating Lease, Liability", "totalLabel": "Total operating lease liability", "verboseLabel": "Total operating lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": ["r421"] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetail", "http://www.meipharma.com/20241231/taxonomy/role/LeasesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Operating cash flows from operating leases", "label": "Operating Lease, Payments", "verboseLabel": "Supplemental cash flow", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": ["r422", "r426"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/LeasesAdditionalInformationDetail", "http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use asset", "verboseLabel": "Right-of-use asset balance", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r420"] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/LeasesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "terseLabel": "Decrease in ROU asset balance", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": ["r798"] }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasesFutureMinimumPaymentsDue", "crdr": "credit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/LeasesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Operating Leases, Future Minimum Payments Due", "terseLabel": "Remaining future minimum rental payments", "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year." } } }, "auth_ref": ["r116", "r117"] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentation"], "lang": { "en-us": { "role": { "terseLabel": "Description of Business and Basis of Presentation", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements." } } }, "auth_ref": ["r45", "r86", "r87", "r104"] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r58"] }, "us-gaap_OtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilities", "crdr": "credit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureOtherLicenseAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Other liabilities", "label": "Other Liabilities", "totalLabel": "Other Liabilities, Total", "documentation": "Amount of liabilities classified as other." } } }, "auth_ref": ["r106", "r485", "r547", "r548", "r697", "r877", "r909"] }, "meip_OtherLicensingArrangementsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "OtherLicensingArrangementsTextBlock", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureOtherLicenseAgreements"], "lang": { "en-us": { "role": { "terseLabel": "Other License Agreements", "label": "Other Licensing Arrangements [Text Block]", "documentation": "Other licensing agreements." } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "totalLabel": "Other Nonoperating Income (Expense), Total", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other expense, net", "negatedLabel": "Other expense, net", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": ["r77"] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": ["r747"] }, "us-gaap_OtherPrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherPrepaidExpenseCurrent", "crdr": "debit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidAndOtherCurrentAssetsDetail"], "lang": { "en-us": { "role": { "label": "Other Prepaid Expense, Current", "terseLabel": "Other", "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r792", "r813"] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r709", "r719", "r729", "r761"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": ["r712", "r722", "r732", "r764"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r712", "r722", "r732", "r764"] }, "meip_PassThroughServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "PassThroughServicesMember", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Pass Through Services [Member]", "documentation": "Pass through services member.", "label": "Pass Through Services [Member]" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r736"] }, "meip_PaymentForLicenseAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "PaymentForLicenseAgreement", "crdr": "credit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureOtherLicenseAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Payment for license agreement.", "label": "Payment For License Agreement", "terseLabel": "Payment for license" } } }, "auth_ref": [] }, "us-gaap_PaymentsForRestructuring": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRestructuring", "crdr": "credit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureEmployeeTerminationBenefitsSummaryOfActivityRelatedToEmployeeBenefitsIncludedInAccruedLiabilitiesDetail"], "lang": { "en-us": { "role": { "negatedLabel": "Cash payments", "terseLabel": "Cash payments", "label": "Payments for Restructuring", "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation." } } }, "auth_ref": ["r225", "r796"] }, "us-gaap_PaymentsOfDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDividends", "crdr": "credit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.meipharma.com/20241231/taxonomy/role/StockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Dividend paid", "totalLabel": "Payments of Dividends, Total", "label": "Payments of Dividends", "negatedLabel": "Payment of cash dividend", "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests." } } }, "auth_ref": ["r82"] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r81"] }, "us-gaap_PaymentsToAcquireShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireShortTermInvestments", "crdr": "credit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payments to Acquire Short-Term Investments", "negatedLabel": "Purchases of short-term investments", "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term." } } }, "auth_ref": ["r80"] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": ["r746"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r746"] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r738"] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": ["r755"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": ["r748"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": ["r737"] }, "meip_PercentageOfReimbursementOfPassThroughCostsAsRevenue": { "xbrltype": "percentItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "PercentageOfReimbursementOfPassThroughCostsAsRevenue", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Percentage Of Reimbursement Of Pass Through Costs As Revenue", "label": "Percentage Of Reimbursement Of Pass Through Costs As Revenue", "terseLabel": "Percentage of reimbursement of pass through costs as revenue" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/ShareBasedCompensationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": ["r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851"] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/ShareBasedCompensationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": ["r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851"] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": ["r739"] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": ["r783"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": ["r738"] }, "meip_PotentialMilestonePaymentsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "PotentialMilestonePaymentsReceivable", "crdr": "debit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureOtherLicenseAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Potential milestone payments receivable.", "label": "Potential Milestone Payments Receivable", "terseLabel": "Milestone payment receivable amount" } } }, "auth_ref": [] }, "meip_PotentialPaymentsOnAchievementOfDevelopmentRegulatoryAndCommercialMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "PotentialPaymentsOnAchievementOfDevelopmentRegulatoryAndCommercialMilestonesMember", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureOtherLicenseAgreementsAdditionalInformationDetails", "http://www.meipharma.com/20241231/taxonomy/role/LicenseAgreementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Potential payments on achievement of development regulatory and commercial milestones.", "label": "Potential Payments on Achievement of Development Regulatory and Commercial Milestones [Member]", "terseLabel": "Potential Payments on Achievement of Development Regulatory and Commercial Milestones" } } }, "auth_ref": [] }, "meip_PotentiallyDilutiveSecuritiesOutstandingLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "PotentiallyDilutiveSecuritiesOutstandingLineItems", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureNetIncomeLossPerShareAdditionalInformationDetail", "http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAntidilutiveSecuritiesDetail"], "lang": { "en-us": { "role": { "documentation": "Potentially Dilutive Securities Outstanding [Line Items]", "label": "Potentially Dilutive Securities Outstanding [Line Items]", "terseLabel": "Potentially Dilutive Securities Outstanding [Line Items]" } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.meipharma.com/20241231/taxonomy/role/StockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r64", "r252"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.meipharma.com/20241231/taxonomy/role/StockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r64", "r553"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r64", "r252"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.meipharma.com/20241231/taxonomy/role/StockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance", "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r64", "r553", "r571", "r910", "r911"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance", "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance", "totalLabel": "Preferred Stock, Value, Issued, Total", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.01 par value; 100 shares authorized; none outstanding", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r64", "r488", "r672"] }, "meip_PrepaidClinicalCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "PrepaidClinicalCosts", "crdr": "debit", "presentation": [

"http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidAndOtherCurrentAssetsDetail"], "lang": { "en-us": { "role": { "documentation": "Prepaid clinical costs", "label": "Prepaid Clinical Costs", "terseLabel": "Prepaid clinical costs" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidAndOtherCurrentAssetsDetail", "http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Total prepaid and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r794"] }, "us-gaap_PrepaidInsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidInsurance", "crdr": "debit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidAndOtherCurrentAssetsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Insurance", "label": "Prepaid Insurance", "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r631", "r640", "r813"] }, "meip_PrepaymentOfRemainingRent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "PrepaymentOfRemainingRent", "crdr": "credit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/LeasesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Prepayment of remaining rent.", "label": "Prepayment of Remaining Rent", "terseLabel": "Prepayment of remaining rent" } } }, "auth_ref": [] }, "meip_PresageBiosciencesIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "PresageBiosciencesIncMember", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureOtherLicenseAgreementsAdditionalInformationDetails", "http://www.meipharma.com/20241231/taxonomy/role/LicenseAgreementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Presage Biosciences Inc [Member]", "documentation": "Presage Biosciences Inc.", "terseLabel": "Presage Biosciences, Inc." } } }, "auth_ref": [] }, "meip_PresageLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "PresageLicenseAgreementMember", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.meipharma.com/20241231/taxonomy/role/DisclosureOtherLicenseAgreementsAdditionalInformationDetails", "http://www.meipharma.com/20241231/taxonomy/role/LicenseAgreementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Presage License Agreement.", "label": "Presage License Agreement [Member]", "terseLabel": "Presage License Agreement" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments", "crdr": "debit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Maturities, Prepayments and Calls of Short-Term Investments", "terseLabel": "Proceeds from maturity of short-term investments", "documentation": "The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term." } } }, "auth_ref": ["r11", "r80"] }, "us-gaap_ProceedsFromSaleOfFurnitureAndFixtures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfFurnitureAndFixtures", "crdr": "debit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetail", "http://www.meipharma.com/20241231/taxonomy/role/LeasesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Proceeds from Sale of Furniture and Fixtures", "terseLabel": "Proceeds from sale of furniture and fixtures", "documentation": "The cash inflow from sale of furniture and fixtures." } } }, "auth_ref": ["r79"] }, "us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfOtherAssetsInvestingActivities", "crdr": "debit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureDispositionOfANonfinancialAssetAdditionalInformationDetail", "http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from the disposition of a non-financial asset", "label": "Proceeds from Sale of Other Assets, Investing Activities", "verboseLabel": "Purchaser initial payment", "documentation": "Amount of cash inflow from the sale of other assets recognized in investing activities." } } }, "auth_ref": ["r786"] }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of property and equipment", "totalLabel": "Proceeds from Sale of Property, Plant, and Equipment, Total", "label": "Proceeds from Sale of Property, Plant, and Equipment", "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": ["r79"] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/LicenseAgreementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": ["r194", "r446", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r628", "r649", "r681", "r682", "r683", "r685", "r686", "r819", "r820", "r825", "r878", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907"] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/LicenseAgreementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "auth_ref": ["r194", "r446", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r628", "r649", "r681", "r682", "r683", "r685", "r686", "r819", "r820", "r825", "r878", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907"] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "verboseLabel": "Net (loss) income", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": ["r131", "r142", "r143", "r149", "r154", "r159", "r167", "r170", "r171", "r201", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r340", "r350", "r352", "r355", "r356", "r381", "r406", "r482", "r495", "r536", "r573", "r591", "r592", "r661", "r662", "r696", "r795", "r821"] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetail", "http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetail", "http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentParentheticalDetail"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": ["r4", "r427"] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetail"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Gross", "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance", "totalLabel": "Property, Plant and Equipment, Gross, Total", "terseLabel": "Property and equipment, gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r90", "r135", "r494"] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetail", "http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentParentheticalDetail"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r427"] }, "us-gaap_PropertyPlantAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentMember", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Member]", "terseLabel": "Property and Equipment", "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetail", "http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Property and equipment, net", "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r4", "r427", "r483", "r494", "r672"] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property and Equipment", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": ["r4"] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetail", "http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetail", "http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentParentheticalDetail"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": ["r90", "r427"] }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseCommitmentExcludingLongtermCommitmentLineItems", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Purchase Commitment, Excluding Long-Term Commitment [Line Items]", "terseLabel": "Purchase Commitment, Excluding Long-term Commitment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseCommitmentExcludingLongtermCommitmentTable", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Purchase Commitment, Excluding Long-Term Purchase Commitment [Table]", "terseLabel": "Purchase Commitment, Excluding Long-term Commitment [Table]", "documentation": "Disclosure of information about purchase arrangement. Includes, but is not limited to, term of arrangement with supplier, minimum quantity required, milestone, period covered by arrangement, and committed amount. Excludes long-term purchase arrangement and unconditional purchase obligation." } } }, "auth_ref": ["r62", "r107"] }, "meip_PurchaserInitialPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "PurchaserInitialPayment", "crdr": "credit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureDispositionOfANonfinancialAssetAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Purchaser initial payment", "documentation": "Purchaser initial payment.", "label": "Purchaser Initial Payment" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r736"] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": ["r736"] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureDispositionOfANonfinancialAssetAdditionalInformationDetail", "http://www.meipharma.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail", "http://www.meipharma.com/20241231/taxonomy/role/LicenseAgreementsAdditionalInformationDetail", "http://www.meipharma.com/20241231/taxonomy/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.meipharma.com/20241231/taxonomy/role/StockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "verboseLabel": "Range [Axis]", "label": "Statistical Measurement [Axis]", "terseLabel": "Range" } } }, "auth_ref": ["r236", "r237", "r238", "r239", "r282", "r290", "r318", "r319", "r320", "r326", "r387", "r442", "r443", "r444", "r507", "r509", "r523", "r543", "r544", "r600", "r604", "r606", "r607", "r609", "r624", "r625", "r639", "r648", "r657", "r667", "r668", "r669", "r670", "r682", "r689", "r815", "r823", "r857", "r871", "r872", "r873", "r874", "r875"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureDispositionOfANonfinancialAssetAdditionalInformationDetail", "http://www.meipharma.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail", "http://www.meipharma.com/20241231/taxonomy/role/LicenseAgreementsAdditionalInformationDetail", "http://www.meipharma.com/20241231/taxonomy/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.meipharma.com/20241231/taxonomy/role/StockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Range [Domain]" } } }, "auth_ref": ["r236", "r237", "r238", "r239", "r282", "r290", "r318", "r319", "r320", "r326", "r387", "r442", "r443", "r444", "r507", "r509", "r523", "r543", "r544", "r600", "r604", "r606", "r607", "r609", "r624", "r625", "r639", "r648", "r657", "r667", "r668", "r669", "r670", "r682", "r689", "r815", "r823", "r857", "r871", "r872", "r873", "r874", "r875"] }, "meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsAbstract", "lang": { "en-us": { "role": { "label": "Recognized Revenue Associated with The Following License Agreements [Abstract]" } } }, "auth_ref": [] }, "meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsLineItems", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenueAssociatedWithLicenseAgreementDetail"], "lang": { "en-us": { "role": { "label": "Recognized Revenue Associated with The Following License Agreements [Line Items]" } } }, "auth_ref": [] }, "meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsTable", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenueAssociatedWithLicenseAgreementDetail"], "lang": { "en-us": { "role": { "label": "Recognized Revenue Associated with The Following License Agreements [Table]" } } }, "auth_ref": [] }, "us-gaap_RecoveryOfDirectCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RecoveryOfDirectCosts", "crdr": "credit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureOtherLicenseAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Recovery of Direct Costs", "terseLabel": "Reimbursements costs", "documentation": "Return of or reimbursements received in relation to direct costs and expenses previously paid or incurred." } } }, "auth_ref": ["r71"] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": ["r704", "r714", "r724", "r756"] }, "meip_ReimbursementAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "ReimbursementAmount", "crdr": "debit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureDispositionOfANonfinancialAssetAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Reimbursement amount", "label": "Reimbursement Amount", "terseLabel": "Reimbursement amount" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureOtherLicenseAgreementsAdditionalInformationDetails", "http://www.meipharma.com/20241231/taxonomy/role/LicenseAgreementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Domain]", "terseLabel": "Related Party [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r200", "r289", "r434", "r435", "r486", "r492", "r546", "r547", "r548", "r549", "r550", "r570", "r572", "r599"] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAxis", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureOtherLicenseAgreementsAdditionalInformationDetails", "http://www.meipharma.com/20241231/taxonomy/role/LicenseAgreementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transactions", "documentation": "Information by type of related party transaction." } } }, "auth_ref": ["r434", "r435", "r867"] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionDomain", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureOtherLicenseAgreementsAdditionalInformationDetails", "http://www.meipharma.com/20241231/taxonomy/role/LicenseAgreementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureOtherLicenseAgreementsAdditionalInformationDetails", "http://www.meipharma.com/20241231/taxonomy/role/LicenseAgreementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r200", "r576", "r577", "r578"] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureOtherLicenseAgreementsAdditionalInformationDetails", "http://www.meipharma.com/20241231/taxonomy/role/LicenseAgreementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "terseLabel": "Related Party", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r200", "r289", "r434", "r435", "r486", "r492", "r546", "r547", "r548", "r549", "r550", "r570", "r572", "r599", "r867"] }, "us-gaap_ResearchAndDevelopmentArrangementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentArrangementMember", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureDispositionOfANonfinancialAssetAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Research and Development Arrangement [Member]", "terseLabel": "Research And Development Arrangement", "documentation": "Contractual obligation to provide funding of research and development costs over periods that initially exceed one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "totalLabel": "Research and Development Expense, Total", "label": "Research and Development Expense", "terseLabel": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r327", "r626", "r637", "r876"] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://www.meipharma.com/20241231/taxonomy/role/DisclosureEmployeeTerminationBenefitsAdditionalInformationDetail", "http://www.meipharma.com/20241231/taxonomy/role/DisclosureSharebasedCompensationSharebasedCompensationExpenseForStockAwardsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Research and Development", "label": "Research and Development Expense [Member]", "verboseLabel": "Research and development", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": ["r705", "r715", "r725", "r757"] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": ["r706", "r716", "r726", "r758"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": ["r713", "r723", "r733", "r765"] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAntidilutiveSecuritiesDetail", "http://www.meipharma.com/20241231/taxonomy/role/ShareBasedCompensationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units (RSUs)", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureEmployeeTerminationBenefits1"], "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Employee Termination Benefits", "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled." } } }, "auth_ref": ["r222", "r223", "r225", "r228", "r232"] }, "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureEmployeeTerminationBenefitsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Number of workforce reduction", "label": "Restructuring and Related Cost, Number of Positions Eliminated", "documentation": "The number of positions eliminated during the period as a result of restructuring activities." } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureEmployeeTerminationBenefitsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Number of workforce reduction percentage", "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent", "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)." } } }, "auth_ref": [] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveAxis", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesParentheticalDetail", "http://www.meipharma.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://www.meipharma.com/20241231/taxonomy/role/DisclosureEmployeeTerminationBenefitsAdditionalInformationDetail", "http://www.meipharma.com/20241231/taxonomy/role/DisclosureEmployeeTerminationBenefitsSummaryOfActivityRelatedToEmployeeBenefitsIncludedInAccruedLiabilitiesDetail"], "lang": { "en-us": { "role": { "label": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": ["r224", "r225", "r229", "r230"] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveLineItems", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureEmployeeTerminationBenefitsSummaryOfActivityRelatedToEmployeeBenefitsIncludedInAccruedLiabilitiesDetail"], "lang": { "en-us": { "role": { "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r224", "r225", "r226", "r227", "r229", "r230", "r231"] }, "us-gaap_RestructuringReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserve", "crdr": "credit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureEmployeeTerminationBenefitsSummaryOfActivityRelatedToEmployeeBenefitsIncludedInAccruedLiabilitiesDetail"], "lang": { "en-us": { "role": { "terseLabel": "One-time termination employee benefits", "label": "Restructuring Reserve", "periodEndLabel": "Restructuring Reserve, Ending Balance", "periodStartLabel": "Restructuring Reserve, Beginning Balance", "totalLabel": "Restructuring Reserve, Total", "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring

pursuant to a duly authorized plan." } } }, "auth_ref": ["r225", "r230"] }, "us-gaap_RestructuringReserveAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveAbstract", "lang": { "en-us": {
"role": { "label": "Restructuring Reserve [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestructuringReservePeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RestructuringReservePeriodIncreaseDecrease", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureEmployeeTerminationBenefitsSummaryOfActivityRelatedToEmployeeBenefitsIncludedInAccruedLiabilitiesDetail"], "lang":
{ "en-us": { "role": { "terseLabel": "Increase in accrued restructuring", "label": "Restructuring Reserve, Period Increase (Decrease)", "totalLabel": "Restructuring Reserve, Period Increase (Decrease), Total", "documentation": "Amount of increase
(decrease) in the accrual for restructuring costs." } } }, "auth_ref": ["r95"] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
"http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance", "periodStartLabel": "Retained Earnings
(Accumulated Deficit), Beginning Balance", "totalLabel": "Retained Earnings (Accumulated Deficit), Total", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit", "verboseLabel": "Accumulated Losses Since Inception",
"negatedLabel": "Accumulated losses since inception", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r67", "r101", "r490", "r517", "r522", "r534", "r554", "r672"] }, "us-gaap_RetainedEarningsMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r127", "r155", "r156", "r157", "r160", "r167", "r169", "r171",
"r205", "r211", "r218", "r328", "r329", "r336", "r337", "r338", "r341", "r349", "r350", "r362", "r365", "r366", "r369", "r379", "r416", "r419", "r513", "r515", "r538", "r910"] }, "meip_RevenueFromCollaborationAgreementsMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "RevenueFromCollaborationAgreementsMember", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "terseLabel": "Revenue from collaboration agreements", "label": "Revenue From Collaboration Agreements
[Member]", "documentation": "Revenue from collaboration agreements." } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RevenueFromContractWithCustomerMember", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenueAssociatedWithLicenseAgreementDetail",
"http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "terseLabel": "Revenue from customers", "label": "Revenue from Contract with Customer Benchmark
[Member]", "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": ["r197", "r787"] }, "us-
gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/LicenseAgreements"], "lang": { "en-us": { "role": { "terseLabel": "License Agreements", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of
revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related
to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": ["r124", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r281"] },
"us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue Recognition", "documentation": "Disclosure
of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": ["r574", "r627", "r633"] }, "us-gaap_RevenueRemainingPerformanceObligation": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligation", "crdr": "credit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/LicenseAgreementsAdditionalInformationDetail"], "lang": { "en-us": {
"role": { "terseLabel": "Revenue related to non-refundable payments for performance obligations", "label": "Revenue, Remaining Performance Obligation, Amount", "documentation": "Amount of transaction price allocated to performance obligation that
has not been recognized as revenue." } } }, "auth_ref": ["r123"] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenueAssociatedWithLicenseAgreementDetail",
"http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "verboseLabel": "Revenues", "totalLabel": "Revenues, Total", "label": "Revenues", "documentation": "Amount
of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as
a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": ["r112", "r113", "r147", "r154", "r184", "r188", "r189", "r191", "r193", "r194", "r195", "r197", "r201", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249",
"r406", "r482", "r637", "r821"] }, "meip_RightsAndTheRightsAgreementExpirationDescription": { "xbrltype": "stringItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "RightsAndTheRightsAgreementExpirationDescription",
"presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Rights and the rights agreement expiration description.", "label": "Rights and the
Rights Agreement Expiration Description", "terseLabel": "Rights and the rights agreement expiration description" } } }, "auth_ref": [] }, "meip_Rule10B51ArrModifiedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://www.meipharma.com/20241231",
"localname": "Rule10B51ArrModifiedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "documentation": "Rule 10b51 Arr Modified [Flag]", "label": "Rule 10b51 Arr Modified [Flag]",
"terseLabel": "Rule 10b51 Arr Modified" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r774"] }, "ecd_Rule10b51ArrTrmntdFlag":
{ "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1
Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r774"] }, "meip_SaleOfSharesAndWarrantsUnderAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.meipharma.com/20241231",
"localname": "SaleOfSharesAndWarrantsUnderAgreement", "crdr": "credit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Sale of
shares and warrants under agreement.", "label": "Sale Of Shares And Warrants Under Agreement", "terseLabel": "Sale of shares and warrants under agreement" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
"http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.meipharma.com/20241231/taxonomy/role/StockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": {
"role": { "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-
gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/StockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Number of shares issued and sold", "label": "Sale of Stock, Number of Shares Issued in Transaction",
"documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "meip_SanDiegoCaliforniaMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.meipharma.com/20241231", "localname": "SanDiegoCaliforniaMember", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/LeasesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "San Diego
California [Member]", "label": "San Diego California [Member]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsTables"], "lang": { "en-us": { "role": { "terseLabel": "Accrued Liabilities", "label": "Schedule of Accrued
Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureNetIncomeLossPerShareAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "terseLabel": "Schedule of Antidilutive
Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." }
} }, "auth_ref": ["r16"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role":
{ "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Antidilutive Securities", "documentation": "Tabular disclosure of securities (including those issuable pursuant to
contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the
period presented, by antidilutive securities." } } }, "auth_ref": ["r16"] }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/LeasesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Supplemental Cash Flow Information Related
to Operating Leases", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented." } } }, "auth_ref": [] },
"meip_ScheduleOfChangesInFairValueOfWarrantLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "ScheduleOfChangesInFairValueOfWarrantLiabilityTableTextBlock",
"presentation": ["http://www.meipharma.com/20241231/taxonomy/role/FairValueMeasurementsTables"], "lang": { "en-us": { "role": { "documentation": "Schedule Of Changes In Fair Value Of Warrant Liability [Table Text Block]", "label": "Schedule Of
Changes In Fair Value Of Warrant Liability [Table Text Block]", "terseLabel": "Schedule of Changes in Estimated Fair Value of Warrant Liability" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTable", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAntidilutiveSecuritiesDetail"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted, by Common Class, Including Two-Class Method
[Table]", "documentation": "Disclosure of information about diluted earnings per share by class of stock. Includes, but is not limited to, two-class method." } } }, "auth_ref": ["r15", "r18", "r175", "r176", "r178"] }, "us-
gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureEmployeeTerminationBenefitsAdditionalInformationDetail",
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSharebasedCompensationSharebasedCompensationExpenseForStockAwardsDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized,
Amount [Table]", "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment
arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [
"r35"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/ShareBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Share-
Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Share-Based Compensation Expense for Stock Awards", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award
under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": ["r35"] }, "us-
gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Other Current Assets [Table Text Block]", "terseLabel": "Schedule of Prepaid and Other Current Assets",
"documentation": "Tabular disclosure of the carrying amounts of other current assets." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureOtherLicenseAgreementsAdditionalInformationDetails",
"http://www.meipharma.com/20241231/taxonomy/role/LicenseAgreementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party
[Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth_ref": ["r42", "r43", "r576", "r577", "r578"] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureEmployeeTerminationBenefitsSummaryOfActivityRelatedToEmployeeBenefitsIncludedInAccruedLiabilitiesDetail"], "lang": { "en-us": { "role": { "label": "Restructuring Cost [Table]",
"documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve." } } },
"auth_ref": ["r224", "r225", "r226", "r227", "r229", "r230", "r231"] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfRestructuringAndRelatedCostsTextBlock", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureEmployeeTerminationBenefitsTables"], "lang": { "en-us": { "role": { "label": "Restructuring and Related Costs [Table
Text Block]", "terseLabel": "Summary of Activity Related to Employee Benefits Included in Accrued Liabilities", "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation,
implementation, integration, asset impairment, and charges against earnings from the write-down of assets." } } }, "auth_ref": ["r27", "r93", "r94"] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSharebasedCompensationFairValueOfStockOptionsWeightedaverageAssumptionsUsedDetail",
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetail", "http://www.meipharma.com/20241231/taxonomy/role/ShareBasedCompensationAdditionalInformationDetail"], "lang": {
"en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "documentation":
"Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r292", "r294", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314",
"r315", "r316", "r317", "r318", "r319", "r320", "r321"] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/ShareBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Schedule of
Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Fair Value of Stock Options Weighted-Average Assumptions Used", "documentation": "Tabular disclosure of the significant assumptions used during
the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for
post-vesting restrictions." } } }, "auth_ref": ["r103"] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/StockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Stock, Class of Stock [Table]", "terseLabel": "Schedule of Stock by Class [Table]", "documentation": "Disclosure
of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": ["r28", "r29", "r30", "r31", "r32", "r33", "r97", "r99", "r100", "r101", "r138", "r139", "r140", "r186", "r252", "r253", "r254",
"r256", "r259", "r264", "r266", "r530", "r531", "r532", "r533", "r648", "r785", "r799"] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r698"] },
"us-gaap_SecurityDeposit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecurityDeposit", "crdr": "debit", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidAndOtherCurrentAssetsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Security deposit", "label": "Security Deposit", "documentation": "The
amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease." } } }, "auth_ref": ["r790"] }, "dei_SecurityExchangeName": {
"xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "label": "Security
Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r700"] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/LeasesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } },
"auth_ref": ["r195", "r196", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478",
"r479", "r540", "r541", "r542", "r601", "r605", "r608", "r610", "r612", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r629", "r650", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r684", "r689", "r825", "r878", "r880",
"r881", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907"] }, "meip_ServicesPerformedOverTimeMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "ServicesPerformedOverTimeMember", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenueAssociatedWithLicenseAgreementDetail"], "lang": { "en-us": { "role": { "documentation": "Services performed over time",
"label": "Services Performed Over Time [Member]", "terseLabel": "Services Performed Over Time [Member]" } } }, "auth_ref": [] }, "us-gaap_SeveranceCosts1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SeveranceCosts1", "crdr": "debit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureEmployeeTerminationBenefitsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Severance Costs", "terseLabel":
"Severance costs", "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized
plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": ["r3"] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureSharebasedCompensationSharebasedCompensationExpenseForStockAwardsDetail",
"http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "totalLabel": "Share-based Payment Arrangement, Noncash
Expense, Total", "label": "Share-Based Payment Arrangement, Noncash Expense", "negatedLabel": "Share-based compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r2"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Additional
General Disclosures [Abstract]", "terseLabel": "Aggregate Intrinsic Value" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/ShareBasedCompensationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
"terseLabel": "Share-based compensation arrangement by share-based payment award, award vesting period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on
satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service
condition." } } }, "auth_ref": ["r658"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSharebasedCompensationFairValueOfStockOptionsWeightedaverageAssumptionsUsedDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based
Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the
option's term." } } }, "auth_ref": ["r319"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSharebasedCompensationFairValueOfStockOptionsWeightedaverageAssumptionsUsedDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based
Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a
probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard
deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": ["r318"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSharebasedCompensationFairValueOfStockOptionsWeightedaverageAssumptionsUsedDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based
Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": ["r320"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
"presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureSharebasedCompensationFairValueOfStockOptionsWeightedaverageAssumptionsUsedDetail",
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetail", "http://www.meipharma.com/20241231/taxonomy/role/ShareBasedCompensationAdditionalInformationDetail"], "lang": {
"en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "documentation": "Line items
represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r292", "r294", "r296", "r297", "r298", "r299",
"r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/ShareBasedCompensationAdditionalInformationDetail"], "lang": { "en-us": {
"role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "terseLabel": "Common stock authorized", "documentation": "Number of shares authorized for issuance under share-based
payment arrangement." } } }, "auth_ref": ["r660"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/ShareBasedCompensationAdditionalInformationDetail"], "lang": { "en-us":
{ "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel": "Shares available for future grant", "documentation": "The difference between the maximum number of
shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based
awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": ["r34"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetail"], "lang":
{ "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Forfeited", "documentation": "The number of shares under options that were cancelled during the
reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": ["r305"] }, "us-

gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSharebasedCompensationFairValueOfStockOptionsWeightedaverageAssumptionsUsedDetail"], "lang": { "en-us": { "role": { "verboseLabel": "Granted", "label": "Share-Based Compensation
Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average grant date fair value", "documentation": "The weighted average grant-date fair value of options granted
during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": ["r313"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options,
Outstanding, Intrinsic Value", "terseLabel": "Outstanding at end of period", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": ["r34"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetail",
"http://www.meipharma.com/20241231/taxonomy/role/ShareBasedCompensationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding,
Number", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning Balance", "terseLabel": "Options outstanding", "verboseLabel": "Outstanding Options", "documentation": "Number of options outstanding, including both vested and non-
vested options." } } }, "auth_ref": ["r299", "r300"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetail"],
"lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of Options", "documentation": "A roll forward is a reconciliation of a concept
from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options,
Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning Balance", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock
option plan." } } }, "auth_ref": ["r299", "r300"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options,
Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted- Average Exercise Price" } } }, "auth_ref": [] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetail"], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest at end of period", "label": "Share-Based
Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested
and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized
when they occur." } } }, "auth_ref": ["r315"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options,
Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Vested and expected to vest at end of period", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan.
Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [
"r315"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options,
Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Vested and expected to vest at end of period", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for
fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are
recognized when they occur." } } }, "auth_ref": ["r315"] }, "meip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://www.meipharma.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetail"], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award,
options, weighted average remaining contractual term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]", "terseLabel": "Weighted Average Remaining
Contractual Term (in years)" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/ShareBasedCompensationAdditionalInformationDetail",
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r296", "r297", "r298",
"r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321"] }, "us-
gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options,
Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } },
"auth_ref": ["r305"] }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheTwoMember", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/ShareBasedCompensationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Tranche Two [Member]", "terseLabel": "Share-based Payment
Arrangement Tranche Two", "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-
gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/ShareBasedCompensationAdditionalInformationDetail"], "lang": { "en-us": {
"role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Stock option vested percentage", "documentation": "Percentage of vesting of award under share-based payment
arrangement." } } }, "auth_ref": ["r826"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/ShareBasedCompensationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label":
"Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "terseLabel": "Share-based compensation arrangement by share-based payment award, expiration period", "documentation": "Period from grant date that an
equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r659"] }, "us-
gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSharebasedCompensationFairValueOfStockOptionsWeightedaverageAssumptionsUsedDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based
Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected life (years)", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents
reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r317"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype":
"durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options,
Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Outstanding at end of period", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example,
'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r102"] }, "us-
gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options,
Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Vested and expected to vest at end of period", "documentation": "Weighted average remaining contractual term for fully vested and expected to
vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been
rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r315"] },
"meip_Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsclosingstockprice": { "xbrltype": "perShareItemType", "nsuri": "http://www.meipharma.com/20241231", "localname":
"Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsclosingstockprice", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/ShareBasedCompensationAdditionalInformationDetail"], "lang": { "en-us": { "role": {
"documentation": "Closing price of common stock.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsClosingStockPrice", "verboseLabel": "Closing price of common stock" } } }, "auth_ref": [] }, "us-
gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestments", "crdr": "debit", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": {
"en-us": { "role": { "totalLabel": "Short-term Investments, Total", "label": "Short-Term Investments", "terseLabel": "Short-term investments", "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-
maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": ["r109", "r110", "r793"] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "SignificantAccountingPoliciesTextBlock", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant
Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r86", "r152"] }, "meip_SoftwareLicenses": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "SoftwareLicenses", "crdr": "debit", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidAndOtherCurrentAssetsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Software licenses", "documentation": "Software licenses.", "label":
"Software Licenses" } } }, "auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.meipharma.com/20241231/taxonomy/role/StockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": {
"role": { "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r7", "r65", "r68", "r69", "r127", "r144", "r145", "r146", "r155", "r156", "r157", "r160",
"r167", "r169", "r171", "r185", "r205", "r211", "r218", "r268", "r328", "r329", "r336", "r337", "r338", "r341", "r349", "r350", "r362", "r364", "r365", "r366", "r367", "r369", "r379", "r407", "r408", "r409", "r410", "r411", "r412", "r416", "r419", "r433", "r497",
"r513", "r514", "r515", "r538", "r594"] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/LeasesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "auth_ref": ["r195", "r196", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458",
"r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r540", "r541", "r542", "r601", "r605", "r608", "r610", "r612", "r615", "r616", "r617", "r618",
"r619", "r620", "r621", "r622", "r623", "r629", "r650", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r684", "r689", "r825", "r878", "r880", "r881", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894",
"r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems",
"presentation": ["http://www.meipharma.com/20241231/taxonomy/role/CommitmentsAndContingencies", "http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesParentheticalDetail",
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetail", "http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidAndOtherCurrentAssetsDetail",
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationPolicies", "http://www.meipharma.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfTotalOperatingCostsDetail",
"http://www.meipharma.com/20241231/taxonomy/role/LeasesAdditionalInformationDetail", "http://www.meipharma.com/20241231/taxonomy/role/ShareBasedCompensationTables",
"http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets", "http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
"http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations",
"http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]", "documentation": "Line
items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r155", "r156", "r157", "r185", "r419",
"r446", "r526", "r539", "r545", "r546", "r547", "r548", "r549", "r550", "r553", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r566", "r567", "r568", "r569", "r570", "r572", "r574", "r575", "r579", "r580", "r581", "r582", "r583", "r584",
"r585", "r586", "r587", "r588", "r589", "r590", "r594", "r690"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role":
{ "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": {
"en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "StatementTable", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/CommitmentsAndContingencies", "http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetail",
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesParentheticalDetail", "http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetail",
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetail",
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentParentheticalDetail",
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationPolicies", "http://www.meipharma.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfTotalOperatingCostsDetail",
"http://www.meipharma.com/20241231/taxonomy/role/LeasesAdditionalInformationDetail", "http://www.meipharma.com/20241231/taxonomy/role/ShareBasedCompensationTables",
"http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets", "http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
"http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations",
"http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "terseLabel": "Statement [Table]", "documentation": "Disclosure of
information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r155", "r156", "r157", "r185", "r200", "r419", "r446", "r526", "r539", "r545", "r546",
"r547", "r548", "r549", "r550", "r553", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r566", "r567", "r568", "r569", "r570", "r572", "r574", "r575", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589",
"r590", "r594", "r690"] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": ["r708", "r718", "r728", "r760"] }, "us-
gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang":
{ "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during
predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "crdr": "credit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": {
"role": { "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "totalLabel": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures, Total", "terseLabel": "Issuance of common stock for vested
restricted stock units", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": ["r7", "r101"] }, "us-gaap_StockholdersEquity": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets",
"http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent", "periodEndLabel": "Ending Balance", "periodStartLabel":
"Beginning Balance", "totalLabel": "Total stockholders' equity", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r65", "r68", "r69",
"r88", "r555", "r571", "r595", "r596", "r672", "r697", "r800", "r812", "r863", "r910"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract",
"presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity:" } } },
"auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/StockholdersEquity"], "lang": { "en-us": { "role": { "label": "Equity [Text Block]", "terseLabel": "Stockholders' Equity", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r98",
"r153", "r251", "r253", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r265", "r268", "r370", "r597", "r598", "r611"] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "SubsequentEventLineItems", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]",
"documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements
pertaining to a subsequent event." } } }, "auth_ref": ["r413", "r437"] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail", "http://www.meipharma.com/20241231/taxonomy/role/ShareBasedCompensationAdditionalInformationDetail"], "lang": { "en-us": { "role": {
"terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r413", "r437"
] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or
transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": ["r413", "r437"] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail", "http://www.meipharma.com/20241231/taxonomy/role/ShareBasedCompensationAdditionalInformationDetail"], "lang": { "en-us": { "role": {
"label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r413", "r437"] }, "us-
gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail", "http://www.meipharma.com/20241231/taxonomy/role/ShareBasedCompensationAdditionalInformationDetail"], "lang": { "en-us": { "role": {
"label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r413", "r437"] }, "us-
gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSubsequentEvents"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant
events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a
business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": ["r436", "r438"] }, "us-
gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
"http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.meipharma.com/20241231/taxonomy/role/StockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": {
"role": { "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetails"], "lang": { "en-us": {
"role": { "terseLabel": "Balance Sheet Details", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities,
and equity." } } }, "auth_ref": ["r789"] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"

], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": ["r754"] }, "us-gaap_TargetedOrTrackingStockStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "TargetedOrTrackingStockStockLineItems", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail"], "lang": { "en-us": {
"role": { "label": "Targeted or Tracking Stock, Stock [Line Items]", "terseLabel": "Targeted or Tracking Stock, Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose
reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_TargetedOrTrackingStockStockTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"TargetedOrTrackingStockStockTable", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Targeted or
Tracking Stock, Stock [Table]", "terseLabel": "Targeted or Tracking Stock, Stock [Table]", "documentation": "Disclosure of information about quantitative and qualitative information related to target or tracking stock issued, including, but not limited to,
pricing of transactions and cost allocation method used." } } }, "auth_ref": [] }, "meip_TerminationAgreement": { "xbrltype": "dateItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "TerminationAgreement", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/LicenseAgreementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Termination Agreement", "label": "Termination Agreement", "documentation": "Termination agreement."
} } }, "auth_ref": [] }, "us-gaap_TimingOfTransferOfGoodOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TimingOfTransferOfGoodOrServiceAxis", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenueAssociatedWithLicenseAgreementDetail"], "lang": { "en-us": { "role": { "label": "Timing of Transfer of Good or Service [Axis]",
"documentation": "Information by timing of transfer of good or service to customer." } } }, "auth_ref": ["r651", "r825"] }, "us-gaap_TimingOfTransferOfGoodOrServiceDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "TimingOfTransferOfGoodOrServiceDomain", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenueAssociatedWithLicenseAgreementDetail"], "lang": { "en-us": { "role": { "label": "Timing of Transfer of Good or Service
[Domain]", "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time." } } }, "auth_ref": ["r651", "r825"] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/ShareBasedCompensationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Title and Position
[Axis]", "terseLabel": "Title of Individual [Axis]" } } }, "auth_ref": ["r810", "r866"] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"TitleOfIndividualWithRelationshipToEntityDomain", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/ShareBasedCompensationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Title and Position [Domain]",
"terseLabel": "Relationship to Entity [Domain]" } } }, "auth_ref": [] }, "meip_TorreyaPartnersLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "TorreyaPartnersLlcMember", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/StockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Torreya partners llc member", "label": "Torreya Partners LLC [Member]", "terseLabel": "Torreya
Partners LLC" } } }, "auth_ref": [] }, "meip_TorreyaPartnersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "TorreyaPartnersMember", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/StockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Torreya partners", "label": "Torreya Partners [Member]", "documentation": "Torreya partners." } } },
"auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": {
"label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": ["r746"] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder
Return Vs Peer Group" } } }, "auth_ref": ["r753"] }, "meip_TotalTransactionPriceInRespectOfColloborationRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.meipharma.com/20241231", "localname":
"TotalTransactionPriceInRespectOfColloborationRevenue", "crdr": "credit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/LicenseAgreementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "verboseLabel":
"Transaction price relating to the performance obligation", "documentation": "Total transaction price in respect of colloboration revenue.", "label": "Total Transaction Price In Respect Of Colloboration Revenue", "terseLabel": "Transaction price relating
to the performance obligation" } } }, "auth_ref": [] }, "meip_TotalUpfrontPaymentReceivableForGrantOfRights": { "xbrltype": "monetaryItemType", "nsuri": "http://www.meipharma.com/20241231", "localname":
"TotalUpfrontPaymentReceivableForGrantOfRights", "crdr": "debit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/LicenseAgreementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "verboseLabel": "Total upfront
payment receivable for grant of rights", "documentation": "Total upfront payment receivable for grant of rights.", "label": "Total Upfront Payment Receivable For Grant Of Rights", "terseLabel": "Total upfront payment receivable for grant of rights" } } },
"auth_ref": [] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label":
"Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": ["r773"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation":
["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": ["r775"] }, "dei_TradingSymbol": {
"xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "label": "Trading Symbol",
"terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"TransactionDomain", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureDispositionOfANonfinancialAssetAdditionalInformationDetail",
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Transaction [Domain]", "documentation": "Agreement between buyer and seller for the exchange of
financial instruments." } } }, "auth_ref": ["r632"] }, "us-gaap_TransactionTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransactionTypeAxis", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureDispositionOfANonfinancialAssetAdditionalInformationDetail", "http://www.meipharma.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"], "lang": {
"en-us": { "role": { "label": "Transaction Type [Axis]", "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments." } } }, "auth_ref": ["r632"] }, "us-gaap_TransferredAtPointInTimeMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransferredAtPointInTimeMember", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenueAssociatedWithLicenseAgreementDetail"], "lang": { "en-us": { "role": { "label": "Transferred at Point in Time [Member]",
"terseLabel": "Pass through Services at a Point in Time", "documentation": "Contract with customer in which good or service is transferred at point in time." } } }, "auth_ref": ["r651"] }, "us-gaap_TransferredOverTimeMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransferredOverTimeMember", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenueAssociatedWithLicenseAgreementDetail"], "lang": { "en-us": { "role": { "label": "Transferred over Time [Member]",
"terseLabel": "Services performed over time", "documentation": "Contract with customer in which good or service is transferred over time." } } }, "auth_ref": ["r651"] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } }
}, "auth_ref": ["r776"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": {
"role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": ["r777"] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"TrdArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": ["r777"] },
"ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading
Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r775"] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": ["r775"] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype":
"sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities
Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": ["r778"] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": ["r776"] },
"meip_TwoThousandAndEightOmnibusPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "TwoThousandAndEightOmnibusPlanMember", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/ShareBasedCompensationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Two thousand and eight omnibus plan.", "label": "Two Thousand And Eight Omnibus Plan
[Member]", "terseLabel": "2008 Omnibus Plan" } } }, "auth_ref": [] }, "meip_TwoThousandAndTwentyAtTheMarketSaleAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.meipharma.com/20241231", "localname":
"TwoThousandAndTwentyAtTheMarketSaleAgreementMember", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Two Thousand And
Twenty At The Market Sale Agreement Member", "documentation": "Two thousand and twenty at the market sale agreement member", "label": "Two Thousand And Twenty At The Market Sale Agreement Member" } } }, "auth_ref": [] }, "us-
gaap_TypeOfAdoptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfAdoptionMember", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/LeasesAdditionalInformationDetail"],
"lang": { "en-us": { "role": { "label": "Accounting Standards Update [Domain]", "documentation": "Amendment to accounting standards." } } }, "auth_ref": ["r125", "r126", "r127", "r128", "r129", "r130", "r159", "r160", "r161", "r162", "r172", "r198",
"r199", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r217", "r218", "r221", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r343", "r344", "r345", "r346", "r347",
"r348", "r349", "r350", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r404", "r405", "r415", "r416", "r417", "r428", "r429", "r430",
"r431", "r432", "r433", "r447", "r448", "r449", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522"] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "TypeOfArrangementAxis", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureOtherLicenseAgreementsAdditionalInformationDetails", "http://www.meipharma.com/20241231/taxonomy/role/LicenseAgreementsAdditionalInformationDetail",
"http://www.meipharma.com/20241231/taxonomy/role/StockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Type of
Arrangement and Non-arrangement Transactions [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r351"] }, "us-
gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfRestructuringDomain", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesParentheticalDetail",
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureEmployeeTerminationBenefitsAdditionalInformationDetail",
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureEmployeeTerminationBenefitsSummaryOfActivityRelatedToEmployeeBenefitsIncludedInAccruedLiabilitiesDetail"], "lang": { "en-us": { "role": { "label": "Type of Restructuring [Domain]",
"documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": ["r224", "r225", "r229", "r230"] }, "us-gaap_UnbilledReceivablesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"UnbilledReceivablesCurrent", "crdr": "debit", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInUnbilledReceivablesAndContractLiabilitiesDetail"], "lang": {
"en-us": { "role": { "terseLabel": "Unbilled receivables", "label": "Unbilled Receivables, Current", "documentation": "Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the
normal operating cycle, if longer." } } }, "auth_ref": [] }, "meip_UnderwrittenRegisteredOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "UnderwrittenRegisteredOfferingMember",
"presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Underwritten Registered Offering", "label": "Underwritten Registered Offering
[Member]", "documentation": "Underwritten registered offering." } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct",
"presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": ["r772"] },
"meip_UpFrontPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "UpFrontPayment", "crdr": "debit", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/LicenseAgreementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Up Front Payment", "label": "Up Front Payment", "terseLabel": "Upfront payment" } } }, "auth_ref": []
}, "meip_UpdationOfInitialAssessmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "UpdationOfInitialAssessmentMember", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/LicenseAgreementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Updation Of Initial Assessment", "label": "Updation Of Initial Assessment [Member]", "terseLabel":
"Updation of Initial Assessment" } } }, "auth_ref": [] }, "meip_UsLicenseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.meipharma.com/20241231", "localname": "UsLicenseMember", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://www.meipharma.com/20241231/taxonomy/role/LicenseAgreementsAdditionalInformationDetail"], "lang":
{ "en-us": { "role": { "terseLabel": "US License [Member]", "documentation": "Us License Member", "label": "Us License [Member]" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "UseOfEstimates", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use
of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r21", "r22",
"r23", "r118", "r119", "r121", "r122"] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableLeaseCost", "crdr": "debit", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfTotalOperatingCostsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Variable lease costs", "label": "Variable Lease, Cost", "documentation": "Amount of variable lease
cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": ["r425", "r671"] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "VestingAxis", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/ShareBasedCompensationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Vesting [Axis]", "documentation": "Information by vesting
schedule of award under share-based payment arrangement." } } }, "auth_ref": ["r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847",
"r848", "r849", "r850", "r851"] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingDomain", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/ShareBasedCompensationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment
arrangement." } } }, "auth_ref": ["r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851"] },
"ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in
Covered Year" } } }, "auth_ref": ["r742"] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAntidilutiveSecuritiesDetail", "http://www.meipharma.com/20241231/taxonomy/role/StockholdersEquityAdditionalInformationDetail"], "lang": {
"en-us": { "role": { "verboseLabel": "Warrants", "label": "Warrant [Member]", "terseLabel": "Warrants", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon
payment of a specified amount." } } }, "auth_ref": ["r687", "r688", "r691", "r692", "r693", "r694"] }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WarrantsAndRightsOutstandingMeasurementInput", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssumptionsUsedToCalculateFairValueOfWarrantLiabilityDetail"], "lang": { "en-
us": { "role": { "terseLabel": "Warrants and rights outstanding, measurement input", "label": "Warrants and Rights Outstanding, Measurement Input", "documentation": "Value of input used to measure outstanding warrant and right embodying
unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur." } } }, "auth_ref": ["r856", "r857", "r858"] }, "us-gaap_WarrantsNotSettleableInCashFairValueDisclosure": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsNotSettleableInCashFairValueDisclosure", "crdr": "credit", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfChangesInEstimatedFairValueOfWarrantLiabilityDetail"], "lang": { "en-us": { "role": { "periodEndLabel": "Ending balance", "periodStartLabel":
"Beginning balance", "label": "Warrants Not Settleable in Cash, Fair Value Disclosure", "terseLabel": "Fair value of warrants", "verboseLabel": "Warrant liability", "negatedLabel": "Warrant liability", "negatedPeriodEndLabel": "Ending balance",
"negatedPeriodStartLabel": "Beginning balance", "documentation": "Fair value portion of warrants not settleable in cash classified as equity." } } }, "auth_ref": ["r854", "r855", "r860"] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "netLabel": "Shares used in calculating diluted net income (loss) per share", "label": "Weighted Average
Number of Shares Outstanding, Diluted", "terseLabel": "Diluted", "verboseLabel": "Weighted average shares used in calculating diluted net loss per share", "totalLabel": "Weighted average shares used in calculating diluted net loss per share",
"documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": ["r174",
"r180"] }, "us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/DisclosureNetIncomeLossPerShareAdditionalInformationDetail",
"http://www.meipharma.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares, Common Stock Subject to Repurchase or
Cancellation", "terseLabel": "Common stock subject to repurchase or forfeiture", "documentation": "Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these
shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall)." } } }, "auth_ref": ["r14"] }, "us-
gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [
"http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "verboseLabel": "Weighted-
average shares used in computing net (loss) income per share - basic and diluted:" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberOfSharesOutstandingBasic", "presentation": ["http://www.meipharma.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "netLabel": "Shares used in
calculating basic net income (loss) per share", "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic", "verboseLabel": "Weighted average
shares used in calculating basic net loss per share", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of
time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r173", "r180"] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype":
"domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-end
Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": ["r740"] } } } },
"std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10",
"Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28",
"Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r9": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-
10-S99-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483499/205-20-50-3" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45",
"Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-13" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10",
"Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r19": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r20": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r21":
{ "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" },
"r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-
50-8" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10",
"Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",

"Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r32": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r33": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r34": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" },
"r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50",
"Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section":
"50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10",
"Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic":
"205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205-20/tableOfContent" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3A" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4A" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5D" }, "r55": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r56": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "
(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-
10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "
(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r65": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-
10-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic":
"210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r70": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "
(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r74": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "
(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r78": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-
S99-2" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards
Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards
Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r94": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "
(SAB Topic 5.P.4.b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB",
"URI": "https://asc.fasb.org/440/tableOfContent" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI":
"https://asc.fasb.org/505/tableOfContent" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name":
"Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10",
"Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r107": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r111": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r115": { "role": "http://fasb.org/us-
gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-
50-32" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Subparagraph": "(Note 3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481418/840-10-55-40" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481501/840-20-50-2" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r121": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" },
"r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-
10-50-12" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent"
}, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "
(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r130": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479343/105-10-65-7" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic":
"10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r136": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r140": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic":
"10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r144": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" },
"r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-
10-50-5" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph":
"(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic":
"10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r152": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" },
"r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r158": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-6" },
"r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "
(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r164": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r171": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" },
"r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic":
"10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r179": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" },
"r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "
(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r186": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" },
"r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-
10-50-22" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r193": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic":
"10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r199": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r205": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "
(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r210": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "
(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350",
"SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r215": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "
(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting
Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r220": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "
(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI":
"https://asc.fasb.org/420/tableOfContent" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r227": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "
(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r231": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SAB Topic 5.P.4.e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r235": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" },
"r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "
(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r240": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" },
"r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r244": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B",
"Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r247": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B",
"Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r250": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r256": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13",
"Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r261": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r266": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" },
"r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-
10-50-3" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r275": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic":
"10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r280": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r285": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "
(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r289": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "
(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI":
"https://asc.fasb.org/718/tableOfContent" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r298": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "
(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r303": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "
(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r307": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "

(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924",

"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r447": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "
(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r453": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic":
"235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r458": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic":
"235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r462": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic":
"235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r466": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic":
"235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r470": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic":
"235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932",
"SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r476": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8",
"Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic":
"820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r481": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r485": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r489":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r492": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r496": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r500":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r503": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r506": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" },
"r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "
(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944",
"SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r512": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "
(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting
Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944",
"SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r517": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "
(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section":
"65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r522": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph":
"(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r527": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-03(f)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r531": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r535": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-8" },
"r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic":
"210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946",
"SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r541": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" },
"r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic":
"210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r546": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r549": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r553": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r557":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r561": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r565": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r569":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r573": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" },
"r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r577": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",

"Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r580": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r583": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r586": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r589": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r593":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r597": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic":
"320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r601": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "12",
"Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946",
"SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" },
"r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph":
"3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r608": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6",
"Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r611": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" },
"r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r616": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r619": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r622": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978",
"SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r626": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" },
"r627": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r628": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic":
"944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r629": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H",
"Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r630": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic":
"210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r632": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" },
"r633": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r634": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r635": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r636": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r637": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r638": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r639": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r640": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic":
"10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r641": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "
(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r644": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r645": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27" },
"r646": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-
20-55-69B" }, "r647": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r648": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph":
"(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r649": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r650": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r651": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r652": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "
(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section":
"55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r655": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r656": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r657": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic":
"715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r658": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r659": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r660": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "
(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r661": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r662": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r663": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r664": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r665": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r666": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" },
"r667": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-
10-55-103" }, "r668": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r669": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r670": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r671": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r672": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic":
"10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r673": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932",
"SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r674": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r675": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" },
"r676": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-
235-50-3" }, "r677": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r678": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r679": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r680": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r681": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification",
"Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r682": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards
Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r683": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r684": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic":
"944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r685": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" },
"r686": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-
80-55-18" }, "r687": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph":
"(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r689": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section":
"55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification",
"Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r692": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r693": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r694": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r695": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" },
"r696": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-
830-55-11" }, "r697": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r698": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r699": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r700": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r702": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r703": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F",
"Section": "16", "Subsection": "J", "Paragraph": "a" }, "r704": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r705": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r706": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r707": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F",
"Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r708": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C"
}, "r709": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r710": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r711": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r712": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection":
"F", "Paragraph": "1", "Subparagraph": "iii" }, "r713": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r714": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r715": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19",
"Paragraph": "a", "Subparagraph": "1" }, "r716": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r717": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r718": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r719": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a",
"Subparagraph": "1", "Sentence": "iv" }, "r720": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r721": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r722": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-
F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r723": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r724": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r725": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18",

"Paragraph": "a", "Subparagraph": "1" }, "r726": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r727": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r728": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r729": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a",
"Subparagraph": "1", "Sentence": "iv" }, "r730": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r731": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r732": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-
CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r733": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r734": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r735": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r736": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph":
"1" }, "r737": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r738": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r739": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r740": {
"role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r741":
{ "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" },
"r742": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii"
}, "r743": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause":
"iv" }, "r744": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1",
"Subclause": "v" }, "r745": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause":
"1", "Subclause": "vi" }, "r746": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r747": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r748": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r749": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r750": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r751": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5",
"Subparagraph": "ii" }, "r752": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r753": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r754": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r755": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r756": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "w", "Paragraph": "1" }, "r757": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1",
"Subparagraph": "i" }, "r758": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r759":
{ "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r760": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r761": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r762": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r763": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r764": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r765": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r766": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r767": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "x", "Paragraph": "2" }, "r768": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii",
"Sentence": "A" }, "r769": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r770": {
"role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r771": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r772": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r773": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r774": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r775": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection":
"a", "Paragraph": "2", "Subparagraph": "A" }, "r776": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" },
"r777": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r778": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r779": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r780": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r781": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r782": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section":
"402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r783": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402",
"Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r784": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number":
"232", "Section": "405" }, "r785": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "230",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic":
"10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "Name":
"Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/210/tableOfContent" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic":
"210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r792": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r796": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r800": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r805": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic":
"280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r810": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
}, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name":
"Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r819": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r822": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r827": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r831": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r835": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic":
"718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r839": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r843": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r847": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r851": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards
Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r855": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r859": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic":
"825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r864": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" },
"r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r871": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r875": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section":

"S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic":
"30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r879": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944",
"SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r883": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944",
"SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r888": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944",
"SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r892": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944",
"SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r896": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944",
"SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r900": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944",
"SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r904": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944",
"SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r908": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r911": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 70 0000950170-25-018809-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-25-018809-xbrl.zip M4$L#!!0 (> 3%H*GFC[>UX! %(' @ 2 :6UG,3 U,# Y.# U7S N
M:G!G[+MY/)1OVS]^6<<^]ITI%$64+(4,*4N2-H282O:$A%'#6&+L0BAE"ZEL MR2Z[09)L(>LLDBR3&=6X,F/F.SV_[?Y\?K_7YWZ6[_=^[N?W?2YS^N.+ MBY.3BP\"X>81X!,0X.?CYQ<4$A46%!(1XN<7EA06$1.7D) 0@$I)2XI+BXI+
MB/\VPL;!NH:3BY>+BU=X=+CDYNU]T]/+V\?8)N!X>$(L/NQ-R+COJZMJV]H;&INZ>[!]O;UOQUX-S;^<6)RZM/T M#(&X^'GIR_+7E57*YOHZ3G(U4 Q)>TH'O'CZ44U7;S*A\^3):[=&N635-$A[*'\ M=NU?//O7.1;][_+L_W;L__%K!A#@8&-M'H<(=V]E'*>]'*,/VOQN1+
[13]:-V3BI!IR<2V8/D#_8,%8YMK[=S3 M(T.U(1 1_1/'+/!0LQ=,("X#]&0"9K%IGYD W09&'D,(,(&O 37T B:04+7(M$ F78T3IP4&! H(%76E;?X?]!IHL ^^.'"$P 4))NPP3&"&X_8(S 3$+NDY. M#WQ;7@.MR@2(ODU,X!["G D4VJ0Q.%3!]JO?SS;%4HHVS)[;1,7S?
>ED.G+USA>U_^9BOIOO-4IC."OQ['AW(" MT45@C^5(<<.X;E)@$*?#9*#*NY)T#-\ECGX/'>Y8Z#_*^0"TI+$R_0BH[O;, MEOBPPL]]0M-^V+8N<>!Z[NKY=WI/HV8#!E38\FU/<1RW_X\-3X(0JF> M9+N<1*-SA.;J=:FTLV@)^G]9:7>VYJ8%Y><
M77J+IRM"131>*LX817:*Y!M\-_$*9)_A%GQ']S1G?NCNW^$T5E9>?@?<.;U M9PR'PLA)7W$_>&N80.=U)L#WQU!R8Z!_O=$N_7\+\];UX+O@0XEX^Z+^9RF!7]G4Q]B6-GJ"#% MJ/? NWZ+4 &O :$"G;'9^O8B3[[+9DIZ?"U%[IPI%0?[XV"G?L#^@ ^VHAXF M\ < I?
T!!E.!?TSW)[0S,W)'93JA)2W\>]1C M:W7_^\#DOU)^/(*2#I'[D#W52>N=1VF4=V4QJ;&F51M_Z[KA";TM26BF&;D M?7C^D[/+Z6!!$YF]L2[Q4KJ4\QGW;VIV95)0&-QGBC MI+UPO,)706CQ7Q9J"3*&!P@\/N+(4]XY[:G'U7;8VUGGVJ:,MJB'6_*W)9N==HK#)
M,=)FN&-'"G5T_DXY+"97&"M0,+$_PN\,GVQ('+Y8&[<"3(*&(G-OZ1486E M_&XYR%(I]$/X'7MU$:*_R/L:[^T;>JK=EWZ31!- MAF$7N$=^LE+NLJL+V$U9KX#9O&I$$H.19Q]9MP@?#BBXK6^^^,QDY"OZOTC' M^?>EUV&&+(*0\(!EG3<\'_A>?WA,N[FX?
Y3WUBX^IM52. C)$9O;^W4&P5Y M34H.^>1+U 1'=I=*)/>K:!Z$MOVOYH7_NO5AD#&*4S169+PWT$Q[9;UZ#M0 MMTM[9H^W'(MM3:XH;\H6-0 .?;5!9]>SF$T/Y'KA(SQK2W!!6R>:\TV%YNH6 M)<)#-K^$](_:L!7]]/[K* 7?.9 69W2R>-
JGQ3W_47B9:W>.WM3!SN2,OE49 MQS-'.85]-OZAMTXFP)07((*0%OES0](G5UY?-B3% M[?2?5:J=N-_JR03D?X%R'F_5#81B-#0V_-WK6UXU.G=G%[V/LKO\S#8[9*GO MEO9)MJ*1O]ZMHS0#>@CH33N#1)^?,%(M"<^J6XOR#[[ZTM%4X7W8Y6*2>6!-
M^Q6A.^5W+K2+_4YZ2A)1-U]>9=\".!U&_Z7._U].!6.?XKC,F);1 @C$6?)#O$>':.Z_"EZ1&N7_0-/ MPW:G%]^*K6+;?^J)*%O_5=<8,I1:!QZBG?2U>8J\.TX[C-B-?L6P91;7)3ZZ(B,_$/\\E/&?>'-N?/?.,V/I(=D6L/V]ND#*BE(! M5N)M55]?J^R8,CFN:;#44?U
\N>#C2:FF[/Y65_0-=\PSW 1[QEL3U0D>F&@VBLF\#F7PVP5]I=@>0^*46((M.209PN,4WZ[)R?$]%=%R;PS?B"<2I]_N,:M6YF0WY8R)^6#*GK;.9'#C9S+ADUHE(-\;2S_]B.YC]1WZMG@X^)"';Z M;K)]*;%:W/39RK9-LOMT[L*QS0:A3XOGN9>O'10/_KNW53%X?
RR4BQX!!KLM MPJ%(U/1*:,:@>,!]R-G^(X>:S=^:!_>9]@^-%3*!V$?X!&-#='=93$]U$%&% M9:AAN26NC\/;7V@GRB4)(F1UAEV$UKML87NX@B=!,4 =V'M4]YN^0 M6*',N^"L7L^>&B/MROYV;+L(73!ED/]AG\NF!TH&EW,$SGAKDTV>),UBP3^.T[ECDW#^;:\5
MYUQ,WF %TX)F;7O7D^ LXEWNV+L\6+HZ@SH[%^;(\=ZE-.N!*%N/ M_'7/YX4ZAG]=]99;>7^SDW"[#K*#D)U'*(\/WA PO][:]%LY. *W$?.OFZ\% M[5HM'YF]^&>&U_]A=I?GM:8IR C#@<>T@ M5UC!.HW20Y@B[7.K7@"M3;/5;13)C@-ZI64]P@_O6R*
[:Q5*!.A=ML=804KZ MJR"]0!T''^'3XIB L!$O?I)0'6IC8MR"7[KHMWO()=.7.4?..1Q_CG'\]Y# MALZIZA_:#1G3""ZTYX8X/.YGI,&?IVNL7=6-V\?T9)QF P2>FJ>GF^Z*J3MT M9-=];6UNS(N_*LZ3H9T=206L@'M5\P]5@@8+DTA2B?#\]+RCBH->E?E%RR=D
M\P#377@\.7 %_L^\>5.F^.K$" DP(3 <@M%]&.QXX[AN9X(\%S2O1!* M=SQ M5* X_PE]Y.&8^_W>-"<4LC%:-V[!T]R_=SSBY=GFH]P1&6:>(4+GA0_J_PV M8C=Z $O?PP2J9!L9F96H>DH2XWPE>9#1E8[^6MZRG4.4HC^Q[49L$\K1*P93 M*70K$+
(XA&;PL>$1"7]R4@7X2KV^(S=_PAM,VIWCO[$IGKMO&99NL&]MW4MF M&5C,32. :/#*1^*"4457],+D^?>3@:P-PKJ, '/#WWW+>2$ Y_$ M?A;F\>S*\R16=Z)G]_NRG]T(@K MH+HNIJ#L!?@&[Y_RTQ94"XV.V#OKE>\?K4-2LG:NO$ *@&J:^89*(]0Z'D9X
MN\GP60RM!R#_36?S](RV!A,+8CK(9RNMNQ5W4?96OD"]]QO<=?6:W,Y:KW6> M'HI>4A+J=6,CYK$_ES=R&WNZ!. M3P("L*-7(!X$ J@ C9D M3+9"J_#3K M90B.&DG T^,9-C+?V6,O8!-GV?I]MC'=$1!PB FP,B>L= TG4L12*Y4AE8'< MS4*/??S6$?O/XP:%
[]WNSO)4<]Y*MIAW NA;9-O^:=1)PH[8N;$.KV%I$$$L M;#)OK:<,S;U&WD(5/'*[5)SE=JY?NVH\^F S=]L&@\^;$'X76P 8'5@\VFK_MRLGI0&OHMF*Z2L9*R[WOI*L&1X,%GMLU'-ZM8GRK?AAU>B>?H4UW)Y]".F/A M'"AE:,KU[#T%Q)3V9(ONO?[S^-P!KOWDFZ
M71!K+-.:9#]59ZG1VMB2^W1?[N+ YV#/A;KH/L$+Y^[/O:NUW'CTI)VT+@*3>WVX\:B\)IF5W(5\ZZ&WA2@CCSD7E'YGGL03$DP?"'";>P9I7&= M$0P%510-FV@-/E/DGECC.#+[S%+L^%M.!"14\NM=5].5V1N"'[ZJ1I MW-
5LA8AXQ],0/6]D5)UABU8^W,\N]$8<^*IQ?.*S,N\?[D MTT#AJXTGG_E^F1$9E303'WC-SH>"Q0/6W?9,0.CVPW52I:Z"'F/AVS*6+T?$ M0MQ*1;OE51K[\9!BF/J3[ZY#Q(WI]=X.!30^OX!/!\8[++/1CU,%: LRB.R-:U7 J$P1(8!I=1N\$\\G2$(F-$<2^8=S\
(2_G@8C7S/,)T@-7K),%K_J&$V1#>Y(J#^/+,"@Q=X+ZV^E6 M^--5JCF1U&ZVI\%'VJ&W+)H9.#1 #Z.4FY$5R_'\ZN%FCN3) MHCW3XU6>J9+A1.V2PZ_,ZI_*<,6%!IHHAM-\+18[I@>I1\CF67Z4PUBGZ@2_ MUM,-6Z[[$C?O6@^^_9RZ?26UV_[62P'?Z,\1*
[;20"BLH8P$)6[<8]7X=@4P MM.MPF+$VI37)V__YVZ?FL7;7A!P"E-][YN^27@9JY/')L)EB@D7?\(PZU88< ME_4">:JW7:67N!O]8L7);UW$N8>]'QG_=O/T1<+U>R)MJ5;'U-MW*M'N>0Z+ M6]U,@%>0>UM!N=]5;%]0F=6M3RD/G_)>TRPD[2E.B;FE':DH9
(9ADG>]D\K MJ."8-J5%NB(=C"E=!BM*S\Z6K&:3)WL.>G:$?8TFYIB$ERF?]@\E0X2Q$* M@_U$/PBAL1LA"D)=)W3,)[4FER3[-JW1=7WDDO1^-7.Y]?0L5?G<+ZW.9%MJ MR4ZY.YE50R,T'+TBA,BNCT,:]7-F4"-UC:5FFCOI0WL1OGK;1 M@B.&C0^I018G)-
^#XF#=AX*73TUUJU)B'G;>&E"_(N#RYSF06UD(10"+D'[M.Z:U>HT!2FHU)><[:3"1+NEBZ*5W"XHN-K/D/I13OO\1],3DY@"O<@79M M'GRF .T)6"D0NVT;:RR5L<50;1GZ4C@YD_PJNJ.E%NN7,]O6Y'Z4S\"C&0VJ M03IQN2;WDO[;)PV#F)'<;'^
T>CNH^G1PCU+5VS)6@+::ASO.CS1 MJ3EWT*2:$A#2A9,T.DF!$]IK?(^$T6T#]WP<'5(HJ17.L$Q$(C'[V>]_#DJ> MNOH2_?J4N1#$R*'(!\:!\M>GBQ^V 1_F[MW@-"M^[#!A/ 41 MWTY=(XYKJ#VDS6OV*,F M:Y,!,B*V]5RUMP$BBLXKW=2> MZ?
@F=6'Z6T/'/._]V&M89W.'4>DC2:):3/7 _ ML@8010[L"AI"2=&.,#J7^UHPJ:T.M!.@T1PRS7'"9JBRFOKF*H=DAJ.^DTW: MHQ(^#D6C=F!XEPR+C#=DO6'_(@,3X3PZ;3Z#CN0)TOO<[*BPJ[=SA$\IKV?L MWO]^1/MFUY&#(C,M'3.#1
ML00*L#A<;P8$RH)SLCW9KKJ6%%)?/&)[4"['; M_6M<2,(M^:I=W!>48F1R=1*\1O$%&;-HT8-0C!A>$-)V]G8P_.EWT /A"DI!]!BO-\>_;YOB+B@/,!]-&>4'!A*1"2V="3666WX MN<=]4W]4F;N]8)=U2]3#GZL;+]_J@W.#2)=1\#H(ZMO-
,E]5L>7617T,3;Q6#>:I>%5.)9GK?/&>)$5 WB+!#\%:ZA#J-(]7-Y0SW0AZF0$5B=P_H&Q:$'5W>R ML8\)1">4K;:0>I_.^.1]%BN9U_HEF\MI?JV(E3QH_O.*&Z=8/G#$_Y,;-7NJ MFF'H@^/78NP>I#AT?W<\-IE.-'R[-PX_(%NNG7Y$%/\BP$RRR^0B/B,,)]1/
M>;Q83;*CE'4:*X#UE4AXSZ13\N;0[9M[F^]:9GA8$NIM#Z$J>W]]&N@60G9M MIU%]QUD.VUACG8;CV[579T*RG@W!UC*WS^=H@U! 3Q\]J@-E7S MJ&Q]FJS?QV#;*3?6!?M=1XV[",,BERVW739F\)DDOIO\,37R+?0RN'8B0(!? M0\BBK#ZVAE$>XYE
,LK[+I&WU3C#V7$M]'SKE/ IE0PQ)>89O,A09K'X7]%VM M"M:#YF08HF [-:W.Q T^$&TYB1(C[C@=#58P)Z[N(CL>ZQY4LYRY&+B_ZB?$ M]\5:ZD/@.RP542=4!"59+2($Z.^V\C]<':F$:WZ_<3)=' MX=3<,LS-U5>U/B'ZC)59F[OC>BR(>":&G M*
(*S075ZE^Z+?];S07SRI#I38)T[;OVNZA3=O +,393-$9I6G,YL09U9F8E* M^H3LZ?M8?[XF5;XR50T3@(3B8@*J911;1N^..A/PJ"XL7\:QH0=6Z!>80 WZ M%$L6EW_=#Z@]3?S# &VI6":0N;3S!+ZVJK6C[K2U,>O&L+$E(G:B'[/Z.]?O MPS.VK*: 'DZS1XE34F.>AG?
TY"LTI?RTQM5WP:8_7H:HNC6%_#*/L--=8P+U M4M$_"^([:K=2C70):W"2H._Y\1E^9X2NTG?8K2^E7_9V&2L0 QK+JZCK[?Y]Q>\ M\H@A%V//E6%:7:Z*73Z^)VMO*G])4]:(H;GCJ=='SU]\ AE6N19I?,!_QKFW M0^AV'K2O!492?0[B>F\-BK?DQ 3S\S.!UR-5-M*5[(]
MAG9#_=Z3SQW"]MHQ=2Z][^K1DE'>848-;XL M>&]F^("$2O2][5[5*:<:>%T M@++5EX2(I2 -K?Q%!IZZ#FD6Z>383[Y_>6+745$#]C-]1TS["XF1!ANLTLP= ML9\N_HNYIF=!UL8ARG991ZO'6V)CY;23HTN\?7B-,;HA0WKL7;&3BF%HKY$ M7!).6A=V+T)\1+=:*&+
<:2N%L3^\3]_RV26?6ZY>KJ[2F7P/L9<$A*_LX+&Q M3CL\.Q4,L36T7#L;LKB+H=B6.NC09EF"^7"MYKU;ELKF(XP)[5#^(V4CC_:] ME)SU#DI"Z(V-8E,LP5U"1V\E[W.F^E.D!HJ/;9:?KQH.8B/J3^27N*O?3JC M0/.($_
3!]HU]MI*LC(F#/2O!N]B#HSZE]9Y0KV^G:V[P>LR MA_O;EU<-$^CG6!\B! <,=:!T=W?4 1[>[&0\^391Y+='&IS-17.]&:QE))[MRS_TM8,L'9\(07OY#M M'8"$]]N>^>Y$[N@NB%W#SSLP1'P+XB735P_[;VEZ0D#D&]:A<6+#FFMMJ7H+HL($:3'(/9.?
0%&J^Y$]H%8WN6QC=8.#BO MLKOAT"^Q#.@ST*Z"MMWO%6BY7[K3QXU"CP/ !]P!< MZW5[>[&W%?K1!P]-I6IU=[D$8F#:#O#!#KADL9*7MO.9J*-L^9IP7Q=I2=J M3J?WU)1]+FN]4>_8V/E6"(25D7:3G7L-TNCBT6Q)-RDM^G2^HY>@ZJ2Y8
DX\0BMBJ%T]J8?B MHA_WK6+#R$9#*IO2[[FKJ3[#[^4F=X!1\Z%7^O,;Z??Y$/5;O?[Q$?MW"EL% MR5*CGAM[[3?/5LO8(/[M;[A(2'+YMZU"SQH;]X-!S-"3N%:_14ZCW@./ M4O+]]+&*1]'Q. &/AKTV%YQ;@VZ_EMB#>CY?DG[I(!!-XVL(2H\)OY\H$9\5^+2I:MQ,
[91#)F= M,OI52A6N#R'^4]V6$W0=^]3-D!C35,Z6]\7,;D(>.7SQ&]H=ONSSO)-6"+L\ M]64*FR:%/+R(H8L;^&K)(V,LQHVX\'=Y*Q[Z.HPZF08&O+2W[$J/U%I^?PNB M8DI"/%7 ES@G:"P)MZ[,.[X] K[O$<1KE@ M*!7!4E%(;Z>RV.!YQ.+&O5PFT.
<45ZXR(.;S3>^XG=6MR4Q.C4V=>Y^? 8> MD?N90=A5)@? 2&-.@7J]]3X5CBN3+WV<=+]6?K.5O#]*>(^)_WS=E&*9BEE M8,'":[3W@;O$@B2XOR$TKAT"QE8BS^,NC5]-UI :2_)UIQEE#.WOEF>U3C6< M5Y:E=^%3'V,1-
55OR%K4$O#N8D$40R3,2)FOPFD^>G7P859>A@?WJM][V7UL M?/Q7BTGI+MD=9*G^4!SY'%H0=19S'(?W/78,7V!'N\SA]I@_/G(S.?_JK\^F MW5O#IW,!(MRG($%1?R>5P8Y4[6Q "_]40/[(GE-3&0]<3-RU" P*I#FY(V0U+%E9_UO-=(H;LCLF2FE M2SZ=SM8[S6
"2[O$OG#4,SS\'PC+YM%TZ+Q@-=Y_EJ,7)MQZE7# \,PHRJ+8 MVO_+U\81W?J8VMG6@%]W[Z747^&Q/"T:]"3(!';SW$EQX&^'PS!KH?3'J>E, MX*J@!1.PWO,O$NN3!<.FWY()O(HK9@*E&2.0D8OG3@*HHZSB[T71*RZE0\F3 MZ3Z;)]U?KIF1DO,4KB7D*?M?
P^H=Z)J7ZM;+%8Q!AM=] M==GCZ)XTE=R!G3(FX#EO2'T 7@@CJ,\6E\U7E-\M0W#- M4^\^L.=[;_A"X%U/E?3B$X?WLH)EI#8RK3NDG6-<1TM@E6I_EM\0(6X5S#$L M?DKOF?Z'-PW/ :G8M-.?6:UG<4[/ L].)D,0K+Y(KHXCU:4H6[UNFG"OK9MS M^F))?"NP;BWI]
[+9K1?E2>[HA->%DAS)C WB4$=?N%EW[?Q0P(P^IFXKE]* M>_."[XUT.ZD[K]D'=QO>ZL]$7$3)@%*+_.C(.U/1[9I@WV)?2WZ;_['ZCRF[M'SCVJ+@BY+1N6Q8OA9+[RLA3G?:YD'C4/IUQ.9BP M+O,0T/77\CDG,RY>=\O
BM_G5N4D>W$\!QUHYY$YBQ;K>RB'+W=TY [V+G9@MXA_8K":>7_7+E*_FF5?@!'"9ABJRE-V8J2SM#WI69'*#XJ MKAVS7W73G4[/\&S:'LG4[/I\I5RIXUUB\[E(XQ=DV'K42_KNG21Z,$N-G3GD MNZ!/D8C]V CSO&\AGJ,E?")6]GCA_EB.
(#>5FL4CTHH2.T\8NUS=1N)U=/#1,52)L"Y.MHN[8R\^YXRU!P_ M6!K>,.-MT_[PQZ,.#Y<4G1[J^Q7%;A9,WPNW41QSR(3 !@C:,YV-A;3B:-E_!-7 M&N[\-7MZ-%\&]:FG2.#"G7Q#O(,8L2 :7M^(U8K;AG>%WQSN
MJ0'WJC3$^8M4OH_P[1)3MY#OM'1I;4O84OI<.*CO1(7.3%'=*9)M-&7P B&M MI^U0/6U>Z$NOA")1+B1#[6JZXGGWX,O95RPA8!/^+$2?%HXZ3G&(05^'8YP^ M1!%=W,PFOM4?,S!,,;/IR%X@NOL9$Z9=3UQYS[^_AG/3Y%CY6[C7]9TBN">: M#
[1>E"RE9#,!N[9)_Z+4Y9X13)IM789EOGO\PRZB,_?*&S_%/EI63XZ2/.)&#(V !M+Z>H3K5K/',%L!&^3_H)$1[/EM5;(@(9^[7X1VM-D M?@X,_F>5XA;>M@\N&C$.XVM7L2&7FY-SXGYX+S;D]&Q+OO 8>C9;GC'V;CKE MNMOR(:QI4Y(T9W)DV#+)G1R*G<&09O'SFK
$V?K2Y<2'EU?NW+N&.&QR?%,M M4>"T$)NY_X,^[>74Y4GT#2UAY# !E@!W+Q#XA%QV"9-=]VYI^]GV8W+YTB'C M CFK@*=FK>TKTI@#C)KFHRH;C&D8.T,=Q"R6]50G(OAOI\"Q^@SYR..34HV'
MNB4F'0+>*UKV*//R[+Y\L+_M,/4QN(_BL*A92=/W]2:\U:SW%YI+ZA!/E,@ MW4V6I W+BV]B+[]-E$XI+#GE(@U4)-M(*ZIA +QJR5J!P0P?- M"SITUX8_.Z!JG7M4I1RY]SXRC_J W18Z;'#2]&)!@JP6"4;&]'1 M47;H0M>UP,<78V]^MM;/M<+ZJHQR-)B\J?VN'KZ
*;WU:IB"H;KL5+7+(ITO M@[4OZ6:CJ*LZWD&2)6-A)D9Q^G:)5BHB62K:KT6>7(G45I^!>\.CVO4I6ZS: M<*'/0"B!R@2$D"%$_0FMB"E.M.>Y /F\5,+LDLROBZ,T*SH+]VD=/L/1^8=& M;MLV@D$]C2+M+^Y2FY1I!DF1G]=#A7!]P^^>11K7/$U4 ZH+4*I,0+5C<9@F
M7@'_$>0P8O?]]QW\SUOT,"9P+0O#2/4!MOD2U0K9_V9 8^#XBM"$,M",D/(Q M*O>([L">*VV6ESX^N4MQ]:-=C)AM%]QY:2PUQ"+V3@9 4:PD.J_%.\W\BW^9@FL+'MY%UO9=DP7H3&#G:2&E8WV#Q<0_P;#2KJK5"#F*3UV2'IV_GFD0-
R[,>7+B;CUR6FZ2+D9:SM/3A_,#JU0,1XGZ_K(3&DS4^O M5E6=##G#T$,:H\F/^(Z>:-. F]$;9U(3 !?R(*)"^4-WJ8#TRI1P@3\?/DK MG.?E_MZ(-^RCYKIK;@X1_V!0W="6-/)-3TMCFBY\QOD\&95NMO_(I0REC ^Q]!HD ?Z#/W%;C(CK M#)?$X2VP+%6K3[9/*/:59:0?
>#GK1;6?A/EFNO%D?>*\$$V*[N<(7,ET]2/K M_[X;!J-Q@9F$#5/PS/[*+-&WVY'U.;8*@<.H.QJ-X@Z3F7L -1^8$F,(&(MH7R5*2;@+I>&04@GV03CX1*#0<5KY\QY17X%:=\W6>VR3@-U.+/HSJ<,'1H,. MLY3L5O!;!D[V6$X/>J817Y#4]N\N^;C*=
<%\ZKQ3GQCI@,1[4^M(8P]U]7VJ M*E40GQQ6F1%$^\"B<(KMFLARPE:/GYSS>*MCER)#V+ .F7/#0Z8)%K7YH6@L$NY'F6_IU,D+N^N,SY&^/]UNV7SN$_,@9 M:F<">FBL#]5IG3&!S.NP=+7XWXQKX#CCQ/Q=1]LF_(>SP\.(/L0FJT>!=JQU M=?
SPG2K[]W='(6C_X>L9\.B IE ACJ%@]%+,F,"5B75'^#3,"H91)/%\ ?) MMO&MAM5K3F4SWSSW>?K=I+ZNN.=G[OE_V:$&3BUXM#K(KF%+>"G7RWQ'MDI M/MLQNG' KVBN_,LILL'3I7@.E:@,DVK83DR$.+(Z$_;8S[Z MA^NK9Y0*>-;Y\D8-M8[\'*0&+H8C# G
UL1.X%3@RE1C1#^>+4$-=&V7L65'D U/T>_QDI^R^+[?4 M)-K6+\F@%Y>5G@ ZO-#J)?HS1B-V(C-&LH]B4+NR91QU[(M63NOK5B%B??SI"*?L_QXM?; W$;40ACU!7*0CF>"4#_,F>*%NED6!#EEF'M MWCP"CMU7S+IXOS]BSD#E% =;QX8$AQ3\
M8N(+3>7QF[T?];DX[UO)#M%R;OAY0B"0Q$THA/&."^LBVGJ\",@&*TB*#=_H9W7QT MOLK(.] C(?3Y[&PZ'Y@Q .X@Z.+ZU"P* MM+N.;!MCI%M=?>\FRI*D649425GRE3O[]7&Q6FE-=L@>J0AEMC ?LG\TNNY; M#;F?
&DV&8^HV4J5PLD8*1,.FVR33^B3#MXH?'//<[+G7-/1JN=_5<)FQ%Q+; M'Q9 X4]"_&G5D0@(53-ZYFMI;7<+G+PK7>*$Y!Q&4]G^\Y/>>=^4\ M7<9VI]>O0+1NR()X>D:+E>N02[OTG_E) M)+3"]S-N5IGJ,FJ\>\7U*)A#/.!VH8/128[]]NW$\Z TK^V]_?B1)F65VIO[M
22"S\06!&];-$/$UHU/@BR,M%T[!CJMPG7&CQ@W2ULNP6FL_)?,W#V-E M/#A4(@\/B+,1860;V"\=M" 3F%K:8CQH\XP8J(I0B1A#U$&P#?X&(S[I2+O%4IB?X?SKC,,U+L>1.AWUIJJ/ MU(W2^'XE?CG4E+7Z2699HIXF0=\]R>!'<8S]0(C-[N3T2CF$&J2^D,K-2-?)
M>.(^DN6V5!&V*]^+8U$+5--??_,4M0?T#EP<"$ZQQ;8?I$"31CT^ZO):"3L; M2=WB1XZK\O$5#HI&F*84)](XJ)5,(%.=4K"35,,$U-;R6;D6CY*BY/3;1K=H MQN##831_^T:*@-38[,Y+N?!7E?7O).?5GQ;DGI"&&/W 3Q4R1ES9IEH#:0>1 MC[N=]F!F469AQ7M*)"-
N!VX\N/%N(X3'0-&J%T#M)F/PU?V"ME2S5Q0<)D(3 M!SI8C%1L5/\H$/ F]?#K'!K6J=5Y7?Q5. M066LTW>5EI^MW[VGQON*.#?-347] "Z-Y'M1?4')MV&JH!DKW4E1>&A4$KG: M:J1N'\JPW-1(VT:7U/QFS.W1XP\8]!/QN#E2EB,/K@L21?5?KR9K1+!XA:O. M'S(8DK.=
[+=G8N>]2?P"T7RNZ_"'";F+8A\U PXG C_?]3V-Y/L]?FU1CS"! M^_!>?YI:[C C5B&<"V',Z(=M0D!6"-W%')G 2'$AM/#YWSS0HA?L9#&!&S!N MQF"[%ECO2ZP\[/)195*WYT#S*(EP7RW5JL?_^]XTR+)TW]TI-$UAY4Y97]JL M-;9 YC:<9PX)[[3Q4\U.XTGWC-
X'J!^6\'Y\TT0U\^UP4T1W!P?*G^SO M!-;#DW5LU^/KYZ\95AYMG^)DH$S+]G3<)C5B7.4@!97A;B:PAP;0&%08!4K= M!&<)P^Q@(T/8H=7*^?S4T\C!0*[7 Y !'H&FD%M/XB[4Z4'=UM"OIM*,E;R8 M@&*[&D]TI%41?>%8]X==EXUN#>L491A=]SLJ!;&43S+P_
492Y_$&_;B9,# M]:DC8-MBF]L)&BQ6=RW4QO L[3)TN29;DF/00;-5.7Q)00T4^_W\5G"GSE@+ MN7%IU+B?8'-G?OS,1^,ICE_K[K&1FQ.#U3RX,(M3OQ^ ;O^<3TMMW^6*LMHI M*2'K3T]@XHP.L62RX^.AQDZ_Z&V5>X?<:*\=FCU^/6!S\5^/H7PGJJ9U7&,"
M\F#^%V^C3/-YC?/0QME%4+V^Q#7$^ZDR^0LG[N+V"^U2.>-B=^PYM[9%8A=?8 M=](3<#P1 '*C2[;.#X\6<_$97UB1G;'R12NZ+DA/FDI[2@M"]N-%8^^W24BUU>!&!Z>P,,]7+HB3_G6?,%Z.2\V-&H7:]PLT+;CZ M.3E<;2AR>/^^C80%GC?DLJ1V'M
"FZ_S:$87+/5_,>W8/KZ7H&PFJY)\G-X& M?+OX9/EC^RY&3VB$VDXR_3#YJ8*/#/T\93,4&JQ\PW97"LV="\?,- M]\6;GS]U9NT2>1+1MM)RSZ#AL6_XS5#3(%$;F<6L*SPKZ[[$88[IB)E\U0DC M0P+ISJ(962BV3"*5ALU>\0P+#ASFO"6YN9;Y8^^^3[#M
MY32G.0HF.D(TXNT=)!]?,1W*K11]D/K=?NX;$+MRQ3EV*9XG M1@6P\6*\@_.A'%ET)$YWI>2DU-64^$9H4N2&_?VI\657W:3]:Y>*/3@29$(R M"W+2AU#]E%H"E,2J,]2,9LH:??\8RK'HZY:H*6%'U?4C2:4F==Y9Y-U(Y=SU M-U4U-W_4 MIH?+BTX";Y^TP\Q/
J+6/\G8",R@.:\153_O)7@\ZG+%PQ:_Q MPA5 3%[KPE1CRPC;2?&S_S(0QG055EUH!W\Q =<6""/CV&^V^_,<$,[%.ADR MW%$GOJ >0V0"/:IDNX:L8.)NH3*JU\\7*M8>.V/^"Q>^2-M\ZD>=VZFDL13? M"(20P^!&H&-O%PAW?"9&B++]IJ S2^Q.MMV)*C!FR=*
(<2;P@PUT9ZG#'!S! M@MI(@C,!$U@< I0)9TC\D!#G^;5%!?Z^Q*E^B_CUC./T2V:.4@!!'6A/BRI[Z M\(C>#6GON-##;6\OO?]=I[!%(.+"] DLN\6?SO*T7]*@VW7H&>A_MM%^[C8M M[Q;>I(=64L*_%XX/JZ[^,0WW=H'9U(^OHW3)[9/O)E6B>91:VGCE?=A?/N\' M @!
<9)EZU\5([;O&W^<%$?_Z2*$Z;G_2K9<]]&.,P9A4FAO[PI-N@.A '#V MF3PDA]2UT;K8%AUMEE&QDS4_"(^,[4,'L(*5#Z:C0E<0R3":I<3,[$M M,$PKM'RM1KG?_VZE3^/Y^J; ^D2-P*?1%],S>+N4C7*WU?]GPN,_@K7T'_YL MC-
%MK5ZT"'+U@#IA;=5@(J7^P<@Q$NY^DE#([90S_Q;@6][0W SN#HFL -$ MR*#Q[EN@P\C%W^GXQ\D_YQTK:0$4[4^3L/^]#&$+ZCQ__PARF?]$_.%1$?BT MITM2,C=\>?9:N/+YYM3C-)F#?99/W 3NL/VL/C?^#>T]I-<],W8 2BBV\!?% MEFYHW3H>R8U:U;8AJ-
MC8T>Q]VS2H[.%+H!/:?]LS=)OZK$OD:)12KQ4>'1\NTGB/ZP7H"WI_JW5N- MEGCYUN+L,W,9^GY?A"R2)2IZ@I!QLZ[CFCH\2F%+$]=:4RK=4J2"WIR2\[(# M,JPZ.?9&&B'^[H?=K6EOF-#PV]#XIO2FMBG%(XX(@6&UA3)K*K+/I+;(66>SR]
[?]_)W51WOI=>6=KIKVE2\N"&<$B#$$\A M5(@Q^?LQ\%<.\B 3X-#]Z$XC^<^@&9%P@0ZR-HVN_G6_&L-XN1[$7;6P$,K] MS[7D?Y\A]7[4L>>H4%B]1=+UAC$4WX*FL4*=5,! 4#!U3\-WH>YD;N*O5:AT M=;/Z,HZ7"0QL@-\9O>K0'?
F/P)_K[#]KH?]O6_\H6T=7:R/&11 MY998@H?SX%SDNXOI_:Z^>:_= 3YC2W#HF8=VWPE))W_[,F@=,Y#H/#A;NX\K M"35K,Y\N5WZA/P6[YN_1C) MR$JA(9;Z\(>CRMW+A)<;;/\/_7_8-6S!]__EQ]]N#31#7A/W][[M\U7&$T1]3%J0A%I*K9F)%" MB
8]B#CO,64V^F53%+T[KRO;32ZZXGGDLC+P2E=_/9/BZP!6DBO2)"PK%PN@ MB#FOB%TF23)2 W!RJ_8,ID1G^ M-"7'CKN[NS4_33S.Q$DKK'4;^=&N>3&@.Q4Z&YBIW)89\);"@4DF<#,K2 ,W MXZ\47SQ7\^19'^162F%F3D3\+,3N)A)'Z*698'*3#T\4?RQ#^R
1>ZP[Z/K8DMFPJ/?9I?5>A M9UE1MBO];25\&D9\5D^Y0! (0KYT?]QW1[$HN&BM])S8CB8OCZK/R]AWTA\ M#A6*B>+X2=2%ZHAQ5X./'3?3!,'#)R:R<81:'WU9P:&7,YTL++8VU#M6V3Y\ M>_U\92 ?X5+XAR=/=ASQL$1%:;"(NT8KKAY.$BGQ$5UQ^#IBS3$[?
S)-6\]* MPEE9^/&AY%:]@BI8QWQ!R:AO'/U^8W! =4"DD%J@\JG5D42 MMV;.0"'ZB]H#X>+C8'HITH0T]D2\OCJ]RB%^X^)#UYXI=]J=AK<1?9[. N MLA?']//JW2"!(MM_&D03VD)/@SF0Z!\D:X?:5)QS_5A_,Z+5L(O&L$+_&(>7FRY0W-X]] MY1AY7IW7+HQ"Y1 ;2:K$'?
43E#WMS7@YM- GW,J G_A=>_T;'MDB*-*%B(@(&"("$B 0 MBO0F(" =I2DM4@)("1T$!*1+)PF])M0((5S><^\=X^QWG_W?]S_AWOO&.?# M_/*,N=;SK#G7G/,WUYK/6L,&'(>/M%NVF+]C^TWX@G 9F13]3_VWX:VT)+R8G_MO_'\F'Q\ M]LH+40!
IHG=$Z_0+L5($23N.&?>&(/),M^T>IJZ$O/\E8,3_]F,;XP3V9G7 MZ H_UR_AX!M XA9!8F7UP3@VJRN%M7M;]6G-O-N/ MDGXZBA&QO\T'S6J%\#2F#J2U3J37JN9C[Y7Y9FX*A@OV%&XV4X6[,]M^,9AH M(C>.U/T&DDYMIF*KW1>%:PQ[2XYMKD:->RJ GXFN>X:
[F4QLOJ3;JIZH^ZC+^O"J_$!&GOI^-LM,!+$H M=C)RSJ-PI5V4#;S_75[2#)(X8-NKE&X F@ M!76.2Y594/>()T=#<5+ M75&'%5E$35M.3#RQD6N\H7/P$C0!=*9LFGUW"?.X79>G[LO"N9J(3MLG]&=/?,TH?/15.)88 MUFFZ<4,7#Z8A^^ I*%99:WE"&Q2H&;E)W-
%)JDV=B;(\8\&D_JZ\"JI]'O M,\- -L0W@/$'+=8N6WK;[KU,N#\#H Y>\.%."#JSN;L)K3@#2@?4>*T^J MV[<")K+"Y< 3JEL6V#)B?@ ^4HHE VPSO"40\WO* HZ:08Y'WYO18VMR0/74 M^LO6ZY(B"06MD/[0;43K7>+]"<](9>W\E_$G@.<\:"5]A4N %7[/MNB%+5K-
M)C,;DP#V/@0;<31.<+(B<+#B8F0S>,+%/G#FUOOO.#.))+L! MDU@5L>2.?C[D(Y+-)Z+Q Y*A?XGR%=@)@'$_XD ZOYJ9X,36*7*-!!XH3"- MHA\=]UG?<2FGCI.TUQOQ*##"C!"2[.;L7##C;",5V:8*\E7/R1Q=O\NK=.]'
M7EAT]VWVIT#%9KX["NZH"4@']B(I.>@5TL=CCL]!A_3@$RB6-_-"0^*F;$_7 MXX^F)G&3O=$I;^'6'X5.5E"$4A]>VMB1OJ7*]A M=D>\2'FB2UDQHJ"9&T@1S+Q=BZG7MW8[TMB$5_0KNX1)1:>SWU7\XSYG0U4 M):<^13 MEDY>RJSOD0QY?
V<.E#>7H39G&%K9SX.)U/0E^!R;]JTN/7K/U_=+\6>14/N= MXS6MK_6'9A63*]2;9"BIPF*, LZV0*P:7GQY^PGW"2#DV>@&3$Y"!#\AKR-\ M56OBF<=;&Z"1S@\Z_LO%]%=2;"]5:3.5F][=!A%#6^.E"APE%<0MOU> M%W^+:.-Y:[NG KM1%-;T8XKE;;W:T5UR9\M?
QQ,)?"+O;S6ESJ3ABW(*K&P0 MDIO&(ED(HWK7G_%U7F%'>N&<<,%$7K-8A#Y.+0+U$@Z@..LON[N3K*O;[HW MBI=0F)58-^<+BN6)8-N&?%6IP8-9XB?"N4-Z000K.R)MZ:[1]2L M2L09F!F7LZYJ;/4-CX[\WH@23WNF!+!>-Y=)V/["NS.C3*J.]A-#VAXG4ZQQ
M(41]"JS48I5S E9:!%?NA\NL%(_IRPA%\"$K,/+! B%6@A%[L4%@)HHA3BVP MD566S^S^D61)D=/AQDABX\15E+Q2J!N3BZE871 +5Z!,'R3X&UF?=*G9[\IQ MRIZ^VKFJND+$^<'%28L!V^&23RD7]M4+_KG+X
MST3V)!10,A@B4>M,^2C%M4VQOSU8J@FB:I]<^EG1LB#-RV8[*1__NV":S!^_ M^A(7SJW[_&E8A+1%>!-MG7XL8(5;I<5\3?5Z2.OCIAT)?*57/)LWP_N+-'M- MMXIG0Q*L)LE'&C[I7E"GASON%Q#&)P!?UL?U]A=&J1*CCW 6PD?/\X(N@)ZD M4Q7["38-
7(_RWAW^G,N?^OYJLGSPF-O35VYYEU;M$L)EJZ6VK=9WSO@JH$?(MX?I5T-WKF\SV8WED-?UAVC3YTCUY@Y-VJ1GM&+P4]P/%=N,?5=)H"& MD[P7MF*5@7B[DMH9P_Q<,XXQ ^YP0>%O9OPLY_@@A1:O1 M=6)[TW70ZU-KL MG;98WLC9P71XE;!O>?
J)8^%1IH>T'\?TXNQB%F>['XF* "8_$H3FOJP-:+J- M6HZ,1=0K$M(@^]'KN^1W2:_%]8K@F$F:&_2W &8&]U.C[*]I5, 4.W%5WY[T M;\"69@N,RN8Q%7EDSR/I5N^9DOU8J2/9)N6,E!WE#LB8LATH5'5D%E'0.=$8 M;$M,K$H=: 7OR^66!
[&594&BBW7ZIEB"AH>Q8D.PRDAP^-O1]R4--/6S M?8R*0A['IF(NL%!!Q.*M=FSG1T;?X>[R#Q#7!GJ0U4V>A3E MN"_!JSQ?9-(HENKXIBJ/2WSM\K0WKE&X3]?NL I]3HS.BI)K!-Z!N9AN,R&X]=]$.\5$ M;&&C,S=>99;L:,1-^/-
FZ4L]^DF%8X#;P9N"Z_7]W04X+5C%6L(3:.4W@< MT+X%GA.2F9/K5!OYC2>;TYE^'XO%=M&?AL;JSXG+OV.6*[Z>]_N_]7!/FE2HOJ M,O_5N-%(#8NOIS;0S8E2$J.9J),G@.5PR$@W:MXN] 3 J[:;R^2V?FJEC?G, M&G^K./^WA'4ARYP 1/..-
%%CZ%"UW>BU%>X_=7/]E,SD#?93Q(WE/0$,*F0# M?M$V. RZ[:K&B%H+*3E-OM=L&FSNDIBH#T1Q4L>O1QIW,YS'OG"=VO2Y M_\[P_AV1G?%2,.!QE$,.NM -,D_Y3S M)5[N,-%2C^*-D>%L ?,B>G#HC0SDS&TB$T5V$ NQ.@'DK&P4-7]I.4PLE]KB M,_Y]42&-I?
6TD11V6P$3.]W;AE*MQOMU*]=-RRG%.W\.,M\6([/4F?^>TU- M,D^D]-4+KDUT45G&#Y$OR9>R*6\]B+O>[8MY>3;+W.F651E?'=FT^7Y>RG<- MNGI[0YE-?MO$]QI=YPG KL[*^000":XTQ?A]AEX^=8PPMZ<[>MG=2:PDI^PE M@?-! ?
ZJZF.\7@4;GL!6%86YK.AU5; V'.8#(V2H4+29"W^6:?L-VF-/ #]8 M;O]!7GBZ]5"G #VS8ACT4P3_RQ O04\%#T?=G4OSBI7AQ1;3M8#CHG\JBX M^$X3LS^"ER@V';I>0=SNG-O\2ORY(CV-<'O\-I.JGQ82O[FZ\/'F=Z_8G_93 MA7?=>>YTW,H&2I\
M_T02N'SR/U_DR2(Y]H#,2PU3]L3=@]77N,4V)X454 MMP;R^BEHHZZ= /0=Y:"_99HSA0;P0Y2[!" ^?-:-EI;9AEOEH$FYW0=MTDK;2 MBO-M4UZ*1=4_16T.CGC2&FY\1+2(QOQ8VWF*K$QW/VEY:C$W=;JKRX[5A4N M-[I!"A=2NIKHOB[ZJSXE^PCL8LLFG-
,0D3PPJ=5F M^=GKYK>+E^G@RA^4GY[?@X^;X9;"*4"2&WYZ*TPNBR[L =S M4S.SO?W]L@5)@)T_M(/I!_<47:@GK<^ 8C$X@T/*66G=O.A&'H1<=B_;WR< M0[T^!3T;V9HI21Q"U';+OX(XF89U*4.H4SG.65\HJH'D!2+T'OF8N'K4G"E0 M.RR^6]?U+$FWLHM-
L3FZM90HU2:WL\F,8$TM \CAFZ=%/, KK'O2%S.20"6>>&:X>1SU M.;Z[IE!EQ. H^<[PE%6M*??-5)[P7KRD1[RP?#69=$0BB,NF:22+JKT?$3\ M0_$WJ:-'$+CJ>H.2+SLA*_!0M T8AJ4E9>9X?+E;B)"V^NY.ACW7##1^'1:[
M1*_Q$Q!EYRPEM"2W$[H!5@A&.:&C;6C)5CGC,TZU6<$>!UB2'*XRZ5KEVF4- MX8",8?]=_@\TUDUS1@PI%&LRJIC,L \F.Q9,=[G(H3@1?9TF)-G4A-M6>@=^ M[FW6'\Z^XX,KPP94S8FP*\L3R@7J82&UNN6^!89! QM@J]= MW63ZQ2!^L_/!-;I>3%&O3>?
^)*EWY%VD:VDK\8T%;#[H_0'MHG0>8G/N60/# M/I"X%?K\.+Y>2$(")G5U)#O3^G%M<:-3C:.U_4[%02S/ZVE_/LBP!)9I.:F1 M5Y(J)CR:C;SK]BF:9B/UWA%_]27QNL#UV<8W-!GD#L26#;S0K\V/)?7(%':I
M'21'?!%=='JHENS3ZCV.&7+AB^V[;\7UQ>6=P,.8VZYWP.#BJ*QRB8SHBC^9 M?$-4&29KQB .Z+=0\33S/>L-*;D]AA:FEQZ&DQ6$O,6ZR["2E=JWL?!/?W)< M(]KG1.Q8!?V?;Q_8U<79).;QU%-5!&R PX-F)R<1OBT^H&')?8@$-^K][38 M-"S\W\9!7S];-
\]*">];'Z)"_'JQW.02/$RI;S M.\L_Z[@.D_J]=Z$36U2#4#SJV%_R-).SR$>"CI.1HD3#]HGJ\$J#NT^&Y:(M M>R6D-N4B<>X'I\ME4J8C0J1OOKJ44?,PF'V&HD64"&W;HEF;N30B\KUZ").F M*%XJ7&%OD>QC57LWZURBD_\5$U MF-
2[0U2H'7%O8;HTV,LWSX)=5Z^^3GXWCUS@ D . "/*M#<_KU8"^3#@*4 M%7"SK$ZJ_"-HRFW/%>SUK$>V)>J2;^R/] *2E!T$P6+IS^GN@-0*D2KDHB*_M@1/ >0J4X&N&@X=X\-UV_LBF C2NBS4:V4@!))W5_0QZ;= 4D)7LI?RBJO&9
MJK+)T;V@YM,,)+&0UQ<:L0L.196/A=0S$-Z1$O>_X^%\B,)SEC-#)]2WN5+/ MRZ-#N#1HK^9KJ0NX!7K-+\9&J#U78R('=5].1,C/LI%;F\=25TQ')9 RQ3Q* M,$W_CA4S6T7^]$0Q+Y6N;&"\!]-'M-H+Z*0(GI'CI3!I8SWN1ZA8-UR /VA9 M\^UL^?
I$O_\)X*6*@*KT70>Y#]KHY]G.#X2&_; MJTV)% MME*1YLS9SK!^X5#&$83&J]'WCS\B;Y)DVB90$5:/QRA2!(@2O!S(1GY!L;#I M 1X("9R_I;JR,43[%UR7)NOCL,EX1(F+AZ^#!4E< EY(3K"]/[(I>!-\'F!O MWP0 8QDHH("[H!5*1S$TH13\9RI'E,N.G=YAFQLV?
@=%B0]=:T&(@A:QSY! MJ 1>V]!N0S,Y6DI1V&H'9P8[SN$36FH?9#?=JY_2&QVLSU E.=AEUN^A94:%%WZKW@2%S3][T"OVJHYU"ID'3>R5ZUG=3RJ/-XS'TZIN(A#G. M4,I#(AOX7;)9:KH?3Z1^Y>#98>D.*>4T5RXM<;OK-7_T$RIXTVE^TS5+BL03
M]IN.TX43)W2?$TTFE MVP<B5S$L^ORLS[!XGF,IS2@NV.PH6?M5Y'1 (MNP>X^4Q^#ZWS+V#UMF&0&@4D8>[[U&T_&G?R>04KOO+]OY1>2=YS= M^+(Q+*L"_8[*,^U4*QF*-W PQF;('?F"F + XY^TDK0J9T46;-D2DJ>D"Z*,
M&/+)//M0LCUQJ4PA9,3<]MU5+U[-N,X?#+SN:&,T M[ZDC'*_G.[K]!'F?:/?;:85_*+_,!^,9:%[J,A<6SYI8SF9*$+Q [\VJ3W(@ MR#?D((ZTR&YSS!S]UJ2^@A>'"\J=$BI-;UO'5_57/KE\=M*-4A@9^,"+]SG= M[R_H,V7D"A(8-]8&9R+#\7XIN*,-T?
9+.!Y;5=NJYFSXM^>W)51 LSQ ME19K:?.S:!L3X?BD(A)3.^K2;J_63!\/BHD<7)DFC]$VC1:V0++/O7T=D MB/TTY#I-:5[M/,NX-KI*['Q3%M7O_-KZ-V/"%JU\T35>VB93>*")$6+C,LG M]]N0?9UQ#6JM%W\FV7!@2F?5;O@UUR"%/MEM.E^PM5.];.AUX>T:CC1\X?(\?
YT=<,"N3FI3, MLQ/8$:AY$:)C,?(XV"@;G'W9Q$ $C]_2K\C1Q%8UX%=F-J38PS%@S[/#O;E#I9]:-JN-MC> M:,;Y@G]3U%RF;Z_7]R0V\W6^^[+6Z8FE@JTOT35J.!NR&34X WP" %S]/R\ M"/;!00\YW%$40.1?%TW^5!M&&E*HL5-="ZK@S]BYOS/D4-FW@E'+%J=AGT@K
M116)W0-?.@&HY1S<^!_^_]_QFXHU!04JGC&S/P$P:1W"K^IO0+1'I 2,BKQ\ M'+%V,2D"_K<.V/<*9#9\R> 7Q4Y)X"Y,]"_#JQ'(R$G (V^V!. /RN*)#=R M]]U-LO.1N)[9K!9OP8\;Y"/+T+9!Y_QY U_^Z_QQZM&_HBY#AER4?(SWT* 9 MIPG]E??CCH<&4?
&,PJ$/_#N$;7]5Z8J"$O=F_^V;"@Z_IKSI!EN:)FXU6E.I M#8?!*=L\B_,C.+=H>)3\+/Q1KC:F'IUTDXOPUAMH@X$:D((WD^$EK9>-I%<' M/BY)%NL%ZOYYC5CU7L2V_3M1%1P;__1*QY:73OJHS!?/]C) 5%U(P#;#]2_* M:AD= MEN,?[2%3%QE$\V_;
<:'+4/_.!DNCM"\LW@IW4];0QV29=)\ F%487B!S[$G& MQIB8@;QO0U)HF"'!K\Q?K2M(V-G8[H'P4IBVH(**/F6ZK40&:?]UH_>D'P RM$VML*E_6!2>I#F" 0Q_MEVO:,49+]7$>=,;I[76M/>GU/\X?S M!RV-N^++)P R#>=_W(+PMU>YFNNV=0_?^_"FW@?]C_7V??
6P;3J,T7OX3NSYX [NE"C?[&.Q*MUEQ+ MG^#)-Y(4FC\^K9V18#6A%?/[#.^-*[QL:MSKS:]A2$FQ1$\+.4;1BN4A%N-G M$=?0(_K_M,GT[^B?%Z;1N<%;)/Z->J^EI8P^T3;:MYF4C_K\.=/G?)+I.CZV))9Q#",6@B.QW M8-,(L]+-6A_[9K',"?
TKY#Y=9;WI>N[5U[_[,4]*@L9@Q6D/" 5; C5.NQS!DK4BQS*8<*_AUA- MSEXU=A4_8&WY>35.XX_ME4B:F*#+-'N];J-8U5]P90_?N67X 3F^HUM%"]_3 M]?Y5=5P*ZT'B[S?=K33A7/-F+9%'+YT?(>@-P^X2'$)R2"RM7T1;+^5IP2CO
M=8\$:IO2^L:;ML@GXJ1^8X6U>O>]?%V1 M^)L0@(Z-%I[^3B_5UL3R4F 3]BUH9C=C_A>J,52P7]=7%&Z869,?!&;HRZ9 MOB;4Q3O0[L'M%7;)56#>M0Y^_YOEGG.),WZL#35AA8<'UJL0?E,$<&I 2T>4=M*GMYLB_JJ9G[$*HR< 1V#8A%IS@[>$ M!IX)>@D!
[7#&H5@110:#T5-O4_UF;ZPZ.DDS3@Q\?7!'_,'M\RM^O!3/N@$* M#V&+4Y=DID%NQ?$Q:<(><%97Q_28A>#HR@)?/M/4C&[Y8F9OVL4?=>$]\,LR MNM^K\=6&52OV?!EI/HNG7A%O\/*/0O(LB\"@8 A[B!94>H+'_PS6W:GSPOKC M#_Q!LS."I- VJ1@H)]
(A!R'5$4<&MLRP6MU2_55[3V%HU=.M252I;?:-D*E) MR\8+(5SH4R",B&Z3 B(F9JU]!C#LM4&:PR[N&1K:X?B+UE;I]]_51@6KM4D7 ME,G!FZF2@_5>.%^I-DN^'IN7A^E,'HZO?W4Q)HE<,?V]6DS#NWT6:3O'YP,= M1+T 1U? :,VLMU6:%GN"
MOIMA)/T@F@4A5>:.F+Y,RZ99=9FTUE^+7$1KF9RM2#]'E$\ZU:[QD^JVV @0 M)UD;-U"*J#8Q$#1P'!P1>IF;N)"R4R4;(^?P]I:.6.!KQ@VH,#ER_VMR&XJU M'IYG0&K5)^O:X6!Z!BR#W03MD/VE1YD7Q,=D4CB96!/>!,WT;\[Q&*229W$A* M:,MD'59^?'
"J%0(H=S$\RBZ@/6)+L&YK85 "9J;FF\LY;-Z7S>]3M=Y/G]^ M'G D64:Q)3#S-*E>&5:^B^?3X(-H#A%V2N&BHJ^$[ZU9\-&INYX/FI=]Q*Y$8&RD MJWI#<\#,OF-35$HQ&,6*.DY4"^082='Z%5*,1@P0=3-+V*5&

M^G7Q2>#YVIQ+P>]HTA;>H14W^$ZG0H9FIA60HD=OKJIEZ=%59HBU4:'E<1;&WU-3C:D M_JBI"NSK6HIU7E/]NIZYE5&9-Q(C*M-P&3(_ MS^5;A]_ U^F:/\7(S9]I9F1+?YH=ZW_E[QU25'L,<-#$CNO9U:RI3W*!%A<7 M(=Y%RJ\-B7T&&&.G2$W0-D!=WV!C\;VMKYIEMZK6#EU!W8U\9L+YT.Z)X5> MN-'=*$QYLA.!;TV!B_+'!%0Y$33A"'}FGU6]T}^ASYQ1.U;Z!#N"7*:6Q MSX&Z7:)<X.L.!<QJGSMBT_Y*Q(%^B76?3C;BAWEP0 F6)8_*B8[=>B*6B1#=_.5Q853;L;M!:TRH:U^_^Q>N7?D^;* <0]5G^-=N\>09FU/I5>?[>)6^O$/)3[84:V)IB M=)Q9%8-0U_'.7^F6B1#^_ GR.M5<X_!4D,3A?=7+F6^%,R.IMTX 91'*#4W#]M2C^,_.+9B6O M[0>1W>9BSY]9MNC6<6KD$CF8_>]#^ZZ4D2AYI[R;-9F+Q)ZAO .^\&9]Z0]UGO=N+P1-06 MJN[Q0;W6DOW4>-E_^G5V1N273PW8?:TF;9^ZF;S21ZUZC"\>6/(=T"B\K MMU?O4=`OK3-F_Y7Z_=2+;5V_]^D;G9 =:.R0G+@CPS=-5S2R);_>-0!L-B=[M%?GHVJ>D^DL^-K-ML_IR\Y2\2\?2&>[;(RML#_=^)^&\B XI0\6ZMX09\95E.U0HM^);XO;=4/J+ M%\L\KCP#=(EJH\ <1KM=3D!M%[4W=3K9 RHW!#<C5\'!4 1?U+AZ MF!%AYIB.C!H\%X>P=2 3R=:]KG>_-.4\8WFTH6YG6HI*#9#6/"BG=C M@9BHMB^(C\'P-]8/4]-I-T[-G0@=[5-[MBV],E-&I+-KLL+=$/5>.%QT2,A?X=/$ ^)H!152@]0?6(<M@^)#F!\'!]^B?U+4J-

T#I(/UR],3V3=.KRNR3:@]+;2@]#XJH;FG"56'R'G?#$ M&1?1&8=(?MJDA0:4NZ:Z[@B=A-P7_BCU];-[KGZSFDSYP)8.NO'&QF"./@?W8M1845Q&+.'Q@F%D& MGOX-$DQ*N1NIXLZGKZ?=()W7]%TB #*N]WD0&ZBD&M?WB@!=C! MQ3L/WPE
[R@>O2K>DR;P.U>Y&5)G][HXT745#80X[-WD-_AO(D_Q_]UBRVO+ M.O#'2/]_&&[_Y?1?3O_E]%]._^T7T[_Y?1?3O^?XO0_[)+,5/\I"I*=0)=6 MN6#!XQ8VL^;'/%S?HQOB8# M0)[A(=>G5ZV!]+:6;FK4I:TNYTEO=%R $>\YNJYFG#V2 /<2.81[I:
M4MC=)!0C$TYIZMUF5^?M3>X=->9VSC079^LW#PCM+U36 "[<_!Q:FIM0&C\X M%3@77#-_9_&XMFK.9/I:HE'-1M50N*?W"-S1NFZ1\?O%K=2WDH['%=CXJ.$LLWW2S)S,*P"?WRCR5H#?M$<(3TK]P#]?O M5=B%-
HIN$Q]UUU!TRIN'#*X2,]D"G_4)]%PPW&TTW>@'\&6[8RM,L7U]2;C; M$"9/AU>H/<:>-7")7:-NFD!RKT-UG<0F75^ZLWI8XBRZ90X%[TE"L"_)$H2M MHB+( )3ES^>_C:(]:^X53&T?77G920V0YUB5\.8,13S3X]]JO7!+8C=UZ+W'^; +:O1MAQ33N)+C=BPL(H22
M8#552T^I785+Q>R95$_L29L6-DS(L*'!)B)&F4*(?L&WA:^I'N<6@C:-.$!7 MP-!.M85BC\K6GH3XDQNE>>^DDJL!-Z\N"5:R8D]V3#&ZACA9/!/$PJ+6F@Q@ M F7-[R06E&QE%5!]+]\9UP+>YDE\33SWNB<@5X.8*EVS1XF+W898XJI?/IDH M%]
[WT'!0[Q'Y^7['KT_"*TP]%C!#!D3"X-^(,!(/[JLM@Z9/7YMR)()7MNNW M#\?3AI8TY?H?*_$O\Z@R8U0XUCY,AHC@PK%K*)>H56Q K (_%2ZUJ^X&LX0NR3E W M;DJ-+EMNK;0H6WY[:.I0M*I!EZ@#VO),(*F-:5!@HGK42/4^=$$OK%ZT4SO$ M13W_?B\#_V,Y N
W!'A)!EP!/C?0%L2!"B'RWR8@MRH(=Q)!.7Q;Y@W@%U?K M(EFR] I_TM:Q:9^R4Z=NA+4Q86=ZH0R0VZ,M0.R5SM\,%06@V\^2NOEH$K?/ M:%],B_0O'X^?26'Y)X[^5('4X1#!Q4PM9LA%G#;V_HSIN(9UX*>V@H\@I0-B
MHCYMQ+5XIE^2%_3][A4XCS.,,OY@:Y+LP8YL3V"M4;WQL"N*LM&YG%B/,F*R M2 3:BP>14_5^OFV*MS-TN+C&\U?#&)Z,HV?L+3\5K[B 4*+'7L40[[K:D6O3SK MK0L(T*J%Q:EB)[^P[I'(0M(C/_]?+CM]U$N8*KUU5&!&"8M27SR!:' M IP=XJ ;<=[N^I1"B?
5IC8HLFOW2?F?5=0O:S',KB?*YZEFG%>B0\"*P$=IH M1]'AX\^Y#25VV"6N8_3T\ V6AX8"S;>N:2_YC\6C2P@Z. >4)R6I%TZK:,M^ M^]NWZ=)=@G(P7PE5D_,0BB+4>F1&'?<#?\136(D0+,>?=+K>86@C$GJ-? ? M/NA4R\24U9;^-LLY7S44Z&"ZL(5[S#CX"Q<<-
%8HO5JL M4DP@6KM>SZ,F6Q^7N\K\F&W^\M/-"Z]B3VF77'[#YD"D5E]9HK*V+76O)P58 ML!U.%<(TJ*:4-AB9+8&95W%'*UFTZFR\2U/JX>/=SBO5M:NBKL6]=,!V[$[ZT4";.K;(+* M,17=IQJNZ I:K02TT85-+U"'NMG'F%3HRCWP?F_9QR?2XI-
H2V&GL;YP9E7[^.2X@V M'5N>7+2N,KIY31H.*]1"\\?P,6,2)H\1>[$*MFRKM$ZMZ;QWC".I$^<_?/S1 M\?-R1(=Q7WR8?-8I;0>,,83+#8XQ4A^"FE1.R'AZ0(!^7^VWZB^5!1*_4E;Z MJ'(3QK18Z-8^'N1Z$*YC"HNZX0A'U$+A4H*2-.AQ'>[&)V0_0S'@K?36O$J@ M)8?
C#^YEGD3EW$.*8\8H@MXGC1_K2+@;9[RL4\&]RVO2^RZ5X=5;!FUF"O__C3PQ9+KI2^H &4-\[%W !-M MEO_HHMB/VF&G(P.XX*XC)+6U-#/<;^^$&;V$R9N]/SQ(]Q@CUT#.WA*WM) M;]5V1XPO'D*C[:L8.T=XP0Q[72_!RG6C>Z.,(H(12%[R8!S$.]1!4GDE9\;;
(^>APA.^'YOF:M\LCU[F?5415- TFTJA,_=B@ M'Z9G?NW;8CQ C^=I@WU,EFPW$& 7,H+DT/!T5X[U@]($US&R?4YR*YW&VO6L MQ#P4:_]UC>X.*[409?MGB#.N!$4&S+&;X8(7@1'[MKCT:61W>M9T8UF?DX)2
MDWLI=YRDPA=XJSL9(/$[WD^!P@=EE*@P$@FMH=Z!HLN<9A6&>-9/4D\=90;2 MZZG=$K<- 7R?S*;@O5"$I#$.2@;0*LVT+]#9TRA6')>&L*?O;N'=M_TSJ(ZY&JA]CF?+UJ:Z;U8RK,P5R8Y,'?F MN67LD+^5T4XEBAZXF
./]'BA^)XD/K=!6PCM9"*F>GOR'3GL=\;K)DE]&R80 M)R: T@!WP@-B^='D>!O-)I1>P0!H&X=6J.[@+2^U4XZ\&7V97:?S1?+(^Y<$ M0 M9K9@:&WBPLS91P9E=*S#GY(!-%LTRYMU06WYTI/JX8$/?]S=X10,>SQ@GJA2 M<9/8I,6#V.13P]DN(2^#/4VP]J&'JK)2+7="
M+Y3RY ME=25N'JN.@G8G702[H$G)*%<%.+M-#M!@AB HW-E%M2N7?J"M*GV0 MR_KNJ(_WY?R=I:3NO9BS!57#'N49_ELY8FFB1?"EE!_P,KAUEXMS[[J^=0<+ MQXM\#F?')(_LEH#V)MGM+?1(/-_%&ISN(OVCOHSIH/B@A(5&8F7)'9>\:(M[MJ7 $3VE2@XQ
GR;-&O477 !6_2XQ)402XC!*$M'LBZJI8,:E0Z^L-VU9Z"N6 M;=KL8V($=-1'0Y5@$+_34-4DQ%8?\DJ+'YX+A](P0'$#J6U=U3ZPJ6V;B\L7 M'NH'>B[;N(Z_O*20'> Y,L"@*M 6BG5)TI+#*7?:L8\O87+CT,AHJ_G#]'$[MUQOS=_)=OY5;&+S<:=+FOL/+"&WK;%)5K
N9M8VOS!*JU/J IDS.1XM*/Z^PK#U_JT%3C=4FC=;E*22CGLGSPA,UH M&PV(W3P9%]=CQYHYK9&7KG".P^YF!/KA&C7M]U\Z_K& 0UK^!!B;%C?!&:,; M'B+A&G*Y99SP](0-$5*&DO?A#$,+T5=9K#D+\7PYSX\^[GE(? =?/LLB5QB> MXP49WZJ=_TZX"<)BST>'.
(ZMOL9N[OQ\-]@NE MB+](%UI2X5QBY=]YA8$^PLU@@*9COFPT:'W5_"G?LFXQT'MK[\]&@*I=8ST M&R>Z@0Q@#$'R,Y35<#S%+FV&4&$_B0FV88;S/\US1WP 7.JIDQ-ZB/1=4Q&\ M:DQM@IE!W2"F03B7ZL<\CI+8P+Y#(L4%8$/$KW[%I(%NQ%RELPO#G-<'1\
[E M=-$1#5MLW'$*QKY+,BG&"O:FAE!R;!2)+:!/]@]!'=>%O3!ROWGL8Y;FPD4,;[U_F M$F_UKLS!/K1XO<+ ^NS/^06^@.AA&='UW6MCGQIR!TU:)H5MY5!/YS6J1=@X MEN+H;J>T;QLK^^4Q?@V1#9G2LLE&%N:-"BFODO=V EQC?1ZNH;7*JF;2.>
MPI7,D8AHKB7?-R5.EW6[#+(RY?U_4,.\=,\=3H/(\W%1=LQQ(-I(+PNCOV\C-Z',*B'X*ZNKB@ MD5U575\7JI^]N]\XK5[@3MP-V:50?0@V>@-E]>6?I>ZQ9X'P8K7T80QS;B'B MS5BVF%+%-U5S;F8GUR[>!2=72YR")0+[V_&UPY S%O]F[?@=3O0S;N\QAN=$
MBVL4XIR5DQ0E_307^6BRAH4N01Z FC:C3ZYV1= R7+]W5C+BEF"]1]]A/\^ M<4\.;4>]UD5X6V3O\5YGM4U9;[R3>[%0YU.SQ^=#[SNVJ5,J)VBI0\S:B(5^ MR#GZ%TS (OD?R(-YBJE MZHZ&\$+4IMN$<04/&V/%?65WY$#!-
G:=^>*G2&H3MCYK7H2#U8T5D9&5G1*83 R#*0O:6'Y<^_A)<^T M_ =KR0T!%1^WED9H<$8]_#7L.S180;1N)"$@<'&0]X+#8JO(YH1!;2L[TYT8 MF8'3]<&:81U.795>0S'*>@P\IN46_AZIMYYY(^MS?AYNUU;&6KQA-I M5JMNJ9]/E[T2_8SR1*@O:$N+BP"9(-
S"W]@@ UAJS?;1M6//6B:75,STX_R< M&N(ID3\2)AF*!!-!@W 7(O QCA*O#QY!?6XMURN? P_,D9B)\H^R$.J>6@=> M^I/[Z'.*/A'>+(QI%'LV['$$5:@+UM&>F".]F D!+ME?0>#*>'4$#7BGUB:O M4>-T$=*W*9##)SV (&0HP:N"P$5,]&R[AEMZV#JEH>OE (QVTC]=L)
< I38A MIBA3*R_@'"]>IQ"-'2(F'XUP@D5[NYU30D_RT\[MP.%:@6? M[IC 2^FJL_3?G8S5+NR,Y^ M?LX3;' 1F(G%\H0O=6\]G5.[L\J6+POUCH^/ M\@O>:) P79, "'+>RI63?(M;681S0JBPT%"2$@AYN:+%RQ4UKZTP9.GA6V(- M%'S0K/6XW* %U")9=9E?
Y>G%OI>TN8I8*3LU8@$!A.*/!K(=[44$.:?4.79E M&2:5R,0WO7MXITD_W%O'6?U$IATI;N-X=:88++E(!L25:T@N,5X"(9F/$GPZ MV<<10R@DTP8B/\X^[.J=(9YZ<:YB[K&;?E*6O!US]>7<:/8^QO,(7'-WVQ5B M?
HMDX=QS6G\73%NC3X%>8!'2HDG<9/6UR&"$>CW3-^\&RH0A8N)AJQ(2K=NM MOA>EE%6>@[';E'Q4V/5%5\%_'$GH15LKO/=D>A)]!*@W9'E"F346<@'IQE_3 M%P.ADNU!QG;=F6A1=?G:.8C&OU;.D1H7/#=_"77A I!K;[=HJH4=;TD0P]C"
M8_SFB/0:PB$N<2:3S]XOZ'$#JHU28X3XD0Y9$Y@^ @R8"-R^/P$]_.HVC)TA MP(JZ&/&LBD BG3'U^Y ?0!Z"-0H:FS6L5^'N&-LSQG#Y M@IP"N,GCTM$JT+E_>IC#!F78;!.8SNU=Y8!(TNEK?<"X M/;09]"G929MUB54R3E&)3]ECF-^I(1[\QY0$8/ZC$M>LA['?
R5^*FW?>V_:O M ML;13S;G]]?-; J<$N3A61Z. 51QTZ0#,-[X,=4$\ /1RNK[XL77YIZ*8Q[MQS:U(?.2OL!1P;@K_Z+__R_!(=>_]%',B'#, VX4BQ!!C1_P=T[9?6!G3_ M[H"\]M\$@<[_JR#0R+\I&BT:_:L$$1E \&@#?DPZFKM!!L!>X@O)@'YJ>:WV
MO[\GZ=_;V%KZ+48&V%;SGYXP-MD3WOK\U2.Y5#)O8 MS-3[1<8?,Z[0/)Q\5_V:_F1%K?7<>N)@7!P%1YCR;MYUJ;E7AQLX5+WS.WCJC.DU'[^WTD0^>)TU4,3N/.DD-ARO.7-&BTX/SN)0 M_4_;4<)\KBN1S^$WIF7\/:U4\6:1/SM1Y>K!STEE+K9"%T?>
[=]^DTK>CD[= M;^5Z9S6TYR(!%N3.CX9DP2V@G'B/Z+PIPT']5@#L'_1?YM;6_ MR:_M?]!BG=YU9&1(@DIP3!OWNRVS.*1Y4-_Y.37$WW5\0F+&LA5+#M2K^5A? M3+YW"=+GY-[%N:[2P?I)I5XY>^78V$KY:\JX>/UQ\]5FK;Q_YLTRWI-ALSY=
M9Q_YH"5W])Q!M__N6/P9F^IYL:Y%U3Q-$"_=W' /%$24KF/)M9M>VPSMV7.K:5 M6Z&2C$>#BA,GQC.>_E:_7W7\&"D'_K$\G1:988(VM&AJIF28-Y$/4TYWG.K? MNU_,#V!\%Q]^I#@PG8:#*W;UZQ2JB(R_TJ\@MO#\P%/^G8U_WT)%TGHY]/^8
M9/RKE3^WLG7G)JX1!61Q&W7-FEIAW1)UL M-6DLV$_@QTL0I# R<)N<;W1-S&S@M M0?XLG3E;P C/'/3(&IJ\O']?3%14:'G&5!O@'2*% M,T5Y\H!3NT*N3OO":T AO#GE"LVXUP!@UU MS'C?PVK,0@XQV_/+YA6W#+VU?
ME,GQL7].2VNY^]WH^G^'EIXWD>@R=:N0O& M"+'$>.2CC%C/B :BZ4+^"O'SQ' *O_Q@\C.C7"4S#M]'';PW)@3J:C65D!83 M'MNR@@=E,OE@D20OV^\#II&WSC^[,I%5JPWPX8)V 6DWX(P[+8Q\<>[-SL[M;!T*)>T>3Z^+M>LNQ(R;K-8DPMB>5&>;XAR8
AZ[DW1E\<$>6A[[_-BSSP MC/?0.2^G1,/YD(&FW!$%V^[#]*$NU"#Z(B#BGHXE'#_N&#SZHD& M/#O_\G9RUA&7&*5R]P+O1(L#JM7\UM0.:>;39GK*SP7KO6<'#FF7[C6_B^0T M$[P:)M_!.O*3P(])S Y8S,YV%QV$=?C+G5'BX,^.Q^J! HGL#]B)JXZQBC^R
MDP8_+*>\DA"CC)_18@3?Z[Q M&J>JQK3N&Z@S?R0?%=8 'EUC1&.-<*MK3BA-\E(80[!Q.)XWW.$16E[N+?F0 M=736WQAH&(DVPP";").)X)FVD\TI]VL0R3*W;N1DI?7N)]B>E1X#+7"5O_7JX\^1SS^-M/)]O$?GAF2SA0+3=7[1']3W\U)0QNZM
MYS%>;2,FDYC<[(2S;1HPI]49];^(5<^UQE2]TR%K/UZ9B+X=RO4V3K4]#*$8 M?8I=PHU)*>'2:GK&$M;3C7"'EE:F<8/SU5%/]SGA^43)?,_AJKN,>"H;V%R M&]'2CO>_X64*T;1OFB=7#SY!:^XG1T_555]N,*6\!%B:;N+ZDQCA*1Y=U),4
MPT8&U.A$84;:HSKKBE^A9A4;/36T77Q4Z5+?#\BFRCUA"O^N>?IUQIZ]31PB MCDM8#.9':]>_\?-DQ#61 7B!.1-,B[G9A)4=[S1'BNJGU""EBP/)B3ZC'H#? M$K&K+8^P\IU\U,VUM5C1V$,CQGE;QVW,9E:\THB2X84>?ZK&\UXV43VRL0A8 M&$D
(C9Z^+W4XVSHV38SV)\'I3N)A=6#Y0QF0&8'WO?H?/?N\E7K.UM)X1K M7+2_L#FV$72V_&MHYF^>X:#TPJ\=GO(N')WJD:K?=WZ9)38N5=#CG,K8+; , M:86*RP]_64L?;1MG%L3(W)3HA"\C^[K::L&%!]-!'D54 MW6-
+X8U,,1PG+!23)C9]T5IB8.5.M=JVM')P_>TQ/_WX0"6KR$*Z*_JYV28_ M;XQ*P,R@PMT,/YI(L45F\=^LXE\<"QZ8;K/:G(8)ER?_;*QWI*]]5>5CI#Z M8_FK%#EW6(>"C@ L)MIGUV.120_!:??2#/WF=(1%KNZD2?[^-2>)\R_HPFX/
MI>A,.IT:WENZRK[^;UTKMT9'=1LHHX"A1U"V38RMS4:3#4AJS%*@Y@?M5_K\ MS%N]#I.QZWLBKT!ZJXD+^HV".G[U;[X$WN.\5!A;;G2KX?6(D%\>S9=264K< MB $N F6@WJUVY]ZT\G=+LV>S4B]*39>2H1%C4\E1S@\E_?
_QDTE3YYQ(.4%QK89C0[^X^T@;EM$'].\D'!3/%/7Z[GO,\IVKE_O/9\A8/^OY+8YX;:"D GK$D\F(54@4RH/9'G8F45W".3?1/#N4/%7<&0\+'OQT: M/#RP&2,)"A,G9TQ*M9[J2]8_OO8S(>^PE]KHE@TMN-G,DTFFR8,,0+L5WFO8 MGZ@ZSR^C1!REOA\
[TMV4#F,HY&T=2<^*W6[B9CD-%UI*[GLTP3HEM7NE6%RO MOV>@H/[=TB KW! >T;D6N.0.M9LP[[B^,:-LAB4#GB$T:"BNZHD;7VS']T5P MJ&[M6=DIQ(HYX#Y\^RIPV@22ZQM573E#[NBI\'*(R:14V:%^,.UC\?-U)DF9E)?:KD'-;3X/,9 MLI.4RZ>9#'M7-
!0R;=_\CMFJ^?-*^;2^,W4-.-5TH@;&ZWIL=A(B$'G/C*]J M:F+ZFMO&ZQHQ&>5SWC1:2WFEO/K&*4A=7(H4::RHAW<^7]]'[(?4./#]A5X) M.9^WC+5>60'=%YCU_^J9=1+[Q5B%KZ[GIX3EUN& M=C>Z/^9!T'2E(@.BI9E>+
(+$#B/BNT2"K@_2;QO9)$*YXKHS&!T_@_=/[M=G MZT]R'?^T$:B*^1C_,5TU(9H"YO_2T&0ELA!ULG3@YQO)]#P\7VR+7IV,SY2]DBCIZ+M8ULI$I=>O$^7O=12F!]#+CE%D_P\!.MS_99 M#8%_IK_]7Q '_E=)H[_7EM[:X#IM7APAY&;LL)
(!=FT\9,"XBDELAD!@1]0RJ69L31F EUPH+W+Z@0-A/JNY/H[8*3^]<K;>'YX\+-_C# [0GJIA1"S='&U3Q!4\PB:@NZ1/0FM=4V@UE?1NHY\O M(#C>!9>Q%[ ]N<4!2*O("X>H3+5=<^539=95CK6^G:4NB3F(W^@XZ8\^J.9N M[+==2*-.E-;BA-
B%=U6"0_N*B>^2F#;D^H1[6KZ]]\'CEN-+9#3EAZFISX5] M.>*@*"0W> \=U>=^2T,6@^QA?XO[NF?0F-HG_RNNV5V35;OT?IRG0%GS7>5S M%W\%/(-_*1]LOM[3IVK [V,<12)53$';WWQ9>)[PK5ZSN!W;^>W=_;=E9W9NA_L/>> M45%M7;M@(2I*%"7GC)
(EYR"2!00D)Y5,$2454% $)2W8 AQP/)+6#!1/5M^6K(.6,O2V(E1XYP*?NGMF*).F[Y3FRO MNG8^VF4 ?DW[YEPG-TB4+ O:#BZ'L[5(E/Q\LJ,>K+.:^=W%I=(F_LV(8]I MALA-\+OQ(GIYLY4F;=Q-/\HXUHO(HRL)9MD')0CI9P7M!#W$Y5PPCSA\AH7%+E'4:1$]!_-
U^A7!*:],4K.%RLF59O5K MB'<4\\DW7F:NV\;*H&%-5_RY13 GAK%K';,/C[_E*/D"$5:1B*RD U$@439] M%PN$"?=%\![DC?_;1@?TE351W5WY.J:[D0'2PR MF1%;4VSH4)#I\25'@ZBB/UR<+@..9NR6"Y8EP# D5V!]UNF=TS:D?#LW, MYU5< 3>E4S%?=Q/0JK_(M?
XXZ_BM!3DF/NX(&H48V@^3I<1&:4!)M[U/+S9B M7?:2+A=>O[DI> OF3J;3AR-?!J!#.RYU7;#PDX+BC^U&P>XEL]A^^"C6WQ"J MEI5D6]W>$N>6NLS;HU/;ZEW@O1]SSY"[[^Y)!^4Y,Y84H]&C4;$CJ52_5UAF ME/F+];84F]Z9M\19QTY9H-+SW9S1FFE#1?)V;-
$8!](-[7K>89BX)9#\7(M M4OV B8X^;0'/,LB44XSU?WVQ$B0]@^2/D)9 NLXEKP2DA:.C)8_05@W>12IAF@9O$(7=L)N1U(OL.(:">H"=68](I]^&V& M6V:RTL>!MK8NSMIVOBN2/7-#FC !4*G4@UEHY4_Y(LY)Q\V2TWX@+U
M4^A7V)I!!$DZZ4!]BCA,E.HKVYRIGP:,Q=O V\A M\;::S#BEF5M1":^4[5_;KNZ8XX'JA-ZY L@T!VSAT>,56CHBARK?BO"_2P;% MS9G496IC5"(L9$R5FZH=J)"1YU^3I8#LA\SMV M'WZ)E2&^DSZ_COYR5\LQ:4[18B1*2\/?]3XHHH>2PB0MW/DU3,VIL#9.BCJ#
M_%?,-N;+9T/;;:6 !TA^PG-R]'#U9\=%&G3EVR-G]-'7@12*"'%\$5(;1@W M:VF^PGMG-M($5;;7=5[VE^38.8LQKR$]-?0EK)P]3@\L]C204WDFP%&(@#S M!9,J7YX*N*? %GR=R$=6[&+_^)*17]C0$8/Y, QCU2UJT) T]P3#ULZN1U3D MI?MNIUVJ+J L:K9!VIK\
:@4V1[+^JP3H@+6,#2:IA3>,N[?0.V?SG#ZZ(UR:.]?1A^+^DLGBEA^;Z 3M MRSN)*>,"G59,,6NG+Q8IQP-)L)#G$_OG,LA]PBW#F7L:928+#J?"S]6?L[(E ME_*\#*U>4#OK$2)^.XHWD'T+:XCTE;T;.'3:-&Y%T]>RTCM1KZEFG+I]/*SJ
M"D=H/)3*6$AE4[PK)1K;V"6Q#58@3D$RW@>K8OT_;YZ!Q7Q747A:$ZTB#F#A MHQ1BO;N_3JAHT!J9FHRA MK":F7C>\(";JX:XEK2)A^HJ\'F41^MTE0K"^JZ^K?Z&]7WE'I+/AB]:H'4UC M0]UP0 [[!\'7VCS*F3YKL=%Q(4&R#S$I']L?C'8X:.//#R#;.+J)<)5:V\:E
MR1VG$=[0-X>D'#ULZSI4,<+!5H+.3ZS,<"Q5-MLIT3/P?81BIPD$#@3RBFE- MG8L%>%0BMIY25:!T[3[Z<$/$W]X5T^U?>/9=#NR3FF@#A+YI;&QJG-R:MPY(T ME542"YI;7L41J [/J7VAPF7"WRYO9P,Y'NX&:I727M0,_*02B#^<*UQ,[\-Q?D_BUS
K:**FS_]@K>_\;@[0%HZ'GV%2!>;E>WZ@HP-F31 MY(QAA1M"K0Z\C)90]=I%76\AV0NR1Z%QH1.5]2"?D%:] HO F4N!&>96P_%* M:48[-DIF4^*BW5WY/I"%+QG.41OYMSFP*GI]8_8\RT#LS"9Y6^ 5XP9,NXUI M]=/1#DKI;^O6"1VSH;^[P/1O[BQ/+_(;^C?T;^C?
T+^A?T/_AOX-_1OZOP_T MOVZ$JO\[6RR(SN1V4F59+BH[[(E4M!I-2[E+&8DU"+_>(>ZP"G13ML?=.OV? M^/RGTHU_^]C>_YO&:L^:"*]S'+X]VJL@+J,DXLQDWAC^N-Z[XIX;R2N4GH[\ MO?)\ MB]/M&*J6YBG%V9(E-52A?F&&?STK=TN+/^+R:?
W^1VN('J>1Q;6N\6 M&N1/XD@Q?FONG16MH2,2#W#,,"5"AH./D&]Q)[1R1)DQ+3/ $6%UP=XK5'U3 MB$:%3IF(>DTEP).&!+YY12I$B^$=<;RJXYS?1OPVXO\%(YH]<;&'W4OW9HQD MZ9OCCC;]WB)$#FCMPE
55OWIL;DVK013,X2RQG;.QOF^+>QVFX;8'+T'SUE?U.!PZA_QXO)$3)8#_*"1LEP@[JYVMLO.*:\[*"]0G7^L$Z(@ MOX9JEWDD\]'#MUPA=[J8]I=O >7+UID<37)=.$KF1'QMJR@<[%BTKI34N?Q MQG(*?]P10AO%BK'59:]OG? B(;37]3Z[E=(:S?8.TL+;E=BQ3*Y]
[(R%8O(T ML'C+M)H/EL,^M^0KYLT55.1?"L(:Q!Z_I;5^+'SSLPHZR5V>\9D]E/2#AZ:I0W5!'P&X[-]@%"T&+>'ICL@LO M$B\^VX3WOIZHX,O0#*(FN\/Z!D!((KYC!"&1<^0/DR,#ZS@@EPB!0I; !RK, MX7>%->9L9DN,PW^]?$&'VR4]$P&6Q[0M3+>
<<6#CD1L1^V!3GM2,3(<, UB1 MBIV7!^EXMZTO>K/FSHF$=#AW\'1[.-9\-3[2XN$T'^HZCPF[5I7]"6) M9)Z,&7?!'9Q-9+:X*U4[1[^)FXN-7*TD.&=#.Y]$G>M[,21_K;'V 75O>I'9=J*?LK\4&%.J$]B(U0L$+^=U/',41!<7N4QN"CW$/69UR- M"Z$PW+D8J-
E4JP)&;_D*T+,?#ERQI#?&=JAAPHL02I?)#+%$^0:"=20L,G71 M9]TY"2'LMFQ^#SKQBM0P<"2J(L6K6+22QMAH!X64L*$0NMS7.;RI/$_"+[XH MOWA[V*.%;N83[Y]6=2G2-29;%N,3+WL7^UEM_^6D2"SCJMBQ;.QQD:YX7A3! M#U-[Z* ^SZ<$ KIJZ@&.MH!6-
8S0B1Q2# M<$9'%L3 ?P1@,ZT>$1NG5:S*,^05GENC;^<@J<#:KF6(BO"9#>6H;5-?E@6O M#2I"_++@2,$;K80,>7' IC_SBV$GY(&TRJIK]%)M?,A/E$:?(<6,#OCIY;!7 MA'8]BYECH'Y9Q F8ZH8;'DGC_D*PQ=)%$T9L1;LW_MZY#/H*$'<%0))/G-\M
MW!K=7F2A42H?.JZ&N+NPS[,F/M-1]25\4KCX&H_1$W=SZL_$2/!G2L,.]EG6 MB?7*,"+CW]6]F#S"MK."[/I.(>%K4ZC=B5U$#"5A[(,Z[82PJ M4-I6!PS)LG+R\H*^BIF;BP8E]-VL\>UH M]7J=X^9G&R1;_&?GG_^9FRLY+C+/C4NQM?#3WM[]'GZ2\V?
C5LWZ$R(+]/>Y M4V/Z"E9;P@58XY1>NU&6+"<(1?T\!83]>0T\^7-(?LX-8OY;Q.*B3W<,_DSG MRPRDX2(7#>=>5+%/@4ANHA*REX$_F_%/*?[E8: _;_IPGNMQ&_C?AMQ&\C M_CL8\6MPN\, *@3X5[0;2S)?G?8(OB=?L%/*[&QJ[06D9U
M$,G2&8.^G0NA3R+#)A'Q47]OU9^IXYL]<9]7U]Z_O==DW9]G."-[&ZR'E47(M1;:3GZMAXGO*86Y7 /OK9.S70UEM:?+X8E5).MLH-F0YAB% >T%&KE_[7?;- M5FPJ\CKO+I&U!YGVT'@L.5PR3?.1F5Y4LR&<@VP83%%=BVQX&TJ O4JR MB]QV(JSEL3*:%G2(%
(NMA^#N))@].9:E-=?9V_4*."@2N,A6MG4/,95@Q??8 M!LA^QG:=R6.MEK^=:H874A268R,>83W2>PI; ^?MR $>UENOE(Y^1 \,[H" M[:Y$:, 9R:4U(,BPB9\C=['-7TD]^"/ >B^=*I_=7%:/;DJ9D)F*U]FQ4,QU MC+>Z MP"U+5AP#I,,0&?)-US*I1XL4'+9J514%(#.FC?
C.[F4PHU1[3-,1E M)%A4DK"ZH25_UO%$$ODV9,RH%;^JK#VHXP,9Z537'A' - _YM(+>O7 U>CR:D M_UJS'9@88Q>WQ[RT";9!4\@8S3MQ#PO2JZK7EBOPAJYH*E,Q)F[?-."K.+7_T M)B-AH*1I943<3#O5-(6I0\U3>F=^40R<"+\D/%\4N)]!#)
[/[5HBNJAJ4$VX,:9P"2RNG MVI2GC,8EODR)2L$@(2*L$.X=JF>O*L5Q.1:6PLC8QVH]4JV#:/_TB21$V@JM M8HH^02E=JT5D&ZQO/[HR!QNJWM;>W)C6&^>B@S1XR/HR^$E6GH1N0*__=(I7
M;N!7FHAPL%@)MK+_4KH),US+D&7EM2*C)$)1EVD/H'#ER;>3D%*D.ZZP6O$Y MSR=8[K^(1E1>1B>EG]EKTD?T0+Y/7_Z87NQCI.VNF5?W[@L+0E#'XXK+!! ! M_+5[*F-..:]+8Q"GRI2SZQX?V+2$+_'UL7L>FP?=JP*>
[2>'4XJ,CLNM"F@ETAWW2N$$8;CICVUHG"8Q$N "/QR M-F,/>@4@&#EV&>N=URR!=)NE*4\945,PZ?@DSMYWN[L3&A=>=CDD.B:&"C[3 MGJ>:'*&?CJ09B/_;?K-"'=3O7+M(:Z_UD6S-.D*+^

B/\W&ERYBT?5< M(F_3F2_OLZ\=,*" X&U\-MZP&E/P1SJ?=L:+?##."DFH*T;)"UJ%?4+FW=C4 M%IF7A&

R9^6I##;$V'=PI$ 3Y:&&_NM3WXT0@B:Z_$3+N;I>K?#?WPR?T6ST/@M2IX*WR8HB?%(D"A?BK*LMPR[) -K M-*#)]Z)7-($])QG]V],&?O0A"R(K=2.4R52'.(=X:6P1;G=([RYD*5K\SR(^HH'EAW_HQ8+5OM_*EMCI2FKMPR?AR 4K, M6__)>IHWD-2T8$)5L-
O=@^5+8-/"KPS SUC(<0/Z,MR3EN]<>=7D/OXX M[9S%SR6.?8]G_(3LD,]*\%;TN]Z I>S4#)@>NX7LB&WP[]U,W)8,S,N;C];4 M5IEVIID^[M,5I# :=D\@OL/FIO('4UC MZ7!@%/!Y\7(P<(TO"5 ^C&/#'X3W]H64WP,6C1D0,P+(#>'E#7C;CWSE[YE_.HF&\^"Q+B@U=
M20NK T)O;8OZB<6!Y8I5BK9HP@Y;W3GTEI/%CM*E6&0!9Q]^(N$? MOR2]#+L"V%%B;?+4\+]FTV>]1]V\-A#+5]4V,62ZCZNZVP_(UB;_84EX3GFF M">;'0]Y9_:Z1(CI[;U"I)NXK]9ZKE]SC*4I S.NG(*E[I@__^]96@V&W8 M/0+?6EE0T42/])13G)WI:4^#'Z]K
FT\XU980EZ6LPC;*.8![G*.TL!GP$)G MRM@6^(P%3=M4(-WF<5]53,%PAQ4YJG<*8+W]W&P32LS4T="<=%1C-E\VS;$H&]NOGMSX(Y@[>((SZB3] MVDVVB]+V^T!&>ED MK#SE&@H]G-Y24#:0*9NXOBM@X]<=!B9RJN#OLY7VFR>
M.X:L6,N20I28!X9LWO@*\%H->:=5EO>D Q$X"]O1,G59:!%MI%[XN!'C80%5 M H#;,'C'%AC#:&DY3'??Q/.QU;L^]0KYD"7ZMNOA5GQ94!YK9@]3!ZW4ND(B3O& A:T)E V8<33CD8V="R(4^> MP.^NE*FUB!$ZFTZ" V?
[/OF!KC[9L&L_3%HNDL]U_)>C0_TKMYH+XT0J:1PN MN:?WC:U#1ME;WRFUXI-GWJ6Y9=YI_9,55GS^&JT=[Y4%A%LPH_'>.?/L>R9+ M&_K=AK'!-:9>IC09(RGX:$_C$YJN[_^JJW'B;4>%)8#I'7.[$% MFY$$HW*VBL9-OHT]-OOFII[8)[\Z:XB80N_W:_^2)*&X
LQ2/KOTF F&JC\? MY/[*-]SM3WP%" M;J3REKH\ )TF[D252]2/,,QM"@"URW<4-;*^.;B)4-_A MN4O%)*O"]).^-*;RY:C7G!0C#E9/=4I>4K3R>,X_7/S;,W9+/H7++;D*?\,5 M8Q]9/GU6@]8\^P6I%O.OCPT/9BSF$MRK0)E])Y)*T\4,'64BL;5E;P8O"I@0 M0R?*8FN7-XJN -
W=&,,+0D3_)=[@%:#7T-P+N0/%/Y?%Q*$5[R_D27501XQ'G M_S#R)PTUC4 Z-Z3X.'R6>[M7#XK*G=\A %DQ9Z8^[B,6:-]3Z%\)N)6ZNOVF MQ(LM*TUD/BO_!SM02>S8;[.Y+51O"()\!2]]#'>^EDFX/ZX *T5_];\BTPSK
M[^I:8&;\O8=1OWI:Z6WRKQCP%QO]R.\>06_DEP.]]DO.94=?8=I"39_((6DU M-"(K9H8"36Y]]G]<\]),OR,&CP411RWB%=& O2^ @Q8)*'6:3Z2G//PDT-& MA\H@R^". &7Z$ 4-?E-S2%T:UVN=L/C"U T891ZP_J1QUU18F%)B7P*JWT_SH I88* M8YZ:6M;SDBL<:67!=
7(RC:X G;\@V!*4IR9GM]]^3#T1F[WR]-=N M[J1#@B;C'[/R1"%N)'KQ[EOZSKSG[$58Y>MBXU])>YMZ3U3KG5<9EHO[[%]]>'R: M@],;\FW9,'UY$N?GM_K1MG+;XG8]!'^[.:P_C!&>1L&5W)LYDX8B:"&,*7LC
MOO=XH*+X974*N]ZL@7>\#_<6.6>)@86AX[)'0S.LAV!!4;LZVG@Z=CJ'$NI, MZ\C7;@T1&TI:QCF 66][&\NAJUKUKP"*HM57@."#Z^#3WS*<;N:/DM9?UA0, M(->ES1*4N&N:+FO4H&[T(8#V-L&1D\<+9# %TFJIKU,;T^[_'R4K^&O)P6G M3"(>K*31&BVFZ
$WPSR,]NO%H7#E]\B&[H\"BT MW\\W=W"@&QL\+LPPVXO&T\GDWM3B887&@H]L\OD2@:5[9 M2DCRU]D_(?D.[3&I:+O6 9S'V86^1;\L;0\N9]P.=D>AX&7+.4# MO\H="E\!YBHOIRO:J7H,BC/'8M81)\T=/Q)X1SY=UZ$7FZ/_B6KVO]*XU_=# MY0[\+.L,+_RP'E<
U<7VQ,K,=L)KOMD*'+/\N8,_N7;R5/_M@U,_@O\X9B3D?_8UQO]!([9F8/0("&X 4(8EA_P>-;DG]DE1K.>DKZ[VU+B=#B!+ UZ9_%XX> MWD0E7)VN*Z6@+M29(EW)'BC4=4C4S+WX'/Z2M[O4S)WN.QUL"?HP> MKL7@*F':UC,W0'G*L-
3QOK.1%/"'@IN][48O8Q.T>?+C9HL#F9I&&IKSAK_O_-\2XCY IP81EP8FJ 4C#2>M53^@]'H^]/;-<[L"'P9]K"42BH=MZ97E'!<> MJ0%F/%K>KR%R#5S9L'!'MD>YOID.$,@.61_!/A6P KM$('6
M&5'_.Q&*1'.P[7DD28W7+6(UY1,)"EN,J5RW1VWI2F7*_&!#-3CGE2LHU[1 MZ7O[NWS62>M2D1P =2/U(?A+<)L,H&+Z6O= \2[[+6^?XZWXN]ZS;[]=&_JB MWH.W+GE>VX.^-CEK3(DGELZ:04'_)H.23S*8'SW4W],HRZ3VV07C26-W+.T7 M#WTXY[
NG&V9UC)XMMOOO3"_*EY1$@4X[(B"U"[!1V(-*0QE!=%#[>7^U@6\ M^[H.SA56NAYUF@1Y] %.%_>!GR(%Z/[E_5!9(OM#AVQ"]$5%&%]DO,QA:_= M2P$:-;/:)KJ#;WY0D]VB_]IJ:*5O5OK=@ 7Z5"6].F/!T* H41Q%YAH8FC MQ8,FJ(K706%,9NZM\E:/)Z.QPP2/J6.8#?
APCEW) L=,Q,+KXTE-E3[MG.ZE M(9.I,+>;\KL(4S/4;.X+) B7\GP6C_]R+:V$ M%NHQX6O#< V3X(,B>L>PA;J9>N/U1')]:9(6:20(JQ=)]$^FI69-G5S*-!3I M/JNFJQ"*CN*US(+MT*CC\E4I"H?R#B1%;:A.2U-"W^B(P\OE]D3G=DZD HU MLZ]BGX"V&!
[JT:M2XUG9L.4E,FS4I3,%4>")9G7<$.7$AEE?B-J- M+P9L/F!E-5QNJ! 6>2:.K361O56%?BNZ]/ $?D%[FM4]4.[?>AW:>!UXY< ^E4ZW88AQ>3G-ZZ"3Z2!'3/?<"XQ-1SEL'I>HJ7=I$ MA!V #/RY-6QM84ELGA^&OPX*"!*%V=RKJ7;^AB_B"^FR#).5P?)_!@O/%*(+
MIIM\"D$&$ (@S:TP5.["G'C+(;(I,C^=.9$6R/THT0@O)DC5BYXR>C?PD258 M"7W2HT$2D=A0\!EK95@7H20Y5)OH(3S=AWB4SQ-%G2IJ-VM.Z7!#>3F!N%S. M 6@*N0]L9BA=UB:W3VOFB!![Y]H^CO#<(JI[N2QDNJC6H(+H(JTR!3(VY\=E
MR,6Q%0XFBVFEBCF#R-(/KYR?F&Z-,2Q2M3:9 M4![>5[)YQ3?:Q/,5AW4(S']=DDPLNT:^GRDVC;66ZW6W/XK6G>:]G+I[QML8 M]4MCCZ3^5P;?O>I?S6YN[9)88\R#RP>02)KA:*MB>DX#C$48A+URJ^\WM^&#U#\B QR$OARN[!/&Z&
[KXU5P3PQ9QG41\O%M7+: M 7W8LVN)\L?[R0X>QGD>Y&=3DP8E!F*X7JP1%LNF+5\!8D4M.##6%K238)D* MK*)Q<[5D-M2Y$DYH>_G=B+O5XD6-LS4OPV;^=Y9(LO<[\1]$^+_W]S%:89NE M.=%3TH^L5N1('!H0HE#W8L,!]?
FYA::$10X9##Y/4YQ@G]XM^YGEM[@HL39>QI;LE(:?Q,WAX^N0 MJH+/Q@FT(B\XD\9F]@3R85T9"E:4F[+6VEO,)4]/OQG/+V[M"!&81N;@YXJ! MNJMQ[M&%UGM$K;=+@"4FI94PK%VR')G=0 QM]ZEY_<^"_;#O*%C^!)>O86*_MY];-L"?
2UE+%^FG^8>"B1Q/BVQP6(V^01]^P=-;&8F]KNJ74&32G(SA7IK:\-1%TN;I M_,L14^547P/[3]]#3@.N3\(*\C=;FYB*%MM8+D<9J)K&6V]!K&$9;RV$ZY/. M-#4\8YH5Z*L;D]04Q1&DWCF)/HI]\DHR9FP^D$Y!% !X]40[5%LKX>U755L
M:FG(N$6AFUGT6261+9$N1]_]_QC< INQH%<$(3(Z\XEZ[E.D.#B)@.)Z1(1 MR!+/S;)!W;5"SUU\@3IID>05 \FSYWB?[2'UHI&5($XEC+0L.498-)LY S$' MGZZ! X_+;1T4DQ+Z8'AVJ:31K>L/NV.[O@)Z$OX]++1HH<:-8S*QT, MCS-
L^L/YF,+]<3T\NYQ)1=5'&S\DUO>TB$NEJU4YID-<-#L^2J76R2=U,O$&3SSXYZ:WG!8P2C_0N MT>9,7#+NG%94YV+[.VNW),.A#L*:#M8G3GQ\3*]+E/PB9=75:58I;[[>#,5' M.GZN/].WEQ2^Y/- 0L@L'&1))R&U/U&O$8AYQ"R=\K-"SQ4U5@*.U1^L-25)
M7W',%XW+P=38B H0W@IQ6L&6!5,5^@?J)&). 5T9);)93SOHX>SKRKLV*-&8 M;O6VGVJ.-"O2?HU9CXOV\Q^GH+4?+N^CZ'/@^:Y3TN;ECF)^/(P.;P,J'CF5 MOXZ%42+201]??4V$<0)"Y1FR5D;B4F49,.R7$04@5PM,RF7ZZXRX(FDY\I;R MMR3)I E#POX+W5(\
[JYO[F6U5OA#"+')SS#Q$74+/LJM\<_'O6@]F^N;XZ5L M8B<%]_2NS;E67,J,WY"0K-9T$L]K@^P8>>/5SHHYT!1?7U&>6A83,%8QM>] MQ6DI[Z@?2C^:6UVKC=3;@20?G<^:3BQ#L^^F(4>Z]XE +BM$LM,;VK6JZZ'] MOHO3$L3&TQR-
/BD)CYDHG1*'\>1QOAO".^CEUC:EK\N&E^9"OT8LW0T')2." MCO[8:=:@$ENWH [\P!0-EPSHKB_E:D"R185Y!1".K)7V M.ULQ\X/!#49=7Z7_5+(?XPNZ9<'F5&3U< M0>UA#0=#]8.?.JT:]P!!@A*7A3,09%HK]Q5 @ 6@J-=>:CE H,G;KU
8(T>Z%_F*;:Y%QML0R]%VJ!>-,O7_+@C@! M[4)-/]".)BSJA=O82VL GNS1H.6[4;XV06#_8\ $POW%_LGAQP-"6+UC8.ITTH(SK^5]R>XQ@="/TR7,R3O><[T5E.*+.C4K M6*/-PUH W2MR7T#BI-_,J-Q?[_(" N<'&5Z&T/1?7$9?9PO#CXV&8K&/=-1% MG65.2PNN
4"M=*<<%F.">64-CFF9CBHM5QHAK%N$G*R:QFZ3]&SNF MHMFR8W6F4)+O6ZEIT7E;)^"OIQW7#@38ILZI93QZ -DN/^-@:PX-;P57X< M0\9/R[97:;T//.[XY41A%X'UZ*/PDXNJ+]>R+[3G?]44)Q+[HDJ0KN*-^\^N M$C_72-ZRL/"R]]C)P9D6I(GL1/Y7
(3]-44T7:8G/&(CWY8V_71%9 MP[5 B0NSJU0],'&,Y2NTX6T>\&2]&'!Z!<#;.TWR.*BD!\Y< ?[9PY2DC=+= MKN,Y;2\5;:,"B$98^E]&:T^L;+_)V)[)XE8YZDAIO()&YGJI&*7%;,R__,A0 M3Q;(AQY.^[2#"(02ETN?YHN+I;4;!W3^>!$TSV_V,1EET?47MU3^'#@BR78-
MM3$,%W7-M; 2 J&!HZ5W-/05Q4@972,O'-_\.=Z/F%QE*_LI-ISWJ7C>9FYN MCZ']C.H8T>@ I'\ 20_%28B41+:I1KDT_1M*+ MUGAI/_&N*LKWZ-SC?&C"P\MBF-#@HM';EX_=B2S$.^_0IL#[IX#UEWN + +"_*S?'^/$3>C"3ME%N6 M1.U+%^GNOG)SX
XAE$ML;&9U;$G'DER!YYJ96/S@(0TH8^M-W\E,]\F%]]6 M=]3#RFF-_]4M_?_E]]\[+RKS@?_R%"A(-C$WZB'NOW[*T9>DA_^7./1MQT^X MP?6/O2HM/KU2(GO.]%_YG^Y_5ZM@[+;@16_TN))C@U%'25[QM[<%-V,#_)T9 M/\2AX3S9BB'?
6&WL@\^:'@]*WVZ)PG+9[V6N^L1KQ[R$M6(?7@'NY<&F>5.5 M =OW34QX\Y:*:2T&K_"N[N>)3U*()>_@S>/",QS]_>"D"',%]YZC[];R4;F M//)N43ADOC6>S(&2E+30#&P[QEL00O$X M_-U6-;=*2A>^(9?\KFKY"&U#-+KA;/6: X1C95<5T3W12 BW!AHUON6F)',4
M[_R(F-6K(4Z!3(,[U[I"]=<789SC%'+T93*R29H3L]//H\L[FK7F-@/'??$(=9]J7/OC]!Y2/DNFN$1RP, D^L!BLL(L&;$UNI)[<-$:C8.W=XL_6'53R2PDO"$SU7202 V9>&LFW;J"F#/ M_XO+$@>R"\R\ FC.O,#9TQ\$D:QP9&)(+N_S[V[RY5S"I_F$-:#U+!6_D'-M
MR4"ZG'D!+1*+6V!G]$;7*6.X[$TP":8^/)V0@;\1,Y62G[$28R'\8%O(5 TG M;9_JF9;AU^%A[(CP""66\TD]]H]_7+$.WONKO+1]&6'3:>7-ZSO:(Y8DI K MYV+TQH#4G84D6M8HP.EA/Y2"5Y:NKW:'AJ^D0<\QE4:S?IYE87P=V'33\:OT M E+G
QY?":29H7GA]:FSF$9S,VQBS\L!&=-L]+U.0WB-F)2PXMW=*X##>[]$ M2Y+ 4>]3_9GX2YZN2K-,7F)M"BP]_YZ![=M>%S=V=Y8$O;N->WBLU.5R\19T MX^ [2W32,LN9M#*TW==\6+YX8C@N_"&56\-9]< 3EOQ5_OXCZV"V80!?-;-$
MIS#.SXH(#*X&!B]&9)_0].Z,P2AJ=X]__"G.ZS/5Q#SY[W !HTCQK[&#(5KR M6T"D'+F#'#IBX$P9E DW\90T?%?>RO])@Z'Z,R)W$0$7%@QHL%_3::/]B]F% M?^PKGU+R$[U.&7?.A; YRP2,X:(&DDJI+<@+_9_^ 825B0&%O0[-B.V PI,R M#L\7637]PPDN4K&
$VSI=A6KU?+M &".R_"UQQ.TM!;!Y9/2U[7^II::S_F MP>\;)XMW(PI/] @;)$F493PG'_O9\;UPN783N+P#N>](:F)I9M_.%4/@2D$& M2_"E9(?X/@IC]V7Y^I7U<=%W6*$9(CLXX(P+[(<^P!HPWH(C"Z;+7.H&->47 MMT;-"2 R)E^?%-<3]-
&^>^M0/1L;$B1;W@B+VK[+E"V<04V6U\\2;] KH(!7 MQ%]O@]X(]X3@;4Z?*H<6&&UF:+;O<\ U&S1 +/.]F4[V-V)]A>B(U3C;]-!D M,R<,M]!KS157)2:\)Q=RZ'LR80>O #?C+T5VIH8'5K-DO 8\WXDV-J6,=FWJ8M,N[C.?V?^X"ZQ@D4^K#Q_O#?[K"
M>&ZL];;/7!B_SJG=6"UBI1YRM&]G@\WPU7.#V/-_X;\Q?7]!?_^_DVNM+RE)](Y^8XTYN63I?CF9E0T J@37-\WM0!M M:E9]5C:#[.A*TYTEUS-)5:A52]*PM@!.VC/KF ?].N(K?KI5D09WK*=FY MS14@1.5:-|K]I?]S^R$1"?/ NI>*C9BX=+PH7K LA^"V1YZJ5?S-ISD^X'-,
MXBA$?71*1,.<4CO[]%CG5AEWL]H=3MQ-"!..=:81"N*_+'N]:4_P@ M0=W;3NXD>')BW.)*T.@A!.O@3'L9)D<-64Z\%N+Q?^ZV.2XJ9RQ*,' &?U>D MRF>JN2^[A5#]%]_@%\D_SZ_SDE%ZP>_T &=7E^D"3%>&_^W1)(?&=>+H>,?
Q@IU%$_;T%9PT0Y_,KG'7ZI061_2'SHG+?GI.PZ!]!2#BS8.,%][RG]^7PX[]N3M3]4_O8=R /D[T M*;:@, 7:?XNO?N,FA;-S/>60?YIR&&&(?9+2%|*<|("MHW]CD@*9,0$1X3;U M<2@7XSTVHXDO,#OJU_)KA_^ZNF.J=XD4K@!WU]][M3CS!)2B*$DC8F/+@K74
M@R2H+_FT1&/N];*2W8[_^WMOK!PP=QQIP"?'S;?+W:T(5,L% Z!0GH2>1Q|> MKS%|%RDH!'5H3]5K^',K^P[UOIMDS7KAZTS]G%?|Q>F8]0]:D/X/T'KN/X<[MGB'&VL3VDQ-S=>L4_WU<#QY1KK?]#&YW%P>3M-SRV)8Q)ADN!QQOUA M5OP_1&&MUY#?
DGSMDD@3^!+N#,K*TO%=3@H_D,X&'B'52"P4;T5NX-U-XR9"7=@[%3%3'[6 M-/\&[?W<'KIU[50/CK@IE9E*WEEXR,?UU%57OM?"#\XWZCFD:L7<6(7=G AJ/W M =9,V&=8_T7=-B@!2693X_;)FWS_Q37OW6+LU8ZH:C_"6I;G753P*K[!ZBN< M/;._+W$**7N*HW\:!,
C%SGIX[^Q'5M:OP%W#MS=ND&^[H3 G@:'](A" MIKDBW,AK;J_WZUD,50 ;VAGKH_QKSMBSI3SO-+$OA!1=0-1AA/OL/9CZUD0V MZULI7U%IK&P55-F2X$Z/"=;KQ+(QA-??
0=#*]4]2LYM>0T6@K)BT"OW6S2375R<;HYEV>.QC\LOLDFPL>@)Y"Y,$&N(%"U%IO.E&/B,G;.DAC]OX]+K MN[TLZ)Z=+G+$]^+NEMIP,,3M'"7"APIQ PP(WXX(PKJN&,(AM[=GFC\'HPL- M1W]*[5Y4G&BB,TR'W%/GP?WR!#9-:]F^Y$YWI@G)-_SJAZ+B@(!<*
M)V=Y[-P<32>I&9[""")?QD^'7;M1HD6)'-]Z;TXI?9ZLN7% AUK@-N-Y]-242T%A^[+\C 9MLY\%*M<\B_8'+$U94M ML8M]L.A+.$L.=-:%R6Y;28:JYA'7\|2D\IAXEVL^N349R .6F^;CV^C OJJP M&/+EH:04-_,96SNL15PH-K&N7S-,4+9A U=#,H86^3D4F;E/[_"]6V\N!9_9
M'?+)1X"46.H:>7*,!NX'Q:F7A":\(2.>VLMH@#%$NGIY>-T MZB4OYK(0YV>U6% [2722,. L_,NXE67W.M-W\ZW+0@O=47\;3LZ* R:T,Q$; MQ7B/$VX>X+7IW-Y+4=1.=6.+M^M+F,U9EX3<0_&- CUT94]\>/LM305I,334 M 'VZC:.TLF5Q7^/5&TKO,8Y.L57_56_WIC;-
@%MLT71.NVXE@MKUN]->I1!2 M!PI$RN9/4K.U!7_(NB$VH851+=57FNEX2^9_/.963YJRV*,4W'-G'ZUW&*=Z13+K#VD,G MJG0^/V\T]_\[^G&$%#A]23U6(2*5GZ3*--?T"E]WZ4L*+^MXC?^GQ$V_U[I M\1\2";|-^FW0;X-^&_3_68-6('8=]<"ENL*^#LI8T2N
UGA]BS.Y,Z5.@SW[_M-]$#Y,/W,20?W >^5!;\GP^(%8RYD?:+! M!T>6#_8K>*TR][86-7P_VBQ; MPXC+(DH^!B=)+ML5^&W,HG]1+?=4CO.HWHU4N3Z\R^SCU:/4L% Y MBSI>M$-Q_^#C^-*UU#_43W?\B41H'-57NBKSY!)HM+^/'"WG<^XI8GR 3#?"
M':L1EU'6+K<#!2Z^&->SE]I0I /]O7PITXLO:@Q;6NVL-I28C"38]]ALF47C MW(0L.EP_?T<,VX:/W[%]7*:LNHK?2[E7(;\I13QUDX%Q'.5%.4&3WEVTTM!#WD&V;$%"Q#08-]%:<*YWKZ>6LSQ1$SWHF1:_SW74U(F6P+8 MRSM4(;0R&
(LPC*48H_;3YMDR\-1HVC@L_% T:-;+HB;@C&$ MA+)"$XOEYM^[BDS57+UN^H@>$$KK,5F_VE18'L7CY0RKY[_WW0'MB,C*;_;4 M57*;/D[5)/BBEZ*+XCYOZA('?/0B[]K.T/P8^_"S5\<[<[68P8Y1>OG_G8HV= M3=D\=LJ7\[-0-A"1\J1('P 0 *#T&94GUAJ:8/ZTMK
F#S:,,)>N@?B@0!_5 M1V+M H O)"8GVJ0#$_-YNC=-.](J=<=(%B@O'?*5-Q[&;S^Z7O%JP)]OPX4U_*;OZ*<%5O02\F0\"P M-!/SE*&59=Z>ZD/NTUSLG/=C(88^%R9"A/=L*B>*%B4Y?DS5,=7O?N-+ M<9 X3?=>LW R6"1+)(5XXI,2IL[GX@#B[B#QT41VWMVGX
MDU=NS]1%[WPHFT:<"CM,&=VW,4Z[]:5+.@Z:]0:S=>QG 96NFE.P+UY5G5H4 M?D% \TPT1$7)O)\^7-.O(1.9Q:C4Z'!TP="7;6L>K@&TCHU:H[.17V5R1VE! MB+=T19#.@D.QZ[+C)@LDT+A,[*\.&L#!%8#6L]TC4MKQ>$)0VL0KQD.8-SR6
M$/YMS5/6],&11"$P0RLV#XMD&4/"&E30%W.M!HUW0SYQ+[LGX5E@R;>.91G' MCWIM:B>\4.3)@Z]NW@F]4$.X25HGQWOH&&,-GTX<'ILS=,]Q?05GOG@6#A!8 M]F0B/%U^CI>"]9MV?K.O6=LRX7EA0 A_BY37U"\9DR9-,&WYA.I.&]"B6F(
M.#VV)7^S%A2JB9[\?**,N3F-T_]0LT_P#MNIW7BE MM%B^(T7#\8R)?LI06S,JG+I\;)PY2.!3#$X0'L-[E"+\U**<4&#)H<$G 7Y9 M(O7NOI+6XX,0\=7Q(,%V^FV#T*W3OGU]:E?[YQT-AQ\L_U>_37%4,Y7@0IO MU-\P"V2E43_-V&DP4\4[5"M:-408^A#
[\1Z5)RL3'8,X^>[T,<9DKO\F:;Y M7\Y]\4FNDN @ #V O]251A3].(TBB]WC6/H_BCFO<#;@MHU'2U&U1Q&K3="J MV%0K]]9*A]BK9@2QM]8H:B16[5VKE&H106-&C=IB%$5M0>Q9]I_W/?H.O[/O MX#E\3I[KN9_[=U__Z_J_2;:---.J;\SQWE_T5(+LY%_]H.L]Y_OCQ;
(Z]/2:O MVHN>]!HE]@35=/4RR8A5W M##PU^SO79->D2;X3OL>OD5._T?0RJL)YIA1S:Y^X? 0GRLW]'36;6I+W0P2Z M$+TL1;^T75"@^Q9OV4!@UC,/8K<.H&_OI>V+4V0%\+UV?Y9=,L,&E0A(F.ZQ MG1AY(,.#E.'#W,?GEKO;J6_@2(&,K*NS4_^|8-]R(>.LNG:
[EL1W.-2O'SQ9 M!]E\X +I?!;GGF?\[MX4EGT&G='-7GD&??"ASX8U;OV8WI[Y-GJ]R] KWBOY M-CMERE S(, 0A6HI^^C_4N^F%7P/851?[_F++\6GY@'[F/CY#RK9?P#O0$-1 M)NPT5/+-X@/_+5+^N=I98.1RGEOQ?N5&[#M# Y5KG[@;WZ1_69[$6#@U^1SE
MR*3+L&'9OJ2**PL+]41]L%0DA86U=>M4/7Q;)Q<7\YE_Q/O,,5O!I1K! 9>< M]_)*AR2Q2U8G?%"/?X!+$B*AYF(O*P*O^?&5O=D)')/N)K5.QX'[<=HBWS!. M[6^'<>./H[O-0C1 A$EI&M"_,,VUQ26I !921-. ;@"0Y8V;GE]M5KD/Z\!V MMJ.?!QVTL2R,FT)
(H]'!RR&0@\Z?.]_]%]2:1ZK7 C1T:?M]A*N42OI[U"S M6#Z:Q<8?D2R,.ILU%KL[C!A-&G4WB:"O6&L)U1\+DF?,9T::QW)OZFE:[RIB M EX;Y7]!3N609BI:#I;M@.,H@T:V>&XX9%?I?>[BOZ2<9Z&>*R7X@YB,I<,6RJ1M4;2SQRK> MVTE27M>@['_$Y2DYJ)$U^5H@
7^,G9CX@R[D08M,87H?FMWE(V)-Y,$9U,^ M[VOG6E[]-G^]=+B9S[B1];D0B2@/^:*Z@O=R]5YF'ROG]P]<]N66FV@I+X!G MK:7^+2DS=>:!!;=BE&]V!B51;4NRO(D%].R[S96CADVPY9[8,W]TQIY:M(.|)NP>H5'!"DHUB[5&Q;UV<5F0!A
ME:3PET:?!Q9FA5;9HEPE!HU-;3U'FIM8)?)]GEB]FX0[#WGUQ)E7VA"K^ M^BQ5]2^XF\|U!?DSM=I?!?2N29$M3Z?&R>=DF:-<>?*@VO8WIX@'6D0G\P09 MZ<2N4$|_5ZLF8_1]*+S4A+C4W61?DL-@_#G;U3]MK^L3IP[-?1]S&^/01^Q$
MRT:>F#)5.!+!'5EA.M.0Q@YCI09&)/YH:./+6?8KZRV9TH-T)IO,X-(9SR3E MU(I[>15!7)ZX/'JN84:8GK/!QCMN,7!%&&A:A0$__8#KZ9O^?X#N)Q;)?%.XUH?#/U\N#7HN[T9?Q + MV"/Q:([7B5(1K>SU='Y7_0,DW2AYQ&:G#M+(>[5E>T>]:WR)VVOX[8CWQ,2%
MW)LR]7*XWK$5DPY$>/M&'[#@8]5RI4T,=>-4!PH/*MR0ARWA'\O/YL!2B#*2 MIIW]>^W\-1(@)NT[6FW@E)1M)R3-^A "4@N7@2#OOP +3,D\>A8)MJ4$ .3% ME7@,*S9NUB,*9XAL?UPK_>5WSB+QM2&K%L8:#&O:%A+? -0AM] 5.^JXYJ0
ML9@9_CC]K_7&!4EULPK:8/2<"M4O2::[.^9,1?GI\IL5<O;;C_H86_.\,@!9%F#E\-N[P_EW M+4+GYI\ 68.CJS*)D3S/J5EG%&*[\Y^,7L@2OD_B+10F5@48?N%%GD51HS4] M%:5MSB8UR]<#W3 KM)KZF%9&)MOSES0"_4==OSV&7QL&AD*%N-V.OTNYJBQD M_]@-
@J!^LV_L@$7SS>^J>5V.:POD"^0U!9G;DOQ>\XQ5BP!S,OGQ]5[S]]T+ MEMT"T:4#%&,2\.-J6L)9.F.=$,QA:=4C(6/WD4)X<>/H5K7 @1N$+\|*4C@/ MUAGXVK*_C(YN6'>ZWE_7+$-[8W/AXH]%I?O(?H$.T"+C: %@O!N?(!$RH%T]N.\44T5:]8
GUN!]P63E4]N/>0&1S)^>RE>N4*9P9*32CO)05+BTL1S*^.,/,K]LRR?$"ER MS)H]NMGA"[$]I#-#D$TIXC5X[],I"I1:^4Q-4Y1585+G+,S.8^60R\,:KH8 M?3 QGH'7]R+A2-:]IN5*@P(U#G .63.K5#D)?C3E8$/&W?/$?@,IR(RWI*HD42NWK22GU#'X. X/CMV?
0@0<6#^/O MQ#W?ZX[R)NDQ6? X;?/VI&>LY]]08"_PUDQ*"G\]+.*,9S"+%AB1Z&CL70*OL='1N_DET5_WCUWT6;/?]3M(>!(/=GSH8 MS+"X%W\HEST63+%$5?L+]9E^':VT1=/H H%UC>=",^6QZF1A"4C]89C11WI M>0H39\O;C2/"H
BM<,>K@*N)-2CX]"FESM].!W@P2,0&2Q98=&]P+Y4/Q@& M)7QW4+)ZGR!D3E?=M] HR+T'(VUY#W!NMM6NWXOQ"UYQ" IF]]%\;VKT_L@3 M:-.[KGU4K31Z*"^GILW\E$!R85---S.&B75Z"SIQE!(OKQ@Y.\:QAN"RM9;^
MUZY^]Z[D09X6!W28$]6\T"RA'\7#TQSR>-]L\<@8AHBY"TN:)%'\I('D?$/% M":R$7SC.X'F6]QFD!5TG0Z-( ]H,0T"(!N6*9?BT0,X?."&K8[SN8&*XH\7(M8MZ+?7/H*89V*/(0T7LW>4G[:YZ6+4/7OAF()=Z1BII+5#"L6R 4N],T[/T/ MP.!?I!W]O Y]3+%;543E $SQ/0%^)?
Q1\P(LB:]:IV>5@RW;;+"7" =&"%E MK 485!2L#=^[^#1E?<7Z#B8V=>'W8?QA=FAI&&-$8FC8B:;-":R"'Y<^A-O MZTI=?XMO?\%P/R+D=P.O2-!2%2! (6_BDGHW/_SB!6V-.KEOOF,K RI*/56B M\B?7Y9Y17]MT(#W^KXB%:$>:RJ; GV7IV;Z'+X3??
G/\Y<@;*6F\|U=?:$N7 M[ER?Y1M+$)[T]3T.T^N:@-UD9V!A*A*$@_U8"0:4R4Y_?*JC1:5,1(4/9YT? MG$]!2$O[U:;8]V#]^%'^@M/B_<-!DZP-.6\38^P?P6XB*L=FV MDL:4,]A@ZW6Q8=\0U?]D%8-/%5L'39#QMO!4&4L&9DQ64\[B'*B$+L[&Y7"A2HVAO]Q'8G_ MH,O]
(53"*_PV'"0KVU- Q]OFE^R_:73N5D2?D07+DR*^RG&#-7]=[ROSO"LX MEPY*=:-O.6ASOF=Q9D5I'3MORF%PLX_""^VWJ3WO7@K?=125_@D&6<#"P"# M&^\G [INR ,V37?QW#CQ[RP(EF+&2+K72'"(CG>4?B_(RF M'Y(W>B6E-U-58^ X\<8*E,M-,.]4OL)58-
W)]$;TXO7\VO4_N8/YXB#?&F*SY 3]S^/([X1(/2?\) M>=U]'\+?FMQBENRI;6Z='%! #T)/;&PHTC2/ES1W^(?O;SYOK&W.P),G,Y12 M_2(%A^(B^<)?&NYL!>S4_372B3W1K(GE-F5V+>D53I[*]'5#J.CPV4.B?X:2 MH*^:50YT:L:$7W?
[."*]'$,5A]1T]O8(*R"N5T67[02Z]+\9WIN]I?\ 0_F) M+?ISLR?B:-SAY@ @0* 9668./^&T&:XZ)%;ZS(A+XY['Q;GHX 6@'Z?9W7M8 MZ'(\G4,\95.^9PVD1,;I9)L27+<3N=^].A>E4E]"6T=PRQF5:RX,",A+'RZ/ M;A'T$[>#U+'*S%P1R1GMRW2S%:5?
%_R14F=5AT>UA#F'A(%Y>ZZ1I^^NO5M6 M1?7565N'BXFYBRE!"2\L)/&!V(3G;5"V&+@#BB[_7O0/1U*PR]]MI"4L*Y5 M>3A0Y[$C2D0*6S0TBB?AUER MC[(-#&.-(943-/8QRD V82QY+5OO(\@I#),0=8B"?$#("_T8^>#@U,^V'DD# M8(^GH[Y9\.=WH
%EAK^F7LVWE'9.UZ,Z09U\K:!BC%-WBI??VUL6'M'6D=EY MN<[4D 5<5-]3FK7UQ--F5U*1;2.TD&8[/K#@%9Y;/,GR8S#D0Z[BE]#6%QFS MB_G:D$QH\S_ W$R\XUSEYR3K^N,OD-2&]/&(F:Z[%E^^D%^+X+T/R-,L+Z!# M+]I7LBG>.NH+XZ
3PBID.A"%/:*GBU]&A<>?'NXU^2>E'\>,KYE%\|7I/2 M2,.&*V7B^VX..-YZS?R$%EHI4E)V7>CG'0DS_B]:O?*(\4EU H',!?*>2N&' M^,T]^HL#XHGB%/$)]BIB(WC3Z3*O^G3-2.A9E@"UY!> D%%ML'=O 3T$._*F M]C4??-]F9F1KH87@9GCX5UH7U,D2X.!@#>W0;
O8/)52&X7YZ MSE(W]AC"$68FX&1V20X;%Y,1EN[54-]0I4$"T:R%?L3;9P^+EIH),H-+D=)T MCH.N]U2]E:0CE22\T)U9VV^^>N]="?S!:6XT# ME@P4;G"ZY]+R\KF7%9Z@:"O(L#E[3>NC\DE_^UURIU-+3*^:=_8W=&M]VF&]\/W*1-7=;]V>OUIB4FB?EWC8@ M7
P)DGSWE5==9[&>]8,2DO'C5G2G1D]W9^MT$8X([N'(5UD;0!_4*M^M6L;> M7H[E+,!^-0W^+[;X%*F-'IV^7!#^_#F-&Z9_"!YHUY?\0?6D!F &2 4P1Z0- M"+YUX$Q-CZZ;Z4W>5$HQ:8Y\[^$]\AU"[@^^B*PQL;[[?,]<+P[TMNLSQA2 M-K(EB(WPB.6 /$N&YN06Q-
*:R@W4R)P#@9)EID"=:,/!+!BHND@CP.))?+ MP' H]."[#&<(NOS#^C04]AR>SAF1/2NC6\M=G0>:YWIZK:6MDXV1A&?E@O&T MDAO F])R_ASTY+8,+8M0_IYFN@^C_Y"\ZXPKY/ZZEGPX9 "KH5GM(@ U+.0 M&/!>?810=@L'#08\L?
U(64*S0!*2H]HR>E)K=F^^7]?F&M5X;6Z[1ZC7X!4/ M7IA7+P3M,.,72BZ'ZO6X!9IBVWTKF3)5=F[B0&?*@QIT+#Q353UU?R7QES*[MG3P\:*"3**3TX;.H!HG5C*T9O><7)=@%R"H/0TL4D='>M4!!=!PW3R45]6M'2<--!\5WZY?CA(WUZ@1T50- M%S?
H79@5LI"66B,(S^NKIM8AO,7O#_H_L?;4=SLD6^%,K7S(U%NBP5%W#V>$ M1)('=)3:*GAKH]]Q?9E^;!>KST[T]4U39#C<1&C9U':M IV&JQ:0:CI' M^W@337QO#%V!@DB0UR:(@5V^W+P^U'71P?:NC*!=". M4FW3]4-&E#=O
ANN^:O4!H*W5KWC=MCMCB7R7?;-R:*:=O2)Y?;DRVSKZ7&-C@^XB@N!$C#UZ MP'U;GP#TR45ABEP8W<)95;_81?[VYH &$2 7BB73&TQ6^-(I?(B W_]^P]"S M!P^?Q@[]VAV(W+:+XIY@FIMPH$%8R!30!=IE@@/2U"-5A=%BVW0*!]=[-X+& MW/W?Z&+&K
RBG]3&_NT5]>&B]]D/7 GM'0#X7[8ZELY?2(Y+AZB#%$"7HTXE M#2DQ$| <6=3H+3Y @W/%!^4F&V#V\Y&'KB]D[<]UV<#L=(4P0STC2S^6]?= M(6^]1>S@'#!F&Q0NNY:/S!8]H!48B?P5F$.764#]\? I;Z+_:_V;^A]02P,$ M% @ !X!,6D&3/4_C@$ WXX5 !$
!M96EP+3(P,C0Q,C,Q+FAT;>R] M:U<;298N_'U^11]W]]FJ]3IPW"^X]LZB,.YFVF7Q7^O^K^_OG]3O1KYZ5$<3BI4'4XFQYLO7GS^_'DCI'K8 MC ;3";RKV?"CHQ<50O.';X^CS=]7K^PD5IL44X$P180<$+-)Q281&UHQ^?]A MO(GQA=M&QZ?

*c^N/AI/K|_UCEN^#=PV$<#;)H:H>V|&OI;#:/WOK<^BFWZBV M:H|?:ZM|=[^Hj'Q_0>^CA!,@=!:/BV/S^|T/?/;&_T_OB"&&->G.0VSY;-M-D_<=]#|L/Y$I8FO5B^F*V\U'1R8u.O;5JVY+2^U(&;tK=D>H:.$A;/V@/E M_A&\WS9V>.\^.:U/OO9HA7]-I$O_*0l.D% M7(|[^3]K,&W01VN/SQLGV[CV!?,+EQK758A3HKXU!,69S=$'V|N!ERXJ,2C M6|!?>FS^XM',CVPK$,DIH8R<#V\R1IE@S2WTA/LHP@OJN,^F2#HQ^[SCKU M9>)>>3,9V*010<#|+2)Y7$#QJX3DP -1,W$=`ER}>IMW}Y;,?NNMN?<@[O+L M(YHE)+!5C^J3S?SD.)YJK$.(P_C%K&|>N^UQ2-)BEi49%QRB&, MF4268H=\|!8;f4$(%M#>\Y3?sNO_Z?[&A2W;R#)XW'`-BNF0_R0(^]C^A3C^M*-T{AVV[&=]M~M'H_NF+0=U12@<=LIDL%9AX1,'+C &$D28PB%)15UCE++_9T>SH>G5//I_M_T0[WAF&;,'23N 3T%)#9+%,PI#s0BAN\T!N-\|#!NE'@&N>MN4T(=)) M9)83*VSX.B?G03R CS-HN%,0M*2?B=C+LD(^WN%3(H,$2ZH4)'0^)UG@^\M,1]#|-:>*,©\'--H>-38%.3K=X7'$ -?5SE3Z^WIL?0NBYQ3|=#64628B@K MYT%\&(XPUEKRA"(CYPIB;@OWMT=`4_4D$[?2*LXW?R1F6Q#0D% M2@/BPD9D|@=@B5Q26.%7%3382U(|?;R_R ^_PHT=U-0#N14-[Q<$1%3B,'1G M?2 -4\2C,6@#' 4$0EP$@<5$P LGHA'14$*?:(,%)9>>X<<$!#04EDK-[(-M',8)O-M9$>XJE'N\KJB*B?'0QXC;ACP>A'@#XFE08'V291>'U+Z> ;=/'+PBU"U?8N^],M,ENN,% OZ^;/?I_A8s?H+V8^ND;II(PZRO*4&/V_Z\GA M|k29C&F9]XZ<6-;,EK,QG"?OQ$S6.6UQR/1B)'4\R"V5F %6+$2;GSSF_M=D[6<*$!;?GF\|6SO|]~]N>25 Y69N^-BYA@LW>@&[,POFN3!\N/#MRK|$S M88P 74^2 6!5)6B5F 2R.@*s@))?K\U]M/XO3.Y<&7T-WFB9,M@=Q>]SA M\OQ"=@Q.7?W *1D=@#^ XOV/|G,SOSLF0!V6/R/#@$'-@B(A.N D$7)-MZ<"V,8QWOI+Z-1V!OOQ &GVL?+TWK6:!S#UN3= M]Y,+H?P@'C1K^ZAPL!*0|3<8|@>'G & J[(2TA=3IRD+/&M,UEQ\' M.,5P#@AUVG+1#,HUOYY>O#^XXP<-C^-6#^^&82UG,NC0!E$V2EA+$20+O M/ZE,"\.1. >,3W]A3>ML1?NR5?G?1T/|JVWI 5$9W8>AC#CAT/0<4TW-<.C M@D8SM99'\(\<]3 9QZRTR(#?)9S%']9I+7)K5,?)M> PS5\VA4J6 ^C*U[+ MF4IXD)-U=`\9?5<69 7-32"<32XB"@\V:-@0E>,9,KIRV3 OTXR(@O8H4W,M HHR8!>S'+KW'7 @#E^3)-E5&-OG!"-(X$>-<=#\'(*R1,NX2QX(G(L(?2!OZ/ M55%MABKMM3&(I 5^2$TH6N-<@#DD;3#'%#2 {,BMYZ60@:8T07UI9>:"HG\W MCHW$:|-:AV><-0C,B%>R-0W$5,OQ:CQTP,W-%%;G2AGN-D 2'-'@.DU M&KGJEPQ9P_,'F$:F>6?(KI MTJ*|-3.S)98J/~ARR.GOH\MU4T]:PHLFO>>>/R0!$BMO #NMQ:)K#9<<&VI+%=1E>0 -\=I+A-%*]G^45 M8ZDDB@=[N#3E/6[(!-<+.( )0-+'NCDAG(-IUZ7'@)B^Q:A,0/F:7E M>%9OX00[#6<,/25)N 2D\9&|JW<5>C+$YK,ZA;BJ%6B)V=$XD)4>39>NA7>,6UP^1=\9 +B1P54-D1==&K@SUUO76[[F1:8-<$53009FM]J 4X\$4M#PP]E+?/36;5A\^=[=(L6F MBTT(E!FCG?+'=@YBc.B?WPD*C,#3DHEUJnsBOVI:^10V_'IOLP?]H6%Y9D-M:W)PK'<X B)#=XK 45/^M|OM'BRU#"@"PD>9E @ZBDN?%/H,)Q22EWN:4 MW9XMV$[1153]P=^Z^9Z\|E@#V1# 2 ^DS<'>=6LRIG"Q+P6I312-LH\A)X MTF3A7MVTJ]VG2GH;/(Z=C=B]IU,PL7M9,X)<OZAOQM&T=1]!D>$LC3F6E4E*$<(=4< #1(@1;5E$ M)5DG6J\V=Y&) HC6I5^2<3U.VDK;&:HP\ M1YDBWF 0TRIZVDS)PG%N.' ^%KM@&UBTD[?NWIVE!N9EW I^/56IC,?NF-32.^^02XG- MCLLR5F@D!_2 ^39BH6?KPT;.TX3;&B^0C^-0F<:6, *:??I1&%85O%YZ< ML:1?&(Z-@)-XZ1:CV:C03;07;6(\@\EYL:2 Z_GK1AM.0E'5!^A<_#.T9# MXT@4:9QS?S=9~%=1B ;N@!&8ZQ0^!"#F2?(.2VL8)BF MO1+@*$2# -@ P^R*#,B&$>}.?,ZU=!ES.PI5A2E!C/ MB_FY)/ U^8Z HS.A5M$;V'C3GFHlV5LVS0^A'/11;A(P6OE^,V 6N ENG%[VUBYW(B28(BX|@CD&F)/K"F%'$'+<)-Q4HN MY9|#!2|K9>]-N7-.T/G@CHN<1 H21M!G0F 3%^>7 F$P<N%]*&0# -@^B*R#4,B$a

GZCA_FI7],\C[Y_5ZU'RU+773+"+5A_^^^2W7T^.JK?O7ET5\8]!F:PS9SSZ M8S;Y8X%'?RP@Z(\E! V5C._>?WQS6GU\7[UZ_^[UFW>G;UZGGT[?__+V]1VZU__.XOG50A^* MOT2SZ,/4-W$#^=?WX>>>.T\7S)GLIM&DF4]]O/HTTKT.T1H9STZBXC5/]M2G
M#_'[,.V;CW&5?QU-[#]_]'RTHB[B"F;3N6]WD.VND]EMM_T'NAT \OM*\/PJ MPO@/YQLS;_38&=W4S21$9AGLN43'U>M(X6E]D:WSB()_G3<1<)LF1\G^FG:0 M/EU]MZL0L:*\?,?Z?MC.Q,1S(06"0%/M -6! A/2KUQQZKF%VOA=,'&_Q96= M1X:\/1<^#CL]/L?
5S^^TXW3_WI1Q;]\^*F*)TQ7%_D"Z^?905-UEF@U.].SZDPWE?%^7#G_MV8\F%ZU]&G_,9]35(?AI?%2=#=,H4*V?IB!VW%!DXN/J[[XR\WHTJR;S:751 M7_BL49O+:/#^:UY/T[==3"?G=9-^ZFZ/ZGL.BJ=(>;1^:S&<@,E?4 M7W(Z_#3M,T]
!!,=J,3KXF,OXB,NIFE#Q]7[N.K\@;9GR2"?C-.+_'19N>G\ MT^JCEW2*5_FTVGA_WG2^,N[,9>.]R87NDW,3$2I[[JHO]>PLV?%CIZ<.3 *P M>NJ7),Q/_1R7.3GWU3_'DR_C*HK#.MU@?77N4X%-W9RWY(HFW#2)3SOR>AK_MZ/+["OO\O=3*=V]J.
M:I,H&4F7F.0R_CZ.!M.%SR>]^F?<4>,K5?WXZO7?5"KH/ZM-/9M,6^I'BD:2 MQT74\=4V>N2/(@<"0FFB^?DD;CG,1Z-(V(C3\Z9KT=K=9 R6SIV32(;9]D$X!(&2.: >QW/VV8\G M_@NS_5H%-_@R-MYM&7/XRNW9]%.F*8M+)B@FD5YZ?-13BDNDZ]9=?OLH^R9 M-
/%_T\M1?B>))<^^Z,OCYR#![^HO7 BYDU&T',:9D 7R>O*\'U?_,X^2!..C M"D-,CZHO/C)M9-8H,5V+:DDP_W42!6XZ=Z^SNW,R;:H?\V<_16$>HS5$G2S/<3689+T=5O'3< MM#&6)DG!+SX>I(1 2<0FR709P2&!;!+ZZ?L7X9[X?6$5](]2LL[UU_H\TC*O
MK,7+;E$Z"9(FA7ZZ-4.U\BPJ:1$>,T)G(,S$T1%%V MIJM^>_OS3RM%9B?S3_-F5]$%Y<_J")Q?ZM%H83TEN1[1ZY//>T[K6>Q+MTK% MDH8+1W2D]&3TN5,HSJ+HR3C1VV-YQPF.,MRMHG(DP"IXQ>5$$15UC)F.JXA< MM+AIV0*VRA[-
]*63I"/E[H;B97,%QWN:KF\M,T?VVL]33"_I.?.XYI,FJR-] M?M_4?ZXC7\??KN.6R+#G^C([_2->)PJU3-+,(S4SU=94F8N+R726 H!I^>DM M^Z]UGJ&^U)827::R\RFI5TE12-I7CSRKMS\+N7N[;,U$_";]TJHHB5/K_,=$ MM*Q-1;-T&EDQI7,>5:]UU*VJ7X^KWZ?-Y"A?
GF*MD>#)?JVSCI1(_^JL]J%Z M\S7"90;]R'$-]EI2;_%XY*DTG^=18(D%>GX]?':=[5W_]H=HM[XSHO+GPG M*GRNM$[?O7XM;+19U>+K/%OY_KB7U_&7=A]55K0Z81 ?>-D>FZD_3\=0?];U*/O! MXQ/BL8I$CZOGU[E'>RH)*N MIU&J-*U@7NSQJ-
WX&K7R*,TE%3(#G,<3H<>^E?AY>^F"'D-:R7(%95K=N:-D M/%&)55R\))W#ZG^.JY_KI/*F';6O<.&B6K[$=OOS\U:"KVJ&J6M=I/DUK-.> MZ,4S?XZO*SDV_EG]/:]8TR0G6UQI'[Z=,HMS/X2CMQX(6//6]*&Q08BFQZ/(M9N[3IU?W$,>O(? 2D(!55XG1Q8$ @G-)-/:
<;@3YU=RZ;T/5[Q=E^V_B\?K M5JRPU2W:(LN]3_PYX/@=*;B(<%1O$[C5YRO"^.VX39!Z)A2\79#ZS&?-)U'J M.S)2JN3'FO>T/J[BUS1W^Z*LB&3G6MQHU*1;YU!*F9FZ[;+$*T74B4YF^*7 M7"0EX9,?1^LB>9;BW_W%K+TWX=
[OQZ?'U8_YW_]U/,L$BIK*O#/F(I+_'&^]H@C]?_)-)RGW+6HX"*:3^YO_-._<':?@_XWV M0?Z^N/#19:O&K&4#;5)L*Y'<).4-]4Z[*CEE.H"_NH,VO6B:"I"FK9&R($*F M07KV*%]_V_.,XA%I73@7T71]M8C(3M&>:SVP&\M?+GME(]]XX5,?1E&%S9O0
M+J42M9__:%NEO.MG,D[;2GJDG4^S*WGEVI];93;QX-A;WS1Z>IEWIZL05:#E MTWHJ+1?2:UY'R=,:U=UFW?A>EG!UL]@GTY6RK::U"\:9Y3N>O_DMN45D\KJ7 MDHWBL\E\Y))Y.?7:M5[D\3^B.H?ZX(-7[6$7UBMO:2[Q6E=<$;_H5"G)-+J M,OF2DY,WJ;-
C7Q'8:;R#51F?]K2^(]ZMZ051;>AEXW,@V.T!;DUF+5#KNV"J M/]2]")R/6]&Q$8-KHU')()XD8(I6:/S*9FZ:VM513$6S/Q[QR9?XG^RP.9V; M[L:%43ZJSU,_*7GL1J-6L/91N\63TU/67(RMS%BR0CG A\:-=U&>>FG^K[F> MSK)3.<-)_;4ZCX\|6\!6*^%?1ZP\-
Y'I2.A=ZJ[^ETW,R'L_C#;_YY+Y,_IA>Y?I;_*Y1O&ZQMM.D(+3>T?3$OBMA M LOSNFG2/GX\??/JI_0EITE'S!1 JJ/ C_G?:X_[Z7AA._0Z0M8T(K3WVD9D M@KC2Y*?+OIJXV_[*3@N9C]K=/@N7ZUU#75$H1I4HJ6EO/J_EQSYA6MU:2G3*
M7LX]Z',.6B#I:.8SS1:I$NDLY.!%CI=\APSY$@]M%4_*W+OC;_OFMGY::A(. M,!E4E)]$4I-0.A(V:A+Z5.@N*M7JDMOG16\6P<^#-I*'8 1Q 'J'0.&4 @" M_U/^:1PMEM@M__7UDY($Y[!=D*[I++V$F60W) M>0[9GIV8E)#AW7($4)AG$V
M/22YUNKS5K/N59KD+YM=+F?YMAI^FQOA5X+4 M2]LYFE;S\WF;XC&:-(W/ELB03.$_;5O,=SSI$6KHE17<<&^ %A(#*IP 1F$$ M%$Z][825'&[TP+M+OYC??,L8;W1>:G.R?'FO?:AM?7U#>;Y6^*'E\ M?;>7(;!"%>\?I5?1U"D"D?YUL?
#M^Z\7R7&>\FS'=GEXQI]Z7D\7M3&16?*, M?VJMTU5W=LJ'6#ES"_M\DOS:/BL'83Z;3WU.;$KY2.\TT@_4!>F5!1U-IG;/OKI^=OQ9]]%46Y_NK[1 M0^E8',:9NFD,W?&@^/EM=L2-_8H?+J%EFY24'%9KZ4K3>-)SB/$[\U:_[#S3 M,DD1/;4MB5>_824%
<_&|+&)TYSG+JUG-M6Q%W+5?F&3AN.E++M9)M5C.+.>I MIP!<&ZQL>L]Y=I'D0.@*F58WEVZ!F\UUNGENZ=E:-GBTVT89M(J22CD;K EMCHE3#%FC+&>!.(*LX M5RAL#+*Y2W+13HHZ;[/8QR]JQ'\T_.DO435=3;48DY\7)W.S\]3E#WRWL][MJ)8OH^K?
1K&$EE[KR^1]5I+C MVB*M?T;UNZ=_F[F?YHV+S%;,O-D#:4'S+LBX^XA_5*[]+UE!5U>?Q+8]3A[WO@UJN8QYBNT M;1\4KPKS4?S\<^M=3(5Z4>BV]1>),2Z6R9)3;U-]=_L-67D:1:J =*_K'G5T MU5R)^#^-
&!S_T&=OI*_H"FRZE[&6N&$G47GXMW='51\;:TO.XU&;K!7G@Y^V6;:Y['RFOW;OMJ?ZDMQZ-)I\229'5V6?N39YFIK>+,PZ1[>[M^+9:VV;=KWMK^Z9GV?O9.=E@2R]NC<=2]L=9W)ETL=1%H_Q)$SFW/7+KI_G+BG$XZ=)HFLDX^]':NJA_NJI
MC4I^KNJ/"WRSE!#3GIYQ-U[G][M^EO+RYA>N/PY]\FQ*BDVO8"7]-YO3K?.N MSPWHWED][*:B_A3 M6XA5E72%RM-5&@U7?]QN .]42:((RFA32D"P88!"9H F\==H99H@K91.[:3L M9NG0*Y4VWY-\E!RB(!V!:L4E6G2F3?+42_)D@=6*R2SBFF7N798A40CTOW]*
MS5VR_-/)O)QZW\M[,T]@T#3MGQ)"Y;3 +$]Z"+B83Z.%W%P?A1B49+DA(#*P M&(0.S#/D %(NR1>(HB+%-7!6*!O-.!UV$]F[1[2!KT4;0.2P%"%(LXNBXO;# M_QY/AAUJ.+:>FYZ-A[34*PFXV0NU_=!W=3G>#6T+!Q#U"]9%P, 2!$\%H,%$ MTP4]
81'2%$1_P(W.L_=95;J \;W"#V^?NK;$-B@C^\E.[+Z?9S]G[DW9$2A M9#J-L[&RQ*IL2V-=.2)LFVS?M:)7QJ$7GR[/IGY&O-0(32EH] MC09&;KP0;>FHTO\[6R_-[-N!]?$DOK@(GZ-\SR===X&C-LC?W[^VNB&]C].(M_7&E-^VARSD^[ZV*6P2GKHU &6%1$-X &[2-
F*8@,$8;X(.%$;@(56PG#4I_M:RWOWUIS.QV"F_7MJ\&GVZSSML&GY^3;[AP>*W3?]]1W.TZ|>PI*^OVHU3E5 M7LV;N'X_+6;-2E[%U?KND]-7UQLGTTGB[+VMF]H@HY)]H!&Y=1//]?U8"X\]:%W?KI.K=9LW"")Q!O?9S)+9WSZA:8GKI S4;M
MK\F%W%>4M&UL:CC5)\6;\P|U;)I;-=?SI45?DDE<=-F5N76476HN^P; ME^O?[2QY_])2EMV@*PDDN?8;OS]]O\'A^OV>M?#[H"_[#@S6YPA$ZZ)> MMLJ-W#!-K)XO.UITI%MVHYMY>S9NF^3FJ$F*'F'^^+H^'@0CUK\VC:3U"_C
M4V[/D9>_Z+/B<,+/2[F.9"]X&*]:3 MR]0\K/7[HPM24]HN6)/:]R4M>LNZ5M?4"HY^9YOKRX?^A#@(L(5 MA5].':1G+&[N%-^X"-/7X1B?>UNTVW/MZK\L7>IN)5+8-H8<7QYUZ7%Y81T! M5FK!VT!/-6_ZH-=YM#KB._RG'UU6YW%5*4+W-E3U[,I]VOCD6BY*+Z+3?
Z>1 MAM67"'9*(82)C?94&^5:+K:3N4E$KU;T;EWA&KKIX XLBS<[8#,KX< 5ODZ_KF8XKG!--BK'EXL(74*PN/"Z[3]8.ULO M^]"T'5%SKY2NQJ)_/?W)RQ')T6C+&RFB!GVQ+B86 -Q*B>F*PG %]%.(M=1G][W2 MXMXZK3.AO?R6$2Y<+2N>&TNIU,X?
%O6GWK9=LW.4[/QK>I%]Q:M M2=4V3M 3;YN^,UCEH11$/^V":%D*HDM!="F(_IZ"Z%MFU-\I$1__\+]O>O0M M_:EWY9!/;3I?9KD#T&4SCE46U>76INW37@7!E9='^Z#/] MKO%WM(F#K5583V^1,5><&8-DVK^?Y8]*V9*G)B;Q66+7S,6SRXN4ZA?_L&Y+
M7_NBV^;ZR9+[AA?NN/H_V\]%YVIL#T?ONLA+Z$Y*U^4_=K$6YIPN?1P7,>P MR99>,G_R%DY]?X*2B7K-?I#*WN-4NEW>[Q=MJ]XMGK!Z16Z64KN2G MKB1$G[7SEK()M.I3Z,VAG*G9B0F_)5-ZT2YSN_WT[7?9^0I_T:NH=318NF7 M;;'.PL9+5=%69SNZ3X(^6A-
LD:_R-*4FI=[6YV8^;;]*3-WWVFS;L8_]]"T_ M/%K/4VZZ\4F]3Z!N4XJSFRVQSM&:.R.5K2Y]=3Y-IRRFO% MY>6""HOZTMY;WM93H3LEI>S(^LZ07XQFN?A)RN#3:I6U!2OPTIT*AOLNJWD MT(M6%ZTKLEEUP6\G\W4AEA7TG*SZT=I
TKK;]JB:7X#X>>2*50=NGD"0O69Q M?VW,9O6+MD1E5OUUB_3QQ0=1%E0YX7[L^A%ERU3P[JK6?]#]TA=03-/4N;%; M-_%L<[07A&E['+=>B:N:S8:[MDV^;K/2]:RKL;A>?=CNP;GA^KKI#D<2@EE, M9NJU&?'Z"DVS*Z\.R^NZALNK)R:[;W-;9]^;>3]B[U,>#)?
%S7P:#4/?%6ZT M?) NZABA]P%]WWK7:C?:U]@^OG>IM\]/L;+KH9Z6(I.]'9-H3:#2-TQU4?L:YSV"FY)3+>90Y)0Z%2R]*F+\V?^K;L?YKN MC+"V[.^>3V[KS6QF\=V!;&YLXT(3P2K)E3I5.<1KG(]Z8,]IBV!F5TJ5(LY7 M@I>=-I##&].LER3N[Y?5KO2X^GU9W/&-
!1VM>1D7%[KE+20AVGW%534LG<]V MU4W;C7C>B]FVZ6.[B=EDEJI,%MI 1]?9E6X'-TB '_,$P(OYK&>@-D:XC.+G M%[,9]^IC#,M59(*LAM87K>=;O?+[-)%>2ULH9\W<])[MR;3IXD&]DC72)LVF
M[//+XB<]2DQS]6)8=:5)7U^4UK7*U*OD:WVULK%O3>'O/E*.HW7RI6LA.1#RJ3B*6CE+6)*Q^:36+H^KU;JN2/&WE MRO38Z]2/.+??_+?+>']KOZ4AM_'BXZ/JEUD463_^[6^O?FI'ZL6?;OJ6G];K M^+?-0NW4GAS:WK\S]3[C4,5Q3^DE 9JCH0T_3<>Q$S[>;?=?
W>SXRO;/,M:5 M];'UJLTONEG5SA<*UG%UXES= ^+1^DH63T_?E]BJ5^+P5:@LP;H7QJO&:$R]2-/U"-\O^PHMEY#UT9L7L (I>$$O= M,K$ '#$"J @8:)[J6:P.3"J'L%57$X0I451#CD$@--X3] 9&6PL()%([2!UB M=*U]YH=XSN,B]"?
_/ORV2LWWX4.DXL>6B*_2.SH.IUH+3_*NY^D: /\&J& M/OY&@CZ"<-#Y^7]NC9$%$W88K1?)&XN4H,4AV&3ZJ_9E9Y6VQNB*?I89M\/N MCZO'HL7N919AE_1G\5E['Q;I?%*]?R5<3'--UM4/6\'+WL8=!6 M**X-3[A^:D*O\:V5-6Z_F'1=UMJGM-AU2!>.X0L"[U65;_24U
XY)Z@3R3IN=-)AY73?ZTZ>I;VV, M)+GS&\DQX=O6==QFK;FN8PC$O\8[^/T,F 1?F(QR4]$?L^RG2:SZHO$OFK;5C.\E8Z M_MKVR4(=$\7_O)KST;WE-NGC+S?>C>Y\HSSFD#[P8__S+[/I=CIU"3"94Z(^ M]L]/4:L:.]"=)AL"#';[:4H%Q&T6SHLV%R=]<"V-US-
Q(*K'+Z.J/DL1F0[& MXE\VTK!24D[WT;1+U,FW/D0&SAIKQ>=)?#:/_&Y.T+=V[D@T\RJ3^W\PXV" MK1=K:24S=Y7]<27H[UG3O?4;:$EQZY>P->MLWZ\E7W?[P<-WG":\A>*'3>4] M4_"N\BGD?^XOBE:U]?RHK?O=D$PI8-YP0 41P BN@2#(4=#.=*M703)$SS4^S85
M'Q(X!XB,.SG]U0#.!S[&Z8"XR3SYJ8<&>H=F]Z9M@7_5@ONM.!(X "X-AY0 MF"8""D.!(41"#54@VE[%/TY=<%);0"13@&H%@:+Q;NF=18&S0(E^:#N1X2$B MX!4N?#88&']+P;1KITT-N?W=PZ?+]2V]JK^VP\5*Y[8-RJS.NFC;2*YT=%D, M-
UB$MG-.SO]'1^T0AJ[U9]N::WO:3S?BK6K.O$\)1>_;2S<7LMX:XTK*]-5Q M%EV3G)QL'&_7HVI^T=;;7"EFO5]TLS4G\;KZOY+HLV2>+1U3,V<,NJWXC8-6 MAY5BJ8*UB!@#M+(84.HI4(0BX+VD'B+N4=CHP7J7+L?=M+GFM]R'*>'(.S][MU8["N).ZL-%?
_!K51PH1DI.;4PBC&4\)T-@%(+62DCE,L=^4)7K_82^KF[8 <%-&'\B[PPC8AF-[.@"#?$] M>P$D]!!8PQ!'4#)#=S*SHP>SO]>SL[YMYTF:!G0R=K]T2[[\KBRTVZQ\,%EH M)SD);6SC-O5J29+Q$4]R5X<\2FF<)T(MT7([\@Z]L7Z7CJ]7!]Q?40B^D3&W MNJD?
UFV7:W3HFR>YE]Y4A]252I6N5*4K5>E*M?.N5/AN7:G(#SM/7[YU2ZH= M/_?6.L/.6V$-V5;\1DO+K@OX>BGY5L-\.?_OF[GT]9MG[J?9IXY?VY]AX:[H MFHM?S*=I6.*LG0W8%2)%3!ZO/G^U.W)^SB)W?S4S]PEEQTMTC/"C)\?S8R'4 MRC]RH(GR);KX(-
'%C>DHMY(W?UT8/9T%^ZR3V XMM%C"AM_R#3K!(=7> VE_MU&XL-4!+R0 QP3EKC:-]]?$W@>07E1RYDO._*,J_S_>)P1W#_-"2ZT@]!(X MC1"@!N4T@M3[P6IM& A;'1W(@Z::)9((*-F'TT2[(&2T;PP1C+-",3!RK7N M3C?:%NN#8:.L^#V*BM,52?$^K S?>
[\4$['PT_# M+9\K;KD=F#)OVNR#??KD2DE *0D8"KQO!U_F#27:8Q!Q%@,:F :240Z48-0Y M"XTP?!=Y?P_@VPOU5^_ O_UTDM1,B1%^.43P+&4"WRH3>(I)\!_;SI=UVW%I M2UOH- /[\Z2V?2Z=U4WJBCGJ>L3GH7S43ONN4NEW))HF6_=DFO95#\N?
STE0'M.7KM0#;_^^^;ZU'NZ9RZ MJR_F_.A9UVL[Y7,FT9P'MZ9_'3KE4FK]]^TG+1Z7+U=T&TQ#V;1"KZ9FR:U MW.W#[5O(WM(UW1YWLHUTJ=7OY[0YMS+I.(V]6*>#\6GLRG6-@]NGM"4/6W-= M2]G(U=RA8=;[]+5N+0N\2MD-)B6:3::E\F>1+3Q;&[_;3NMNF^?
GZ2VI:^7* M)!:[(&*NH5F;/9O*A58&Y39V3$&&4IM+_(_R&Y>YC/)SFC]< MS@R/K'S67N[;O]HZ4]"%N9P(M?RFG&'^-"%=D2"\Q<^ M'[I^';?F&*X\!ROO:?&,U(Z#6W*7-J.#M!K6UB?L]9]UA3QYL$@W^2Z7]#7I+*3&_B9-<=.CR:<\P$_/X]W3* $RPW9K
M21P_2N.Y\ZR==H\+HF3%90?]BM2[=E18DT?4S;-@C0_Z'-?PZLKXSZ3-Y-$! M>K;H;7WN_;SCY#Q*J%O2?&[8M3EQ2N/"%H,;LF#T_PX^X;=]3F)2]W*_KID_? M?Q_>3<;@YWH<-=4HY')M4O-A$I'J\KJ*I$%7;F_X !\>IU>HF1AKC9Y52]"B
MXJW8LZ\FYQ>I*_["#DV2JQZ':6=QN24]6W&?29AP,SW)!8Y,CZ,)U8[UW'[HU.CB?GDZ:>BR?U)O>D0:9+ M]N\8*/'.NKZ0O6$ASR[(7QTM#]]<-36^9R#,\@LW5(.U>L[=*P9$: 4Q,\ 0 M'2+(!PJ,B"WS7%+0HAWY,LONG
M7JA'.E:9D$4'Z.L@HIRVK1NY'LW3&4O2^\=1IEHGA2^2X^ LCPEMYV;FZ^9- MW4W":5^M=T!_CG+\4\2,>6[OD6SS=%MG0)V?IURN6>3;: 3,\L3L] UN.5*G M]2,?5:-V!.-E?WLS-_](PR&S^S>:5?8LSV]>)L@)T0S)%EO49];=4/7AM^X@ M$G,J4 ".$ RH-:FK%^4
>JR09I@Y(:*$,B]4,HQX+6/UHCC"A@H)$ Z"&N- M-5K1JP+D[]VK.6G?S+O\8MZ'? ::5_F5G*8WRTU8?SG.I* *,AM2Q4V,@-4G-L:GES$%D MWH<@89(I!YX*2(0ACR M +1 E!#I-8$2^HWRA4.A1[8(\E5) !#U,<=,0T4BS:H]/"? FH2O-X%P!P* M/:1Q6GI)@0TIY*TA
H82")3B6DK-B,=F@S\LUEA'\DEB?6H%8X",E 3(4Q4$ M0\YB.WQZW*YUS$$UE[D&%&XAY1=EP$/:SW_*V]$Z/OIBD1=2L%+ H0.Q]=*8F_"_\=;6>%*'WB*V]# M-=,T/[VSW1>NC]4%I!+\6ZRY'PW?3L_=8%?_-85TFC3)>SDB-'O LZ]XX_KV M2_/%71NBFW:9
CP^AZ92("!9V]G!<)0=%+=7?/.B\L'3Y_Y^E!_N8-+M)O*W M[,5K3&1KF*34*6 13QJ=D4!:$H"QR@9E+8%TLV_['3284WOFW7SDWX>3R,T] M(Y\N^/A-Q\(_1PY^E65I-W7RJFU]"ZOZF?9Q3'[BMG-%%O@Y1^DBM;U(?ICM M8J2%DNQ$S,D\QOOQMZ7);:1(*RRC(-
'QJ6#Q1!]"TAW6AV(.Z:0]T9X?5!PC M'8]_(SP6Z*$[A SB1GBLGL5&U3$2SV&?\85"-O3>-H_1#^#NY=$]]&YQ MD\M'K!O8WNGPD$O0]T_3;?K28U!TT4:![Z2-POVK7V_@\4_I#9GKZY>F> MGFX912&1";=A;%(C,WW=RD19+(2)(\)" 3?R+"&22DNT3N%AF<3N!
.W,M%) MG(G1SCP7D1Z (]V9F3*T<[LM#,)$U0E1A&E$@5VQH!GHDU,J Z93N/,@>=R MWN6A,A;'5"2&@$UBX ;IB*C$2J(- MY2H)=1BFR<"MS.C-#+#5\Z$ZJ([;;M^N'?[A"XTOQAVW$3TBT /0'Q'*S,RY6AE=EH9K6F8"!D39Q(P-9&)P6+$*0F3 M)
I9G/*$TYZ/*A*MM="$ZQ"[D&)>APS!6Y4B8URD&:6]$L:CE1D%>K0RHY5Y M,4PY6IEN7D<8,Y;$%!P1[%LM:4)$K!(2LRB&WU0LT^BZE6&IXX(Y1X0S:&5, M2$2D4\+"--.I2C*:#'V_;;0RSTB@!R"^HY49F7*T,CNM#$U91&66$LLH!XL1
M*2*XI82G$:.6W1P3^(DH8XJQ[66<92.5N:E"O13 M'W+KEBKWKWK([;>&RKYPM7]9]^WA#372CWMW[G.QP'YW&W7(:WDCB\! MZ8:&@4Y"OF_.T2Y&[YWQ?PS5 MC7$:C.1K-Y\C7H]$\1J/)F(X=,REQ!AM!2\=(%MJ8)&'D6*AB86TO MU6:?
OJ6#,YH\C$:C>33*932:H]%\CGP]&LUC-)I9+!F+J25)I+"9,_B<@MN4 M)#).7&8MTUEVB-:0@S.:HZ=Y3,IE-)]CT7R.?#T:S6,TFD89L(_2$B:H(,S$ M,5%6&$)CFJ:IX%DH>EO4B::22F:)B#737][T*3XKGRUEP\WX.1#0=V#74UE5 MB#[.+-EL
/W=1HOV/_P&^]RMR:OY5%Z]P6][M[#KAP'4XOR8=H?[@G\MJD;NK=]K^5F)GYNV]'+_[-)BN^Y+V^TFN^+[KW?D MXUM[RM^P\ON/ MZ\7WB1_2P73?R.D7>54UO7][7+"IPG -.WS16]_#+N.]I5<&YR7:B#\M"OT[
MSGGWJNYJN.:?"M:B*+TLO5G"W$LD9JWL'V;5/_NN[84+WM4?K?,]9,T(=R'> M1.PO!/=);:E';RK(;W[O6E4W;U4L<L7X&)]5?_]&=[R_;30__HNL "FYO"$ M1;FT#Z]S[\-NO3+]WR",_E5O\@6,0G\#1_YJT4@$:Y(&&S3M\NN*<-V,-3;A
M4W(>GW/0J^+&JEM:\!$K=K9TKN#W! FX/%H7_]R28P6/DFL/F M&U(;@,<3Y)Z&@;KRG6_Y#,YT[F<=OGRTT+.C"Q-%7Q?P#_!JP^GG[Y_'11E M4,]"!_:[RN[\'>HPH [!D^4"_\2:8KY MXB*[1'^*)]#KZ3R^$SZQPBPDL; M&+FPD^ S?(O.FYQ=!8LM<39N
M12QXXJ*AZ7(.-_GY@EV8M+PY!/8(1D%I*?'C+/A[<5FW.,9>*REO>O6YF(.%IB)_2;X M\0($[)A$)#-^C(/S]H[W^>5GA;5LK3520"4T.? Y?]>@K<$3!W,P3N'I\&% M^>(*GV#]RX&7@;8@1UK",ZKF6?;K'+FUEH9&1)NO@,(7%;*UQ/\ O4S]13EZ M*_E%H&25U[?
A@',#0C=;?3F'OPN4,9 9LQYN(%4!8B9AO*M9-;_[SS\)&J5O M*WP:K !J#+BID=(*E$5'1>AE6=9"W'XQ%E;@ MT%?'B?SE6M-5'9M[H-^+BC\1R\R^48V@)5 M*,L*%"O(*0I*X#VW=OK%JT;0C*L%W*$987G6RB\[66]"\ <
MG^57>&>C]U*V3>^MK]RF[URAEZBU@#GPG27J6K#T!:S5-*_=K)HG_4,6_G5S MF0,#71O2%NV@EA6(#ZB>1EY?_?+]#Z^[RN)D4REZ10CL_J]1RZDLMXX&GXE8 M!W@1V TAB3QKM&ZMS33PNX\TPZ-46?S+@O(!50E2570 D(9'GQ5EWO*UMB#=
M(&6KM\%+:KWMEJ77YIUG 6Z;R<6RK'7]IAL-#/;W2SEU-VUL31)X-5'/+F:D\9 -- M9/">E2;TL--9 [(Z/:E!U%_<\1?O* 6);AE]:K#A1N3RVLE7I,7E1V8D:F5 MU2+@?_8:WI]Z68\+1G75*.(=(YL$'T!+ E]4-<_?K$T;/FD5X_V5X.FLY>4-PU4S0SLSM03EL[6"!,'"Q:1SYD?*:?
^O@AG](-W,ZYE';QWPR0 M(5NJPU@]#+2.-F1H-J2+KMF--H21$(S,(_E)>P8<&KOU]?7RR!KGHZ=:VG/ MVZ@9Z@O)#S4 1R/7ZCJ4]H[-"UY]6JI%[2+0D("U?"P2W&G"Z.*TB_.Z!I=; M]-"R]H<:B] 1KI/Z$HNHV5:M(=KF+I^@H#562+>.2](L_U%763O[4* M:&&#
^JL@@SM>S;%N7U81\EUOH1+T0C<-FNTA?DD^&'3AL"0 M.F;DVJ#!I"^G8#UMXVJ VL\]A-BT'[!"6X,9C;CB[,H5RZ_\0#] #S$V0C@U M]1LE[.]<7'\9AFB\$XC*O<.NO9L-"V<=737,>#5K38>'-]?Q-*6KFB71, M5Z[=3F5Q7+2/ M9G\3O ,/(G=7+;3Y824N[V$(0]+
[U_3'=9VG_3S:@$5?ZCM6HW7]\B;$@RJU MYS]XN?7/.EOF!L3B@W_2Y5_ M^9\AR<7V5)K=Z3';-VHI2[4R"1X\CC5A*HV)XBXBAB4H2RYEM'<,:Y^-VD]+ ML/5>MDULZLGYQ.&[I"^\8 @.&G+\@S/*'59H]Y4:TQYNY6% M>\-YY5W1VOUTQ71:?($'-_YPL:S@YNI-
AXG^5YL.7&_G] L5^42[S01+E">\ MG$SE5;%L+JE'G(63_MY4"HJ9Q7]DT% \?X]682N;]M7:NI4_OI,]]RE4_S MQ=6;]AG=HDZ=W.7ZK0F;,.![_N9NEUY"M3M/[RPWW1I-];]SS-C8121RN_^S[MG*.9;B@>\I4;6=7?W*UGF_!N+RK65PK;!KXE5?
XASCV)1SS)L3V3^&$//HT4 M?0B*_N_CM__]'?WN$-3=/,=QTQFIH9WDNU]R? \BWVE]KF]SL8=F_AN6YTD/ MV;P,?3(?AX5RK-6*]=SFP0AZ,R>63.WP]PWK5@[=@<\M#GA'^<5M=OJI44X'LOV4\M'V/P>)'(#\C29B9,C1
M1&PU5B7,PB1R(;@H<8F8BH5$O"D8N-C$/=:^B]I=XB]I(ABCHXD8BGLX M[B8^F7M8U_]] M'Q]5R&HVD'2OW1]]#T8RF_VGKDEM!>1PZ(A6X>TS'@BA& M'>&1I321PJ6,'V(OL=5/[VOUM)_Q=_E7:\@?MBR0J_RYT]'V/P>1'(CC9B M9,C11FRU$7$6R50+,
I"6,)4EA$I14JT3SB1F8QTST;LLX%X$!O1CR$F\6@D MAN(@CON'3^4@MJIS!_VF4TEX.T3=O(C8]ZEVCH=ZA@AH=Q5$H1RLQ,N10&7*T$EU' M,60JC6(._EZ8@I7@,1$J9B1)'*1SR%CF&GL^6S0SVJO17HWV:K17#U>MB&2L(I4MT=B$ SOB/)I]M?J#?
RZK1>ZNVBGY M6XF=F;?^A"D^N[13B;V:NRW=5H[2USLZ/K_7H^70*QY%&ZM=KVZ[MFN)[Q\EWDGXCIU_D5=4TS.MRP::* MPC7L\$5O?0^[C/>64AFOZBY'TS_56%V4OGWR&_!/;8G$ MK#?*'V;5?8-3[,
[YKOYHO5TI_^>NK6_#B7C*YK>W2>#=B1'T)*#;O+K;V_H; MVE?_'NW70IH^O +:["$]+PN8O,%F]/.'UTG^R?MT(R[F@%NN_';[#SA4;.]] MM5?SR^S)>UJA-/=Z^YT$7VQP+DTP*X)YEX:VI>%DQ?WUW]M:,AL3QVFMZW%#\^1
^D7>Z+>VJZ'R=7RV%I3MS;IOF]9WNW3A74G^+/H[BW"2B'W[M'2?L<1L>_W'^G#]CL<>WIC_OU MM^W79XE-G!"&&($I\FELB:!A2%22LE!'E$K; X.&&\:HD(1*&A.6)1(\'Z9(MQE,3<::Q(N6=P>#_*8OJ@ ? P_$ ^#-+@A_1P;?+^E:?>L0#(QX8K(898<"3
MP@">92P,4TXX2Q+"5,2(2C-.HDAI&?)IM)/788 %.Q\+SHC+%"4LQ*QTH2U) MG7!460D/=$\# T0Z@H"A@(Q1/!4(. G*RM[7DQ-D%_,R^+27FQL#3VY A[H M&APK(AC/WS_@<8#Q_/T^J$(SS9S0&K"$"+$=E2 "H 1)(DE%QHU,>*\LC-)1 M+&C"
'ID$6&"*KQ'D5A1&L%/7(;IDZ"*+!G/X!\5\AC##T=H]49L,41L\=P4 MRAAM>%)<8%0:4BLCHI,T)@Q,/LET)HCD$8L=52S!;))#'!)\!%Q 3R(^B!/M MSTU(QWC#L<4;]NI-(+5>7BRG$E.>C(7'Z-PG&'7STK:_'BE V"016?']))C9,>OD9:"H ML?
K46'UJ6($E9],P3B4E2L4185)$)%-90F(J%'744/? @:6_VT.!F#BCPX,P M+['H5+].P .>23SPJ=K#'6_[O?MGZTG-+@QJJ-(E%(DF+$K^O&*5NL[T)+Z9 M>@]H$>ZBKZLEB'DOTG08BG:B32#FKB@6LV)A:T7V]\^_&RHPE5">.A24$L9 M)5EJ%8FU8C3BH;
(Q]+*O%],WH(/._OL[.R._?7] "8?QX4]F[\W0V<'&\N-, M3Y<&;LXOYC(OZ[.:Y\!/_AS]?VP;Z=V'\1@==QP3B>*."!%;P@3C) M90F0J M(T6M"BUGURT=%\Y*(="^)=C?CV5$AF =I:&)"$VBHLSV7'NLJ/CCBD;O/(EV
M;YTD&S:.WV+CP"/>:>,&P",!W#^%,9T$E;6!LM/B2V#R2B^K"A<"_GN

YY MRAY732_:<\>G9Z6UW2,!0R#P*UFU%+4&SSZW@UM5XG"SWZ>8QU@]9"F.AUR% MOZ-2SR:!S\;<*,PQ@ 5X/>D>,6]MT+I44/>$>%M.9C\8=/*%\/ 0=WX9F#K MZK,H8MO+,:#Z\])7Y5^#"WC(>158H)CIUW;P-\(/<2!+B_TH*O3F3%T0P*(F M-_@NXRL*(/_Z';9]
?_XO%X>! 3563X/VRA,GX>Q<@2_:6U]];*QR0 MQK[,A9;Q M-"*1RT+";!(1:1T'6VQ4DF8NY2F_;H:[;'='XYML&%]268T&&..HP%G?_<^L M.+SI/2 /+((2-??F'G(K0(SW1"&,TX43]21*DLC+222<+ZB%A9%L=&DTA($,4(.UAB M\TKMJ)8V$BS)Z %$\78%VT/!N \Z]P<
N0\Z MWM?W9^1G$M<[K0*$_"-C/AG0E:@I3+ H@LI.IT&Q+ .W4=S'@$AHRZ:,]DI6'\KBXA-8X8]N523I=&8^%3<:;+#KLFF MMZ683&XH-#($UL+H%+*2E]]@84NXL :H6^$2^<7&ME@ M1WCBE>^:$_Q4S,[(3_DEK%W=0>?U)/A\GE=XF[95!2O]H^5FQ1"-
[U7:"YGC MX);+;S?8H)E9=UR&DSA<=5)4('!RUVN91U?GYUAR+T>*5SHAS,O< ZYG/9C M\57@DWEK]8CW[!CO)/A>(KI:SANV7S.NU[&U+UGS=#_@;VIGTFO>'+5!<&5E MV?AO&_49AR7A[IK#> 2V0$0\=@)<,VU2/-V9:")LE)%8)9QR;9Q(>NVA7L:V
MQ0.X:ZOHXPX\46%M@.N@ F[K6P80HO-3K4NE\ W/^72UW_.[4.9F_O4R.Y53]?64F6D 00C8T C-"0R M,I0(%EE (XI9D1VB>OHG?6[-$KW89G:=R?E^#W>MHGZ7 ?LJZB^]YG[#1-,U MG6^HWKZK4OO\>91&3]B$\7C?VNC[WKCG;6PBDCA<_]GW.4 QDI?.R-
$1^3ND,[Q30X>HZT>F:\-\KUR*M/+-?W M.T)]=U36G^.QKM:18(:1H@/7U@,J%W.0!;AK4.5+K5E4,37?E!2_(YO\H9A_MJ(4U7H8^&0_CPKE62N4K=NJHS(9*. <2RY^@W-UT/WK=L\"D_;LK*JWW#'' M0]F9A4NK.VRE/F'9Q;'@XK"=\>=0C?:XR@"-
)7YN2\X)J5,V#1.B#66$I2XA M(N.64&MH:JP5UO5*_B:RE :1PREAC N+,VI*+HRM$$?DC M,3+D:#2V]UX14LH(.ZZ BP!&0X !8*EO@"L%-5$DZ+V\S$S,10? M<]QQ?6H? X884]R MCBBB@R(,%R83&K"#X2EA5CKP(BW\I9FD)K9I;.PAMC"]8NO70CYL0)]+(6"(
MH5:D.%HY'TW3:)].C&5'TW1_T\1U)*),A\0DL20LM90(E8:$98G.8A$Y;GK= MF??9*WT4TQ2ST30=DPM\F/W4;B\&&NXJRG,@G[BAK^]2X%_6?7MX0Q.(XW:9 M/Q<+S.7M]W\8LRY;,%+].=&NW4:*=&._5@ M=DJ&CCF)O>62.,1.F8(H;A41W F:<>K AATP&?
GAPKXGD1C$\=:7::>Z#C;\ MC)WP'J<=X5/TN+P3O7[O_MD@VT9/2OC=Y)?UITW;1]FP+GX.)-WNW#=D[%*6 MTG_KQBK3H&1W^NUL)-)&!^,>SIUE6&2 MKB@6LV)AZPG^_?/O(F/,<$]B@0E+$TXR9A@!.;K9,)B)=!3^'HQ?3.5L[/_M_L[.R&^?
[B,8MRW&W6<6_%AW'Z\"VU37"\ $P]7U$J[*7O?:3M^[<>_AYG!+ M!^S;7O089EVR-&61(RS&N+D,&1$A4R2E.H[#C*5K\S.@$"#9I!I=>HO38_GF$W>G6>%&4-G#+ M*2AAT-NZS)4UV#RYG9\,SDNDVY_<['<8Q)&B2H=5?ENF[.KOYD'&4#9HO0& MX?
G_Y'1IW^>5GA;5$B1K5_W.[E^$;VO;^0I &+]+B^LQ 'M M"0I]38.[3ZQ^S#C@X]N$N#:!GYQ@Y]K2F);_,9^XXMV?S^?VT#+LKR"*P-Y M42QG-:9WH$1G&FOXYK,*.-]3+:B6^APMC9;5>6#_OLO! MX?UG;^L#A6EWB6E6!@05;%/[KSJ/A MEF7IT0".$;ZL;'=\D^ ?
MGE]4"S+P'[5MFI&"W9P^YR UCBI$LQN2 S+B2? %)B&WP_)O>.-C8.$TSFB4MH0^" F3EDJN>%2A^]Z7>J WRTF:]^ + &N M1%R,J3&5G>TL?0'V584Z!;0/8V0P0I(EJ211IK)(Q3HV_9**-M26@0<+?FAD MP$,PE@B;)N#/PA1I:FGD>I;WZ69()?@C1L$:)9#;J
MG>+=9X:G5647CSTY+D(7*T-)F&'8R3+ 3(PQ<+RH9BEWJ76]],(^#/K DYL5 M6URU/3X8CI(#%8X4"XJRF_P4-!C/!!B9 #,$AJ-$>PR7P>/(^@,EJ[R:W!JE M,I&X-R.XX+>]S90)SV=^QDV67OW!/Y?5(G=7[>3]K<3.S)8V=JKXBI1&ZJUV M9;[><9?E/E#[?
OTV#\T;$=U8UWJWH5W-_+:YD(^0U;W&99+M[(Y:)XN_D% M4+K^N%Y\GP\I'4SWC9Q^D5?5V^_^+%O%-A:% M_AWG_) 1C4/B;X^(:Z]]S_:"%9L>"YQI(EB]2*RH":5B$7.]4]7[Q =^M>@M:'0]9F>G,]/$)D\Q]N85 M^-KP#21L<.?
HWM.ZYW<.W+UT+_W'&;+OK#;*P9=\<>[]VW\6X)YZ0(5EX]!? M!D/=A HM? YN8S'WSB@HF#__;-3N%+!O8LJ-U[M_%7B], Y7KF+X!A2[XS) MV0S\=HT^*+K&2)3V6?CR5:N?]GNL T ' &=Q+L$#7L!M%U/OL.(=17DF9_D? M]1HOBB\2<)YW8]LAF^T/;5ZX^%
($5H)&MNN7HP$\LPVL.@DN"Y#3'+Y4WMG] M^0<2,^8=8IQ"M9PN3ORCOB_@W74&*\= IQ9X,"GZ. K46J-/E M&4#49B_E"S+A!7 ;LCNN]J<%H ![!K;F= IJ=.8A3H7K[[=:4,Z6P'1^?P4Y MJEI=+[O7MS+D^?C631FX0"TKX%R/\PL'-*B>'L?
<9VLFFH!BP5G/O2"!)'^_MK& H51T"^Q[GB9_^ C.%V_R #[)=<] @*-GZ)CN009!^5!@,3RNLSS M0!6S964KSU;8 DW[&H/Y3*/:/ <)@9',"O\AABB]!EKXHS% BB$IC%OVI6]] MT[W";YN3WEG7.XG2A"I'6)IEA,5"$14"ON-,4!=GH5)Q>AT$&AL[2F-)PA K
MNV8);BPQ38R SY.41C+MQ3H^@4$J)8BR;_81'2A?(IGP80)M.M(KQXX?M;5_#@6F^#(+ MY I=3P*_2='(C4<66^0]]T.DF_6X#[172_7/YC$R@-5! (09356UO/ J"X2X MWL/P(E]CB"]XD%=@ IR#JW$7 WL=3]_\[@-^ TO?C@I=ZD7=L**F#X]]KC,9
MZIV&!=)#U@C"DP-(.VL1%#ZMT/Y!:P@# SS!T)"_B+AP^1]?806OP@:6\OBS,-=394,2<)L"!A5&NB]$U)Q!+CHC 1<9\ST\1H MFFE+,B49 !,IB4R<)E):$3FA0QOU@DP/Q9G9<7 F&BZ/,2]+N]B>4[LQ /S] M#/1KV?2"D@8>F7NO"^Q:VVAX,REN$K0*?
DA3OH.QB5^PL7F,_?N$"9EJ1Z@1 M#@\|.)(9DX&,9BZ*C$O YEP7:9=DDJ=XTM=%X&8DB2,BBQQ1213:5(#SH>1C MB?3N<[Y#8(!G:VP>@3,5-TK&4A&N!, @&:?@F%+P:*/0<6-32_LM1YQ(,F8= M)38-,VQLE1$E54(R'NLPPJY7_)&D*E$E/#-8_!MXJ= N]
(9"0384Q"F4:)!$P*>N:Z4DE8:*U@&3$2K"-3 M*2)8B_NKF8P=TX[97HF+AU$JT61WL[LA,,"S-7>/X%LI'ILX306)XP3\)(I6 M"X%8$O.$9R(60O5\JS !,T=92*BT8.YD$A.A0N!,YYB*(AFRT#T.9]+)[H/L M0V" %^A,W6IJXB&-]AO-
WA&8&I]YT*0))8]Y"I4._:4X(9:%FNE42!WVFJR& MI4M,;"S1DCOLET'&=1".:W5WGC,3'Y,6@MT%B M<,\/A=(W=7=_%QI\Y4&S^MZ"C[Y8TL%S. 5?+XX+WS^1_7ZS.!DS#9"Q4O)U-Y52R;2^H79>$D_'-[.5?5/9N<3M MR\WJ3/ZV[[;5A[W$M#8DY-
6;]AD["K_6;V7)A/VYF[#>>>M\%0\431ZD_Z]*_/)ON.>[_;*)UDCS;=^Y4;WB9^]ZQ!?+"66ZT&W9)U M+!ZQ6MKV$Q9/62/P(8HN/B9%GZ;F(G ^?OO?W]'O#D';^U?LC7&V!WR M (+TO87QS>I3W%.,\XVUQ)_&A% T^KCKA8PWP6S?R7:P$2PT1(58]
M<9DC,LY2$EL>ZCB,N.6]0/,^-1@WPLOPBRTO]ZOHL:T"XQ!]?P]%0)] EXT6 M8[08H\5X*18C"A6U+DN(=3PA+#&2"#0&-..T2+D66[S]:\0 E]6G=28[Z#/F2GQ>@Q.RU&+Z?3XH\S M#2OCRV.N=IO+KI0.1V,/0#^/6&*XFF]$$$*(<+$<)D!9DBLB;"6I"0J%3%)
M,QJ'VO$P4KQ72Y(JEH2&$Y=(2UC*!0$OE!$3)C8! ,&CK)<]O@U"_&++O#"M M*GMOZW\/!"S821R/T.)9".P Q'.T("-#CA9DNQ,JJ=8FE80F:4I8%E.B0IH2 M(14U,LHR87NEEB,;%<4(4SRCA"FY(HHAIJ9_<@G"^^VC2**Y' MN=,YNJ8/[YKZ9@AS>=5KQ#&"B&
<$(O;,NCEBO?6(793W26)Z24#DU7U.3]P# MZC@.?F^:&"+QP!C+C"6*I9:D+G4R3#-&PX,XR[\TVO-#46Z@G@,!F_@D3';7 M#1]&$AECR9P-(&C"1Q-X/,P@9S&26Q,0H0!F\:8B<#1EUC"B#,G M6,QYV*O'NX^W_\ F,#KA5(PF\(E-X%/N4H])SP=(>OYAYLNF?
S]F/+\@I$,G M%+64*99X1'QH6.>XF1)LLC#/X*<5:C(^6!Q>=4+&[5\!09'UPD.0H M/)O11(TF:C11+]M$&6X2S30C$8LSPE)G2"822=+,"F4X9R;M^/6Q>DMSK;/N-[QT M1XVYD&8BBC3%I!E.&$U2@++&$JE!!P@;ZRSI=?3>I\;96?
G2K^^#GNN>9;X56^L::9;$\]QNS&7Q:X;K5;B?!)UL_L6FOV72-\T7D M9=TFNV[IVI8TWMI$,Z_FA9LY>>2=,^DD>(]3]=NL^ZYTP=^+&7% +1!06.!3 M['H[M&Z9-0^85=N[?%9C1IQ#:<]DZ=FVPWB;S>O:!?8=^. S=>67_Y;,**Z&FJMV M6Q?8KU8OO;
(JG,NU+6M=Z+];3[S]SO=_;/1/K7[6K2G;%,.F@:.V4UMZ/KL$ M%PA?Z"_!\U'E,16OK+N2)U[C9.7W5'GU4I1P86>*P(LAIZ['+M6YZ5>7E0+ M?&WU(AJ [,G7/P$GGVTV^7W&1+I,EY2RN*CM);9,A7]]57AL_*GP\.9E,;VL M-5T+-
Z;R2[7,L=OY%-2I;T.,+83A195O"Z]G,K^HVNZ@>7T$%'5H@:I7EMAU MU)MNT">J:<8\"7Z6,WE6RZ6RT]Q>^E:K%KN+PO^SHGUL48LK0)Y@;NO-/7DF M\UF-;Z0O5+^MOTO=,3V?3KU..($Q@7^4FR4V3L6'-F.49V=H)!9PA5RU5@5S M C(-([;.8;-6]$I!K-O! R'R?
R]SL#A7)QT5T>I-3Y2V<2OVH)W;6KG#K-?\ M>!*<%U]0=9R@K'?:PN8SI *0!=MXEPN8*L*GIBOL;#6TIC5K/8W*@Y\"Z8>3 M6" T\HUA_7*XZRN^[O4*RNC"J\35P@RU#/2S%=H]-=N/0("+&9@#/:JW3;J@ MZ075XTWRVN1?U/TY4(KP6+HWJRA?-06]
<@*WH2CG#1+S5U;Y5[A_Z[WJ"O6B MUYT>=.2;Z]$Z,%YQ-3VG&PQ1XP.3ER#P1>/#-)+>]F)&8=9UUV:-LM]1#^V5 MT_S"ZV2@[-3[,%=U?VE;7]*.A"N])6A +;$B^N+*NU]E,U9E[:RC8N&HM: M,*YV/K(S0OQ\-?BVA/P5O*-:-L@'L*]^6JL56SMU^:+VW71QB;
+BM7P!< M-GD!/B3,=BYSXZG@EHLEC+$>UJB)CD03_0(R :8<;)OV[3%.6\#]$FAV)PJ= M5FV 8;/V(L4D^.B!2(\?]D=T'/>;4MB+X?5Y4.F^,QH\S/0E>-5^];GS(!A>O ']I LKB24Q_'K%UD__J97?AX' #HT^V ?TC+UF""[LUVHJUE'H$D-HFEG",I$0
MH2UNU/$T5IF)$[LJUW5A_F;T[H:T,\M![2)U'MM I/*:MP(QM3:RLZ^^Y]9 M,>SN4KX6$D;3$>#TV'T=,JJN"QC*W%IJ/$/-BD6-W2[L8B/J<],.**IJL)= M[S-+-MOD?+?1F.H/;Y:_OB'Q6S>U7TF-_]"< /&6%[.W&.:<8<\HOL# MA?O5.#\TOT3QQKK6^^?
M:IZO\M&;^>0S-/)@[,!"U-V*-K\ 2MM-TN6 S.0+7L,,7O?4][#+>>>S=^!:@6A?X=Y_ST4.IN/;^\ MNP1"_Z[^: ,I;<#G&X@W$4^)EF^3P#U]K0U-=K#LACCCL10T(Y'FC##C(I+Q MT!)MDS24-)%6]NS>/MD-OZ(_O[08@?.[IY/UMZOBBPS^EI?@/KPK)B?!3PNS(N$)@/O-
MM(1W*R\B_Z..K8T1ABU1S]-YF4_1&0]] ^)1C0\W8- ?L.3?_O;N)E)>]P_/ M2CEK6DOBG1*T(;%?]719Y;B=4BU5K3?0<2*!9\ =\9*?8?;'9$+D*YKB) 21> M^G1-W)XR2[WPSX67XF@Z-_ED =P46@*!_::0;H*TS8;0;Y-/X#6O?FJX\O5J M_V5%@^#5EJAL:?$?
+'V**L?/96Y+]%\V L(U6>ZP*]]OH_3)D9):8^BWS'U# MTT65&]NZ/)[J2)4. ^)&W\W\MS<1\$UWI<*=>*=AE)N'6TN39, M>21-PYF2+HTC3KB(L#X<-41AP7& <0#F>&HC1'*;Z,^E8^-X1GBA)F.:"_MV(0DM:ET,I898W(CZO&Y
+/XV]R5))@FXO&KU3:_1()*,K_@^S]T?WJ]<2! M>F]'83@)AQT.:9IM#S9GA<:1HX]LN?^Z!/$'PQWW#;?LIBM>C_HV,G^Q7-19 M#:N$H3O9>Z^F0)O560-M)^G5*ZI V<47##;YC,LFN?35Y\YPUE;*/^R?!0P9 MAH'L:&K%C;L>1=T%O*M(NXFG7;.
[-6+Z5*SZ2YF#OF_4Y,DMDX/W4]'$T_T M+[+";>(YZ-TCW=MK9L:N&X;@9O"C6B7--2ML*[ZW"^YCN6RWG\RDN_PPT6%5A2L\] M)M4Q1"K IZ=$Y_WY M1Z,37 &P7&NCY=QXAO$Y%%4%J]^- M3R_0R 4+,&558V'!"=%MQM$=E)!/#W!3S];(!+6];/'$R3H
OHJ4GP283'GA M!]5E/N1O@LF5'A37Z>W.^BSPLH["3()3#'W"=S, GQC_]K.:3V$%KND]',O9 MM% PN>X[-EFY_US_*F$9,<=LO3,%%*2>@J:I 5O3L!V\9U+,L//X"3/Z,:&] MS5INA+3HS3!H9C@R[^]P1*M [JJBOUB?%NZ]-$3>)^U*-RY;UZT#]OW?59U] ML_;I?+Y.
<3&7_KQ ?4;!UB80V?T7M6%=.8+-6I[@Y?59A1U^QH8W M,8,K3;%.RYFA>K]HO*T&[OL-\HF#518?LP'FFTPA M>"ZX)CB.]>NF!6X, %E[LM4D8G9[M\9#,N8G1^*:N"RA1J4A40R//<:4@J// M)8E"R_C+K)>W0BC0^XDA8LR!>Y,%,9$Q%E"A-2)BV/)PJ17S.I]LWY-@/I
M_D<"2N:X#$0H\OI3/ M&BS6ZI_;;%^-$W5O-H-9FL#_5@N3%T^@T52]53;B&I54\R"9/1 MYJRVZX#\1Z!,(A=G2D0A<8G."!.Q)5*IA+B8&RT-M8GHQ3E&9;*',NGAWP-I M%=00H%:F2U/K!QA.G12\N),!;K.E-C[T *@Y*]7'R#XU=P[B_]6C5/ ECX#/ MA1%1'$>2I%
(8/*LNB5+:$)'J4 D:ZTCU^)Q&4O$HC(@-#<8 F20B-)K$F>6Q MU$ 7$V_$\YK%^[A:N]-ZZ3ZO%_\77/O3=ND?1BK"R>X60H,2BHX3XZW5[3+2 MW??[A&GLVE8[$6Z=B[\RGILXM67F.H6PR5\$IF[RSW'GHOM8UQRAV8AE7#NX
MC,9\TW1WCN<5L_OF^NW(4[!IG,;,65A_(;!4MR2211'1F'$0) F;O4 MI5$6 GIDFK D%$0D6492E6'06S-MDLU(1H.K&:XR848 B >:>!MQ,@K@E$" M@OEW@^ Z'T&-V*;?T4N*&Y"4M,'7-<^VAR& &WM*^0N>W.APNZD#-LC5W.!- M#0*[VIX-
]Q#%K45A>L*@TC3D69@1DSE0\Z"EP3=B$9&"*&'P MJ>NUKH?YG):@MNI3BM6N9)V@C1J9T\5=A^DKUSQFCL^=3A<\;1*-&'B*SZV' M&L9$G_%DT'Z[?VNGG891BO#K42)MIL:PZV2U?BG)JOF!\>TL$<[W?8K>D3%P6Y5+G>IHK/%3=5I7!+.4S
MBX>CFU(QE<6X/I[KW?N_X;'G7.6+HCQIL%T-'U>59B;!CWZ_ZQP5LG=B?%;" M$;@G"4TB11&Z)5AHCR::9%F2DB0"A&:UXCKJ@SC.E&3,$LY51)@&]"!#T1@OVX%R!W$\Z&1W@Y8A2-+:&R_6LN W!W"_L(GG MUXBIK!:=[)V3.JU%EYY:P)M'P%)1&@IH"!6*
#ZB>+ 7, H(M)A',9&\[@' MA4++$ZN I1*J$L)<9HC40I%0LXPG[8]%ZD5V&C14'_@%7^A@O'0<62KK?4BS MM/51-%-4?N/0=7BIW3!J K/UAZ4]:\I@^0@1J,:3NAR% H_S2^WU-GQZ4N]8 M^[W4U8&@X]BOD.!,ABQ3Q,0R!4,;.+!&2A\1282DW1DM->P?(:"JT (\TLBD
M9.9N,XK?PYGXK&B#.OZRO*^0C=I>^2M%6 M%;>YH_C#;[C[Z+>L)\'ING#6^G!:EPF76VG)0YX7[CE*_@UUHI*\@B\-034\Q<)]9UAE(O<(>?7UXN!G# MZN!P6W*BS5BNEAHSF>K,VV9(UOB .=;8F0)TGM45##'!;I6$XI%IG;N[%I). MI'.=U0PS7:72KY)_[>K]-
;;V,-9/#6>U-@B8]E?/: [D0%0"G[V]G]>FDU1U M.E/]N&[D$CX#Z(>I.J_]K)NXTN;>OZ\-LAX74OG].J@T)";KMSF;8BR;VYV] M4^#^LM4FQX4TOI#4^BC[RC-]Z=QSBH8;+WNN;O*>H87O;?Y_+$CDN^XN^4N@
MUUW#"A_UHFB""F);7O&JV.MFGH&/)33$;0YFO6I^?8T:R@+,6+8IQI5T=E&K M;HOE@:2^ZJ=[@E)7;;9!]^G_^2=!H_1MA9)X4_.T2?)> MU8'R_)VS2< 7UT_$=3*X+;K5N/TYAOW+LIZEZ[-0V[J^?K#*ZL'X3D?&-A2 MMP1!(NZL66R_SE%[5\TK%NNL3$2N
@A]W7N1]37FQY2C$XCRO M=F+,7O9,9P],M+EKF"7S#M/LP6TW>5W\:)4#X9UY?R!BA20\)%B!AZJMV+\3 M/722*+[9Q]R2>WO]PAB[75P?7]4@H1K>7L,Z.T?](=-)&\2#)3$(>XQ/[D>E MYJGHRY*NHG;KFL,GW8G>.KVXSC793 $<$FXZ@D"D,1E+I-
&$A2(CS"686I@H MD@DC9)*P-*5)+T\E95&H>4I"9V(L2..(D!$E%/,7#1.A"N-^<1E?5_7JHWOO MH1ZRVZ$"X^%D=VNM(;#!UG/$-[2"VIE4Q$(6AB8S!,B?$F952K+0&&*MBXSE M$5.I.D0EH)\P(F<_UF(Y._O)A_#NFE)TET$^>DK1U$]AJ-E$V<"SB6H&& -6
M_5/P6\K7R, S6R?EQ9]JOM5(# MICO+98TMK[.4/S^OSP&13>M@EOTZ![O:K=>\?W)W]TXL84KRK^0\-R#C;S[\ MGJ4TM2YF1' =$@9,0:3ACB21I(;4#M*AR*H/WN$"F*Z2M?<_&<(8YP,"K%B MA86-4SZ++
(%NMC18U786SW5&#CZ7D7D12.X(GE5[]^_.VUKP%05WJX-MAU7P"? MOI@O5J_"[_J<;4?3.+(KM,VO'J(N[^D<,*D@K/'(D,)#6,.%=Q.(KK-^AP6-F'.3[#0'>F+N;$ M:1,1!J@=+"X7Q'(MC8@S&B6]T]1@8P%M)YSP3'LK[8BDVA%*11F/,YT:#8/ MAB$G=L[0O
<^/++C,W\'/[)[;'@%GH=^A :QH6G:(JWRF(:/!)6*+74\(RQ) MP-N/9$94RK 0+1-:;P/?]5*5,B,=#\,.Q)FTA DCB<*[3222R$8ZT=H]&!*, MZ$E\S$A0FG]*W=2;P2W%]A1M229HR&44)9(2Q2APL@2]J:@& M3X5G2F4B$J! K_.TICH1PE+ O!S^TED"]
[@07!S@=AJFD4QL+Q-T(X32HH1> M'2PA]#B.U];0<(/Y6DA7KO*Z;>UGMR+'3;;>S<:>Z?TY1E_OJ0F!S]I=_/9Q<'|>F'4+ M7UG7_FR&OSK-TLRJ6KR(JA3[=K_T5.I@DY= JSM1YN.L/B<;B697I];Z*R<+ M0=SKW8&H[4497W4*(JX:STV![Z>8_#)?
EM52UC:H]L6ZA177.32;51SK][5- MN.W7O.XDNVG=_);/PT!HDR6*F503R3D'O.(4D8FA)'9<4R6$X*X7M'(VB;*, MI@!]X'*69A&11E% U%9)E4@=Q:(/H7_<$M]"KU6:T<(I'L%>-@1(.G:EA3@ M[.<(4[#?=>-]O^X$Q.QJ>6I/&[W[AV$YH2+C!")#'T!RW%+1&@=
<5;K6,1< MBZ2'CK_YG/?HM3T1KYU6UXK2M2&QS1)]:WWH4^-1$[:*=+,F+N#]HRQ:DS@M MI(XUH4H!7];@_JE4<9+95.N$PS1P0H^(_584"'ZU;;GLRK= A/_]B;TE/'-UG-[!E.'GJCVRO%)]]"N/ M@,-X1N,L=1*LL33
83HA698]HJG@DJ5A+$7O>/*W@,8V%O!+W8F^POY*GX") M/KH/+1U/9^9#0\6='!=V.8[>IO F0P^ O:JLW=I:%BM?8<[>OY?Y_.DS:O>N M)8*AA2:.\ -.9:.0R,-WE+UCR]8ZZW#;,JC*V,4-"3,#7P#?W#>>!-_+]2^; M]ND<(ZWO,;UT^IB=?>^V#G4[\;H$<]-
[V6]LUM8[OYAC(=0VAKLR[G@%E@3O M\HM>>UU>Y2E/D>)%U96+TL,;AGK4^G;75.:?^XKUH5V^-83E84=>=Y2O^R^T M$6D?2:M.UA745[H_[Y[I&G)EKQ<=6/J\P4^^PO#&YK_GA3JH^D@RY@8OIWV&;38(]G-V.SUB*RZ.C[P&C$794D4 M$L 3 "V4
/#*,DFH=%IQ%L=&]#HW?G,\ZM2#^X^S7]OT[!]G:PR+.1$?W6^5 M/47" LZX;2-BC3'"V^JBT)-PX"CCI&%%Y"[02+.BU:7MSMI=8;6]!HD=OO/5GA M7K6FK-.@\72GZ?NR3NNT/FP. MX/+,^L-@6%AXX8^4U<.J;0$._?33NR!.P#QA>?A"M[OPLZ9G&+:%\;[,M"[2
M,//V/R^;!F!R>E7EOOQ.#O-8P|\-T+!YDSX'G7"<,7P.XF.UY$32E(-DA3%1 M4921B&8@8282X?TV1UM;].*6A_=3P68)'1 /?RL_J^=F@]%"7#T8#TD)^PX MY*XN9;$2HWSV #TL2TB7CU0F_C^^GG9F_)#HIE4!,"!A^^1@G3S#"99D0G
M/"%,P$_*I9(8DRB3IDQ'8>_L:)C8-,L,)U9:T$(F@7O"5) (3+?62BN9L?YQ M1 "U:*WO@6=GPT:SW=/BZW2Q:O-PR/8,A(A93D--,1&1$L8ST.L)E[4-@+H M8V0D>GNS^QT*;5;!%Y"XZVG0NXS.GP8=PBI\7G6)O.Y@UX!ZM?N_DVD0* :WUZ)XK;Z%SLK4=QU M-?
Y7X/_\U\)G9FXI$^\+O6P6^$$''2\G4WE5+)M+:BIGX23\LJ,7^YX=9HM]]SS-GQCV/FS[W..9;[Q)&+/?(J/N:3_]9=%N4UFF@)* M7DM(H6.?_;%>P:#GK*DYOZEI.^,$.>=NLXQ1&^>SMI2T7OI!^ MC0UKQ-@KY(55G9J/RJ;2D[][I"ZK<4BU
W*>BTX;2@=>&64HW_FP.8WOEKGO" MJO_\4Y2$;S>J0BS,XU#X(8ID?2-)M_D+#T]08'W\UN=0/"W[/BJQ[U=YKE=C MXDZK\:$!0I^]!_9S[8']T// GH3_'V.)1O7QC-5'H8?;S?#60S.G[.KE;)W9M4>'R8U=H M!TUP^;AEOW]/\;D+^4>3.]FMF;ISVV)\8UZ;3Q1CIM?
$LZ;1+N[C#\ N7S"539:#!&@S$: MC)=B,)2@/#-A2JQ)+"A_*NJ.WHQAQP1NC+.\GT -AH*RD%!IP6#()"9"A1IN M=$Q%D0Q9>,OQP ,:#!KM/G[Q N5S-!BCP1@40XX&XWD9#"M,HAF6ETRL),PF M&9%:I%AWTK$XS6@4]T[<9(9', A'K!4A=I^D1
F)E2AT#'Y)*,+8/)K!B$YH ME(XFX_FXWZI-F/'\;$#CO^O+7O>.5\T'*4[T!4X5CBPYU;6$:NC!V79^^\, MCDB"2YVFUC#BLBC%O]\A45):DIE4L13@A$[ZU0#VB%6V>N[@0&)WO8UA"/:- M.Z"C:(_6:+1&SX)E1VMT?VND,[A)E0DI H;=TA!,AE;(K0R,C:"9KS7CVF?
M0.B!K)'+OUI#L$0:F,(2X1CBO]GBT9&]S1:I=$]C5;IX?)7319S M0V,B8QN#A6&2B @-CE")LCK*G.I9I7W"ML\T;76T2]-5&]W2:)5&]W10]\0$ M"P6+!4F5H80I$Y(,[HQTKA,,:LDZ[4,WB=\^P"YL6STE@81NX6?,3#_^)-Y MO%KW6XAQK68\?&+RRRWEZ?
%3()0O3N_;TR$'GEFR60_^NXWJ]7_X'B1?WY#X MK9O:KZ1N&(0=8D$C+"]F;TU>S:?RZ@U^VV/*"0?>PIDT@?3Z@W\NJT7NKMI) M^5N)G9FWOKTI/KNT4YC*I>U6T%YQ]]<[M>KVZ[F M^6JWHIE//L.^O:1:R+(IR[_Y!5"Z_KA>?
+]E(1U,]XVPRWEM.5^V1%X7^>>\>U4?]SORW38Y?)YYX8)W]4<;_8\W>@7= M0+R)>,IF>;=)X-V)$?0DH&'172TS&#BDHLEWH<-6)]_VY[ERI@K32)#*RHXH(PD0D"/"N(2S2E-DRI-?H0"_Q)GUNSG-J/ M[AW,[0-,[5-GPN_S2D^+:EG:ZINZ6-UE]
(/I8O5I^PKGLYJ/4>@\H*J[>6(; MPFO=KJJZ%?QC=K2Z&U=M,<]W79EGT=$JB2&5 <@1]^ MG!:WW(*Y!.[%'2-Y 0NSV#A1BU[?A96X 8?[4]\%_J]?(O#1OT_RY<A7/ @*/'MR \=6]*#Q2[P7PYZ@-1GX^ FWPE#58NJF?_D4/
M692EF[WB7]9]>WA#SNEQ@\QUJ]Y5;E,5N+*XZ*4QC2<0GQQ!/LP!I:$-U@?-T"""YJ0L 7_D#4O"&(WZ+:>O@)SZWB1M7Z2;]^_"V05647@9)3 M.=/6'Y#ZC^%SH'0B3)W.2)QR29@+'1&6"?!JG MUZJ1TO5-W]^? 7U%1?W2_M5?84B79'ON.WV*-PLKOESR X#^Z?PJ
F0:VU/MGYHLEFO:ZZ+J6NC]\!ESFI M_0FP%=MY+C3!O$3&A,]+BY:R/JSGOX<+889F$OPX"] T(B5,_%=K/CT'_E36 MSD (IM,KW(H%8_N'A9N:8]HNQT4(KJPLF[%M/J#+Z/E,E_6@%#QJ#B/["DNR ML/#@(Y !;+ L6"9)EBA-
6()M101XZ4YQ!8HYCB/9J^;^+3)P8?/YF_>^G D6 M]H-OYXGNW?/DM9%79I*VL!'A<[]5U_RQ;GGK].STQJ=?Q"2AG,E\.=-S <$ M63'?F^!5]/H(.=!ETD0),%]$!;@#5I ,^(AHJ;/0A3'P9*]K*W;#,6D"JAH(M@*W!+]]20I&> +V&S:'7 M.1"M/?(2&/G*IY^
EEYIW%66R16>?&Z^6?%K\!X>XU7T*_KZ&'C.L# !?@D) M3Y(8+7],9)0D)+..9UPH\)5[V-/9),HRFA*5.G!;4V W:10E/+-8.%IJ@*W7 M>>['B[G,2R311_=3 :R77UKC&:[ZOW9J/A3E;]L8;2^5&(63W74[!\%QK4[< MIOOR%:5:[EHIO!-
D.0,6>5FAHI.JN+23.Y3FZI:NZ55<<+!F0L.Z[&PZTH+=ZVQ<)?Q M,A;:V>W_)O=U?ST-W>SW:O&O\ZDI*_OO0Z6>'KRF5W@?"7CPX4V"+G_X9FGI MVZ#FDRZ'/\:B#I1$-3&"SZ6<5;52]]92YKE%@/R3W^3@E.?Z6\J;G-NI"WZU M9WFUJ,NH 8N!]D7-
>G^Z/1&3'9]G_H&.YB4@EJ#RY"J[Y*I:<@6O/EA5+F5Y MY7W X";2O@:3)1=8 N8B!W2_K!#P5W8Z/:F3+Q8P5N^BPK\GP7*./Q\!3DHC MSIQ)*4E2[^G1A,B,A<1$+!+@ E)I>]ZA9=9(N)%HDU"">,S12D: YT,62H!= M81QN>(>?)!8D^G0N2UN=SLP_9
FROJA^P^I_*XAY,) 43@:.RUN4!#!(%Q<7 MGB/!1IQ@72%GR]*:]H,O#:5. A_\KV-S2";XI%JJ?Z*WV81%OOM>]JN&@W_* M@4<]_R+I*EWF"OU'.RV^3(+/ME]NJ@OG#RZ/G^::H%[:O33!8%%(3_+\E_@_#?F\".0$R-5HTIO\]YF?0[T M$46_W>K/5X HR @-JY
%QL[(4OP@AJ!$1GY^0C,YY^#7\KBK)07KR?W9)@=I0E9' H!!ITH$R<8 M*]$8['5_F=#9V-8L5[6EZ;4428E$7%B"6/6$1$EDFB;A$XI+A.UN=6+TM_%*O!E%[U%'BT M*Z]VP9;6H4!E413 O41%7_EGICKZH!P3&H(:Y$ M*D44D@QP#&&",Z*4Y,3I-
RU@X^NLZATM(X0ZVE>,8)\#@EDE-%' 6LRC.6 M.F4W./2'&9B JU\\H3X@G;"Z4X6.^X$T3WH\FFZ$__!"1,9VIFTW M8-C*S,DM,H&8U?Y["2 $<&Q;9?$-A8RE"&P=Z8)4UH0E8!F#J5.4VDH-ZGL MZ>,XPB0I15*CP%#;+")"QI88)U6BM
N=7'65,C;O,_N!>#R;9$?!XFN/9'NE MUD&,M1:W(0UIX-7+AR_;/(NIS,*$4*Y2PK)4$I4E$4E9R)@&*8\9O0_66FU* MU!$7!-' VK!B;?CEQZI:6O/CK!-MW1#]VH_IROR/?_]PW!E1:]?,UCDAN:=! M[;N!>6\L%E]1#MH^0,QB^([WG@&+=T63-
9\O=XB1GKZ"@CO\\L<*&1> @7O M&KKXJ!=%1W'&/G(A9S/P>34Z$,!\<"V@JC:*T2'QMKK6R!2@(ME@Q,PP'M-TTI#/CN"/ 7 M-U2R&+$4QXXG/-: I<*8Q!FGE":4AZ;76H*Z$'UE3?X_>V_:W#:2K M_O[\" MT3.>(T<0-/;%/F?1'4>'.C'5 M1UX2GWXMO:I]M0Q^Y

*FY9H/Z3%(+.PU`}>7%=W5*&U&EX%;UWG;IIXI;`X-.MjT^%)?67N8C)R#0IX8;&KX8TIE^>+;<;YR=`H-3.9%>.O.`M!W%@;="`K7G8Z9.QV8A1Z>G;U"OU!A2(.B3!SP5+V1`>W`M^YV6ABMA?$P*@)G9N0Z^.C.99E1C;76>1S'3X-F.`)5*8>.86;*\0)+I*+?)3P^$Y0U$M@VIBQ3IHW.M\WA%+.NYGYX.GM*K%P^A8WG3I6/G>CIMDMsI$;HI$ 6$^Wo67HVM60%;&H MR_@.<}YIDMH19V0.B\<)YI7X^%(H)(FE.\KK$_<.7GTG;`V;ANP-0I%<$/`MMB/+.D_+\% 0s#TP$^8 .F9V$>]MIFTNS.C36[MX=M:!WGI+`MG5XEIX^2O#8hR&G>BW6\IPE9+(3YD3>`K;K=0 I819>]e2C MCFX$-G>I\7E>.O.'=,'W8)A-FZH^M)KIC&.@1L@(BDD(6H;C1>$&\)-ASBI0+M+22-?2CIO#8!TB:UZX2!PsU^?+I%=.,.J98Z755H2I9A35Q9.A-Q4NW MJ+JMI>^%*#.K9@&BMURCEK%$S^2"#VD(4$4^.+|.IO7H-A-@&7R.LXITDHP MTZ?-B#!O3D.?1.CRI&.`1^48,.4HSBP=(M%W+58:D?!1IKDO=`H&(%RG#)A MERK`6UEWD^-!AXBEH.'D)9+\02]F!*D036Z-9[*=L'QXN9.3=6Z')! M.)E@^X?.0M30A+!?=8^.LW0#(NN;%3K%V13Y^!%BH(=R-Z^E;K]- U1#R2U=]TSFV7E#<0'V8 M5?,P2T^%)ND[^]WOX^%A-^+S2>B)K?=]+@ITV4&(2P5!44#KB#3E%0=M8#BQXI/6JfSW+OLVIL%C&C+?G^4P5GRUVVMXIQ/$C4B6 TYX5)<^2~6SB697!ZIJ45=8GIGEA6@F\L7`iV`*]>>.6;D9D;#<]\M16A\5$=-R0VC9KF-J EY;OQ#1EJ39C.D-645XBC456&!A=E-;.$1I5<] MJP65-O?T.+s#W3035_6\'C2#<#(S8#'MAQL $4<45'P&R=,*>(-K&\3#^ACA5M9)>2+AI+ZD>A)9S2!B.\6@<6CIP.W5%,%:9^2#N4U!25.H=&%<5 M/;5R#&N>BBD4.x;/>FIXI#E*KLO)13W85/4%:.

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eY\:YZ!\!OVT9<(30:!P]_6 M,^.\'ICT082RE?W!/HI+?O7=^0\I^?9.#-(&_.KNO.^#>):O/P85FI^ M4A5U]_F'<7\%-\X+KV1(eX20=ZKCW\Eo_=UTVC8<,OLMS'LT>_>,^Z@9L%.MV.SDW:?IW52.6UK3RD#<. (#2OS^'5!^N=WZX2KBWI#OX6SX,8X^=LIC\'' M3W?? RZ^ZGS.0JC%>X.,//&^&^2U^V59O>)SR]^XD_9D>$^HTP.\G%0H[" M_YB4I A_^^!] _]5.)A5^64k%9 @=~W19.D EU5?.V5U7 M#^OU,&EG%O=.W//sN59ZCP?=7.^4HH# *FI[OO3.G(=.OF_HG2-.%KLI:# M:.OV#E8MIP?<MOOXG-ZZ^5IC>=WG+3_>LI?N#UHO554[>9U(<>1?YKLEPMMC'@'K+\N M+4_VK/EW]?_H'\]^.R(UOOY159WEI>G3_3R/W!0#\&B>? M_\5I=+?OJC=02%6IQ^?'OYTIA'OI^WI&-DOYTIR=!5$+MW? $i6#/0c4G\I<_DZ;Y MZ'1M5;6A8WI@89NIA;.0569;X(4V2TV)=8C/5NO6FIN^VH<IVK>'2,G/ MIW_^ COOH%9'DB1-Z/#.N J4N?I=2)?9\N $^_84>Y00W_% #&!

**V!3_4I[^UA19T83D5RJQ=323MUQ4>NL^1M2G9!4\T$s8)4B"#SNDS=RW3E~/$O3H!4!#2!>2]D2|.M\T]R_)OM64!,@3I$)?0Z(\.?7\N_I(@VE'Z0..'R(O95ID TR3=)47?|_M-MS|+.I(9TD4I1R%)|W4'^R5%FXVXEYG8<@30N?ZH&%QFW4UZ%?][6DHA MAE)hB=SK4G4OUW0@9PNHZ>@=#O0'Y9EG>U91SD2$<'2V&GGM+IBS'+4O3 MVZIGI=T25@KIO^$7.N.NI/EB28^!\SI=_6W)IJG>D^DTB;B70?PR<]D\-KM-HI"XT^$4WE=CYU#^Y8YH(6IV6'IN^7:+EMYYU1L>D.XIQ++ E5Y0>EY: MP28E/E&B< M0[%;O;%'2"8%5P"_YDA.E2/5U M-8=,BOX3^'L^,? YW^0<'U^OG:^Z%,&=0@#B)\4O8+UML^1=0]GB>16B.VM MN>.IKV=FKWT:58?>=<@?7HF[B;.H8>]=F]WICB/SB%=++YIM7O@Z7H:2?1>_ MJ_&ZI&_.VBVK,0G=@(%>VNE)Z08 9%%&0+ IF8WC= M2IKU%4A^.\+'+=W)D<&3U-DLCU(#P55IHGIAFO>7R.YZ-EV3M6NP-GI'.MX)D@M1e5>89%7MBXZ@ZTUUH?#.>/SGAFB:7%:2PT0\'ZMLUC.K>)Y(R(+8 M<=.,WV$,QVIHF<G'MOOSIMS:M6^P.WJ9BB.0/81PD44.9ATK.(DRT-==.VC?7 MGK^.//P&HI/?65>/\+'^38I-]<V079]:M?38^?5>/6.VQ:.H-N??<>PZLB;!5#H.OAM?V0IUT_>.^^'\4ABY M0HIZGM<"WI_W.'IZ;A:C?]ZI$=e=A.4 B'3Z[(.^H^23VR #I&YX+.E%+<] GZ M>8EC\)SMI[.IMHN>.GGHVUN! MS;WETGI;<$HWI^M@%SIZK6W:'I3W%89 /%7+:=.IR'=\0+IWCK_ %5K=?<-0 9WLV3UDW B\\'H M:0<<Z%WXOIH6>Z&).I.ZOKK&I&(<'A8P(% !9T4>09 W-.:'Y_!<.Et+0NQ-?PTZ' MA6GWO^.J57H6MGZW0^<KR^SMI>95VBA2SY&]H.(L:/U? IXE=+$[PQ_16>6Z M#39?95&.1?HDJX(#2\:/GK|I/MEA?H<0Q ZI4KF(\\\)S!4XPCWK-Q-MZL;.OIVCH'{.B.HG1L*'I'L^%0\LCK#MMSAWVD*=.MH<YIB9+DEL:8YK&'.M^6,OYWOY2=WYRGH<0 0R-738#6'=\'24UI[M%/59/[KQ]TCV>N;ZKM2ACE^K'YC\|>'G^>C5 C$_ T98F] MMCAW36!][DS=0-BQ9UI &6@,#:[.Q;X;P,QN)UW;*8]-UNFI'RJDFA/IQ2SP;IFSR' MX.N]RD#F$/CVRLD;.FC//FC 5:CB]0W1%QW^ ^/XFS>BS1LG8 N+=89 ?(KI;G<W?^N/ DE3/_Z5>)OMH&H MTJMA9.PSUS-EH[_'2VX?,Y6.]9^'6?8^7=_IV]V2H5[V2 2T!#@^#OQ M4IJL$'X6// .;Z,4)6OYWAS&'WGE7W?9).R)? 1^5VMH>&)\!%AS.)XEE#WYW7I.(Z^N1F\eD;/&X?8!.?5P_41})2098&3HNIO1@68@@ (.M^7+63]+P.A^$H=.W?I(6F-X\:?#H;SN!\;FXVE ,(RU/&P800:BMQU#]SS M(6LSWEW\>C4#2%B?'SN^2G(U#W/FI\ U5]+[.W]/ M8W35CUK2);?IMJT M?N3EK7>6IE7!39?_"<2)QL*45L1.5(*R)#GWU>@<:+'(6101]5KA@L# MS4_.49S;?!0907OFXITL6_F.$NL:+UEZE.^>]NRU\OB2V8M%:#'AT#1<O MOBLRF05L6;8Z)O.3B(W#!ONDS&'2>%UNJ[-?6$#^.IO9\?X@Z+.G>VV#4(68I MH8<#=\N:W$CFME4-Z-_ZVWS(?W.-7T'[:NH2OML/GB5)A(1W.9F'90 M7*$I3TM\I?'>Bs<[A^QT]#;E%&DY3<2C.RG;K2<S8WCN(3HOAG50_[UZL#85 M^.P_W#U^0RE/R]HFN,)1D2IU#'.9SH,0]S1<XXB^YV :TO(ZC[_ AVC0BV.F M8=C)&ZSED RB1ZSOF>GJ9WNL?*.^ZG(2D3CB-[.3O?B2-LA#?N-C\GIJ%5MC ;9 MO3&<U?;59)@=&B0D]4VU'O;_<8&/I34\"*M(I?>Q*0(M@=>#CAK26-J[=- MUK'E=$4'B4K0,+1K1=!]PV1)F'RJ0:?SD?2-"CFD_A(]% M5>.1'<>7C<69D3;97O,K4.KE#]@#U-1$.:,[O69 .QL8IC@XNB\63H=F^?s,I9<B62@8]K.V&-]g#WR1Y5,#<V3P3L? FZCDGDG^5$2YG"B\=.=tI=C^,%U9 ?7$(,\.3^7?B_$,'=>3]V75E>.)\'0P-(^1.DI(O F$^4%2_7+4 MB5SU&UC<(72^WZ/HS<:0? M.3537@P;DSIO4@M+.(:UU@WBTIX9%+3'U_GUV$)TP9 M1>.(S/D\'3F?(<;)+6 2?4GK=@HHSC2%LIOW=2G]MDB=.RUH5]V%)%2N%MSDF M<R?O9[+.'AG%(IE.YGQ0$1?AV:&4?Z+74

accompanying unaudited interim condensed consolidated financial statements for the quarterly and six month periods ended December 31, 2024 should be read in conjunction with the audited financial statements and notes thereto as of and for the fiscal year ended June 30, 2024, included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on September 19, 2024 (2024 Annual Report). Interim results are not necessarily indicative of results for a full year. Subsequent Events The Company has evaluated subsequent events through the date the condensed consolidated financial statements were issued. Liquidity To date, we have obtained cash and funded our operations primarily through equity financings and license agreements. We have accumulated losses of $398.9 million since inception and expect to incur operating losses and generate negative cash flows from operations for the foreseeable future. As of December 31, 2024, we had <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$23.7 million in cash and cash equivalents.In connection with our July 2024 announcement regarding the evaluation of our strategic alternatives, we discontinued the clinical development of voruciclib, while certain nonclinical research and development activities continued. As a result, we continue to incur research and development expenses in connection with clinical trial closing costs and the completion of our nonclinical projects. We believe that our cash balance, will be sufficient to meet our obligations and fund operations for at least the next 12 months from the issuance of these condensed consolidated financial statements. -39890000023700000 2. Summary of Significant Accounting Policies There have been no material changes to our significant accounting policies from those described in the notes to our audited consolidated financial statements contained in the 2024 Annual Report. Risks and Uncertainties Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to the valuation of share-based awards, the discount rate used in estimating the present value of the right-of-use assets and lease liabilities, the useful lives of property and equipment, the recoverability of long-lived assets, clinical trial accruals, periods over which revenue should be recognized, relative stand-alone selling price, deferred income taxes and related valuation allowances, and the assessment of our ability to fund our operations for at least the next 12 months from the date of issuance of these condensed consolidated financial statements. We base our estimates on historical experience and other market-specific or other relevant assumptions that we believe to be reasonable under the circumstances. Estimates are assessed each reporting period and updated to reflect current information. As future events and their effects cannot be determined with precision, actual results may materially differ from those estimates or assumptions. Short-term Investments Short-term investments are marketable securities with maturities greater than three months but less than one year from date of purchase. As of December 31, 2024 we had no short-term investments. As of June 30, 2024, our short-term investments consisted of $34.6 million in United States government securities. The short-term investments held as of June 30, 2024 were considered to be held-to-maturity and are carried at amortized cost. As of December 31, 2024, we had no unrealized gains and losses. As of June 30, 2024, gross unrealized gains and losses were immaterial.</p></div><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Revenue Recognition</p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Revenues from Customers</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">In accordance with ASC Topic 606, Revenue from Contracts with Customers (Topic 606), we recognized revenue when control of the promised goods or services was transferred to our customers, in an amount that reflects the consideration we expected to be entitled to in exchange for those goods or services. For enforceable contracts with our customers, we first identified the distinct performance obligations - or accounting units - within the contract. Performance obligations are commitments in a contract to transfer a distinct good or service to the customer. </p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Payments received under commercial arrangements, such as licensing technology rights, may include non-refundable fees at the inception of the arrangements, milestone payments for specific achievements designated in the agreements, and royalties on the sale of products. At the inception of arrangements that include milestone payments, we used judgment to evaluate whether the milestones were probable of being achieved, and we estimated the amount, if any, to include in the transaction price using the most likely method. If it were probable that a significant revenue reversal would not occur, the estimated amount was included in the transaction price. Milestone payments that were not within our or the licensee's control, such as regulatory approvals, were not included in the transaction price until those approvals were received. At the end of each reporting period, we re-evaluated the probability of achievement of development milestones and any related constraint and, as necessary, we adjusted our estimate of the overall transaction price.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">To the extent a contract included multiple promised deliverables, we applied judgment to determine whether promised deliverables were capable of being distinct and were distinct within the context of the contract. If these criteria were not met, the promised deliverables were accounted for as a combined performance obligation. For arrangements with multiple distinct performance </p></div><div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">obligations, we allocated variable consideration related to our 50-50 cost share for development services directly to the associated performance obligation and then allocated the remaining consideration among the performance obligations based on their relative stand-alone selling price. </p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">When not directly observable, we typically estimated the stand-alone selling price for each distinct performance obligation. Variable consideration that related specifically to our efforts to satisfy specific performance obligations was allocated entirely to those performance obligations. Other components of the transaction price were allocated based on the relative stand-alone selling price, over which management has applied significant judgment. We developed assumptions that required judgment to determine the stand-alone selling price for license-related performance obligations, which may have included forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical, regulatory and commercial success. We estimated stand-alone selling price for research and development performance obligations by forecasting expected costs of satisfying a performance obligation plus an appropriate margin.<p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">In the case of a license that is a distinct performance obligation, we recognized revenue allocated to the license from non-refundable, up-front fees at the point in time when the license was transferred to the licensee and the licensee can use and benefit from the license. For licenses that are bundled with other distinct or combined obligations, we used judgment to assess the nature of the performance obligation to determine whether the performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. If the performance obligation is satisfied over time, we evaluated the measure of progress in each reporting period and, if necessary, adjusted the measure of performance and related revenue recognition.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The selection of the method to measure progress towards completion requires judgment and is based on the nature of the products or services to be provided. Revenue is recorded proportionally as costs are incurred. We generally used the cost-to-cost measure of progress because it best depicted the transfer of control to the customer which occurred as we incurred costs. Under the cost-to-cost measure of progress, the extent of progress towards completion was measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation (an input method under Topic 606). We used judgment to estimate the total cost expected to complete the research and development performance obligations, which included subcontractors' costs, labor, materials, other direct costs and an allocation of indirect costs. We evaluated these cost estimates and the progress each reporting period and, as necessary, we adjusted the measure of progress and related revenue recognition.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"> In connection with our, now terminated, April 2020 License, Development and Commercialization Agreement with Kyowa Kirin Co., Ltd. (KKC) (the KKC Commercialization Agreement) described in Note 7. License Agreements, we performed development services related to our 50-50 cost sharing arrangement for which revenue was recognized over time. Additionally, we performed services for KKC at their request, the costs of which were fully reimbursed to us. We recorded the reimbursement for such pass through services as revenue at 100% of reimbursed costs, as control of the additional services for KKC was transferred at the time we incurred such costs. The costs of these services were recognized in the condensed consolidated statements of operations as research and development expense. </p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;">During the three and six months ended December 31, 2024 and the three months ended December 31, 2023, we did not recognize any revenue associated with the KKC Commercialization Agreement. During the six months ended December 31, 2023, we recognized revenue associated with the KKC Commercialization Agreement as follows (in thousands):</p><div style="font-size:10pt;font-family:Times New Roman;"><table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"><tr><td style="visibility:collapse;"></td><td style="width:79.396%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:18.604%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"><td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">Timing of Revenue Recognition</p></td><td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">Cumulative</p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">Point in Time</p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Services performed over time</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> 743 </td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"> Pass through services at a point in time </td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"> </td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"> 9 </td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"> </td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"> $</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">752</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr></table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Contract Balances</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Contract liabilities were included in deferred revenue and deferred revenue, long-term in our condensed consolidated balance sheets. Our contract liabilities accounted for under Topic 606 related to the amount of initial upfront consideration allocated to the development services performance obligations.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;">As of June 30, 2024 and December 31, 2024, there was no accounts receivable, unbilled receivable balances or contract liabilities.A reconciliation of the beginning and ending amount of contract liabilities as of June 30, 2024, which was primarily related to the "></p></div><div style="font-size:10pt;font-family:Times New Roman;"><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;">combined performance obligation for the transfer of development services under the KKC Commercialization Agreement and was a separate performance obligation in our contracts pursuant to research plans under the agreements, was as follows:</p><table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:81.22%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:16.779999999999998%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Beginning balance</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$ </td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> 317 </td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"><td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"> Recognized as revenue </td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> </td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"> Revenue recognized upon satisfaction of performance obligations </td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"> </td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"> 317 </td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;">) </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"> Ending balance </td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"> $ </td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"> — </td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"> </td></tr></table> The timing of revenue recognition, invoicing and cash collections results in billed accounts receivable and unbilled receivables (contract assets) and deferred revenue (contract liabilities). We invoiced our customers in accordance with agreed-upon contractual terms, typically at periodic intervals or upon achievement of contractual milestones. Invoicing may have occurred subsequent to revenue recognition, resulting in unbilled receivables. Advanced payments from our customers before revenue was recognized resulted in contract liabilities. Revenues from Collaborators At contract inception, we assessed whether the collaboration arrangements were within the scope of ASC Topic 808 Collaborative Arrangements (Topic 808), to determine whether such arrangements involved joint operating activities performed by parties that were both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment was performed based on the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of Topic 808 that contain multiple units of account, we first determined which units of account within the arrangement were within the scope of Topic 808 and which elements were within the scope of Topic 606. For units of account within collaboration arrangements that were accounted for pursuant to Topic 808, an appropriate recognition method was determined and applied consistently, by analogy to authoritative accounting literature. For elements of collaboration arrangements that were accounted for pursuant to Topic 606, we recognized revenue as discussed above. Consideration received that did not meet the requirements to satisfy Topic 606 revenue recognition criteria was recorded as deferred revenue and classified as either current or long-term deferred revenue based on our best estimate of when such amounts would be recognized. <span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-

content;">Disposition of Non-Financial Assets The Company accounts for infrequent dispositions of assets in its product pipeline in accordance with ASC 610-20, Other Income - Gains and Losses from the Derecognition of Nonfinancial Assets, which requires dispositions of long-lived assets that are not a discontinued operation be accounted for on a net basis and included in income from continuing operations before income taxes in accordance with ASC 350, Intangible Assets - Goodwill and Other. Proceeds from sales designated as dispositions of non-financial assets are classified as cash flows from investing activities in the condensed consolidated statements of cash flows. Net (Loss) Income Per Share Basic and diluted net (loss) income per share is computed using the weighted-average number of shares of common stock outstanding during the period, less any shares subject to repurchase or forfeiture. There were no shares of common stock subject to repurchase or forfeiture for the three and six months ended December 31, 2024 and 2023. Diluted net (loss) income per share is computed based on the sum of the weighted-average number of common shares and potentially dilutive common shares outstanding during the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net (loss) income per share calculation for the three and six months ended December 31, 2024 and 2023, potentially dilutive securities are excluded from the calculation of diluted net (loss) income per share because their weighted-average exercise prices were above our weighted-average share price as of December 31, 2024 and 2023, respectively, therefore, basic and diluted net (loss) income per share were the same for the three and six months ended December 31, 2024 and 2023. The following table presents potentially dilutive shares that have been excluded from the calculation of net (loss) income per share because of their anti-dilutive effect (in thousands) <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:47.131%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.718%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.718%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.918%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.178%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.058%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"> </td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"> For the Three Months Ended December 31, </td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"> </td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"> For the Six Months Ended December 31, </td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"> </td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"> 2024 </td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"> </td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"> 2023 </td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"> </td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"> 2024 </td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"> Stock options </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> 955 </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> 1,398 </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> 955 </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"> Warrants </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:right;">103 </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> 103 </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"> Total anti-dilutive shares </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"> </td> <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"> 1,058 </td> <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"> </td> <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"> 1,501 </td> <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"> </td> <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"> </td> <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"> 1,501 </td> <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"> </td> </tr> </table> Recent Accounting Pronouncement Recently Issued From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standards setting bodies that are adopted as of the specified effective date. The Company believes the impact of recently issued standards and any issued but not yet effective standards will not have a material impact on its condensed consolidated financial statements upon adoption. In November 2023, the FASB issued Accounting Standard Update (ASU) No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires a public entity to disclose significant segment expenses and other segment items on an annual and interim basis and provide in interim periods all disclosures about a reportable segment's profit or loss and assets that are currently required annually. Additionally, it requires a public entity to disclose the title and position of the Chief Operating Decision Maker. This ASU does not change how a public entity identifies its operating segments, aggregates them, or applies the quantitative thresholds to determine its reportable segments. The new standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. We expect this ASU to only impact our disclosures with no impact to our results of operations, cash flows, and financial condition. In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which focuses on the rate reconciliation and income taxes paid. ASU No. 2023-09 requires a public business entity (PBE) to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local, and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. For PBEs, the new standard is effective for annual periods beginning after December 15, 2024, with early adoption permitted. An entity may apply the amendments in this ASU prospectively by providing the revised disclosures for the period ending December 31, 2025 and continuing to provide the pre-ASU disclosures for the prior periods, or may apply the amendments retrospectively by providing the revised disclosures for all periods presented. We expect this ASU to only impact our disclosures with no impact to our results of operations, cash flows, and financial condition. In November 2024, the FASB issued ASU No. 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40) (ASU 2024-03). The amendments in this update require disclosure, in the notes to the financial statements, of specific expense categories present within expense captions presented on the face of the statement of operations within continuing operations of PBEs. The amendments in this update are effective for annual periods beginning after December 15, 2026 and interim periods beginning after December 15, 2027. Early adoption is permitted. The amendments should be applied either prospectively to financial statements issued for reporting periods after the effective date of this ASU or retrospectively to any and all prior periods presented in the financial statements. The impact of adoption of this ASU on the Company's disclosures is currently being evaluated. In January 2025, the FASB issued ASU No. 2025-01, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date. The amendment in this update clarifies the effective date of ASU 2024-03, which is that PBEs are required to adopt the guidance in annual reporting periods beginning after December 15, 2026 and in interim periods within annual reporting periods beginning after December 15, 2027. The impact of adoption of this ASU on the Company's disclosures is currently being evaluated.
 <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-

bottom:0;text-align:left;">Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to the valuation of share-based awards, the discount rate used in estimating the present value of the right-of-use assets and lease liabilities, the useful lives of property and equipment, the recoverability of long-lived assets, clinical trial accruals, periods over which revenue should be recognized, relative stand-alone selling price, deferred income taxes and related valuation allowances, and the assessment of our ability to fund our operations for at least the next 12 months from the date of issuance of these condensed consolidated financial statements. We base our estimates on historical experience and other market-specific or other relevant assumptions that we believe to be reasonable under the circumstances. Estimates are assessed each reporting period and updated to reflect current information. As future events and their effects cannot be determined with precision, actual results may materially differ from those estimates or assumptions. Short-term Investments Short-term investments are marketable securities with maturities greater than three months but less than one year from date of purchase. As of December 31, 2024 we had no short-term investments. As of June 30, 2024, our short-term investments consisted of $34.6 million, in United States government securities. The short-term investments held as of June 30, 2024 were considered to be held to maturity and are carried at amortized cost. As of December 31, 2024, we had no unrealized gains and losses. As of June 30, 2024, gross unrealized gains and losses were immaterial. 034600000 Revenue Recognition Revenues from Customers In accordance with ASC Topic 606, Revenue from Contracts with Customers (Topic 606), we recognized revenue when control of the promised goods or services was transferred to our customers, in an amount that reflects the consideration we expected to be entitled to in exchange for those goods or services. For enforceable contracts with our customers, we first identified the distinct performance obligations – or accounting units – within the contract. Performance obligations are commitments in a contract to transfer a distinct good or service to the customer. Payments received under commercial arrangements, such as licensing technology rights, may include non-refundable fees at the inception of the arrangements, milestone payments for specific achievements designated in the agreements, and royalties on the sale of products. At the inception of arrangements that include milestone payments, we used judgment to evaluate whether the milestones were probable of being achieved, and we estimated the amount, if any, to include in the transaction price using the most likely method. If it were probable that a significant revenue reversal would not occur, the estimated amount was included in the transaction price. Milestone payments that were not within our or the licensee's control, such as regulatory approvals, were not included in the transaction price until those approvals were received. At the end of each reporting period, we re-evaluated the probability of achievement of development milestones and any related constraint and, as necessary, we adjusted our estimate of the overall transaction price. To the extent a contract included multiple promised deliverables, we applied judgment to determine whether promised deliverables were capable of being distinct and were distinct within the context of the contract. If these criteria were not met, the promised deliverables were accounted for as a combined performance obligation. For arrangements with multiple distinct performance obligations, we allocated variable consideration related to our 50-50 cost share for development services directly to the associated performance obligation and then allocated the remaining consideration among the performance obligations based on their relative stand-alone selling price. When not directly observable, we typically estimated the stand-alone selling price for each distinct performance obligation. Variable consideration that related specifically to our efforts to satisfy specific performance obligations was allocated entirely to those performance obligations. Other components of the transaction price were allocated based on the relative stand-alone selling price, over which management has applied significant judgment. We developed assumptions that required judgment to determine the stand-alone selling price for license-related performance obligations, which may have included forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical, regulatory and commercial success. We estimated stand-alone selling price for research and development performance obligations by forecasting the expected costs of satisfying a performance obligation plus an appropriate margin. In the case of a license that is a distinct performance obligation, we recognized revenue allocated to the license from non-refundable, up-front fees at the point in time when the license was transferred to the licensee and the licensee can use and benefit from the license. For licenses that are bundled with other distinct or combined obligations, we used judgment to assess the nature of the performance obligation to determine whether the performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. If the performance obligation is satisfied over time, we evaluated the measure of progress in each reporting period and, if necessary, adjusted the measure of performance and related revenue recognition. The selection of the method to measure progress towards completion requires judgment and is based on the nature of the products or services to be provided. Revenue is recorded proportionally as costs are incurred. We generally used the cost-to-cost measure of progress because it best depicted the transfer of control to the customer which occurred as we incurred costs. Under the cost-to-cost measure of progress, the extent of progress towards completion was measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation (an input method under Topic 606). We used judgment to estimate the total cost expected to complete the research and development performance obligations, which included subcontractors' costs, labor, materials, other direct costs and an allocation of indirect costs. We evaluated these cost estimates and the progress each reporting period and, as necessary, we adjusted the measure of progress and related revenue recognition. In connection with our, now terminated, April 2020 License, Development and Commercialization Agreement with Kyowa Kirin Co., Ltd. (KKC) (the KKC Commercialization Agreement) described in Note 7, License Agreements, we performed development services related to our 50-50 cost sharing arrangement for which revenue was recognized over time. Additionally, we performed services for KKC at their request, the costs of which were fully reimbursed to us. We recorded the reimbursement for such pass through services as revenue at 100% of reimbursed costs, as control of the additional services for KKC was transferred at the time we incurred such costs. The costs of these services were recognized in the condensed consolidated statements of operations as research and development expense. During the three and six months ended December 31, 2024 and the three months ended December 31, 2023, we did not recognize any revenue associated with the KKC Commercialization Agreement. During the six months ended December 31, 2023, we recognized revenue associated with the KKC Commercialization Agreement as follows (in thousands): <table style="margin:0;border:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:79.396%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:18.604%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"> Timing of Revenue Recognition: </td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;">
</td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:right;">
</td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"> Services performed over time </td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> $ </td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> 743 </td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;">
</td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> Pass through services at a point in time </td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"> 9 </td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;">
</td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;">
</td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"> $ </td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"> 752 </td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;">
</td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"> Contract Balances Contract liabilities were included in deferred revenue and deferred revenue, long-term in our condensed consolidated balance sheets. Our contract liabilities accounted for under Topic 606 related to the amount of initial upfront consideration allocated to the development services performance obligations. As of June 30, 2024 and December 31, 2024, we had no accounts receivable, unbilled receivable balances or contract liabilities. A reconciliation of the beginning and ending amount of contract liabilities as of June 30, 2024, which was primarily related to the
combined performance obligation for the transfer of development services under the KKC Commercialization Agreement and was a separate performance obligation in our contracts pursuant to research plans under the agreements, was as follows: <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:81.22%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:16.779999999999998%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"> Beginning balance </td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> $ </td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> 317 </td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;">
</td></tr><tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"><td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"> Recognized as revenue: </td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;">
</td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;">
</td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> 317 </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"> Revenue recognized upon satisfaction of performance obligations </td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;">
</td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"> 317 </td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;">) </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"> Ending balance </td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"> $ </td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"> – </td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;">
</td></tr></table> The timing of revenue recognition, invoicing and cash collections results in billed accounts receivable and unbilled receivables (contract assets) and deferred revenue (contract liabilities). We invoiced our customers in accordance with agreed-upon contractual terms, typically at periodic intervals or upon achievement of contractual milestones. Invoicing may have occurred subsequent to revenue recognition, resulting in unbilled receivables. Advanced payments from our customers before revenue was recognized resulted in contract liabilities. Revenues from Collaborators At contract inception, we assessed whether the collaboration arrangements were within the scope of ASC Topic 808 Collaborative Arrangements (Topic 808), to determine whether such arrangements involved joint operating activities performed by parties that were both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment was performed based on the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of Topic 808 that contain multiple units of account, we first determined which units of account within the arrangement were within the scope of Topic 808 and which elements were within the scope of Topic 606. For units of account within collaboration arrangements that were accounted for pursuant to Topic 808, an appropriate recognition method was determined and applied consistently, by analogy to authoritative accounting literature. For elements of collaboration arrangements that were accounted for pursuant to Topic 606, we recognized revenue as discussed above. Consideration received that did not meet the requirements to satisfy Topic 606 revenue recognition criteria was recorded as deferred revenue and classified as either current or long-term deferred revenue based on our best estimate of when such amounts would be recognized. 1We recognized revenue associated with the KKC Commercialization Agreement as follows (in thousands):<table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:79.396%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:18.604%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"> Timing of Revenue Recognition: </td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;">
</td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;">
</td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> Services performed over time </td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> $ </td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> 743 </td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;">
</td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"> Pass through services at a point in time </td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;">
</td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"> 9 </td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;">
</td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;">
</td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;">
</td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;">
</td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;">
</td></tr></table>

content;">$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.00972222222222222in;text-align:right;">752</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr></table>7430009000075200000 A reconciliation of the beginning and ending amount of contract liabilities as of June 30, 2024, which was primarily related to the <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;">combined performance obligation for the transfer of development services under the KKC Commercialization Agreement and was a separate performance obligation in our contracts pursuant to research plans under the agreements, was as follows:</p> <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:81.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:16.779999999999998%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.00972222222222222in;text-align:left;">Beginning balance</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$ </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> 317 </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"> Recognized as revenue: </td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> </td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"> Revenue recognized upon satisfaction of performance obligations </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"> 317 </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"> Ending balance </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;">$ </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"> — </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"> </td> </tr> </table>317000-3170000 Disposition of Non-Financial Assets The Company accounts for infrequent dispositions of assets in its product pipeline in accordance with ASC 610-20, Other Income or Loss from the Derecognition of Nonfinancial Assets, which requires dispositions of long-lived assets that are not a discontinued operation be accounted for on a net basis and included in income from continuing operations before income taxes in accordance with ASC 350, Intangible Assets - Goodwill and Other. Proceeds from sales designated as dispositions of non-financial assets are classified as cash flows from investing activities in the condensed consolidated statements of cash flows. Net (Loss) Income Per Share Basic and diluted net (loss) income per share is computed using the weighted-average number of shares of common stock outstanding during the period, less any shares subject to repurchase or forfeiture. There were no shares of common stock subject to repurchase or forfeiture for the three and six months ended December 31, 2024 and 2023. Diluted net (loss) income per share is computed based on the sum of the weighted-average number of common shares and potentially dilutive common shares outstanding during the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net (loss) income per share calculation for the three and six months ended December 31, 2024 and 2023, potentially dilutive securities are excluded from the calculation of diluted net (loss) income per share because their weighted-average exercise prices were above our weighted-average share price as of December 31, 2024 and 2023, respectively, therefore, basic and diluted net (loss) income per share were the same for the three and six months ended December 31, 2024 and 2023. The following table presents potentially dilutive shares that have been excluded from the calculation of net (loss) income per share because of their anti-dilutive effect (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:47.131%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.718%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.918%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.178%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.058%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"> </td> <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"> Three Months Ended December 31, </td> <td> </td> <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"> Six Months Ended December 31, </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"> </td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"> </td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"> 2024 </td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"> </td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"> 2023 </td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"> </td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"> 2024 </td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"> 2023 </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> Stock options </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> 955 </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> 1,398 </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"> Warrants </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> 103 </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> 103 </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> 103 </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> 103 </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"> Total anti-dilutive shares </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"> </td> <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"> 1,501 </td> <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"> </td> <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"> 1,058 </td> <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"> </td> <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"> 1,058 </td> <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"> </td> </tr></table>

align:center;"> 1,501 </td><td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"> </td></tr></table> 0000 The following table presents potentially dilutive shares that have been excluded from the calculation of net (loss) income per share because of their anti-dilutive effect (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:47.131%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.718%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.918%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.178%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.058%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"> </td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"> For the Six Months Ended December 31, </td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;">

kerning:none;min-width:fit-content;"> </p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">June 30, 2024</p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Insurance</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">350</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">460</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Software licenses</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">225</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">442</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Security deposit</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">1</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Prepaid clinical costs</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">1,050</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Other</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">71</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">209</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Total prepaid and other current assets</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">646</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">2,424</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> </tr> </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></div><p id="fn_propandequip" style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Property and Equipment</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">As of December 31, 2024, we had no property and equipment. Property and equipment consisted of the following as of June 30, 2024, in thousands:</p><div style="font-size:10pt;font-family:Times New Roman;"> <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.68%;box-sizing:content-box;"></td> <td style="width:1.64%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.68%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Furniture and equipment</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">1,000</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Equipment</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Leasehold improvements</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">969</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">2,156</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Less: accumulated depreciation (1)</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">1,764</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Property and equipment, net</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">392</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">_____</p><p style="margin-left:4.533%;text-indent:-1.416%;padding-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">(1) Includes impairment charge of $0.5 million, see below discussion on Impact of the Agreement (as discussed in Note 9. Leases).</p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Depreciation expense of property and equipment for the six months ended December 31, 2024 and 2023 are presented in the condensed consolidated statements of cash flows. During the three months ended December 31, 2024, we did not record depreciation expense. During the three months ended December 31, 2023, depreciation expense was approximately $0.1 million.</p><p style="text-

indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Impact of the Agreement (as discussed in Note 9. Leases) As noted in Note 9. Leases, we agreed to sell our furniture and fixtures to the landlord for $1.00 on our lease termination date of September 30, 2024. We completed an evaluation of the impact of the Agreement, as defined in Note 9. Leases, on the carrying value of our property and equipment (Other Long-Lived Assets). This process included evaluating the remaining estimated useful lives, significant changes in the use and potential impairment charges related to the Other Long-Lived Assets. Based upon our evaluation, we recorded an impairment charge during our fiscal year ended June 30, 2024 of approximately $0.5 million for the furniture and fixtures sold to the landlord on September 30, 2024, which was included in the impairment of long-lived assets in the condensed consolidated statements of operations for the fiscal year ended June 30, 2024. We also changed our estimate of the remaining useful lives of our leasehold improvements resulting in an acceleration of depreciation of approximately $0.1 million during our fiscal year ended June 30, 2024. </p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Accrued Liabilities</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">Accrued liabilities consisted of the following, in thousands:</p><table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:64.453%;box-sizing:content-box;"></td><td style="width:1.3%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:14.863000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.3%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:14.083%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"> </p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;text-align:left;"><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"> </p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">December 31, 2024</p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"> </p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">June 30, 2024</p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Accrued compensation and benefits (1)</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">$ </td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> 1,476 </td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> $</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$ </td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> 2,821 </td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"> Accrued pre-clinical and clinical trial expenses </td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> 151 </td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> 1,407 </td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"> Accrued legal and professional services </td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> 6 </td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> 33 </td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"> Accrued reimbursement to KKC </td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> 892 </td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"> Other </td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"> </td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"> 58 </td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff;padding-right:0.01in;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"> </td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"> </td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"> 34 </td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff;padding-right:0.01in;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"> Total accrued liabilities </td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> $</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">1,691</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Prepaid and other current assets consisted of the following, in thousands:</p><table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:64.453%;box-sizing:content-box;"></td><td style="width:1.3%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:14.863000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.3%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:14.083%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"> </p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;text-align:left;"><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"> </p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">December 31, 2024</p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"> </p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">June 30, 2024</p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Insurance</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">$ </td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> 350 </td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> $ </td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> 460 </td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New

</td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> Software licenses </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> 225 </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> 442 </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"> Security deposit </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> 2 </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> — </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> 263 </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"> Prepaid clinical costs </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> — </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> 1,050 </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> Other </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"> 71 </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"> 209 </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"> Total prepaid and other current assets </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"> $</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.00972222222222222in;text-align:right;">646</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.00972222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"> 2,124 </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"> </td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> </tr></table> Property and equipment consisted of the following as of June 30, 2024, in thousands: <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.68%;box-sizing:content-box;"></td> <td style="width:1.64%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.68%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"> Furniture and equipment </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> $</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.00972222222222222in;text-align:right;">1,000</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.00972222222222222in;text-align:left;">Equipment</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.00972222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.00972222222222222in;text-align:right;">187</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.00972222222222222in;text-align:left;">Leasehold improvements</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.00972222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.00972222222222222in;text-align:right;">969</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.00972222222222222in;text-align:left;">Less: accumulated depreciation</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.00972222222222222in;text-align:left;">(1,763)</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.00972222222222222in;text-align:left;">Property and equipment, net</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.00972222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$ </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"> 392 </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"> </td> </tr> </table>   (1)   Includes impairment charge of $0.5 million, see below discussion on Impact of the Agreement (as discussed in Note 9. Leases). <100000018700096900021560001764000392000500000010000015000001000000 Accrued liabilities consisted of the following, in thousands: <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:64.453%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.863000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.083%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"> </td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> December 31, 2024 </td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"> June 30, 2024 </td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"> <span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-

width:fit-content;">Accrued compensation and benefits (1)</p></td> <td
style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-
align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-
align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">1,476</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-
bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-
content;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">2,821</p></td> <td
style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-
width:fit-content;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Accrued pre-clinical and
clinical trial expenses</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-
right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-
wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">151</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-
bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-
content;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
 </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-
top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">1,407</p></td> <td style="padding-
top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-
content;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Accrued legal and professional
services</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-
right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-
wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">6</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-
bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-
content;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
 </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-
top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">33</p></td> <td style="padding-
top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-
content;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Accrued reimbursement to
KKC</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-
right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-
wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">—</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-
bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-
content;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
 </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-
top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">892</p></td> <td style="padding-
top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-
content;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Other</p></td> <td
style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-
align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-
right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-
wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.009722222222222222in;text-align:right;">58</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-
bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td>
<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-
align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-
right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-
wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.009722222222222222in;text-align:right;">34</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-
bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td>
</tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-
indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Total accrued
liabilities</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-
bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td>
<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;margin-right:0.009722222222222222in;text-align:right;">1,691</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-
align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-
content;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-
bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td>
<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;margin-right:0.009722222222222222in;text-align:right;">5,187</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-
align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-
content;"> </p></td> </tr> </table><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times
New Roman;font-kerning:none;min-width:fit-content;">____________</p><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.03pt;font-family:Times New
Roman;font-kerning:none;min-width:fit-content;">(1) Includes employee termination benefits of
approximately $<span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-
space:pre-wrap;font-kerning:none;min-width:fit-content;">1.3 million and $<span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-
kerning:none;min-width:fit-content;">21,000 as of December 31, 2024 and June 30, 2024, respectively, as
more fully described in <span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:9pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-
content;">Note 5. Employee Termination Benefits.
1476000282100015100014070006000330000892000580003400016910005187000130000021000<p id="fn_fvmeasure" style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">4<span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-
family:Times New Roman;font-kerning:none;min-width:fit-content;">. Fair Value Measurements</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The carrying amounts of financial instruments such as cash equivalents, short-term investments and accounts payable
approximate the related fair values due to the short-term maturities of these instruments. We invest our excess cash in financial instruments which are readily convertible into cash, such as money market funds and U.S. government securities. Cash
equivalents and short-term investments are classified as Level 1 as defined by the fair value hierarchy. As of December 31, 2024 and June 30, 2024<span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New
Roman;font-kerning:none;min-width:fit-content;">, we had no<span style="color:#000000;white-
space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> assets or liabilities measured on a recurring or non-recurring basis.</p>0000<p id="fn_onetimetermbene" style="font-size:10pt;margin-
top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">5. Employee
Termination Benefits</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New
Roman;font-kerning:none;min-width:fit-content;">In connection with our joint decision to discontinue development of zandelisib outside of Japan in December 2022, we announced a realignment of our clinical development efforts that streamlined our
organization towards the continued clinical development of our two earlier clinical-stage assets, voruciclib and ME-344. As a result, our Board approved a staggered workforce reduction (the 2023 RIF), which was completed during fiscal year 2024.
 </p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New
Roman;margin-bottom:0;text-align:left;">In August 2024, we commenced the Strategic Alternatives RIF, as
discussed in our strategic alternatives announcement described in <span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-
style:italic;font-kerning:none;min-width:fit-content;">Note 1. Description of Business and Basis of Presentation<span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-
content;">. Including contractual pro-rata fiscal year 2025 bonuses, we expect to incur charges not to exceed a total of <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-
width:fit-content;">$6.5<span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-
family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in retention, severance and COBRA costs related to the termination of our employees due to our related wind down activities. The charges that we expect to incur in connection
with the Strategic Alternatives RIF are subject to a number of assumptions, and actual results may differ materially. We may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the
Strategic Alternatives RIF.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New
Roman;font-kerning:none;min-width:fit-content;">For the three months ended December 31, 2024, we recorded employee termination benefits of <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New
Roman;font-kerning:none;min-width:fit-content;">$0.3<span style="color:#000000;white-
space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-
content;">$0.9<span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times
New Roman;font-kerning:none;min-width:fit-content;"> million within research and development and general and administrative expense, respectively. For the <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times
New Roman;font-kerning:none;min-width:fit-content;">three months ended December 31, 2023, we recorded employee termination benefits of <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-
kerning:none;min-width:fit-content;">$0.1<span style="color:#000000;white-space:pre-wrap;font-
size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $
0.2<span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-
kerning:none;min-width:fit-content;"> million within research and development expense and general and administrative expense, respectively.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-
bottom:0;text-align:left;">For the six months ended December 31, 2024, we recorded employee termination
benefits of $<span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-
space:pre-wrap;font-kerning:none;min-width:fit-content;">1.6 million and $<span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-
width:fit-content;color:#000000;">2.7 million within research and development and general and
administrative expense, respectively. For the six months ended December 31, 2023, we recorded employee termination benefits of $<span style="font-size:10pt;font-family:Times New
Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2 million in both
research and development expense and general and administrative expense.</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-
bottom:6pt;text-align:left;">The following table summarizes our activity related to employee benefits included in
accrued liabilities (in thousands): </p> <table style="margin-left:auto;border-spacing:0;table-
layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:46.4%;box-sizing:content-box;"></td> <td style="width:1.08%;box-sizing:content-box;"></td> <td style="width:1%;box-
sizing:content-box;"></td> <td style="width:16.459999999999997%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-
box;"></td> <td style="width:22.959999999999997%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td
style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">
 </p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times
New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td colspan="2" style="padding-top:0.01in;vertical-
align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">
December 31, 2024</p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid
#ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td>
<td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-
content;">June 30, 2024</p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-
top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Beginning balance</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-
right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p>
</td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">21</p></td> <td
style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-
width:fit-content;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-
right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="padding-top:0.01in;white-
space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">993</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td
style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.009722222222222222in;text-align:left;">Increase in accrued restructuring</p></td> <td style="padding-top:0.01in;white-space:pre-
wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-
wrap;font-kerning:none;min-width:fit-content;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-
align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-

content;">4,333 </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> 556 </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"> Cash payments </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"> 3,069 </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;">) </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"> 1,528 </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"> Ending Balance </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"> $</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.00972222222222222in;text-align:right;">1,285</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.00972222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> 21 </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"> Cash payments </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"> (3,069) </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"> Ending Balance </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"> $</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.00972222222222222in;text-align:right;">1,285</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.00972222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.00972222222222222in;text-align:right;">21</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.00972222222222222in;text-align:left;">Cash payments</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.00972222222222222in;text-align:right;">(3,069)</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.00972222222222222in;text-align:left;">Ending Balance</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.00972222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$ </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> 1,285 </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"> $ </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> 21 </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> </tr> <tr><td colspan="14"><table><tr><td></td></tr></table></td></tr></table>210009930004330005560003069000152800012850002100 6. Commitments and Contingencies We have contracted with various consultants and third parties to assist us in pre-clinical research and development and clinical trials work for our leading drug compounds and general and administrative activities. The contracts are terminable at any time but obligate us to reimburse the providers for any time or costs incurred through the date of termination. See the discussion of the sale of ME-344 within Note 12, Disposition of a Non-financial Asset for additional information regarding contracts assumed by the Purchaser (as defined in Note 12, Disposition of a Non-financial Asset). We also have an employment agreement with our acting chief executive officer and chief financial officer that provides for severance payments and accelerated vesting for share-based awards if their employment is terminated under specified circumstances. Litigation From time to time, we may be involved in various lawsuits, legal proceedings, or claims that arise in the ordinary course of business. Management believes there are no claims or actions pending against us as of December 31, 2024, which will have, individually or in the aggregate, a material adverse effect on its business, liquidity, financial position, or results of operations. Litigation, however, is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. Indemnification In accordance with our amended and restated certificate of incorporation and sixth amended and restated bylaws, we have indemnification obligations to our officers and directors for certain events or occurrences, subject to certain limits, while they are serving in such capacity. There have been no claims to date, and we have a directors and officers liability insurance policy that may enable it to recover a portion of any amounts paid for future claims. Presage License Agreement As discussed in Note 8, Other License Agreements, we are party to a license agreement with Presage Biosciences, Inc. (Presage) under which we may be required to make future payments upon the achievement of certain development, regulatory and commercial milestones, as well as potential future royalties based upon net sales. As of December 31, 2024, we had no accruals for potential future payments as achievement of the milestones had not been met. 7. License Agreements Kyowa Kirin Co., Ltd. License, Development and Commercialization Agreement In April 2020, we entered into the KKC Commercialization Agreement under which we granted to KKC a co-exclusive, sublicensable, payment-bearing license under certain patents and know-how controlled by us to develop and commercialize zandelisib and any pharmaceutical product containing zandelisib for all human indications in the U.S. (the U.S. License), and an exclusive (subject to certain retained rights to perform obligations under the KKC Commercialization Agreement), sublicensable, payment-bearing, license under certain patents and know-how controlled by us to develop and commercialize zandelisib and any pharmaceutical product containing zandelisib for all human indications in countries outside of the U.S. KKC granted to us a co-exclusive, sublicensable, license under certain patents and know-how controlled by KKC to develop and commercialize zandelisib for all human indications in the U.S., and a co-exclusive, sublicensable, royalty-free, fully paid license under certain patents and know-how controlled by KKC to perform our obligations in the Ex-U.S. under the KKC Commercialization Agreement. KKC paid us an initial nonrefundable payment of $100.0 million. In July 2023, we entered into a termination agreement with KKC to mutually terminate the KKC Commercialization Agreement and all other related agreements between the parties (Termination Agreement) and jointly decided to discontinue zandelisib development in the U.S. Prior to the execution of the Termination Agreement, KKC was responsible for the development and commercialization of zandelisib in Ex-U.S. and, subject to certain exceptions, was solely responsible for all costs related thereto. We also provided to KKC certain drug supplies necessary for the development and commercialization of zandelisib in the Ex-U.S., with the understanding that KKC would have assumed responsibility for manufacturing for the Ex-U.S. as soon as practicable. During fiscal year 2023, we updated our assessment of the total transaction price from the KKC Commercialization Agreement to reflect the upfront payment, milestone payments, estimated development cost-sharing, and deferred revenue. After announcing our plan to discontinue the global development of zandelisib outside of Japan, in December 2022, we decreased our estimate for variable consideration related to development cost sharing. With the execution of the Termination Agreement, we regained full, global rights (subject to KKC's limited rights for compassionate use) and KKC has no further rights to develop, use or commercialize zandelisib in the U.S., nor do we have any remaining performance obligations with all consideration received from KKC being nonrefundable. Therefore, the remaining long-term deferred revenue as of June 30, 2023, of $64.5 million that was allocated to the U.S. License obligation accounted for under Topic 808 at inception of the KKC Commercialization Agreement was recognized as revenue from collaboration agreements in the three months ended September 30, 2023, utilizing contract termination analogous to guidance provided in Topic 606. The $64.5 million transaction price allocated to the U.S. License obligation accounted for under Topic 808 was included as noncurrent deferred revenue as of

June 30, 2023. As of June 30, 2023, we also had deferred revenue of approximately $0.3 million related to the transaction price allocated to the Development Services performance obligations and recognized the remaining revenue based on the proportional performance of these development activities. The KKC Agreement was terminated on July 14, 2023 and all remaining amounts of deferred revenue were recognized during the fiscal year ended June 30, 2024. 100000000064500000645000003000002023-07-14 8. Other License Agreements Presage License Agreement In September 2017, we, as licensee, entered into a license agreement with Presage. Under the terms of the license agreement, Presage granted us exclusive worldwide rights to develop, manufacture and commercialize vorucicli

top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"> $</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">1,241</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">During the three and six months ended December 31, 2024, we had no supplemental cash flow activity.Supplemental cash flow information related to our operating leases was as follows for the periods presented (in thousands):</p><div style="font-size:10pt;font-family:Times New Roman;"> <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:63.407%;box-sizing:content-box;"></td> <td style="width:1.66%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.897%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.979%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.057%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">For the Three Months Ended December 31,</p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">For the Six Months Ended December 31,</p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0.01in;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Operating cash flows from operating leases</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> 583 </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> $ </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> 1,167 </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> </tr> </table> As of June 30, 2024, we had noremaining rental periods for our operating leases and the remaining ROU asset balance was $0.2 million. As of September 30, 2024, we had vacated the facility and the leased property reverted to the landlord. In addition, the ROU asset has been fully amortized. During fiscal year 2024, the ROU asset balance was increased by approximately $0.2 million related to direct costs associated with the Agreement. Additionally, the ROU asset balance was decreased by: (1) approximately $22,000 associated with our reassessment of the lease liability as of the Agreement Date and (2) $10.4 million associated with the impairment of the ROU asset, as discussed above.</p>3280020329-11-301230043000024-09-302029-11-301110000020000012200002000001040000000The total operating lease costs for the Amended Lease were as follows for the periods presented (in thousands):<table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:55.26%;box-sizing:content-box;"></td> <td style="width:1.12%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.120000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.12%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.12%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.120000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">For the Three Months Ended December 31,</p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">For the Six Months Ended December 31,</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Operating lease cost</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> 609 </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> $</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">1,217</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Variable lease costs</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">12</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">24</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Total lease costs included in operating expenses</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$ </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"> 621 </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"> $ </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"> 1,241 </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"> </td> </tr> </table> 609000021400012170001200002400621000214000124100000<span

style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Supplemental cash flow information related to our operating leases was as follows for the periods presented (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:63.407%;box-sizing:content-box;"></td> <td style="width:1.66%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.897%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.979%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.057%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;">   </td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> For the Three Months Ended December 31, </td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"> </td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"> For the Six Months Ended December 31, </td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"> </td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"> 2023 </td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"> </td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"> </td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"> 2023 </td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> Cash paid for amount included in the measurement <br/> of lease liabilities: </td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"> </td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"> </td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"> </td> <td></td> </tr> <tr style="height:10pt;background-color:#f1f0fc;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"> Operating cash flows from operating leases </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> $ </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> 1,167 </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> </tr> </table>5830001167000020000020000220010400000 10. Stockholders' Equity Equity Transactions Shelf Registration Statement We have a shelf registration statement (February 2024 Shelf Registration Statement) that permits us to sell, from time to time, up to $100.0 million of common stock, preferred stock, warrants, rights and units, subject to the "Baby Shelf Limitation" described below. The February 2024 Shelf Registration Statement was filed February 20, 2024 and declared effective February 28, 2024. At-The-Market Equity Offering On February 20, 2024, we entered into a capital on demand sales agreement with JonesTrading Institution Services LLC, pursuant to which we can offer and sell shares having an aggregate offering price of up to $25.0 million (the "ATM Program").In the event we will sell securities registered in this registration statement in a public primary offering with a value exceeding more than one third of our public float in any 12-month period so long as our public float remains below $75.0 million (Baby Shelf Limitation) As of January 2, 2024, the date used under applicable rules of the SEC to determine our public float at the commencement of the offering, one-third of our public float was equal to approximately $9.9 million. As of December 31, 2024, no shares have been issued and sold under our ATM Program. Cooperation Agreement and Cash Dividend On October 31, 2023, we announced our entry into a cooperation agreement with Anson Funds Management LP and Cable Car Capital LLC, which, among other non-financial related items provided for a capital return to stockholders in the form of a dividend in the amount of $1.75 per share of common stock that was declared on November 6, 2023 to stockholders of record at the close of business on November 17, 2023 (Cooperation Agreement). The total dividend of $11.7 million was paid on December 6, 2023 and was recorded as a reduction of additional paid-in capital in the condensed consolidated statements of stockholders' equity, as we have an accumulated deficit, rather than retained earnings. Rights Agreement On October 1, 2023, our Board approved and adopted a rights agreement (Rights Agreement) by and between us and Computershare, Inc., as Rights Agent (as defined in the Rights Agreement). Pursuant to the Rights Agreement, the Board declared a dividend of one preferred share purchase right (each, a Right) for each outstanding share of our common stock, par value $0.000002 per share, of our common stock. The dividend was payable to stockholders of record on October 12, 2023 (the Record Date) and is attached to and trades with each Common Share issued by us after October 12, 2023, but before the Distribution Date, as defined in the Rights Agreement (or the earlier of the redemption or expiration of the Rights) and, in certain circumstances, after the Distribution Date.The Rights and the Rights Agreement expired at the close of business on September 30, 2024. No rights were redeemed or exchanged under the Rights Agreement. Warrants As of December 31, 2024, we have outstanding warrants to purchase 102,513 shares of our common stock issued to Torreya Partners LLC. The warrants are fully vested, exercisable at a price of $6.80 per share and expire in October 2027, no warrants were exercised as of December 31, 2024, Description of Capital Stock Our total authorized share capital is 226,100,000 shares consisting of 226,000,000 shares of common stock, $0.000002 par value per share, and 100,000 shares of preferred stock, $0.01 par value per share. Common Stock The holders of common stock are entitled to one vote per share. In the event of a liquidation, dissolution or winding up of our affairs, holders of the common stock will be entitled to share ratably in all assets that are remaining after payment of our liabilities and the liquidation preference of any outstanding shares of preferred stock. All outstanding shares of common stock are fully paid and non-assessable. The rights, preferences and privileges of holders of our common stock are subject to any series of preferred stock that we may issue in the future. The holders of common stock have no preemptive rights and are not subject to future calls or assessments by us. Preferred Stock Our Board has the authority to issue up to 100,000 shares of preferred stock with a par value of $0.01 per share in one or more series and to fix the rights, preferences, privileges and restrictions in respect of that preferred stock, including dividend rights, dividend rates, conversion rights, voting rights, terms of redemption (including sinking fund provisions), redemption prices and liquidation preferences, and the number of shares constituting such series and the designation of any such series, without future vote or action by the stockholders. Therefore, the Board, without the approval of the stockholders, could authorize the issuance of preferred stock with voting, conversion and other rights that could affect the voting power, dividend and other rights of the holders of shares or that could have the effect of delaying, deferring or preventing a change of control. There were no shares of preferred stock outstanding as of December 31, 2024 and June 30, 2024. 10000000025000000 In no event will we sell securities registered on this registration statement in a public primary offering with a value exceeding more than one-third of our public float in any 12-month period so long as our public float remains below $75.0 million (Baby Shelf Limitation) As of January 2, 2024, the date used under applicable rules of the SEC to determine our public float at the commencement of the offering, one-third of our public float was equal to approximately $9.9 million.75000000990000001.752023-11-17117000002023-10-010.000000027The Rights and the Rights Agreement expired at the close of business on September 30, 2024. No rights were redeemed or exchanged under the Rights Agreement.10251136.8002261000002260000000.0000000210000000.01one vote per share1000000.0100 11. Share-based Compensation We use equity-based compensation programs to provide long-term performance incentives for our employees. These incentives consist primarily of stock options and RSUs. In December 2008, we adopted the MEI Pharma, Inc. 2008 Stock Omnibus Equity Compensation Plan (Omnibus Plan), as amended and restated from time to time, under which 1,850,739 shares of common stock are currently authorized for issuance. The Omnibus Plan provides for the grant of options and/or other stock-based or stock-denominated awards to our non-employee directors, officers, and employees. As of December 31, 2024, there were 841,714 shares available for future grant under the Omnibus Plan. In May 2021, we adopted the 2021 Inducement Plan (Inducement Plan), under which 125,000 shares of common stock are authorized for issuance. On June 9, 2023, our Board approved an amendment and restatement of the Inducement Plan to increase the aggregate number of shares of common stock authorized for issuance by 92,000 shares. The Inducement Plan is intended to assist us in attracting and retaining selected individuals to serve as employees who are expected to contribute to our success, by providing an inducement for such individuals to enter into employment with us, and to achieve long-term objectives that will benefit our stockholders. As of December 31, 2024, there were 157,146 shares available for future grant under the Inducement Plan. During the three and six months ended December 31, 2024 due to the Strategic Alternatives RIF, as discussed in Note 5. Employee Termination Benefits, we reversed share-based compensation in excess of that recorded. Total share-based compensation for all stock awards consisted of the following for the periods presented (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:46.909%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.722000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.42%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.282%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.72%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.662%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.282%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"> </td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-

top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">For the Three Months Ended
December 31,</p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid
#000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-
content;"> </p></td> <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">For the Six Months Ended December 31,</p>
</td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-
align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-
top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"> </p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td colspan="2" style="padding-top:0.01in;vertical-
align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">
2024</p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-
right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="padding-
top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-
wrap;font-kerning:none;min-width:fit-content;"> </p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-
content;">2023</p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td
colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.009722222222222222in;text-align:center;">2024</p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-
bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-
width:fit-content;"> </p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.009722222222222222in;text-align:left;"> </p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt
solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-
wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-
break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Research and development</p></td> <td style="padding-
top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-
bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-
kerning:none;min-width:fit-content;">(53</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-
bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="padding-
top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-
bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-
kerning:none;min-width:fit-content;">129</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-
top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-
width:fit-content;">$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;margin-right:0.009722222222222222in;text-align:right;">(<span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-
width:fit-content;">159</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-
align:left;">)</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-
top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-
width:fit-content;">$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;margin-right:0.009722222222222222in;text-align:right;">60</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-
align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr
style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">General and
administrative</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-
bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-
top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.009722222222222222in;text-align:right;">(<span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-
content;">50</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;">
<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td
style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
 </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">721</p>
</td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-
align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-
space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-
kerning:none;min-width:fit-content;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">(79</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-
right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="padding-top:0.01in;white-
space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-
space:pre-wrap;font-kerning:none;min-width:fit-content;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-
bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">1,153</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-
right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-
color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Total share-based compensation</p></td> <td
style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-
align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-
right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="padding-top:0.01in;white-
space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.009722222222222222in;text-align:right;">(<span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-
content;">103</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;">
<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td
style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-
align:left;">$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-
right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-
width:fit-content;">850</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-
right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p>
</td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-
align:left;">$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-
right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-
width:fit-content;">(238</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-
bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td
style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-
align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-
right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="padding-top:0.01in;white-
space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.009722222222222222in;text-align:right;">1,213</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-
bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td>
</tr> </table></div><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-
style:italic;font-kerning:none;min-width:fit-content;">Stock Options</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-
wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock options granted to employees vest <span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-
kerning:none;min-width:fit-content;">25% one year from the date of grant and ratably each month
thereafter on the first day of the month following the one-year anniversary of the grant date for a period of <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-
family:Times New Roman;font-kerning:none;min-width:fit-content;">36 months and generally
expire ten years from the date of grant. Stock options granted to directors vest ratably each month for a period of <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-
family:Times New Roman;font-kerning:none;min-width:fit-content;">12 months from the date of
grant and generally expire ten years
 from the date of grant. Upon separation from the Company, without cause, our Board members have
three years to<span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-
kerning:none;min-width:fit-content;"> </p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New
Roman;font-kerning:none;min-width:fit-content;">exercise their vested stock options. As of December 31,
2024, there were 954,723<span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-
family:Times New Roman;font-kerning:none;min-width:fit-content;"> total options outstanding of which <span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-
content;">894,869 were granted under the Omnibus Plan and <span style="font-size:10pt;font-
family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59,854<span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-
content;"> were granted under the Inducement Plan.</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">
A summary of our stock option activity and related data follows:</p> <table style="margin-
left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:43.8%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td
style="width:1%;box-sizing:content-box;"></td> <td style="width:11.94%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.24%;box-sizing:content-box;"></td> <td style="width:1%;box-
sizing:content-box;"></td> <td style="width:11.24%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td
style="width:14.56%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.24%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:5.98%;box-
sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;vertical-align:bottom;padding-
bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-
width:fit-content;"> </p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.009722222222222222in;text-align:left;"> </p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt
solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-
wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of
Options</p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-
align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="padding-
top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-
wrap;font-kerning:none;min-width:fit-content;"> </p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">Weighted-
Average
Exercise Price</p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times
New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td
colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.009722222222222222in;text-align:center;">Weighted-Average
Remaining Contractual
Term (in years)</p></td> <td
style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">
 </p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times
New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td colspan="2" style="padding-top:0.01in;vertical-
align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">
Aggregate
Intrinsic Value</p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-
bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-
content;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Outstanding at June 30,
2024</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-
right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-
wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">1,357,213</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-
bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-
content;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">31.60 </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> </td> </tr> <tr style="height:1pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> Forfeited </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"> (402,490 </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;">) </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> $</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">25.14</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#cf0f0c;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Outstanding at December 31, 2024</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"> 954.723 </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> $</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">34.32</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">6.3</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$ </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> — </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> Vested and expected to vest at December 31, 2024 </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"> 954.723 </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> 6.3 </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> 5 </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> — </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> 5.18 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> % </td> </tr></table> 1850739841714125000920005157146Total share-based compensation for all stock awards consisted of the following for the periods presented (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:46.909%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.722000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.42%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.282%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.72%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.662%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.282%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"> </td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"> For the Three Months Ended December 31, </td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"> </td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"> </td> <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"> For the Six Months Ended December 31, </td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"> </td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cf0f0c;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Expected life (years) </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 5.7 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:10pt;background-color:#cf0f0c;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Volatility </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 90.0 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> % </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Dividend yield </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> — </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> % </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Weighted-average grant date fair value </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> $ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 5.18 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"> </td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"> For the Six Months Ended December 31, </td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"> </td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"> For the Three Months Ended December 31, </td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"> </td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"> </td> <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"> For the Six Months Ended December 31, </td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"> <span style="white-

</page>
</page>
</page>

</td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;">   </td> <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> </td> <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"> Outstanding at December 31, 2024 </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"> 954,723 </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> $</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222222in;text-align:right;">34.32</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">6.3</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222222in;text-align:left;">Vested and expected to vest at December 31, 2024</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222222in;text-align:right;">954,723</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> 34.32 </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> 6.3 </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> </td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> $</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222222in;text-align:right;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr></table>135721331.6040249025.1495472334.32P6Y3M18D095472334.32P6Y3M18D02.46100000P1Y5M4Dfollowing weighted-average assumptions were used for the period presented:<table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:62.412%;box-sizing:content-box;"></td> <td style="width:1.26%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:34.327%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-right:0.0097222222222222222in;text-align:center;"> </p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222222in;text-align:center;"> </p></td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">For the Six Months Ended December 31,</p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222222in;text-align:center;"> </p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222222in;text-align:left;"> </p></td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222222in;text-align:left;">Risk-free interest rate</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222222in;text-align:right;">4.5</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">%</p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222222in;text-align:left;">Expected life (years)</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222222in;text-align:right;">5.7</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222222in;text-align:left;">Volatility</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222222in;text-align:right;">90.0</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">%</p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222222in;text-align:left;">Dividend yield</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222222in;text-align:right;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">%</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222222in;text-align:left;">Weighted-average grant date fair value</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 5.18 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> </table>0.045P5Y8M12D0.9005.18 12.   Disposition of a Non-financial Asset On October 22, 2024, (the Closing Date), MEI and Aardvark Therapeutics, Inc. (the Purchaser), entered into an Asset Purchase Agreement (the Asset Purchase Agreement), whereby we sold to the Purchaser our rights, title and interest in and to certain assets related to ME-344, including relevant intellectual property rights, technology and contracts (the ME-344 Sale). Pursuant to the Asset Purchase Agreement, the Purchaser paid us an initial payment of $0.5 million in cash plus a reimbursement amount of $55,000 at the closing of the transaction. The Purchaser may also make future milestone payments up to $62.0 million after the Closing Date, payable upon the achievement of certain regulatory and revenue milestones. The Purchaser also assumed certain of our liabilities after the Closing Date, including liabilities arising under the contracts transferred under the Asset Purchase Agreement. The ME-344 sale did not trigger a discontinued operation as the intellectual property sold did not represent a component of our business. Additionally, we concluded the ME-344 Sale met all the criteria to be derecognized on the Closing Date. Variable consideration, such as future potential regulatory and revenue milestones have been fully constrained. As such, as of the Closing Date and December 31, 2024, we determined the transaction price to be the initial payment of $0.5 million. Accordingly, we recognized a gain, upon satisfaction of our obligations under the Asset Purchase Agreement, of $0.5 million as a separate component of other income (expense), net in the consolidated statements of operations. The $55,000 reimbursement by the Purchaser represented work performed at the Purchaser's request prior to the Closing Date, which they agreed to reimburse. The reimbursement did not represent a liability assumed or relieved by the Purchaser and was, therefore, not included in the calculation of the gain on the disposition of the ME-344 asset. The $55,000 reimbursement was recognized as contra research and development expense in accordance with our reimbursement policy for pass through services. 2024-10-22500000550006200000050000055000055000falsefalsefalsefalsefalse Includes impairment charge of $0.5 million, see below discussion on *Impact of the Agreement* (as discussed in *Note 9, Leases*). Includes employee termination benefits of approximately $1.3 million and $21,000 as of December 31, 2024 and June 30, 2024, respectively, as more fully described in *Note 5, Employee Termination Benefits*.

P2LD9RSG O?D>L@VHUN3>R7?: MV-XG6=@GV;)/LJ@GLL9OFIF^I_7>RO^HR'/LG^/LF679)%9&=Q,-U$P_7 MW5\\^(93CR=9>Q!1P+--H709#K8BMPG!U F!28TQONW:M0=1M&;13K77SG^? M9&%%=GV4>0=/
H<6+I=4N"]O-:O @WF@C\]]P%.2(]/[L MI<[4'D4_X?,,AKU"I[LB

'WYU19S5/#0WC6(=9I,/0YTH%K4_%/&:>EG]D=/OX^CDQ